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Background: The addition of adjuvant trastuzumab to chemotherapy has significantly improved outcomes
for people with human epidermal growth factor receptor 2 (HER2)-positive, early, potentially curable
breast cancer. Twelve months’ trastuzumab, tested in registration trials, was adopted as standard adjuvant
treatment in 2006. Subsequently, similar outcomes were demonstrated using 9 weeks of trastuzumab.
Shorter durations were therefore tested for non-inferiority.
Objectives: To establish whether or not 6 months’ adjuvant trastuzumab is non-inferior to 12 months’
in the treatment of HER2-positive early breast cancer using a primary end point of 4-year disease-
free survival.
Design: This was a Phase III randomised controlled non-inferiority trial.
Setting: The setting was 152 NHS hospitals.
Participants: A total of 4088 patients with HER2-positive early breast cancer who it was planned
would receive both chemotherapy and trastuzumab took part.
Intervention: Randomisation (1 : 1) to 6 months’ or 12 months’ trastuzumab treatment.
Main outcomes: The primary end point was disease-free survival. The secondary end points were
overall survival, cost-effectiveness and cardiac function during treatment with trastuzumab. Assuming a
4-year disease-free survival rate of 80% with 12 months’ trastuzumab, 4000 patients were required to
demonstrate non-inferiority of 6 months’ trastuzumab (5% one-sided significance, 85% power), defining
the non-inferiority limit as no worse than 3% below the standard arm. Costs and quality-adjusted
life-years were estimated using a within-trial analysis and a lifetime decision-analytic model.
Results: Between 4 October 2007 and 31 July 2015, 2045 patients were randomised to 12 months’
trastuzumab and 2043 were randomised to 6 months’ trastuzumab. Sixty-nine per cent of patients
had ER-positive disease; 90% received anthracyclines (49% with taxanes; 41% without taxanes); 10%
received taxanes without anthracyclines; 54% received trastuzumab sequentially after chemotherapy;
and 85% received adjuvant chemotherapy (58% were node negative). At 6.1 years’ median follow-up,
with 389 (10%) deaths and 566 (14%) disease-free survival events, the 4-year disease-free survival
rates for the 4088 patients were 89.5% (95% confidence interval 88.1% to 90.8%) in the 6-month
group and 90.3% (95% confidence interval 88.9% to 91.5%) in the 12-month group (hazard ratio
1.10, 90% confidence interval 0.96 to 1.26; non-inferiority p = 0.01), demonstrating non-inferiority of
6 months’ trastuzumab. Congruent results were found for overall survival (non-inferiority p = 0.0003)
and landmark analyses 6 months from starting trastuzumab [non-inferiority p = 0.03 (disease-free-
survival) and p = 0.006 (overall survival)]. Six months’ trastuzumab resulted in fewer patients reporting
adverse events of severe grade [365/1929 (19%) vs. 460/1935 (24%) for 12-month patients; p = 0.0003]
or stopping early because of cardiotoxicity [61/1977 (3%) vs. 146/1941 (8%) for 12-month patients;
p < 0.0001]. Health economic analysis showed that 6 months’ trastuzumab resulted in significantly
lower lifetime costs than and similar lifetime quality-adjusted life-years to 12 months’ trastuzumab,
and thus there is a high probability that 6 months’ trastuzumab is cost-effective compared with
12 months’ trastuzumab. Patient-reported experiences in the trial highlighted fatigue and aches
and pains most frequently.
Limitations: The type of chemotherapy and timing of trastuzumab changed during the recruitment
phase of the study as standard practice altered.
ABSTRACT
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Conclusions: PERSEPHONE demonstrated that, in the treatment of HER2-positive early breast cancer,
6 months’ adjuvant trastuzumab is non-inferior to 12 months’. Six months’ treatment resulted in
significantly less cardiac toxicity and fewer severe adverse events.
Future work: Ongoing translational work investigates patient and tumour genetic determinants of
toxicity, and trastuzumab efficacy. An individual patient data meta-analysis with PHARE and other
trastuzumab duration trials is planned.
Trial registration: Current Controlled Trials ISRCTN52968807, EudraCT 2006-007018-39 and
ClinicalTrials.gov NCT00712140.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 40. See the NIHR Journals Library website for further project information.
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Glossary
APHINITY Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer: phase 3
randomised clinical trial.
CLEOPATRA Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer:
phase 3 randomised clinical trial.
General Data Protection Regulation A regulation in EU law (2016/679) on data protection and
privacy for all individuals within the European Union and the European Economic Area.
FNCLCC-PACS 04 Fédération Nationale des Centres de Lutte Contre le Cancer. Programme Adjuvant
Cancer Sein. A randomised controlled trial of trastuzumab in women with axillary lymph node positive,
HER2 positive early breast cancer.
HERA A randomised controlled trial of trastuzumab after chemotherapy in HER2-positive early breast
cancer. A trial from the Breast International Group.
HORG A Hellenic Oncology Research Group randomised, controlled trial of trastuzumab duration of
6 months versus 12 months in HER2 positive early breast cancer.
IDEA International Duration Evaluation of Adjuvant Therapy collaboration, a meta-analysis of
randomised controlled clinical trials of adjuvant chemotherapy duration for colorectal cancer.
NeoSphere Neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory
or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
PHARE Protocol for Herceptin as Adjuvant therapy with Reduced Exposure. A randomised controlled
Phase III trial of 6 versus 12 months trastuzumab in HER2-positive early breast cancer.
Short-HER A randomised controlled trial of 9 weeks’ versus 12 months’ trastuzumab.
SOFT Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With
Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Trial.
A randomised controlled Phase III International trial.
SOLD Synergism or Long Duration. A randomised Phase III controlled clinical trial of 9 weeks’ versus
12 months’ adjuvant trastuzumab in HER2 positive early breast cancer.
TEXT Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With
Hormone-Responsive Breast Cancer. A randomised Phase III controlled trial.
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Plain English summary
The background
There are several different types of breast cancer and some are called ‘HER2 positive’. These cancers
can often be cured by treatment with chemotherapy and a drug called trastuzumab (also known as
Herceptin®; Roche, Basel, Switzerland). Although the first trials of trastuzumab used 12 months
treatment, we did not know if less treatment could work as well. A small trial in Finland showed that
giving trastuzumab for just 9 weeks was also effective. We know that trastuzumab can have some side
effects, including heart problems, so it was important to see if we could reduce the length of treatment
time, which is usually 12 months.
What did we do?
We wanted to find out if we could treat patients safely with 6 months rather than 12 months of
trastuzumab. We carried out a clinical trial called PERSEPHONE, in which over 4000 patients with this
type of early breast cancer took part. Half of the patients were given 12 months of trastuzumab and
half were given 6 months of trastuzumab.
What did we find?
We found that the two groups of patients had very similar benefit from treatment. At 4 years after
diagnosis 90.3% of those who had received 12 months of trastuzumab were alive and free of any breast
cancer recurrence, compared with 89.5% of those who had received 6 months. In other words, 125
patients would need to be treated with 12 months’ trastuzumab rather than 6 months’ trastuzumab for
one more person to be alive and cancer-free 4 years from diagnosis.
The side effects?
Severe side effects of trastuzumab were seen on at least one occasion in 24% of 12-month patients
compared with 19% of 6-month patients. More patients receiving 12 months of trastuzumab had to
stop trastuzumab early because of heart problems (8% of 12-month patients compared with 3% of
6-month patients).
What does this all mean?
We have shown that 6 months of trastuzumab has similar outcomes to 12 months in treating patients
with HER2-positive early breast cancer but with fewer severe side effects, including heart problems,
fewer visits to hospital for patients and significant cost savings for the NHS.
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Scientific summary
Background
The incidence of breast cancer continues to rise in Western Europe and North America and breast
cancer remains a major health problem, despite considerable improvements in the treatment of the
disease. Trastuzumab (also known as Herceptin®; Roche, Basel, Switzerland) treatment in patients with
human epidermal growth factor receptor 2 (HER2)-positive early breast cancer has proved a major
advance. However, the choice of 12 months’ adjuvant trastuzumab in the pivotal registration studies
was arbitrary. As the beneficial effect of adjuvant trastuzumab was detected early in follow-up (median
of 1 year), it was reasonable to hypothesise that the majority of the adjuvant benefit may result from
the first months of therapy, rather than 12 months of treatment being required for the same effect.
This hypothesis was supported by evidence from the FinHer trial, which randomised patients to
chemotherapy with or chemotherapy without 9 weeks of trastuzumab. The trial demonstrated a
significant benefit of 9 weeks’ trastuzumab over no trastuzumab to a similar degree to that
demonstrated in the registration trials of 12 months’ trastuzumab.
Objectives
To compare 6 months of trastuzumab with 12 months of trastuzumab in terms of non-inferiority
and safety. Mapping on to standard practice in the UK, the trial recruited patients with HER2-positive
early breast cancer as determined by local diagnostic pathology tests and standard staging protocols.
End points
Primary end point
l To assess disease-free survival and non-inferiority of 6 months’ (nine cycles) compared with
12 months’ (18 cycles) trastuzumab in patients with HER2-positive early breast cancer.
Secondary end points
l To assess overall survival non-inferiority of 6 months’ compared with 12 months’ trastuzumab in
patients with HER2-positive early breast cancer.
l To assess the expected incremental cost-effectiveness (cost per quality-adjusted life-year) for
6 months’ compared with 12 months’ trastuzumab.
l Cardiac function as assessed by left ventricular ejection fraction during trastuzumab therapy, and
analysis of predictive factors for the development of cardiac damage.
Secondary objectives: substudies
l Trans-PERSEPHONE: tumour blocks (paraffin-embedded) were collected prospectively from patients
in the study for molecular and candidate gene analysis as prognostic and predictive markers
(separate protocol).
l Trans-PERSEPHONE-SNPs: blood samples were collected prospectively from patients in the study
for single nucleotide polymorphism analysis to research genetic/pharmacogenetic determinants of
inherited susceptibility to HER2-positive breast cancer, prognosis and trastuzumab response and
toxicity (separate protocol).
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Trial design and methodology
The trial was a prospective, randomised, multicentre, open-label, non-inferiority, Phase III clinical
trial. Patients were randomised (1 : 1) to either 12 months of trastuzumab (standard) or 6 months
of trastuzumab (experimental), with randomisation occurring at any time before the 10th cycle of
trastuzumab. Randomisation was by telephone to the Warwick Clinical Trials Unit, where a central
computerised minimisation procedure used stratification variables. These were (1) local diagnostic
pathology-reported oestrogen receptor status (positive or negative), (2) chemotherapy type
(anthracyclines without taxanes, anthracyclines with taxanes, taxanes without anthracyclines or neither
anthracyclines nor taxanes), (3) chemotherapy timing (adjuvant or neoadjuvant) and (4) trastuzumab
timing with reference to chemotherapy (concurrent or sequential).
Treatment and investigations
Experimental arm
Patients in the experimental arm received 6 months’ trastuzumab intravenously every 3 weeks for
nine cycles; this started in cycle 1 with a loading dose of 8 mg/kg and subsequent doses were 6 mg/kg.
When the subcutaneous formulation of trastuzumab was licensed this was able to be used in the trial
at a fixed dose of 600 mg from the start. Patients who commenced on intravenous trastuzumab could
be switched to the subcutaneous formulation at the discretion of the treating clinician.
Control arm
Patients in the control arm received 12 months’ trastuzumab in the same dose and formulation as for
6 months’ treatment.
All patients had HER2-positive breast cancers, reported in accordance with UK Royal College of
Pathologists HER2 testing guidelines. All laboratories testing for HER2 were part of the National
External Quality Assurance Scheme. Patients’ breast cancers were either immunohistochemistry
score 3+ or immunohistochemistry score 2+ with HER2 gene amplification on in situ hydridisation.
All patients received chemotherapy as adjuvant or neoadjuvant treatment and received trastuzumab
either concurrently with or sequentially after chemotherapy. Trastuzumab was given concurrently
with the non-anthracycline component of chemotherapy. For the first 2500 patients, left ventricular
ejection fraction was measured at baseline and then 3-monthly for 12 months from the start of
trastuzumab. For subsequent patients, left ventricular ejection fraction measurements were taken
every 4 months, as had become standard in the UK. All chemotherapy regimens used routinely in
standard practice were allowed in the trial.
Sample size determination
The trial was designed to allow demonstration of non-inferiority of the experimental arm (6 months’
trastuzumab) in terms of the primary end point of disease-free survival compared with the control
arm (12 months’ trastuzumab). The power calculations assumed that the disease-free survival from the
standard treatment of 12 months’ trastuzumab would be 80% at 4 years. The margin for non-inferiority
was set as a 3% level, implying that the 4-year disease-free survival of the experimental arm should
not be below 77%, a difference equivalent to a hazard ratio of 1.17. On this basis, with 5% one-sided
significance and 85% power, a trial randomising 4000 patients in total (2000 in each arm) would have
the ability to prove non-inferiority of the experimental arm.
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Follow-up
Follow-up was 6-monthly for 2 years and annually thereafter for a further 8 years to reach 10 years
from the date of first trastuzumab treatment. A protocol amendment in 2018 allowed for annual
follow-up by telephone call or e-mail, depending on standard practice at the site.
Inclusion criteria
l Histological diagnosis of invasive breast cancer.
l No evidence of metastatic disease.
l Known hormone receptor status.
l Overexpression of HER2 receptor.
l Bilateral breast cancers were eligible provided that one of the tumours overexpressed the
HER2 receptor.
l Clear indication for neoadjuvant or adjuvant chemotherapy based on clinical and
histopathological features.
l Patients were fit to receive neoadjuvant or adjuvant chemotherapy and trastuzumab in the opinion
of the responsible physician.
l No previous diagnosis of malignancy unless:
¢ managed by surgical treatment only, and disease free for 10 years.
¢ previous basal cell carcinoma, cervical carcinoma in situ or ductal carcinoma in situ of the breast.
l Not pregnant and not lactating, with no intention of becoming pregnant during chemotherapy, and
agreed to adopt adequate contraceptive measures if they were pre-menopausal and sexually active.
l No concurrent medical or psychiatric problems that might prevent completion of treatment
or follow-up.
l Aged ≥ 18 years.
l Written informed consent for the study given at any time before the 10th cycle of trastuzumab.
Exclusion criteria
l Significant concurrent cardiac disease or significant concurrent comorbidity that, in the opinion of the
responsible physician, would add to the risks associated with trastuzumab or cytotoxic chemotherapy.
l Inability to comply with protocol requirements.
l Received more than nine cycles of trastuzumab.
l Any other condition that, in the local investigator’s opinion, would make the patient unsuitable to
participate in the trial.
Outcomes
The primary end point of disease-free survival was calculated from the date of diagnostic biopsy
to the date of the first invasive breast cancer relapse (local or distant) or death, or to the date of
censor in patients alive and relapse free. Overall survival was calculated from the date of diagnostic
biopsy. As randomisation could occur at any time up to and including the ninth cycle of trastuzumab,
a landmark analysis was carried out from 6 months after the start of trastuzumab. Additional analyses
of invasive disease-free survival [to include invasive contralateral breast cancers and second primary
invasive cancers (non-breast)], distant disease-free survival, and breast cancer-specific survival were
carried out. The number of trastuzumab cycles received per patient was recorded, along with the route
of administration and the reasons for any deviation from the protocol. Left ventricular ejection fraction
was defined as low if < 50% or if reported as low without quantification. Incidence of clinical cardiac
dysfunction, defined as symptoms or signs of congestive heart failure or prescription of new or altered
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cardiac medication, was recorded every 3 months for 12 months. A cardiologist (CP) was a member of
the trials group and reviewed the cardiac toxicity together with the chief investigator (HME) and other
members of the Trial Management Group.
The cost-effectiveness of 6 months’ trastuzumab compared with 12 months’ trastuzumab was
assessed 2 years after the start of trastuzumab, based on the landmark analysis, using a within-trial
analysis. A secondary within-trial analysis was conducted adopting a societal perspective. A de novo
decision-analytic model was also developed to assess cost-effectiveness over a lifetime horizon.
Patients were also invited to regularly report their trial and treatment experiences in a free-text
page in the quality-of-life booklet.
Results
Of 4088 patients, 2045 were randomly assigned to 12 months’ trastuzumab and 2043 were randomly
assigned to 6 months’ trastuzumab. Sixty-nine per cent (2825/4088) had hormone-receptor-positive
disease; 90% (3683/4088) received anthracyclines [41% (1696/4088) without taxanes and 49%
(1987/4088) with taxanes)] and 10% (400/4088) received taxane combinations without anthracyclines;
and 54% (2188/4088) received sequential trastuzumab and 46% (1900/4088) received concurrent
trastuzumab. Eighty-five per cent (3462/4088) of patients received adjuvant chemotherapy and, of
these, 41% (1419/3462) were axillary lymph node positive and 58% (2017/3462) were axillary lymph
node negative; 47% (1626/3462) of tumours were ≤ 2 cm in diameter and 50% (1734/3462) were
> 2 cm. At 6.1 years’ median follow-up, there were 389 (10%) deaths [182 (9%) in the 12-month arm;
207 (10%) in the 6-month arm] and 566 (14%) disease-free survival events [270 (13%) in the 12-month
arm; 296 (14%) in the 6-month arm]. The 4-year disease-free survival rate was 90.3% (95% confidence
interval 88.9% to 91.5%) in the 12-month arm and 89.5% (95% confidence interval 88.1% to 90.8%) in
the 6-month arm. The hazard ratio for 6 months compared with 12 months was 1.10 (90% confidence
interval 0.96 to 1.26; non-inferiority p = 0.01), demonstrating non-inferiority of 6 months’ trastuzumab.
Congruent results were found for overall survival (4-year rates, 94.9% vs. 94.2% for 12 and 6 months,
respectively; non-inferiority p = 0.0003), and also in a landmark analysis 6 months after starting
trastuzumab, with 4-year disease-free survival 88.7% versus 88.4% (non-inferiority p = 0.03) and
overall survival 93.2% versus 92.6% (non-inferiority p = 0.006). Survival curves of invasive disease-free
survival, distant disease-free survival and breast cancer specific survival were comparable with those
of the protocol-specified primary and secondary end points.
Forest plots for disease-free survival showed heterogeneity in the treatment effect for the timing
of trastuzumab (sequential and concurrent; p < 0.001). Patients receiving concurrent trastuzumab
and chemotherapy appeared to do better with 12 months’ treatment than with 6 months’ treatment
(hazard ratio 1.54, 95% confidence interval 1.19 to 1.99), whereas with sequential trastuzumab
6 months’ treatment appeared non-inferior (hazard ratio 0.87, 95% confidence interval 0.70 to 1.07).
It is important to note that the type of chemotherapy used and the scheduling of trastuzumab and
chemotherapy were decided by the investigators and not randomised. Patients in whom concurrent
rather than sequential scheduling was used were more likely to be node positive (53% vs. 32%;
p < 0.0001) and had larger tumours (> 2 cm: 55% vs. 47%; p < 0.0001). The majority of patients
given sequential treatment received six cycles of anthracycline-based chemotherapy and this group
has the longest follow-up as this was the predominant chemotherapy in the early years of the trial.
Heterogeneity was also found for chemotherapy type (p = 0.01), although this result should be interpreted
with caution, as it is driven mainly by an apparent effect in the small taxane-only group. No heterogeneity
was seen for oestrogen receptor status, timing of chemotherapy (adjuvant/neoadjuvant), age, tumour
grade, menopausal status and immunohistochemistry score; and for adjuvant patients there was no
heterogeneity for axillary nodal status, tumour size at surgery, and a composite of oestrogen receptor
and axillary node status.
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Clinical cardiac dysfunction was reported more commonly in 12-month than in 6-month patients
[228/1987 (11%) vs. 156/2008 (8%) respectively; p < 0.0001]. A small absolute difference was
observed in the first 6 months (8% of 12-month patients, 6% of 6-month patients, p = 0.01), with a
larger difference during the 7- to 12-month period (8% vs. 5% respectively, p = 0.0002). Trastuzumab
was stopped early because of cardiac toxicity in 146 out of 1941 (8%) 12-month patients and in 61 out
of 1977 (3%) 6-month patients (p < 0.0001). Low left ventricular ejection fraction was recorded in
228 out of 2042 (11%) 12-month patients and in 175 out of 2038 (9%) 6-month patients. There was
little difference in falls in left ventricular ejection fraction, with an absolute decrease of ≥ 10% from
baseline to < 50% seen in 164 out of 1964 (8%) 12-month patients and in 131 out of 1961 (7%)
6-month patients. Substantial falls in left ventricular ejection fraction to < 50% after a baseline of
≥ 59% were seen in 109 out of 1964 (6%) 12-month patients and in 86 out of 1961 (4%) 6-month
patients. In the first 6 months, this was similar in the 12-month arm (64/1955; 3%) and the 6-month
arm (70/1957; 4%), but in the 7- to 12-month period it was higher for the 12-month group (71/1880;
4%) than for the 6-month group (33/1701; 2%) (p = 0.0015).
During the 12-month period from starting trastuzumab, a higher proportion of 12-month patients
than of 6-month patients reported at least one adverse event of severe grade according to Common
Terminology Criteria for Adverse Events version 3 (grade ≥ 3, or 2 for palpitations): 460 out of 1935
(24%) and 365 out of 1929 (19%), respectively (p = 0.0003). The toxicities that were reported in excess
in the 12-month patients compared with the 6-month patients, in decreasing order of frequency, were
fatigue (11.5% vs. 8.6%: p = 0.003), muscle/joint pains (11.3% vs. 8.8%: p = 0.01), pain (5.2% vs. 3.1%:
p = 0.001), palpitations (4.8% vs. 2.8%: p = 0.002), cough (4.1% vs. 2.2%: p = 0.0007) and chills (3.6% vs.
2.0%: p = 0.003). The excess toxicities were seen predominantly during the 7- to 12-month period.
Health economic analyses demonstrated that 6 months’ trastuzumab resulted in significantly lower
lifetime costs than and similar lifetime quality-adjusted life-years to 12 months’ trastuzumab, and
there is a high probability that 6 months’ trastuzumab is cost-effective compared with 12 months’
trastuzumab. The cost-effectiveness of 6 months’ trastuzumab is less certain in predefined subgroups.
Further analysis is required to understand if there is a population of patients at sufficient clinical risk
in whom 12 months’ trastuzumab would be considered the more cost-effective option. Analysis of
patient-reported experiences showed that side effects from trastuzumab had a significant impact on
daily life; the most frequently reported were fatigue and aches/pains.
Conclusions
We have demonstrated that 6 months’ trastuzumab is non-inferior to 12 months’ trastuzumab in the
treatment of HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse
events. The trial accepted all patients who were HER2 positive and were receiving or planned to receive
chemotherapy and trastuzumab treatment, and for the whole trial population we have demonstrated
non-inferiority. This is the only reduced duration study to demonstrate clear non-inferiority, and these
results support the consideration of reduced duration trastuzumab for patients at a similar risk of
recurrence to patients included in the trial.
Trial registration
This trial is registered as ISRCTN52968807, EudraCT 2006-007018-39 and ClinicalTrials.gov
NCT00712140.
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Chapter 1 Introduction
Breast cancer and biology of HER2-positive disease
Breast cancer is a significant health problem worldwide and is the most common cancer occurring in
women in the UK, with an incidence of 54,700 diagnoses per year (figures from 2017).1 This represents
31% of all new cancer diagnoses in women. Although breast cancer also occurs in men it is uncommon,
accounting for only 390 cases per year in the UK. A total of around 11,400 deaths are due to breast
cancer each year and in women this represents the second most common cancer cause, accounting for
15% of all cancer deaths.1 Overexpression of human epidermal growth factor receptor 2 (HER2)
is recognised as a poor prognostic feature of breast cancer2 and has been found to be present in
12–15% of all breast cancer cases. Subsequently, the molecular intrinsic subtypes3 of luminal A and B,
HER2-enriched, and basal-like have helped to define breast cancer prognosis more precisely and have
improved clinical management and treatment decisions. These four main intrinsic subtypes are all
found in HER2-positive disease, and dominate the biological and clinical phenotype.4 Patients with
HER2+/luminal A disease seem to have a relatively better outcome than patients with the other
subtypes; in particular, patients with the HER2-enriched intrinsic subtype were found to have the
worst prognosis, a finding confirmed in the integrative cluster of breast cancer analysis.5
Trastuzumab treatment: metastatic and adjuvant
Significant HER2 overexpression leads to ligand binding and activation of cell division and tumour
growth. Treatment of HER2-positive breast cancer with the monoclonal antibody trastuzumab
(Herceptin®; Roche, Basel, Switzerland) was one of the first targeted cancer treatments to be
developed and tested. It represented a major advance in the management of metastatic disease,6,7
producing significant improvements in response rates and survival. This signal of response soon led
to registration studies of trastuzumab given with chemotherapy for HER2-positive breast cancer
early in the disease, and cure rates improved. A Cochrane review of all of the adjuvant trastuzumab
studies published in 20128 demonstrated that there were 40% fewer cancer recurrences and 34%
fewer deaths with adjuvant trastuzumab. The magnitude of this effect has also been demonstrated
indirectly in molecular studies of tumours sampled before the introduction of adjuvant trastuzumab.5,9
These showed that the HER2-enriched group without adjuvant trastuzumab had worse survival than
those with nine other molecular subtypes, including basal-type triple-negative breast cancer.
Adjuvant trastuzumab studies
After the success of trastuzumab for treating metastatic disease, registration trials were carried out in the
early disease setting. The duration of treatment used in these pivotal registration trials was 12 months,
although no evidence existed to support this length of targeted treatment in the adjuvant setting.
HERA
HERA was an international, multicentre, randomised trial that compared 1 year or 2 years of trastuzumab
given every 3 weeks with observation in patients with HER2-positive and either node-negative or node-
positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or
adjuvant chemotherapy. A total of 1694 patients were randomised to 2 years of trastuzumab, 1694 were
randomised to 1 year of trastuzumab, and 1693 were in the observation arm with chemotherapy alone.
Results were first reported in the New England Journal of Medicine10 for 1 year of trastuzumab compared
with chemotherapy alone. With a median follow-up of 1 year, 347 disease-free survival (DFS) events
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(recurrence of breast cancer, contralateral breast cancer, second non-breast malignant disease, or death)
were observed: 127 events in the trastuzumab group and 220 events in the observation group. The
unadjusted hazard ratio (HR) for a DFS event in the trastuzumab group compared with the observation
group was 0.54 [95% confidence interval (CI) 0.43 to 0.67; p < 0.0001], representing an absolute benefit
in terms of DFS at 2 years of 8.4%. Symptomatic congestive heart failure (CHF), including severe CHF,
developed in 1.7% of the women treated with trastuzumab.
Subsequent follow-up confirmed the beneficial effect. The 2-year analysis of the HERA trial demonstrated
a benefit for overall survival (OS) as well as for DFS (HR for OS 0.66, 95% CI 0.47 to 0.91; p = 0.0115:
updated HR for DFS 0.64, 95% CI 0.54 to 0.76; p < 0.0001).11 These results confirmed that trastuzumab
given sequentially after adjuvant chemotherapy has a significant benefit with a median follow-up of
2 years. The emergence of benefit after a median follow-up of only 1 year suggests that there is a
significant effect from the first months of trastuzumab therapy. In addition, it is important to note
that during the HERA trial trastuzumab was given sequentially after at least four cycles of standard
chemotherapy, demonstrating the same degree of benefit as seen in the trials that used concurrent
trastuzumab and chemotherapy.
Longer-term follow-up results of HERA have been published, confirming significant benefit for 12 months’
trastuzumab compared with observation at a median follow-up of 8 years.12 This is despite nearly 50% of
patients in the observation arm ‘crossing over’ to receive adjuvant trastuzumab after the early results
were reported in 2005. There is no dispute about the significant benefit of adjuvant trastuzumab in
HER2-positive breast cancer.
The HERA trial also tested 24 months’ trastuzumab compared with 12 months’ trastuzumab. The results
for the 24-month arm showed no additional benefit in the 2013 publication after 8 years’ follow-up,12
or in the further publication in 2017 after 11 years’ follow-up.13 Therefore, 12 months remained the
standard of care throughout the world. In the accompanying editorial to the 2013 publication,14 Heikki
Joensuu discussed the biology of HER2-positive breast cancer that leads to aggressive clinical behaviour
and early cancer recurrence. He went on to say ‘The HERA results lend support to the hypothesis that
patients with HER2 amplification do not benefit from long treatment durations with HER2-targeted
therapy, but might be managed best with effective regimens of short duration’.14 Interestingly, had the
HERA trial been analysed and reported after only 3 years, a benefit for 2 years of trastuzumab would
have been found. However, with longer follow-up,13 both 1- and 2-year DFS and OS are identical, and
any earlier difference has disappeared.
NSABP B-31 and NCCTG N9831
The second paper published in the New England Journal of Medicine15 included the combined results
of two US trials that compared adjuvant chemotherapy with and adjuvant chemotherapy without
concurrent trastuzumab in women following surgery for HER2-positive breast cancer. The National
Surgical Adjuvant Breast and Bowel Project trial (NSABP B-31) compared group 1 (doxorubicin
and cyclophosphamide followed by paclitaxel either every 3 weeks or weekly) with group 2 (the
same chemotherapy plus 52 weeks of trastuzumab beginning with the first dose of paclitaxel). The
North Central Cancer Treatment Group (NCCTG) trial N9831 compared three regimens: group A
(doxorubicin and cyclophosphamide followed by weekly paclitaxel), group B (the same chemotherapy
followed by 52 weeks of trastuzumab after paclitaxel) and group C (the same chemotherapy plus
52 weeks of trastuzumab initiated concurrently with paclitaxel). The studies were amended to include
a joint analysis comparing groups 1 and A (the control groups) with groups 2 and C (with trastuzumab
given concurrently with taxanes). Group B was excluded from this first analysis because trastuzumab
was not given concurrently with paclitaxel. The trial was reported when 394 DFS events had occurred,
of which 133 were in the trastuzumab group and 261 were in the control group (HR 0.48; p < 0.0001).
Three-year DFS was 87.1% in the trastuzumab group, compared with 75.4% in the control group,
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showing an absolute difference of nearly 12% in favour of trastuzumab. Trastuzumab therapy was
associated with a 33% reduction in the risk of death (p = 0.015). The 3-year cumulative incidence of
severe congestive heart failure or death from cardiac causes in the trastuzumab group was 4.1% in
trial NSABP B-31 and 2.9% in NCCTG N9831.
Subsequently, longer-term follow-up16,17 confirmed the benefits of trastuzumab given for 12 months.
At a median follow-up of 8.4 years, there was a 37% relative improvement in OS with the addition of
trastuzumab (HR 0.63, 95% CI 0.54 to 0.73; p < 0.001) and an increase in the 10-year OS rate from
75.2% to 84%. DFS rates also improved by 40% (HR 0.60, 95% CI 0.53 to 0.68; p < 0.001), with an
increase in the 10-year DFS rate from 62.2% to 73.7%.17
Analysis of NCCTG N9831 on its own was able to address the comparison of the three arms.16
The non-trastuzumab control arm was AC-paclitaxel (doxorubicin, cyclophosphamide and paclitaxel)
chemotherapy, the second arm was AC-paclitaxel with sequential trastuzumab for 12 months, and
the third arm was AC-paclitaxel with concurrent trastuzumab starting with paclitaxel and continuing
afterwards to complete 12 months of weekly treatment. With a median follow-up of 6 years, the
5-year DFS rates were 80.1% and 84.4% for the second and third arms, respectively. There was an
increase in DFS with concurrent trastuzumab and paclitaxel relative to sequential administration
(HR 0.77, 99.9% CI 0.53 to 1.11), but the p-value of 0.02 did not cross the prespecified O’Brien–Fleming
boundary (0.00116) required for this arm of the trial to be stopped early in the interim analysis. However,
following the publication of these results in 2011, concurrent as well as sequential trastuzumab and
chemotherapy were adopted as a ‘standard of care’ and, subsequently, concurrent treatment became
the preferred option.
BCIRG-006
The Breast Cancer International Research Group (BCIRG) study of trastuzumab in women with
HER2-expressing early breast cancer (BCIRG-006) examined concurrent treatment of trastuzumab
with a non-anthracycline-containing chemotherapy regimen (docetaxel and either carboplatin or
cisplatin).18 In BCIRG-006, 3222 patients were recruited, and similar numbers of node-positive
and high-risk node-negative women were randomised to each of three arms: adjuvant doxorubicin,
cyclophosphamide and then docetaxel plus trastuzumab (AC-TH) or doxorubicin, cyclophosphamide
and then docetaxel (AC-T), or docetaxel, carboplatin (or cisplatin) and trastuzumab (TCH). After a
median follow-up of 65 months, there was significant benefit in DFS and OS in both groups treated
with trastuzumab, compared with the group who received AC-T, who had a 5-year DFS of 75% and an
OS of 87%. Among patients receiving AC-TH, the 5-year DFS was 84% (HR for the comparison with
AC-T 0.64; p < 0.001) and OS was 92% (HR 0.63; p < 0.001). Among patients receiving TCH, the 5-year
DFS was 81% (HR 0.75; p = 0.04) and OS was 91% (HR 0.77; p = 0.04). There was no difference between
the two trastuzumab-containing arms, although the study was not sufficiently powered from a statistical
point of view to confirm non-inferiority. There was a numerical trend for TCH showing a lower 5-year
DFS (81% compared with 84% in the AC-TH arm), although there was significantly less cardiotoxicity
among patients receiving TCH than among those receiving AC-TH.
FNCLCC-PACS-04
This was the only study that failed to demonstrate an advantage of adjuvant trastuzumab.19 Five
hundred and twenty-eight patients with operable node-positive breast cancer were randomised (1 : 1)
to anthracycline-based chemotherapy with or without trastuzumab and, in a secondary randomisation,
with or without docetaxel. The 3-year DFS rates were 78% (95% CI 72.3% to 82.5%) and 81% (95% CI
75.3% to 85.4%) in the observation and trastuzumab arms, respectively. There was a 14% reduction
in the risk of relapse (HR 0.86, 95% CI 0.61 to 1.22; p = 0.41, log-rank stratified on pathologic node
involvement), which was non-significant. All patients in this trial received sequential trastuzumab, and
this result, together with the NCCTG N9831 analysis,16 which was the only trial directly comparing
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concurrent with sequential trastuzumab, resulted in a gradual shift in UK practice to increase the
numbers of patients receiving trastuzumab concurrently with chemotherapy. This coincided with the
increasing use of anthracycline-with-taxane chemotherapy combinations, which were approved by
the National Institute for Health and Care Excellence (NICE) for the treatment of node-positive
breast cancer during the course of the trial.
Shorter-duration studies
FinHer
Soon after the results of the registration trials, the FinHer trial was published.20 This study compared
docetaxel with vinorelbine for the adjuvant treatment of patients with early breast cancer. In this
trial, women with HER2-positive tumours were also randomised to receive chemotherapy with or
chemotherapy without concurrent trastuzumab. Two hundred and thirty-two women were recruited
who had axillary-node-positive or high-risk node-negative HER2-positive cancer. They were randomised
to receive three cycles of docetaxel or vinorelbine with or without concurrent weekly trastuzumab
for 9 weeks, followed by three cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC). In the
subgroup of patients who had HER2-positive cancer, those who received trastuzumab had significantly
better 3-year recurrence-free survival than those who did not (89% vs. 78%; HR for recurrence or
death 0.42, 95% CI 0.21 to 0.83; p = 0.01). Docetaxel was associated with more adverse effects than
was vinorelbine. Importantly, despite trastuzumab being given immediately before anthracyclines,
this arm was not associated with reduced left ventricular ejection fraction (LVEF) or cardiac failure.
The FinHer trial demonstrated that a short course of trastuzumab administered concurrently with
docetaxel or vinorelbine was effective in women with HER2-positive breast cancer.
Subsequently, at a median follow-up of 62 months,21 the benefit of 9 weeks’ trastuzumab was maintained
in the exploratory comparison of docetaxel and trastuzumab followed by FEC with the same treatment
without trastuzumab (HR 0.32, 95% CI 0.12 to 0.89; p = 0.029). However, this was not the case in the
comparison of vinorelbine and trastuzumab followed by FEC compared with the same treatment without
trastuzumab (HR 0.92, 95% CI 0.47 to 1.83; p = 0.82).
Hence, when the PERSEPHONE trial started in 2007, whether or not similar outcomes could be achieved
with durations of trastuzumab treatment of < 12 months was an important question worldwide.
E2198
This was a trial of the Eastern Cooperative Oncology Group (ECOG)22 that was set up to compare the
cardiotoxicity of a short course of trastuzumab with that of the conventional 12 months of trastuzumab.
This was not published until 2015 and therefore did not inform the design of the PERSEPHONE trial.
In addition, it was not powered to demonstrate non-inferiority in the 12-week trastuzumab arm. The
trial included 227 women with stage II or IIIa HER2-positive breast cancer. Patients were randomised to
12 weeks of paclitaxel and trastuzumab followed by four cycles of doxorubicin and cyclophosphamide
or to the same treatment with a total of 1 year of trastuzumab (standard arm). The primary objective
was to assess the safety of the different durations of trastuzumab therapy, in particular with regard to
cardiac toxicity, which was defined as CHF or LVEF decrease of ≥ 10%. DFS and OS were secondary end
points. The frequency or severity of cardiac toxicity did not increase; three patients in the experimental
arm and four in the standard arm experienced CHF. There was no difference in 5-year DFS, which was
76% and 73% for the short and standard arms, respectively, with a HR of 1.3 (95% CI 0.8 to 2.1; p = 0.3).
There was also no statistically significant difference in OS (HR 1.4; p = 0.3). The trial was not powered
for efficacy; however, the longer duration of trastuzumab therapy did not demonstrate a signal for
marked superiority. Retrospectively, this trial provided some additional evidence for the efficacy of
shorter-duration trastuzumab.
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Duration of trastuzumab studies
PHARE
Based on the FinHer results, the French group Institut National du Cancer developed the PHARE
clinical trial to compare 6 months’ trastuzumab with 12 months’ trastuzumab (Table 1). Randomisation
into the PHARE trial occurred between 3 and 6 months after a patient had started trastuzumab, which
was one of the differences between PHARE and PERSEPHONE. At the start of PERSEPHONE, all
patients were randomised before starting trastuzumab, but subsequently randomisation was permitted
at any time up to and including the ninth cycle of trastuzumab. In PHARE, patients were stratified
by oestrogen receptor (ER) status (positive or negative) and concurrent or sequential trastuzumab
and chemotherapy. It mapped on to standard practice in France and was carried out as a multicentre
study recruiting 3384 patients: 1690 randomised to 6 months’ trastuzumab and 1690 randomised
to 12 months’ trastuzumab. In the original statistical plan outlined in the first publication in 2013,23 a
margin of non-inferiority of 2% was calculated on an assumed 2-year DFS of 85%. This was the 2-year
DFS figure that had been predicted from the first results of the HERA trial.10 The number of patients
required was 7000 to have a 5% level of significance and 80% power to confirm non-inferiority of the
experimental arm with an upper confidence limit below the HR, which was calculated at 1.15. In an
international collaboration with the PHARE group, PERSEPHONE will carry out a pre-planned joint
analysis of results, which will allow a non-inferiority comparison of 6 and 12 months’ trastuzumab
with a margin of non-inferiority of 2%. This requires a total of at least 7000 patients to be entered
into the two trials. The PHARE trial defined the HR of non-inferiority in the statistical analysis plan
before the start of the trial, and then applied this when the analysis was carried out. This is an important
difference between the statistical analysis of PHARE and that of PERSEPHONE. In the latter we defined
non-inferiority as an absolute difference of no worse than 3% below the standard arm’s 4-year DFS
rate, and the HR limit was to be calculated at the time of analysis using the real, observed DFS of the
standard arm.
HORG
The Hellenic Oncology Research Group (HORG) study24 randomised HER2-positive patients between
6 and 12 months (see Table 1). Randomisation occurred prior to the commencement of chemotherapy,
which was dose-dense FEC given every 2 weeks for four cycles with granulocyte-colony stimulating
factor support, followed by docetaxel given every 2 weeks with granulocyte-colony stimulating factor.
A total of 481 patients were randomised between trastuzumab for 6 or 12 months, and this was
started concurrently with docetaxel chemotherapy. The non-inferiority margin was set with an absolute
8% boundary, and an estimated control arm 3-year DFS of 85%. The authors state that this produced
a HR for the non-inferiority boundary of 1.53. With a type I error of 5% and 80% power, 239 patients
were required to enrol in each arm within an accrual period of 3 years. The trial recruited 481 patients
over nearly 8 years (between June 2004 and May 2012), which was longer than intended.
SOLD
The SOLD (Synergism or Long Duration) trial25 was co-ordinated from Finland and included
international centres (see Table 1). This trial arose directly out of the FinHer trial and patients were
randomised between standard 12 months’ trastuzumab and a shorter course of 9 weeks’ trastuzumab.
All patients received single-agent docetaxel for three cycles concurrently with trastuzumab. This was
followed by three cycles of FEC chemotherapy. Patients randomised to the standard arm completed
12 months’ trastuzumab following completion of chemotherapy, whereas patients randomised to
9 weeks’ trastuzumab did not receive more after chemotherapy was completed. Patients were
randomised prior to any adjuvant treatment and all patients received the same chemotherapy; all
therefore received trastuzumab concurrent with chemotherapy and upfront. Over nearly 7 years
(January 2008 to December 2014), 2176 patients were recruited from seven countries. The SOLD
trial was originally powered as a superiority trial, as it was anticipated that the standard 12 months’
treatment would lead to a significant increase in cardiac deaths, which was not the case. The original
sample size calculation was for a trial of 3000 patients. The primary end point was changed to
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TABLE 1 Trastuzumab duration trials
Trial name/trial design PERSEPHONE/duration
of trastuzumab with
chemotherapy in
patients with early
breast cancer:
6 vs. 12 months
PHARE/protocol of Herceptin
adjuvant with reduced
exposure, a randomised
comparison of 6 months vs.
12 months in all women
receiving adjuvant Herceptin
HORG/6 vs. 12 months of
adjuvant trastuzumab in
combination with dose-dense
chemotherapy for women with
HER2-positive breast cancer: a
multicenter randomised study
by HORG
SOLD/randomised Phase III
study comparing trastuzumab
plus docetaxel (HT) followed
by 5-FU, epirubicin, and
cyclophosphamide (FEC) to the
same regimen followed by
single-agent trastuzumab as
adjuvant treatments for early
breast cancer
Short-HER/multicentric
randomised phase III trial
of two different adjuvant
chemotherapy regimens plus 3
vs. 12 months of trastuzumab
in HER2-positive breast cancer
patients
Duration of trastuzumab 6 months vs. 12 months 6 months vs. 12 months 6 months vs. 12 months 9 weeks vs. 12 months 9 weeks vs. 12 months
Trial recruitment and
location
October 2007 to
July 2015, UK
May 2006 to July 2010, France June 2004 to May 2012, Greece January 2008 to December
2014, international
December 2007 to November
2012, Italy
Actual (n)/target (N) 4088/4000 3384/3400 (revised from 7000) 481/480 2174/2168 (revised from 3000) 1253/2500
ER positive (%) 69 58 66 56 68
Node negative (%) 58 55 20 60 54
Tumour size ≤ 2 cm (%) 47 53 – 56 41
Adjuvant
chemotherapy timing
85 100 100 100 100
Chemotherapy type
Anthracyclines (%) 41 16
Taxanes without
anthracyclines (%)
10 10
Anthracyclines and
taxanes (%)
49 74 100 100 100
Trastuzumab timing
Sequential 54 43 0 0 0
Concurrent 46 57 100 100 100
5-FU, 5-fluorouracil; SOLD, Synergism or Long Duration.
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non-inferiority of DFS in the experimental arm, and a non-inferiority boundary of 4% on the true
(observed) 5-year DFS rate of 88.7%. This resulted in a HR limit of 1.385, and the final sample size was
2168 patients (1084 patients in each group). The primary analysis was planned to be an event-driven
analysis after 366 DFS events or when the last patient entered had been followed up for 2.0 years
after randomisation, whichever occurred first.
Short-HER
Short-HER26 was an Italian government-sponsored trial with a similar design to the SOLD trial
(see Table 1). The standard arm consisted of four cycles of anthracycline chemotherapy [doxorubicin
and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC)] followed by four cycles of
docetaxel with trastuzumab given 3-weekly, followed by completion of a full 12 months’ trastuzumab.
The experimental arm was similar to the SOLD trial, with concurrent docetaxel and weekly trastuzumab
for three cycles followed by anthracycline chemotherapy for three cycles (FEC) and then no further
trastuzumab. This study was designed to assess if a shorter trastuzumab administration is non-inferior to
the standard of 12 months with respect to DFS. Non-inferiority was defined before the trial started as an
absolute difference of no worse than 3%, and the non-inferiority HR limit of < 1.29 was set. The sample
size was estimated by setting an alpha of 5% and a power of 0.80, which resulted in a requirement for
372 events and 2332 patients. However, accrual of patients was slower than expected and, to comply
with timelines set by the government funding body, the trial had to complete recruitment after 1256
patients had been enrolled. The data analysis was carried out after 198 events but, because of lower
recruitment than planned, the study was underpowered for its DFS end point (statistical power 56%).
As well as the standard frequentist approach, a Bayesian analysis was planned.
Pragmatic design mapping on to standard practice
The PERSEPHONE trial was a pragmatic trial set up in the NHS in 2007 and mapped on to standard
practice in the NHS. Therefore, once study sites had been initiated, and had been set up with all the
approvals necessary to be part of the trial, all patients who it was planned would receive chemotherapy
and trastuzumab could be approached to take part. The advantage of this pragmatic approach is that
it is a reasonable assumption that, following completion of the trial, the results would be implementable
without concerns that the population of standard patients was in any way different from the population
tested in the trial. In licensing trials the entry criteria are necessarily restricted and very tightly controlled
to ensure a high level of medical fitness in the patients entered.We were clear that in the PERSEPHONE
trial we aimed to investigate how 6 months’ trastuzumab compared with 12 months’ treatment in the
patients whom recruiting clinicians on site would be treating as standard in their clinics.
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Chapter 2 Methods: recruitment and
study conduct
Trial design
PERSEPHONE was a UK prospective, randomised, non-inferiority, multicentre, open-label Phase III
clinical trial to examine if the administration of 6 months of trastuzumab is non-inferior to 12 months
in patients with histologically confirmed HER2-positive early invasive breast cancer receiving a
standard chemotherapy regimen in the adjuvant or neoadjuvant setting.
The key aim of PERSEPHONE was to establish whether or not a shorter duration of trastuzumab
(6 months/nine cycles) is non-inferior in terms of efficacy to standard of care (12 months/18 cycles).
Eligible patients were randomised equally (1 : 1) to receive 12 or 6 months of trastuzumab as well as
chemotherapy. After completing treatment, patients were followed up for 10 years.
The current standard of care for early breast cancer patients with HER2-positive disease is to give
chemotherapy and 12 months of trastuzumab, which is given as 17 or 18 cycles depending on local
protocols. At the start of the trial, trastuzumab was given mostly sequentially after chemotherapy
(in the majority of cases, this was anthracycline based without taxanes), but practice gradually changed
during the trial and trastuzumab was increasingly given concurrently with chemotherapy. PERSEPHONE
had a safety stage built in to confirm that concurrent administration of chemotherapy and trastuzumab
was safe during the trial. Data ‘in real time’ on serious adverse events (SAEs) and treatment delays
for the first 100 patients of this cohort were collected and analysed before being discussed by the
independent Data and Safety Monitoring Committee (DSMC) (see outcome of the safety phase in
Chapter 3, First 100 patients receiving concomitant trastuzumab and chemotherapy).
Research objectives/end points
To compare 6 months (nine cycles) of trastuzumab with 12 months (18 cycles) in terms of non-inferiority
and safety in a prospective, randomised, non-inferiority, multicentre, open-label Phase III clinical trial,
mapping on to standard practice in the UK.
Primary end point
l To assess DFS non-inferiority of 6 months’ (nine cycles) compared with 12 months’ (18 cycles)
trastuzumab in patients with HER2-positive early breast cancer.
Secondary end points
l To assess OS non-inferiority of 6 months’ (nine cycles) compared with 12 months’ (18 cycles)
trastuzumab in patients with HER2-positive early breast cancer.
l To assess the expected incremental cost-effectiveness [cost per quality-adjusted life-year (QALY)] of
6 months (nine cycles) of trastuzumab compared with 12 months (18 cycles) of trastuzumab.
l Cardiac function as assessed by LVEF during trastuzumab therapy, and analysis of predictive factors
of development of cardiac damage.
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Secondary objectives: substudies
l Trans-PERSEPHONE: tumour blocks (paraffin-embedded) will be collected prospectively from
patients in the study for molecular and candidate gene analysis as prognostic and predictive
markers (separate protocol).
l Trans-PERSEPHONE-SNPs: blood samples will be collected prospectively from patients in the study
for single nucleotide polymorphism analysis to research genetic/pharmacogenetic determinants of
inherited susceptibility to HER2-positive breast cancer, prognosis and trastuzumab response and
toxicity (separate protocol).
Research hypotheses
1. Six months’ trastuzumab in early HER2-positive breast cancer is non-inferior to 12 months’
trastuzumab, which is the standard treatment.
2. The incremental cost-effectiveness of 6 months’ trastuzumab is significant when compared with
12 months’ trastuzumab.
3. Six months’ trastuzumab is significantly less toxic than 12 months’ trastuzumab in terms of clinical
cardiac dysfunction, LVEF decrease, and rates of stopping treatment early for reasons of
cardiac toxicity.
Study conduct
Sponsorship
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge are joint
sponsors of PERSEPHONE.
Ethics, regulatory and research and development approvals
The trial was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) on
10 May 2007 and received a favourable opinion from the North West – Haydock Research Ethics
Committee (REC) (previously named North West REC and then North West 5 REC – Haydock Park)
on 9 August 2007. Local research and development department approval was obtained at each
participating NHS trust before patients were randomised. The trial was conducted in accordance
with the principles and guidelines of the International Council for Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use,27 Good Clinical Practice (GCP),28
UK legislation,29,30 Cambridge and Warwick Clinical Trials Units Standard Operating Procedures and
the REC and MHRA approved protocol. The current trial protocol is available online at the Warwick
Clinical Trials Unit website.31
Management of the trial
The Trial Management Group (TMG) was a multidisciplinary team of clinicians, statisticians, translational
scientists and patient advocates who had considerable expertise in all aspects of trial design, conduct,
safety, quality assurance and analysis. This group was in charge of running the trial. The TMG met
regularly by teleconference to discuss site set-up, recruitment targets, safety and all matters pertaining
to efficient conduct of the trial. After recruitment was completed, the focus of the TMG was data
collection and case report form (CRF) completion.
The overall supervision of the trial was provided by an independent Trial Steering Committee (TSC)
appointed by the National Institute for Health Research (NIHR) Evaluation, Trials and Studies
Coordinating Centre, Health Technology Assessment (HTA) programme (the funder of the PERSEPHONE
trial). The independent TSC consisted of an independent chairperson (an oncologist) and two other
independent members (a breast surgeon and a statistician) and members of the TMG. The NIHR HTA
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programme and the independent TSC monitored the trial conduct and progress through regular reports,
face-to-face meetings and teleconferences about the trial.
The independent monitoring of the trial was undertaken by the independent DSMC, which was
established to advise the independent TSC if there was evidence that or a reason why the trial
should be amended or terminated based on recruitment rates or safety and efficacy. Reports
containing recruitment, protocol compliance, safety data and interim analyses of outcomes (which
were confidential and not shared with the investigators) were presented regularly for review along
with results from other relevant trials. At each review, the independent DSMC considered whether
or not the trial should be stopped prematurely for ethical or safety reasons, including unexpected
frequency or severity of toxicity, early indication of an inferior outcome in the experimental arm,
unsatisfactory futility analyses or the publication of new data.
At the design stage of the PERSEPHONE trial, it was agreed with the PHARE TMG that one member
of the independent DSMC would serve on both trials’ independent DSMCs, with their roles and
responsibilities clearly defined for each committee. Details of the membership of the independent TSC,
TMG and independent DSMC can be found in the Acknowledgements.
Trial site set-up
A total of 158 hospitals from NHS trusts and health boards in England, Scotland and Wales participated
in PERSEPHONE and 152 sites recruited patients (96%); three were screening sites only and three were
opened for the purposes of patient follow-up only. A list of all participating sites can be found in the
Acknowledgements. Before a site was activated to recruitment, a trial initiation meeting was held, in
person or via teleconference, to provide study-specific training to all staff members working on the trial.
Continued support was offered to both existing and new staff at participating sites to ensure that they
remained fully aware of the trial procedures and requirements.
Monitoring
Several levels of monitoring were applied through the trial.
Remote monitoring of sites was carried out on several occasions and especially after amendments to
ensure that the investigator site file (containing the instructional materials and documentation required
for the conduct of the trial) was well maintained.
Central monitoring of all data was carried out throughout the trial. Data were routinely cleaned, and
queries were sent to sites if needed after (1) automatic validation checks during data entry, (2) manual
checks (discrepancies between forms) or (3) annual data freeze to generate interim data-cleaning reports.
To ensure that sites were competent, triggered on-site monitoring was carried out occasionally if
serious breaches and/or safety issues were reported.
Since 2010, the sponsor’s regulatory team has been monitoring Addenbrooke’s Hospital on an ongoing
6-monthly basis. Addenbrooke’s has been the highest recruiter throughout the trial. Monitoring
involves source data verification for consent, eligibility criteria, LVEF and SAEs. It also includes
reviewing the investigator site and pharmacy files. Concurrently, the trial master file held by the
Cambridge co-ordinators is reviewed, with a particular focus given to any SAEs and non-compliances
reported by all participating sites.
The Warwick trial management file of the PERSEPHONE trial was audited by the MHRA in 2012 and
the Cambridge trial management file was reviewed by an independent auditor on behalf of the sponsor
in 2015. No critical findings were identified following these reviews.
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Patient information and informed consent
Patients potentially eligible to participate in the trial according to the criteria (see Participants) were
identified either during a multidisciplinary breast cancer meeting held at each of the sites or, more
occasionally, from clinic lists if chemotherapy had already started.
Patients were invited to participate in PERSEPHONE during consultations in oncology clinics, where
systemic treatment options were discussed. Here the local principal investigator or co-investigator, or
another sufficiently trained individual at the discretion of the principal investigator, discussed the trial
with the patient and provided her with a copy of the patient information sheet (see Report Supplementary
Material 1). Patients were given sufficient time (at least 24 hours) to discuss participation in the trial with
their family, friends and general practitioner (GP) and had the opportunity to ask questions. Patients who
were willing to participate were asked to provide written informed consent (see Report Supplementary
Material 1) to the principal investigator, co-investigator or other sufficiently trained individual.
Since 2010, consent for sample collections has been included in the main patient information sheet/
consent document and made mandatory. This covers a blood sample and the use of the patient’s
tissue archival samples removed at the time of surgery (and at diagnosis for neoadjuvant patients).
The information and consent related to the collection of quality-of-life data are in a separate
optional document.
HER2 testing
HER2 testing was carried out and reported in accordance with the UK Royal College of Pathologists’
HER2 testing guidelines. At the start of the trial, these were the 2004 guidelines,32 which were updated
in 200833 and 2014.34 All laboratories testing for HER2 on samples from NHS patients are required
to carry out testing in accordance with this guidance and to be part of the National External Quality
Assurance Scheme for both immunohistochemistry (IHC) and in situ hybridisation (ISH). In the lifetime
of the trial for recruitment (October 2007 to July 2015), three different guidelines were followed,
depending on when a patient entered into the trial.
The 2004 guidelines32 for semiquantitative IHC stated that breast cancer samples should be considered
to be HER2 positive if, on formalin-fixed, paraffin-embedded sections, strong, positive, complete membrane
staining is apparent in > 10% of cancer cells. IHC was to be considered negative if there was no membrane
staining (IHC score of 0), if < 10% tumour cells had membrane staining (IHC score of 0) or if > 10% tumour
cells had membrane staining that was faint/barely perceptible and incomplete (IHC score of 1+). IHC
was to be considered borderline (IHC score of 2+) when membrane staining was weak to moderate and
present in > 10% of tumour cells. According to the guidelines, an IHC score of 2+ should be followed
by fluorescence in situ hybridisation (FISH) and conventionally expressed as the ratio of HER2 signal to
chromosome 17 signal (HER2 ratio). Tumours showing a ratio of ≥ 2 were considered positive and those
with a ratio of < 2 were considered negative regardless of HER2 copy number.
The guidelines were updated in 2008.33 Minimum workload recommendations were introduced and
laboratories were required to perform at least 250 assays per year for IHC and 100 assays per year
for ISH. IHC scores of 0 and 1+ were the same as in the 2004 guidelines. The cut-off point for IHC 3+,
indicating a positive result, was increased to > 30% of cells with strong, complete membrane staining.
The IHC 2+ category was expanded to include cases with 10–30% strong complete staining in addition
to the previous definition of > 10% moderate staining. Categories for ISH and gene amplification
were refined. A HER2 ratio of < 1.80 was considered HER2 non-amplified (negative). A HER2 ratio
of 1.80–2.20 or HER2 gene copy number 4.0–6.0 signals/cell was considered borderline and the test
was carried out again. If the HER2 ratio was 1.80–1.99, the tumour was considered non-amplified and
therefore HER2 negative, and if the HER2 ratio was 2.00–2.20, the tumour was considered amplified
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and therefore HER2 positive; this was a subtle difference from the American Society of Clinical
Oncology and College of American Pathologists guidelines, which did not further clarify the FISH
borderline group. If the HER2 ratio was > 2.20 or the HER2 gene copy number was > 6.0 signals/cell,
then the tumour was considered amplified and positive.
Further updates of the guidelines in 201434 redefined an IHC score of 3+ as > 10% strong, complete
membrane staining, the same as in the 2004 guidelines. ISH was considered negative with a HER2/CEP17
ratio using a dual probe of < 2.0 and an average HER2 gene copy number of < 4.0 signals/cell. In tumours
that were IHC 2+ (borderline), ISH testing was required. In these cases ISH was considered borderline/
non-amplified when a dual probe HER2/CEP17 ratio was < 2.0 with either an average HER2 gene copy
number of 4.0–6.0 signals/cell or a ratio of 1.80–1.99. In these cases the test was repeated and if the
same result was obtained the tumour was regarded as HER2 negative, whereas a dual-probe HER2/
CEP17 ratio of ≥ 2.0 or an average gene copy number of ≥ 6.0 signals/cell was considered to indicate
HER2-positive cancer.
These changes over the course of the study would have affected only a small percentage of cases. In a
review of the pooled data from the BCIRG breast cancer clinical trials, 0.5% of cases had a ratio of
< 2.0 and a HER2 gene copy number of ≥ 6.0 (changed from negative to positive in 2008).35
Screening and randomisation procedures
Sites were asked to screen patients with early breast cancer for their eligibility for the PERSEPHONE
trial. We requested that screening logs be completed for all patients who were considered for the
PERSEPHONE trial. We asked sites to record on the screening logs the date of screening, the patient’s
date of birth, if the patient gave consent, if the patient was randomised and, in the event of patients
not being consented or randomised, the reasons. These screening logs were requested from sites every
6 months for 6 years, and then annually for the last 2 years of recruitment.
The trial was an open-label, unblinded trial. Following the assessment of their eligibility during screening
and collection of their written informed consent to be entered into the trial, patients were randomised
(1 : 1) to either 12 months of trastuzumab (the standard treatment, comprising 18 cycles) or 6 months
of trastuzumab (the experimental arm of the trial, comprising nine cycles). Randomisation was carried
out by staff at each site telephoning the Warwick Clinical Trials Unit, where a central computerised
minimisation procedure used the following stratification variables: ER status (positive or negative);
chemotherapy type (anthracyclines without taxanes, anthracyclines with taxanes, taxanes without
anthracyclines or neither anthracyclines nor taxanes); chemotherapy timing (adjuvant or neoadjuvant);
and trastuzumab timing (concurrent or sequential).
Trial treatment and settings and locations
The trial treatment is trastuzumab and it is considered an Investigational Medicinal Product for the
purpose of the PERSEPHONE trial, which is conducted with a Clinical Trial Authorisation in the UK.
Route
Trastuzumab was given intravenously to all patients until 2013, when the subcutaneous formulation
became available in NHS hospitals.
Following the approval of amendment 11 by the MHRA at the end of 2013, the PERSEPHONE trial
allowed participating sites to use the subcutaneous formulation. Switching between intravenous and
subcutaneous administration was at the discretion of the treating clinician.
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Setting
Trastuzumab was prescribed neoadjuvantly (pre surgery) or adjuvantly (post surgery).
Trastuzumab was prescribed with chemotherapy (concurrently) or post chemotherapy (sequentially).
The PERSEPHONE trial recruited patients in both settings.
Dose
Patients were randomised to:
l research arm – to receive nine cycles of trastuzumab (6-month arm)
l standard arm – to receive 18 cycles of trastuzumab (12-month arm).
Each cycle had a 3 week duration with a loading dose given on day 1. Treatment was expected to be
administered as per standard practice.
Intravenous route
The starting/loading dose of trastuzumab was 8 mg/kg.
The maintenance dose (6 mg/kg) was given 3 weeks after the starting/loading dose, and subsequent
doses were given 3-weekly at 6 mg/kg.
Subcutaneous route
There is no loading dose for subcutaneous trastuzumab administration. Subcutaneous trastuzumab was
given at a fixed dose of 600 mg in a volume of 5 ml as per the summary of product characteristics
(SmPC).
Trastuzumab doses
The trial mapped on to standard practice and guidelines for dosing followed the SmPC for trastuzumab.
In terms of cardiac guidelines, measurement of LVEF using either echocardiography (ECHO) or a
multigated acquisition (MUGA) scan was recommended. At the start of the trial this was carried out
every 3 months for 1 year in both arms, and then, after a protocol amendment, the interval between
ECHO or MUGA scans was increased to 4-monthly. The guidance in the SmPC was to hold trastuzumab
if LVEF fell by an absolute value of ≥ 10% below baseline and to < 50%. Cardiac medication could be
started by the principal investigator; measurement of LVEF was repeated after 6 weeks, and trastuzumab
could be restarted if LVEF was > 50%. The protocol stated that the maximum hold of trastuzumab for
cardiac problems should be 12 weeks. If trastuzumab was restarted, then a reloading dose of 8 mg/kg
intravenously was to be used with a delay longer than 7 days. In the second half of the study, some sites
adopted new national guidelines to use cardiac medication and continue trastuzumab if the patient was
asymptomatic and LVEF was > 40%.36
Treatment location
Most patients were treated in chemotherapy units. However, to relieve these very busy hospital-based
facilities, some participating sites started to administer trastuzumab outside chemotherapy units.
Some patients were treated at home by an external clinical provider (Healthcare at Home Ltd). A few
PERSEPHONE patients were treated in a GP surgery or a mobile unit (chemotherapy bus). As long as
this was part of the standard practice at the site, it was allowed once the trials office had given its
approval and made sure that the appropriate contracts, training and safety measures were in place.
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Other treatments
Chemotherapy: commonly used regimens
Details of the chemotherapy regimens received by all patients (as per local institutional protocols)
and whether trastuzumab was given concurrently with or sequentially to their chemotherapy were
recorded in full, along with reasons for any early cessation of chemotherapy. Chemotherapy regimens
were based on local protocols, which were informed by both licensing and NICE guidance.
Endocrine therapy
For women with ER-positive disease, systemic hormonal therapy is advised following completion of
chemotherapy and definitive surgery. Concurrent hormone therapies could be administered with
trastuzumab, although not with chemotherapy. The PERSEPHONE protocol stated that all endocrine
therapy was at the discretion of the responsible clinician in accordance with standard local therapy
protocols. However, the following guidelines were suggested: for women who remained pre-menopausal
after completing chemotherapy, hormonal therapy options included ovarian suppression and tamoxifen.
Entry into the Breast International Group EORTC trials SOFT (Suppression of Ovarian Function
With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal
Women With Hormone-Responsive Breast Cancer Trial) or TEXT (Triptorelin With Either Exemestane or
Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer) was suggested.
For postmenopausal women, tamoxifen or aromatase inhibitors could be used for a minimum of 5 years
(or tamoxifen for 2–3 years, switching to an aromatase inhibitor after 2–3 years). Adjuvant hormonal
treatment received by the patient was recorded.
Surgery
The PERSEPHONE protocol did not stipulate surgery as part of the trial. Surgery was carried out
in accordance with standard practice at each site. Primary surgery was carried out in all patients
receiving adjuvant chemotherapy and trastuzumab, mostly consisting of either wide local excision and
axillary surgery (sentinel lymph node biopsy with or without axillary nodal dissection) or mastectomy
and axillary surgery. Some patients in the trial received neoadjuvant treatment, and in these patients
definitive surgery with wide local excision or mastectomy and axillary surgery took place after
chemotherapy was completed.
Radiotherapy
The PERSEPHONE protocol stipulated that radiotherapy should be given after definitive surgery
according to local protocols. Radiotherapy could be given concurrently with trastuzumab. All
radiotherapy treatment received by the patient was recorded.
Participants
The trial sought to recruit patients with HER2-positive early breast cancer who were or would be
receiving trastuzumab. Patients were recruited from oncology departments in NHS hospitals covering
England, Scotland and Wales.
Inclusion criteria
Patients with the following characteristics were eligible to enter the trial:
l A histological diagnosis of invasive breast cancer.
l No evidence of metastatic disease.
l Known hormone receptor status.
l Overexpression of HER2 receptor. Bilateral breast cancers were eligible provided that one of the
tumours overexpressed the HER2 receptor.
DOI: 10.3310/hta24400 Health Technology Assessment 2020 Vol. 24 No. 40
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Earl et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
15
l Clear indication for neoadjuvant or adjuvant chemotherapy based on clinical and
histopathological features.
l Fit to receive neoadjuvant or adjuvant chemotherapy and trastuzumab in the opinion of the
responsible physician.
l No previous diagnosis of malignancy unless:
¢ managed by surgical treatment only, and disease free for 10 years
¢ previous basal cell carcinoma, cervical carcinoma in situ or ductal carcinoma in situ of the breast.
l Not pregnant and not lactating, with no intention of becoming pregnant during chemotherapy, and
agreed to adopt adequate contraceptive measures if pre-menopausal and sexually active.
l No concurrent medical or psychiatric problems that might prevent completion of treatment or follow-up.
l Aged ≥ 18 years.
l Gave written informed consent for the study at any time before the 10th cycle of trastuzumab.
Exclusion criteria
Patients with the following characteristics were ineligible to enter the trial:
l significant concurrent cardiac disease or significant concurrent comorbidity in the opinion of the
responsible physician adding to the risks associated with trastuzumab or cytotoxic chemotherapy
l unable to comply with protocol requirements
l received more than nine cycles of trastuzumab
l any other condition that, in the local investigator’s opinion, would make them unsuitable to
participate in the trial.
Data collection
Schedule of assessments
Table 2 shows the schedule of assessments for patients considered for entry into the PERSEPHONE
trial prior to randomisation, as well as for patients during their treatment and follow-up. Most of the
assessments for PERSEPHONE were mapped on to standard practice.
Toxicity
Based on the available data on the frequency of toxicities experienced with trastuzumab treatment, the
4000 patients recruited to PERSEPHONE were expected to adequately power the analysis of toxicity to
allow detection of any clinically relevant differences between the treatment arms, if they existed.
A change in the eligibility criteria for PERSEPHONE was implemented on 11 September 2009 (after
316 patients had been randomised) to allow patients to be randomised before receiving their 10th
cycle of trastuzumab. In the case of patients randomised into PERSEPHONE after the start of their
trastuzumab treatment, we did not collect information on the toxicities or SAEs experienced during
any treatment administered prior to randomisation. In the case of patients randomised before starting
trastuzumab, we planned to collect all toxicities and SAEs experienced during their entire treatment.
Cardiac toxicity
Patients were assessed for symptoms or signs of congestive heart failure and information on new or
altered cardiac medication was recorded during follow-up visits while on trastuzumab. Cardiac function
was assessed using LVEF, either by ECHO or by MUGA scan depending on standard practice at each
hospital. As per the recommendations from the trastuzumab SmPC, we requested scans for each patient
at baseline and every 3 months for 12 months from the treatment start date. This was revised to
standard practice (minimum of 4-monthly) in PERSEPHONE protocol version 4.0 on 31 October 2013.
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Translational research collections
In parallel with the NIHR HTA programme funding, Cancer Research UK supported a translational
collection of blood and archival tissue samples through the Trans-PERSEPHONE grant.37 The patient
information sheet detailed collection of blood samples and tumour tissue collection (from the surgical
specimen in those receiving adjuvant trastuzumab and from the diagnostic biopsy and surgical
specimen in those receiving neoadjuvant chemotherapy). After patient consent was obtained, blood
and tumour samples were requested.
Blood collection for pharmacogenetics/genetics study (Trans-PERSEPHONE-SNPs)
Trans-PERSEPHONE-SNPs aimed to collect two tubes of whole blood (2 × 9 ml) from patients, to be
collected on one occasion at any time before, during or after treatment.
TABLE 2 Schedule of assessments
Event
Prior to
randomisation
Trastuzumab treatment visit (every
3 months for a year after starting
trastuzumab treatment; patients in
the research arm MUST follow the
same follow-up schedule as those
in the standard arm)
Follow-up visits (every
6 months in year 2;
annually thereafter
for 8 years)
Informed consent for trial ✗
ER status ✗
HER2 status ✗
Full blood count ✗
Biochemical screen ✗
Chest X-ray (or chest CT if
standard practice)
If suspicion of metastases
Whole-body scintigraphy and
liver ultrasound or abdominal
CT scan
If suspicion of metastases
Medical history ✗
Physical examination, weight ✗a ✗a ✗a,b
LVEF assessment Done as per
standard practice
✗c
ECOG performance status ✗ ✗ ✗
Quality of life questionnaire ✗d ✗e ✗f
Health-care resource used
assessment questionnaire
✗d ✗e ✗f
SAEs ✗
Survival/recurrence disease
status
✗ ✗
CT, computerised tomography; ECOG, Eastern Cooperative Oncology Group.
a Includes clinical follow-up, and questioning patients regarding symptoms of progression or recurrent breast cancer.
b Once a patient had been discharged from clinical review, physical examinations did not need to be performed for
the purposes of the trial. Telephone follow-up was permitted for patients who had been discharged from clinical
review. Follow-up by e-mail was permitted subject to local information governance policies.
c To be carried out 3, 6, 9 and 12 months after start of trastuzumab. After protocol amendment October 2013, to be
carried out after 4 and 8 months.
d Patient to complete the baseline questionnaire.
e Patient to complete the 3-monthly questionnaire.
f Patient to complete the 6-monthly questionnaire at 18 months and 24 months.
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The purpose of collecting this was to build a bank of germline deoxyribonucleic acid (DNA) from breast
cancer patients with HER2-positive disease and to carry out germline genome-wide sequencing for
pharmacogenetics studies and prognostic and predictive candidate germline mutations. Analysis is planned
of (1) germline single nucleotide polymorphisms (SNPs) predisposing to cardiac and other toxicity from
trastuzumab, (2) germline SNPs predisposing to HER2-positive breast cancer, and (3) germline SNPs linked
to outcomes from adjuvant trastuzumab and any interaction with duration of therapy.
Archival tissue blocks collection (Trans-PERSEPHONE)
Trans-PERSEPHONE is a collection of archival tissue (formalin-fixed, paraffin-embedded tissue) from
PERSEPHONE patients. As per standard of care, following surgery, several formalin-fixed, paraffin-
embedded blocks per patient were made at sites for diagnosis purposes. One or two representative
block(s) were requested from the site’s pathology department. This bank of HER2-positive tissue is to
be used to investigate prognostic and predictive molecular signatures of HER2-positive breast cancer
and, in particular, to explore this with respect to treatment duration (comparing 6 and 12 months of
treatment). Analysis of tumour and normal tissue will involve (1) tissue microarrays for IHC of protein
gene products and in situ hybridisation analysis and (2) whole-genome profiling using expression and
DNA microarrays.
Safety
First 100 patients receiving concomitant trastuzumab and chemotherapy
PERSEPHONE had a safety stage built into the trial to confirm that concurrent administration of
chemotherapy and trastuzumab was safe within the trial. Data ‘in real time’ on SAEs and treatment
delays for the first 100 patients of this cohort were collected and analysed before being discussed
by the independent DSMC (see outcome of the safety phase in Chapter 3, First 100 patients receiving
concomitant trastuzumab and chemotherapy).
Serious adverse events/reactions
The definition of a SAE for the purpose of the PERSEPHONE trial was any untoward medical
occurrence that at any dose resulted in:
l death
l a life-threatening experience
l initial or prolongation of existing hospitalisation (Hospitalisation was defined as an inpatient
admission, regardless of length of stay, even if the hospitalisation was a precautionary measure, for
continued observation. Hospitalisation for a preexisting condition, including an elective procedure,
that had not worsened did not constitute a SAE)
l persistent or significant disability/incapacity
l a congenital anomaly/birth defect
l a new primary malignancy.
l Any other event that was judged by the responsible investigator to warrant particular attention and
for the purposes of the trial included symptomatic LVEF reduction.
Details of all SAEs were documented from the point of randomisation, and therefore not necessarily the
start of the trastuzumab treatment, in the trial until 30 days from the last administration of trastuzumab.
SAEs occurring after a patient’s 30-day follow-up assessment were reported only if the investigator
believed that the study drug or a protocol procedure may have caused the event.
Each principal investigator was advised to report SAEs using a specific SAE form within 24 hours of
becoming aware of the event.
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Assessments of all SAEs for expectedness and relatedness were made promptly by the chief investigator.
A SAE was deemed to be a serious adverse reaction (SAR) when it was assessed as possibly, probably or
likely to be related to trastuzumab.
Listing of SARs was submitted to the MHRA in accordance with national requirements on a yearly
basis through development safety update reports/annual safety reports.
Suspected unexpected serious adverse reactions
When the nature and severity of the SAR was not consistent with the trial reference safety information,
the event was unexpected and therefore classified as a suspected unexpected serious adverse reaction
(SUSAR).
The reference safety information for the PERSEPHONE trial was the trastuzumab SmPC.
The PERSEPHONE Cambridge office reported SUSARs to the MHRA and REC within 7–15 days as per
UK regulations.
Serious breaches
To ensure that appropriate action was taken to protect patients, maintain trial integrity and comply
with legal requirements and any applicable regulatory guidance, protocol and GCP non-compliances
were collected by the trial office before being assessed by the chief investigator and the sponsor.
Any departure from the protocol or regulatory requirements that was likely to affect to a significant
degree either the safety of a trial patient or the scientific value of the trial was classified as a serious
breach, queried, followed up and reported to the authorities (MHRA and REC) as per UK legislation.
Discontinuation of trial treatment
Patients’ trial treatment was discontinued in the following circumstances, which were reported on the
withdrawal CRF:
l The patient opted to discontinue their randomised treatment arm or chose not to comply with the
trial procedures.
l The patient was found to be ineligible (i.e. they had been randomised inadvertently without meeting
the eligibility criteria).
l The investigator decided that the patient’s trial treatment should be discontinued because of toxicity.
l The patient did not recover from treatment-related toxicity to an extent that would have allowed
further trastuzumab treatment.
l The patient had disease progression (radiologically confirmed) while on trial treatment.
l The patient became pregnant while receiving trial treatment and decided to continue her pregnancy.
l During trial treatment the patient relocated to a site that was not participating in the trial.
Follow-up data were collected for all patients who discontinued treatment. Treatment data were
collected for patients who had withdrawn but continued to receive trastuzumab up to 12 months,
unless the patient had withdrawn because of relapse.
Withdrawal of consent
Patients could withdraw their consent to participate in the trial at any time by explicitly refusing to
receive any further trial treatment, in which case no further trial treatment was given.
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Additionally, patients could withdraw their consent for further data or samples to be collected, in which
case no further data or samples were collected. However, data and samples collected up to the time
consent was withdrawn were included in the data reported for the trial.
Database and data processing
The PERSEPHONE database is held at Warwick Clinical Trial Unit on a Microsoft SQL Server 2012
(Microsoft Corporation, Redmond, WA, USA) system with imposed rules for data entry, which include a
valid range for responses, linked dates and patient identification numbers.
Data were single entered into the database by trained study personnel. The trial statistician carried
out checks for missing data and plausibility of entered values to enable further queries to be resolved
before freezing the data for scheduled analyses.
Protocol amendments
Protocol amendments as well as amendments to key documents such as the patient information sheet
and informed consent forms were reviewed by the REC and/or the competent authority before these
amendments were implemented. The amendments were also approved locally by sites’ research and
development departments.
The key amendments are listed below.
Protocol amendment February 2009
In February 2009, version 2.0 of the protocol was submitted to the authorities. The alterations were
to remove limitations of and offer more flexibility in the chemotherapy criteria and options available
to patients, such as using the company Healthcare at Home Ltd to administer trastuzumab at
patients’ domiciles.
Protocol amendment July 2009
In July 2009, a major amendment was made to the protocol to change randomisation to any point up
to and including cycle 9 of the trastuzumab (6 months). Recruitment had been lower than expected
and, after extensive consultation with the TMG, TSC, the PHARE group (French trial) and the funder,
it was agreed that this was the best option to increase recruitment. As a result of this, changes to the
health economic data collection were also made, streamlining it to the patient questionnaires. Detailed
health resource use data were collected for the first 300–500 patients only, rather than for all 4000
patients. Mapping the trial on to standard practice also significantly reduced data collection for sites.
Protocol amendment July 2010
A new patient information sheet was designed and submitted to the authorities in July 2010 to improve
patient acceptability. Not only was accrual less than expected, but < 60% of the patients consented for
the translational substudies, which was lower than in other studies we have conducted. Both the TSC
and the patient groups who were contacted for advice strongly believed that (1) the original patient
information sheet was too long and complex and (2) when patients agreed to take part in the trial, the
substudies should be incorporated into the study as a whole. The TMG, together with patient advisors,
therefore developed a more patient-friendly patient information sheet that incorporated the two
translational substudies.
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Protocol amendment October 2013
The protocol was amended again in October 2013, mainly to reflect the changes to the environment of
the trial:
l A full update on recently published data was added to the introduction of version 4.0 of the protocol.
l The long-term follow-up data of the HERA trial12 confirmed the significant benefit for 12 months’
trastuzumab compared with no trastuzumab control at median follow-up of 96 months (8 years)
but also demonstrated that 24 months’ trastuzumab brought no additional benefit to 12 months’.
Interestingly, had the trial been analysed and reported after only 36 months, a benefit of 24 months’
trastuzumab would have been found. However, with longer follow-up, both the 12- and the 24-month
DFS and OS curves are identical.
l Despite a relatively short follow-up, the preliminary results of PHARE were published and
showed that the trial had not proven non-inferiority after a median follow-up of 42 months.
The PHARE results23 did show that, in a prospectively stratified analysis of subgroups, only patients
with ER-negative disease receiving sequential chemotherapy and trastuzumab appeared to be
significantly disadvantaged by receiving 6 months of trastuzumab. An examination of the mature
DFS and OS curves from the HERA trial shows a clear separation of the 24-month and
12-month curves after 36 months, which resolves with more prolonged follow-up. This time point
was the same as that at which PHARE had been analysed.
In addition, following scrutiny of the published PHARE data, the PERSEPHONE Independent Data
Monitoring and Safety Committee confidentially examined the data in the PERSEPHONE trial. As a
result of this, the committee advised the TMG and Trial Steering Group that there were no adverse
signals in the PERSEPHONE trial data and that the trial be continued.
l The equivalence of the subcutaneous formulation of trastuzumab and the intravenous formulation
was reported38 and therefore version 4.0 of the protocol stated that the use of the subcutaneous
formulation was allowed.
l This low-risk trial was made flexible, with the aim of making it as pragmatic as possible (i.e. following
standard practice to facilitate recruitment). In particular, cardiac function, which was initially assessed
every 3 months for 12 months, was subsequently evaluated at intervals up to 4-monthly in accordance
with a change in standard practice guidelines.36
Protocol amendment December 2018
Protocol version 5.0 included changes to account for the European Union General Data Protection
Regulation, revised trial timelines and permission to follow up patients using sites’ standard practice,
which could include telephone and e-mail follow-up.
Statistics
Statistical analyses were performed using SAS® version 9.4 software. SAS and all other SAS Institute
Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA
and other countries. ® indicates USA registration.
Non-inferiority design
The non-inferiority design of clinical trials was introduced to evaluate new treatment approaches,
drugs, devices, biologics and other medical treatments to demonstrate whether or not a new treatment
is a ‘good substitute’ (i.e. has similar efficacy to that of an established treatment).39 Increasing in use
by a factor of 6 over a 10-year period, this design is especially useful when evaluating whether a new
treatment offers greater safety, reduced toxicity and reduced cost, together with confirmation that
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efficacy is not effectively compromised. It is the favoured design for trials in oncology that seek to
de-escalate treatments by reducing either the duration or the intensity and therefore reduce toxicity,
improve safety and improve patient experience. Cancer trials that have used this design include the
IDEA meta-analysis,40 which established that 3 months rather than 6 months of an adjuvant capecitabine/
oxaliplatin regimen for colorectal cancer is non-inferior and significantly less toxic. The non-inferiority
of outcomes for head and neck cancer was demonstrated for positron emission tomographic scanning
surveillance followed by radical dissection if demonstrated positron emission tomographic scanning
positive or equivocal results, rather than routine radical neck dissection.41 The TAILORx study used a
non-inferiority design to compare adjuvant chemotherapy and endocrine therapy with endocrine therapy
alone in women with ER-positive, HER2-negative, node-negative breast cancer and a moderate recurrence
risk (score of 11–25) on a genomic test (OncotypeDx; Genomic Health, Inc., Redwood City, CA, USA).
The trial demonstrated that endocrine therapy alone was non-inferior to adjuvant chemotherapy with
endocrine therapy.42 All of the trials examining reduced durations of trastuzumab in HER2-positive breast
cancer have used non-inferiority designs.23–26
Sample size and non-inferiority limit/margin
The PERSEPHONE trial was designed to allow the non-inferiority of the experimental arm (6 months’
trastuzumab) compared with the control arm (12 months’ trastuzumab) to be demonstrated in terms of
the primary end point of DFS. The power calculations assumed that the DFS of the standard treatment
of 12 months’ trastuzumab would be 80% at 4 years as this was the result available from the HERA
trial.10 The margin for non-inferiority was set as a 3% level, implying that the 4-year DFS of the
experimental arm should not be below 77%, a difference equivalent to a HR of 1.17. On this basis,
with 5% one-sided significance and 85% power, a trial randomising 4000 patients in total (2000 to
each arm) would be able to prove the non-inferiority of the experimental arm.
The trial was expected to recruit for 4 years, with an additional follow-up period of 5 years, and allowed
for loss to follow-up of up to 4%. The sample size was calculated by simulation assuming unadjusted
analysis with a Cox’s proportional hazards model. The sample size also allowed for the 4-year DFS rate
of the control arm to vary between 77% and 83%. The independent DSMC monitored the assumptions
underlying the sample size calculation throughout the study.
Statistical methods
All randomised patients were included in all analyses where possible. Patients were analysed according
to the treatment group to which they had been randomised on an intention-to-treat basis. Analyses
were guided by the PERSEPHONE statistical analysis plan, which was prepared before data were
available, and subsequently agreed by the PERSEPHONE independent DSMC.
Patient and tumour characteristics were presented to evaluate the comparability of the treatment arms
and also the generalisability of the results to clinical settings. Categorical variables were presented
using counts and percentages, and continuous variables were presented using either mean [standard
deviation (SD)] or median [interquartile range (IQR)] depending on normality, and all were tabulated
by treatment arm. A Consolidated Standards of Reporting Trials (CONSORT) flow diagram43 was also
presented (see Chapter 3).
Primary end point: disease-free survival
The primary end point of DFS was measured for every patient from the date of diagnosis to date of
first relapse (local or distant) or death. Patients who were disease free and either on follow-up or
lost to follow-up were censored at the latest date at which they were known to be alive and disease
free. Survival curves were plotted using the Kaplan–Meier method. Non-inferiority was defined as no
worse than 3% below the control arm’s 4-year DFS rate. To test the non-inferiority of the experimental
arm (i.e. 6 months’ trastuzumab), the HR was estimated using a Cox’s proportional hazards model
containing only the trial treatment effect. If the 95th percentile of the estimated HR was less than
the critical value, then the experimental arm (6 months’ trastuzumab) was regarded as non-inferior.
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Critical values were calculated for different scenarios with regard to the observed 4-year DFS on the
control arm, as follows:
l With a 4-year DFS on the control arm of 80%, the critical value to be used was 1.1712853.
l With a 4-year DFS on the control arm of 85%, the critical value to be used was 1.2210943.
l With a 4-year DFS on the control arm of 88%, the critical value to be used was 1.2713341.
l With a 4-year DFS on the control arm of 90%, the critical value to be used was 1.3217671.
Proportionality of hazards was checked using an assessment of log–log plots.
A secondary analysis adjusting for stratification and baseline prognostic factors was planned. The
treatment effect on DFS was also presented for stratification variables (ER status, chemotherapy type,
chemotherapy timing and trastuzumab timing) using HR plots with interaction statistics using methods
described by the Early Breast Cancer Trialists’ Collaborative Group in 1990.44
Timing of primary analysis of primary end point
In 2015, the TMG and independent DSMC assessed the latest 4-year DFS rate for trial patients
randomised to the control arm. This was found to be approximately 88%. The primary analysis of the
primary end point for the 4000 patients was therefore planned to be undertaken when 500 DFS
events had been observed, using a conditional power calculation.45
Pre-planned early stopping guidelines
Initially, the PERSEPHONE protocol stated that, to control the overall alpha level, interim analyses
of non-inferiority of the experimental arm with regard to the primary outcome would be reported to
the independent DSMC using conservative tests, with significance determined by a p-value of 0.001.
In 2015, the TMG and independent DSMC concluded that there was an additional requirement for
prospective formal futility stopping rules.
The timings of the interim analyses for futility were configured on the 500 DFS events required for the
primary analysis of DFS; these are shown in Table 3, including a recommended harm analysis46 at 25%
of the total number of events.
Using a p-value of 0.01 (one sided), the HRs in the final column show the limits above which, with the
corresponding number of events observed, the trial would have been stopped on the grounds of futility
(i.e. concluding that non-inferiority could not reasonably be expected to be achieved).
The three interim analysis times specified above were reached in October 2012, June 2014 and March
2016. The independent DSMC considered the report presented to them and concluded that the data
were immature and that there were no signals in the data that caused concern or would warrant a
change in the study plan. The results found at these three time points did not cross the boundaries
specified in Table 3.
TABLE 3 Timing of interim analyses for futility
Percentage of total number of
events required (% of 500) Number of events required HR limit
25 125 1.52
50 250 1.34
75 375 1.27
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The first of these time points (i.e. October 2012) coincided with the presentation of the PHARE47 and
HERA 2-year data.48
As the PERSEPHONE independent DSMC was confidentially examining the data in the PERSEPHONE
trial, it advised the PERSEPHONE Trial Management Group and Trial Steering Committee that there
were no adverse signals in these data, and recommended that the trial continue. On the strength of its
advice, the NIHR HTA programme agreed a funding grant extension to complete recruitment of 4000
patients and to allow appropriate follow-up.
Landmark analysis of disease-free survival
To remove the effect of timing of randomisation (as patients could be randomised any time during
their first 6 months of trastuzumab treatment), an exploratory landmark analysis was planned. Patients
were included in the landmark analysis population if they were alive and disease free at least 6 months
after the start of their trastuzumab treatment. The cohorts for comparison in the landmark analysis
were checked for balance in terms of demographics and baseline disease characteristics. DFS was
then recalculated from the landmark time point (6 months after the start of each patient’s trastuzumab
treatment) and the number and time of DFS events across the two randomised arms since the landmark
time point were assessed. Kaplan–Meier curves were plotted from 6 months after start of trastuzumab
and, to test non-inferiority of the experimental arm (6 months’ trastuzumab), the HR was estimated
using a Cox’s proportional hazards model containing only the trial treatment effect.
Overall survival
Overall survival (all-cause mortality) and a sensitivity analysis of cause-specific mortality were assessed
using Kaplan–Meier curves and a Cox’s proportional hazards model containing only the trial treatment
effect. OS across treatment arms was also assessed by stratification variables (ER status, chemotherapy
type, chemotherapy timing and trastuzumab timing) using HR plots with interaction statistics. A landmark
analysis of OS was also undertaken.
Trastuzumab treatment delivery
The total number of trastuzumab cycles administered per patient is shown graphically, separated
by treatment arm. Counts and proportions for the reasons for early discontinuation of trastuzumab
treatment as per protocol were documented. The total duration of trastuzumab treatment was calculated
from the date of first infusion until 21 days after the date of the last cycle. Counts and proportions of
the number of cycle delays/holds are presented, split by treatment arm, along with the stated reasons for
them. Following an amendment to the protocol (see Protocol amendment October 2013), trastuzumab was
allowed in the trial in its subcutaneous formulation at a fixed dose of 600 mg for each cycle without a
loading dose. Method of administration for each trastuzumab cycle was recorded and is presented in
tabular form (see Chapter 3).
Adherence to the PERSEPHONE protocol with respect to trastuzumab treatment was also assessed
using a subgroup analysis including only cycles of trastuzumab administered to patients after they were
randomised into the trial. Therefore, this analysis excluded any variation in trastuzumab treatment
given before randomisation that adhered to local practice but was not in accordance with the
PERSEPHONE protocol.
Toxicities
Initially, an analysis of all of the toxicity data received from all randomised patients was undertaken.
For each toxicity in turn, each patient’s worst reported Common Terminology Criteria for Adverse
Events (CTCAE) grade was identified and the frequencies were tabulated.
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Following this, an analysis was undertaken on the population who were randomised upfront before 
any trastuzumab treatment to compare the randomisation arms in terms of the frequency and severity 
of toxicity through their first 6 months of treatment and, for patients randomised to 12 months’ 
trastuzumab, through their second 6 months of treatment. The frequency with which patients 
experienced each CTCAE grade was tabulated.
Serious adverse events
Frequencies of SAEs, SARs and SUSARs are presented by treatment arm. Frequencies of reasons for 
reporting, severity, causality and outcome are tabulated by treatment arm; a full breakdown of reported 
primary event categories of the SAEs and SARs is also given.
Patient and public involvement throughout the trial
PERSEPHONE is one of the first of a series of trials in the National Cancer Research Institute cancer 
portfolio assessing ‘something’ versus ‘something less’ in a non-inferiority context. Essentially, the 
concept of ‘less than standard’ treatment is worrying for some patients, as they feel that the decision 
to have less treatment may result in their cancer coming back. Treatment given in a clinical trial setting 
comes with a ‘comfort blanket’ that it is given per protocol and that the trial team is there to support 
the patient throughout treatment and beyond. PERSEPHONE benefited from the inclusion of a patient, 
Maggie Wilcox, who reviewed the trial materials and processes in the early stages as a member of the 
wider Trial Management Group. Maggie ensured that PERSEPHONE was presented at several early 
consumer group meetings to elicit opinion about barriers to recruitment and to brainstorm strategies 
to aid recruitment. In addition, the concept of non-inferiority trials was explained and the acceptable 
non-inferiority margin of 3% was endorsed, with a view to reducing this to 2% in the pre-planned 
meta-analysis of this trial with other reduced duration trials. Other patient and public involvement 
activities were supporting the patient booklets, collecting patient-reported experiences and raising 
awareness of PERSEPHONE at every opportunity. At the end of the study, Maggie was part of the 
team that reviewed the patient-reported experience data. The active patient and public involvement 
has benefited the dissemination and report-writing stages by including the patient voice and resulting 
in the change to guidelines so that patients do not continue to receive more treatment than they need.
Patient review of trial information and trial conduct
At the start of PERSEPHONE, Maggie, who was the consumer representative in the National Cancer 
Research Institute Breast Cancer Clinical Studies Group, was co-opted to help with reviewing the 
patient materials and facilitating the patient focus groups during which the study was explained. 
These focus groups were instrumental in our revising the patient materials and streamlining the 
number of consent forms that the ethics committee had mandated (five forms reduced to two) owing 
to the translational substudies and quality-of-life data collected. Initially, patients were being lost to 
recruitment as the consent process was too long and the research team did not have time to approach 
patients. Maggie informally asked various consultants why they were not recruiting patients to this 
trial, and feedback highlighted the time needed for consent and the burden on the research team and 
patients when using the five consent forms. Maggie sent a letter to the ethics committee requesting 
that the consent forms be reduced from five to two and once this was agreed by the committee it 
greatly increased the numbers of patients approached and recruited.
Throughout the trial, the study team engaged with the charity Independent Cancer Patients’ Voice; 
Maggie is president of this charity, and it has reviewed patient materials including the patient leaflet 
and clinic posters. Independent Cancer Patients’ Voice was formed in 2009 by a group of cancer 
patients with a keen interest in research; it is a patient-led organisation that aims to bring the views 
and experiences of cancer patients and their families and carers into the cancer research community. 
Independent Cancer Patients’ Voice believes that clinical research is enhanced when patients are in 
partnership with health-care professionals, instead of passively receiving health care.49
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As a result of Maggie’s involvement with PERSEPHONE, Independent Cancer Patients’ Voice was
invited to work with researchers at the University of Warwick and University of Cambridge; this has
been invaluable at all stages of the trial.
Other local groups such as the consumer group at Guilford and the Camazons at Cambridge have
contributed to focus groups on the barriers to recruitment. The patients endorsed the trial and the
continued importance of the question being addressed.
Patient participation in dissemination
The PERSEPHONE results were first presented at the American Society of Clinical Oncology in 2018,
which was followed by a Lancet publication that was e-mailed to all of the recruiting centres. Patients
were asked as part of the consent process if they wanted to receive a copy of the results once these
were available. A patient-friendly summary of the key findings was sent alongside the main paper.
Maggie reviewed the one-page summary and simplified the content for easier understanding. Including
patients in the dissemination of patient-approved materials is essential for wider dissemination. Finally,
Maggie volunteered to be interviewed by the press and provided a quotation for the PERSEPHONE
press release.
The final phase of the patient involvement will be a survey of patients to see what they think about
the impact of these results and to endorse a recommended change in the guidelines.
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Chapter 3 Results
Screening and recruitment
Screening
Routine screening logs were requested from sites every 6 months for 6 years and then annually for
the last 2 years of recruitment. Screening log returns were low; however, analysing the logs that
were returned, 1848 out of the 7975 (23%) patients known to have been screened were recruited.
The most common reasons that screened patients were not recruited were that they preferred to
receive standard treatment (26%), they were ineligible (24.5%) or they declined to take part in the
trial without giving a reason (16.5%) (see Appendix 1, Table 26).
Recruitment
Between 4 October 2007 and 31 July 2015, 4089 patients were randomised from 152 sites: 2045
to 12 months’ trastuzumab and 2044 to 6 months’ trastuzumab. Cumulative recruitment over time,
compared with predicted accrual revised in October 2009, is shown in Figure 1. There was some slowing
of recruitment in the second half of 2012, and it then remained steady at a reduced level. This was when
the PHARE trial reported its early findings at the European Society for Medical Oncology,47 a result
that failed to demonstrate non-inferiority. The presented data that were subsequently published23 were
reviewed in detail by the independent DSMC alongside a confidential report of the PERSEPHONE data. The
independent DSMC noted that the results from the PHARE trial had been reported with a median follow-up
of 42.5 months and a primary end point of DFS at 2 years, and it interpreted the results as inconclusive.
Following a confidential review of our trial data, the independent DSMC reported to the TMG and TSC
that, taking into account the new data from PHARE, together with our own safety and efficacy data, there
was no reason to stop the trial early, and it encouraged continuing to full recruitment of 4000 patients.
All active sites were informed of the independent DSMC review and the advice to continue recruitment.
Consolidated Standards of Reporting Trials flow diagram
In total, 2045 patients were randomised to 12 months’ trastuzumab and 2044 patients were randomised
to 6 months’ trastuzumab (Figure 2). One patient was double randomised and followed randomisation
to 12 months, and this duplicate is the only randomised ‘patient’ excluded from the intention-to-treat
analysis. Full treatment details are available for 1942 out of 2045 (95%) 12-month patients and
for 1979 out of 2043 (97%) 6-month patients and therefore these are the patients included in the
treatment analysis. The numbers of patients in each category of treatment are shown in the CONSORT
flow diagram (see Figure 2). Notably, 82% of 12-month patients and 89% of 6-month patients received
the number of cycles to which they had been randomised. In the 6-month arm, 5% (102/1979) received
more than nine cycles of trastuzumab. Seventeen per cent (336/1942) of 12-month patients received
fewer than the randomised 18 cycles, the most common reason being cardiovascular toxicity (146/336;
43%), followed by patient request (94/336; 28%) and relapse or death (26/336; 8%). Among 6-month
patients, 6% (113/1979) received fewer than nine cycles, the most common reason being cardiovascular
toxicity (60/113; 53%), followed by patient request (26/113; 23%) and relapse or death (12/113; 11%).
Recruitment by site and across treatment arms
The full recruitment by site is shown in Appendix 1, Table 27, with randomisation to 6 or 12 months,
and the percentage of the total recruitment. This demonstrates the importance of recruiting from this
large number of cancer units (n = 128) and cancer centres (n = 24) to achieve the high recruitment
target. The majority of recruitment was from cancer units, with the research personnel supporting
the trial provided initially by the National Cancer Research Network and then by the integrated newly
developed Clinical Research Network in England; the NHS Research Networks in Scotland (funded by
the Chief Scientist’s Office); and the Health and Care Research Office in Wales.
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FIGURE 1 Recruitment over time.
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Median follow-up 6.0 years (IQR 4.5–7.6 years)
96% patients with > 2 years’ follow up
182 (9%) deaths; 270 (13%) DFS events
Allocated to 12 months’ trastuzumab
(n = 2045)
Randomised
(n = 4089)
Analysed, n = 2045
Excluded from analysis, n = 0
Enrolment
Full treatment details available (n = 1942/2045; 95%)
Received allocated intervention (n = 1601/1942; 82%)
Received more cycles (n = 5/1942; 1%)
Received fewer cycles (n = 336/1942; 17%)
Reason(s) for receiving fewer cycles
• Cardiovascular toxicity, n = 146 (43%)
• Patient request, n = 94 (28%)
• Relapse/death, n = 26 (8%)
• Other, n = 75 (22%)
• Unknown, n = 18 (5%)
Allocation
Analysis
Treatment
Follow-up
Median follow-up 6.1 years (IQR 4.5–7.7 years)
96% patients with > 2 years’ follow up
207 (10%) deaths; 296 (14%) DFS events
Allocated to 6 months’ trastuzumab
(n = 2044)
Analysed, n = 2043
Excluded from analysis, n = 1
• Double randomisation, n = 1
Full treatment details available (n = 1979/2043; 97%)
Received allocated intervention (n = 1764/1979; 89%)
Received more cycles (n = 102/1979; 5%)
Received fewer cycles (n = 113/1979; 6%)
Reason(s) for receiving fewer cycles
• Cardiovascular toxicity, n = 60 (53%)
• Patient request, n = 26 (23%)
• Relapse/death, n = 12 (11%)
• Other, n = 21 (19%)
• Unknown, n = 5 (4%)
FIGURE 2 The CONSORT flow diagram.
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Withdrawals from trial treatment
Patients were withdrawn from trial treatment for reasons specified in the protocol, and this occurred
for 346 (17%) 12-month patients and 223 (11%) 6-month patients. Among 12-month patients, the
most common reason for withdrawal was toxicity (8% of patients randomised), followed by patient
request (5%) and disease progression (2%) (Table 4). Among 6-month patients, the most common
reason was patient request (6%, with 100 patients requesting a change to standard treatment of
12 months), followed by toxicity (3%), disease progression (< 1%) and ineligibility (< 1%). Follow-up
data were collected from all withdrawn patients, except 106 patients (12-month patients, n = 65;
6-month patients, n = 41) who also withdrew their consent for further data collection.
Ineligible patients
Nineteen patients were deemed ineligible after randomisation (12-month patients, n = 7; 6-month
patients, n = 12), principally for previous cancers or ductal carcinoma in situ treated with radiotherapy
as well as surgery:
l 12-month patients –
¢ four with previous cancer/ductal carcinoma in situ treated with surgery and radiotherapy
¢ two who were HER2 negative
¢ one with primary cancer confined to the axilla.
l 6-month patients –
¢ seven with previous cancer/ductal carcinoma in situ treated with surgery and radiotherapy
¢ two with metastatic disease
¢ one who was HER2 negative
¢ one who had received > 9 cycles of trastuzumab at time of randomisation
¢ one who had been double randomised (excluded from analysis).
TABLE 4 Main reason for withdrawal from trial treatment
Main reason for withdrawal 12-month patients 6-month patients Total
Toxicity 171 (8%) 69 (3%) 240 (6%)
Disease progression 40 (2%) 11 (< 1%) 51 (1%)
Ineligibility 6 (< 1%) 11 (< 1%) 17 (< 1%)
Non-compliance 7 (< 1%) 2 (< 1%) 9 (< 1%)
Relocation 6 (< 1%) 2 (< 1%) 8 (< 1%)
Pregnancy 1 (< 1%) 1 (< 1%) 2 (< 1%)
Patient request 94 (5%) 118 (6%) 212 (5%)
Change to other treatment arm 9 100 109
Toxicity 23 4 27
Wanted to stop treatment 18 4 22
To use Healthcare at Home 14 – 14
Reason not specified 8 4 12
Wanted 17 cycles 9 – 9
Other 13 6 19
Other 21 (1%) 9 (< 1%) 30 (< 1%)
RESULTS
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Follow-up data continued to be collected for all patients unless they withdrew from the study and
requested not to be followed up. The remainder of this report comprises 4088 randomised patients:
2045 randomised to 12 months’ trastuzumab and 2043 randomised to 6 months’ trastuzumab.
Data return
Return rates of trial CRFs from sites to the Clinical Trials Unit were very high, with > 97% of all
expected baseline and treatment CRFs returned and > 90% of all expected annual follow-up forms
returned (see Appendix 1, Table 28).
Baseline characteristics
Patient and tumour characteristics, split by randomised treatment arm
Table 5 shows patient and tumour characteristics split by whether patients were randomised to
12 months’ (n = 2045 patients) or 6 months’ (n = 2043 patients) trastuzumab. Patient and tumour
characteristics were balanced across the two randomised treatment arms in terms of both minimisation
variables and other prognostic factors. Forty-one per cent of patients received anthracycline-based
chemotherapy, 10% received taxane-based chemotherapy without anthracyclines and 49% received
TABLE 5 Baseline characteristics of all patients, split by randomised treatment arm
Characteristic
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
ER statusa
Negative 632 (31) 631 (31) 1263 (31)
Positive 1413 (69) 1412 (69) 2825 (69)
Chemotherapy typea
Anthracycline based 851 (41) 845 (41) 1696 (41)
Taxane based (no anthracycline) 198 (10) 202 (10) 400 (10)
Anthracycline and taxane based 994 (49) 993 (49) 1987 (49)
No taxane and no anthracycline 2 (< 1) 3 (< 1) 5 (< 1)
Chemotherapy timinga
Adjuvant 1735 (85) 1727 (85) 3462 (85)
Neoadjuvant 310 (15) 316 (15) 626 (15)
Trastuzumab timinga
Concurrent 949 (46) 951 (47) 1900 (46)
Sequential 1096 (54) 1092 (53) 2188 (54)
Sex
Female 2041 (99) 2041 (99) 4082 (99)
Male 4 (1) 2 (1) 6 (1)
Age (years) at randomisation
Median (range) 56 (23–82) 56 (23–83) 56 (23–83)
< 35 50 (2) 45 (2) 95 (2)
35–49 552 (27) 557 (27) 1109 (27)
continued
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TABLE 5 Baseline characteristics of all patients, split by randomised treatment arm (continued )
Characteristic
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
50–59 608 (30) 656 (32) 1264 (31)
60–69 617 (30) 582 (29) 1199 (30)
≥ 70 218 (11) 203 (10) 421 (10)
Nodal status at surgery (of the 3462 adjuvant patients)
Negative 1001 (58) 1016 (59) 2017 (58)
1–3 nodes positive 478 (27) 486 (28) 964 (28)
≥ 4 nodes positive 245 (14) 210 (12) 455 (13)
Unknown 11 (1) 15 (1) 26 (1)
Tumour sizeb (of the 3462 adjuvant patients)
≤ 2 cm 823 (47) 803 (47) 1626 (47)
> 2 and ≤ 5 cm 779 (45) 786 (45) 1565 (45)
> 5 cm 87 (5) 82 (5) 169 (5)
Unknown 46 (3) 56 (3) 102 (3)
Tumour gradeb
I (well differentiated) 28 (1) 34 (2) 62 (2)
II (moderately differentiated) 631 (31) 645 (32) 1276 (31)
III (poorly differentiated) 1325 (65) 1297 (63) 2622 (64)
Unknown 61 (3) 67 (3) 128 (3)
Ethnicity
White 1658 (81) 1649 (81) 3307 (81)
Asian 57 (3) 52 (3) 109 (3)
Black 52 (3) 45 (2) 97 (2)
Other 17 (< 1) 21 (1) 38 (1)
Unknown 261 (13) 276 (13) 537 (13)
Menopausal status before chemotherapy
Pre 567 (28) 579 (28) 1146 (28)
Peri 110 (5) 151 (7) 261 (6)
Post 1145 (56) 1072 (53) 2217 (54)
Not assessable/not available 223 (11) 241 (12) 464 (12)
Reported prior use of cardiac medication
Yes 44 (2) 55 (3) 99 (2)
No 2001 (98) 1988 (97) 3989 (98)
IHC-score and FISH positivity (HER2 test result)
3+ 1462 (71) 1489 (73) 2951 (72)
2+ and FISH positive 551 (27) 510 (25) 1061 (26)
HER2 positive – IHC and FISH score not available 32 (2) 44 (2) 76 (2)
a Stratification variable.
b Of largest invasive tumour at diagnosis.
RESULTS
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anthracycline and taxane-based chemotherapy; therefore, 90% received anthracycline-containing
chemotherapy. Sixty-nine per cent of patients had ER-positive tumours and 31% had ER-negative
tumours. Eighty-five per cent of patients received adjuvant chemotherapy and 15% received neoadjuvant
treatment. Of those patients receiving adjuvant chemotherapy and trastuzumab, 58% were node negative
and 41% were node positive; 47% had tumours ≤ 2 cm and 50% had tumours > 2 cm. The profile of
standard prognostic factors of ER status, nodal status and tumour size for the population included in
the trial was considerably better than that for patients in the licensing trials (HERA, NSABP B-31 and
NCCTG N9831, and BCIRG-006), and similar to that for patients in other trastuzumab duration trials
(see Appendix 1, Table 29).
Patient and tumour characteristics split by adjuvant and neoadjuvant patients
Appendix 1, Table 30, shows the patient and tumour characteristics of all patients, split by whether they
received adjuvant (n= 3462 patients) or neoadjuvant (n= 626 patients) chemotherapy. As can be seen, more
neoadjuvant chemotherapy patients than adjuvant chemotherapy patients were ER negative (39% vs. 30%:
p< 0.0001), received concurrent chemotherapy and trastuzumab (79% vs. 41%: p< 0.0001), and received
anthracycline and taxane chemotherapy (89% vs. 41%). In addition, fewer neoadjuvant chemotherapy
patients than adjuvant chemotherapy patients received anthracycline-based chemotherapy (9% vs. 48%) or
taxane-based chemotherapy (2% vs. 11%: p< 0.0001 for differences in types of chemotherapy). The age
profile for neoadjuvant chemotherapy patients was younger than that for adjuvant chemotherapy patients
(p< 0.0001), and more neoadjuvant chemotherapy patients were pre-menopausal (39% vs. 26%; p< 0.0001).
Follow-up was shorter for neoadjuvant chemotherapy patients (5.4 years, IQR 4.1–7.2 years) than for
adjuvant chemotherapy patients (6.2 years, IQR 4.6–7.7 years).
Patient and tumour characteristics split by whether patients received concurrent or
sequential trastuzumab and chemotherapy
Appendix 1, Table 31, shows the patient and tumour characteristics of all patients, split by whether they
received chemotherapy and trastuzumab concurrently (n= 1900 patients) or sequentially (n= 2188
patients). As had been expected, 79% of concurrent patients received anthracycline and taxane-based
chemotherapy compared with 22% of sequential patients, 3% of concurrent patients received anthracycline-
based chemotherapy (E-CMF) compared with 75% of sequential patients, and 18% of concurrent patients
received taxane-based chemotherapy compared with 3% of sequential patients (p< 0.0001). Patients given
trastuzumab and chemotherapy concurrently compared with sequentially were more often node positive
(53% and 32%, respectively; p< 0.0001), were more likely to have larger tumours (> 2 cm: 55% vs. 47%,
respectively; p< 0.0001), were more likely to receive neoadjuvant treatment (26% vs. 6%, respectively;
p< 0.0001) and, in addition, had shorter median follow-up (concurrent 5.3 years, IQR 4.2–6.6 years, vs.
sequential 6.7 years, IQR 4.2–6.6 years).
Change in characteristics and standard practice over time throughout the trial
The characteristics of the patients being entered into PERSEPHONE and standard practice by the
clinicians over the 8-year recruitment period from 4 October 2007 to 31 July 2015 were seen to
change (Figure 3). The rate of ER-positive tumours increased from 62% of all patients randomised in
2008 to 74% of all patients randomised in 2015. The use of concurrent trastuzumab with chemotherapy
increased from 24% in 2008 to 70% in 2015. The type of chemotherapy also changed. Anthracycline-
based chemotherapy decreased from 63% in 2008 to 25% in 2015, taxane-based chemotherapy without
anthracyclines increased from 7% to 18%, and anthracycline and taxane chemotherapy increased from
30% to 57%. In 2008 only 13% of patients received neoadjuvant treatment, but by 2015 this had
increased to 20%. The PHARE trial presented early results in October 2012 and published in June
2013, including a subgroup analysis, which supported the use of concurrent chemotherapy particularly
in ER-negative patients. The trends continued in the trial for more anthracycline and taxane-based
chemotherapy to be used, for more concurrent rather than sequential treatment, and for more ER-
positive patients to be included. Among the adjuvant patients the proportion who were node-negative
increased from 53% at the start of the trial to 60% in the final year of recruitment, and tumour sizes
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FIGURE 3 Changing characteristics and treatments of patients randomised into PERSEPHONE: (a) stratification variables
for all patients; and (b) prognostic variables for patients receiving adjuvant chemotherapy. CT, chemotherapy. (continued )
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decreased, with 46% having tumours of ≤ 2 cm at the start of the trial and this increasing to 58% in the
final year of the study. The prognosis of patients entered into the study was good at the start and had
improved further by the end of the study.
Timing of randomisation
On 11 September 2009, after the first 316 patients had been randomised, eligibility was changed to
allow patients to be randomised after receiving up to nine cycles of trastuzumab. Table 6 shows the
numbers of trastuzumab cycles that patients had received prior to being randomised into PERSEPHONE,
and the numbers are well balanced between the two arms: 44% of 12-month patients and 43% of
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FIGURE 3 Changing characteristics and treatments of patients randomised into PERSEPHONE: (a) stratification variables
for all patients; and (b) prognostic variables for patients receiving adjuvant chemotherapy. CT, chemotherapy.
DOI: 10.3310/hta24400 Health Technology Assessment 2020 Vol. 24 No. 40
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Earl et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
35
6-month patients were randomised prior to any trastuzumab; 81% of 12-month patients and 80% of
6-month patients were randomised up to and including four cycles of trastuzumab; and 98% of patients
in both arms were randomised up to and including eight cycles of trastuzumab.
Chemotherapy type
At randomisation:
l 2188 (54%) patients reported receiving sequential chemotherapy and trastuzumab
l 1900 (46%) patients reported receiving concurrent chemotherapy and trastuzumab
l 3462 (85% of the 4088) patients reported receiving adjuvant chemotherapy
l 626 (15% of the 4088) patients reported receiving neoadjuvant chemotherapy.
The chemotherapy regimen received is known for 3968 (97% of the 4088) of PERSEPHONE patients:
1987 (97%) 12-month patients and 1981 (97%) 6-month patients (see Appendix 1, Table 32).
The most commonly given regimens were fluorouracil, epirubicin, cyclophosphamide and docetaxel
(FEC-T) (39%), FEC (27%), EC (6%) and TC (5%), and these rates were similar across randomised
treatment arms.
l 12-month trastuzumab patients most commonly received FEC-T (40%), FEC (27%), EC (6%) or
TC (5%).
l 6-month trastuzumab patients most commonly received FEC-T (39%), FEC (28%), EC (5%) or
TC (5%).
FEC-T was the most common regimen received by patients receiving chemotherapy concurrent with
trastuzumab (64% of patients) and FEC was the most common regimen received by patients receiving
chemotherapy sequential to trastuzumab (51%):
l Concurrent chemotherapy and trastuzumab patients most commonly received FEC-T (64%), TC (9%)
or epirubicin, cyclophosphamide and docetaxel (EC-T) (6%). Trastuzumab was not given concurrently
with the anthracycline component of chemotherapy.
l Sequential chemotherapy and trastuzumab patients most commonly received FEC (51%), FEC-T
(18%) or EC (11%).
TABLE 6 Trastuzumab treatment received prior to randomisation
Trastuzumab cycles received 12-month patients, n (%) 6-month patients, n (%) Total, N (%)
0 898 (44) 884 (43) 1782 (44)
1 295 (14) 293 (14) 588 (14)
2 203 (10) 205 (10) 408 (10)
3 172 (8) 140 (7) 312 (8)
4 109 (5) 121 (6) 230 (6)
5 112 (6) 124 (6) 236 (6)
6 95 (5) 92 (5) 187 (4)
7 63 (3) 76 (4) 139 (3)
8 65 (3) 60 (3) 125 (3)
9 33 (2) 48 (2) 81 (2)
RESULTS
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FEC-T and FEC were the most common regimens received by patients receiving adjuvant chemotherapy
(36% and 31%, respectively) and FEC-T the most common regimen received by patients receiving
neoadjuvant chemotherapy (61%):
l Adjuvant chemotherapy patients most commonly received FEC-T (36%), FEC (31%) or EC (7%).
l Neoadjuvant chemotherapy patients most commonly received FEC-T (61%), EC-T (17%) or AC-T (4%).
In total, 389 (10%) patients reported receiving fewer chemotherapy cycles than initially planned: 197
(10%) 12-month patients and 192 (9%) 6-month patients. The most common reasons provided for this
were patient request (n = 92) and sepsis/infection (n = 78).
Of additional interest is the cross-tabulation of chemotherapy type against the timing of the
treatments (Table 7).
Protocol deviations/non-compliance
To 16 April 2019, 303 protocol non-compliances were reported (see Appendix 1, Table 33). The
PERSEPHONE trial treated patients in 152 sites and most protocol non-compliances can be explained
by the fact that specific requirements of the trial were missed as a result of the standard practice
at the site: the number of cycles, the extra labelling required by the regulatory governance or the
3-monthly LVEF measurement schedule.
Almost half of the non-compliances were linked to trastuzumab treatment. Patients did not always
receive the number of cycles prescribed in the randomisation, nine or 18, and reloading doses of
8 mg/kg after breaks of over 28 days were sometimes missed, with patients receiving the standard
6 mg/kg dose instead.
Just over one-quarter of protocol non-compliances were related to Investigational Medicinal Product
issues. Most commonly, patients were administered trastuzumab that was not labelled as per GCP, and
this was explained by the fact that the patient had not been marked as randomised in the PERSEPHONE
trial in clinic and/or in pharmacy. Patients also sometimes received non-Investigational Medicinal
Product stock via Healthcare at Home.
Another common non-compliance was in the LVEF measurements, which commonly were incorrectly
spaced, were missed or could not be interpreted. The trial required a LVEF measurement every 3 months
up to 12 months, whereas standard practice changed in 2010/11, leading to some sites reducing the
monitoring to 4-monthly. This change to standard practice was included in the protocol amendment in
TABLE 7 Treatment timing information across chemotherapy types
Timing
Chemotherapy type, n (%)
Anthracycline based Taxane based
Anthracycline and
taxane based
No taxane and
no anthracycline
Chemotherapy timing
Adjuvant 1642 (48) 386 (11) 1429 (41) 5 (< 1)
Neoadjuvant 54 (9) 14 (2) 558 (89) 0 (0)
Trastuzumab timing
Concurrent 55 (3) 342 (18) 1503 (79) 0 (0)
Sequential 1641 (75) 58 (3) 484 (22) 5 (< 1)
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October 2013. On rare occasions, an abnormal LVEF score was overlooked and trastuzumab treatment
continued instead of being interrupted.
Nineteen patients were found retrospectively not to be eligible; one of these was a patient who had
been double randomised.
Six protocol non-compliances were considered major and were reported as serious breaches. All of
these breaches were separate incidents and are detailed in Serious breaches.
Trastuzumab treatment delivery
Full trastuzumab treatment details are available for 3921 out of 4088 (96%) patients: 1942 out of
2045 (95%) 12-month patients and 1979 out of 2043 (97%) 6-month patients. Between them, 50,856
trastuzumab cycles were given: 32,611 to 12-month patients and 18,245 to 6-month patients.
In total, 41,093 (81%) were administered intravenously and 9763 (19%) subcutaneously.
A total of 3365 out of 3921 (86%) patients received the protocol-specified number of trastuzumab
cycles as per their randomised arm. Significantly more 6-month patients than 12-month patients
received their randomised number of cycles [1764/1979 (89%) and 1601/1942 (82%), respectively;
p < 0.0001] (Figure 4).
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FIGURE 4 Number of trastuzumab cycles received, split by randomised treatment arm: (a) 12-month patients; and
(b) 6-month patients.
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Among those randomised to the 12-month arm:
l one received no cycles of trastuzumab owing to cardiac dysfunction identified 15 days
after randomisation
l 132 (7%) received 1–9 cycles of trastuzumab
l 1809 (93%) received ≥ 10 cycles of trastuzumab
Among those randomised to the 6-month arm:
l two received no cycles of trastuzumab, one because they were ineligible (HER2 negative) and one
because they had a diagnosis of metastatic disease 20 days after randomisation
l 1875 (95%) received 1–9 cycles
l 102 (5%) received ≥ 10 cycles.
The reasons why 449 patients (12-month patients, n = 336; 6-month patients, n = 113) had fewer
cycles than the number specified in the protocol for their randomised arm are shown in Figure 2.
The most common reason for receiving fewer than the protocol-specified number of cycles was
cardiovascular toxicity [146/336 (43%) 12-month patients, 60/113 (53%) 6-month patients], followed
by patient request [94 (28%) 12-month patients, 26 (23%) 6-month patients] and relapse/death
[26 (8%) 12-month patients, 12 (11%) 6-month patients].
Length of time on treatment
The protocol-stated total duration of trastuzumab treatment is:
l 378 days for 12 months of trastuzumab (18 cycles each 21 days apart)
l 189 days for 6 months of trastuzumab (nine cycles each 21 days apart).
The median (IQR) time in days on treatment was:
l 383 days (378–392) for 12-month patients
l 190 days (189–197) for 6-month patients.
The good compliance with the protocol reflects the tolerability of each of the treatment arms.
Frequency and reasons for delays/holds of trastuzumab treatment
Of the 50,856 trastuzumab cycles received in total, 34,557 were administered during the first 6 months
of treatment and 16,299 were administered during the second 6 months of treatment.
l In the first 6 months of treatment, delays/holds were reported in 2685 (8%) cycles, by 1769
(45% of the 3918) patients:
¢ 1420 (8%) delays/holds reported by 920 (47%) 12-month patients
¢ 1265 (7%) delays/holds reported by 849 (43%) 6-month patients.
l In the second 6 months of treatment, delays/holds were reported in 1203 (7%) cycles, by 802
(42% of the 1911) patients:
¢ 1132 (7%) delays/holds reported by 753 12-month patients (42% of the 1809 who had
≥ 10 cycles)
¢ 71 (6%) delays/holds reported by 49 6-month patients (48% of the 102 who had ≥ 10 cycles).
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The 3968 reasons for the 3888 reported delays/holds throughout treatment are shown in Appendix 1,
Table 34. Interestingly, delays/holds were much more likely to be a result of patients’ requests
and logistic reasons than because of toxicity. Reasons recorded in the 12-month/6-month groups
were, respectively, 23%/22% for patient holidays, 15%/15% for logistical and administrative reasons
(rescheduling for bank holidays, change of clinic days, waiting list, poor intravenous access), 7%/5%
by patient request for personal reasons and 5%/5% for booked surgery/radiotherapy/procedures
(permanent line insertion). Only 5%/6% were due to cardiotoxicity from trastuzumab; 4%/6% were
due to sepsis (probably chemotherapy related); 4%/3% were due to unrelated medical problems; and
2%/2% were due to awaiting cardiac function tests.
However, 7798 (15%) of the 50,856 trastuzumab cycles received were given prior to randomisation
into PERSEPHONE. Of the 43,058 trastuzumab cycles received under the PERSEPHONE protocol by
3864 patients:
l delays/holds were reported in 3396 (8%) cycles by 1915 (50%) patients –
¢ 2289 (8%) by 1170 (60%) 12-month patients
¢ 1107 (8%) by 745 (39%) 6-month patients.
Toxicities
We have full treatment dose data from 3921 randomised patients, totalling 50,856 trastuzumab cycles
of information. However, toxicity data were requested only on cycles received after randomisation into
the trial. Therefore, 43,058 (85%) of these trastuzumab cycles from 3864 patients have full toxicity
information available: 28,856 cycles in 1935 12-month patients and 14,202 cycles in 1929 6-month
patients. From these cycles, each patient’s worst reported CTCAE grade for each type of toxicity has
been calculated (Table 8).
Categorising patients into whether they had ever reported a toxicity of severe grade (CTCAE ≥ 3,
or 2 for palpitations) during the 12-month period from starting trastuzumab, a higher proportion of
12-month patients than 6-month patients reported at least one adverse event of severe grade [460/1935
(24%) vs. 365/1929 (19%) respectively; p = 0.0003]. There was a significant excess of some toxicities in
the 12-month patients compared with the 6-month patients. In order of frequency, these were fatigue
(11.5% in 12-month patients vs. 8.6% in 6-month patients; p = 0.003), muscle/joint pains (11.3% vs. 8.8%;
p = 0.01), pain (5.2% vs. 3.1%; p = 0.001), palpitations (4.8% vs. 2.8%; p = 0.002), cough (4.1% vs. 2.2%;
p = 0.0007) and chills (3.6% vs. 2.0%; p = 0.003) (Figure 5).
To ensure that the toxicities reported were unlikely to be due to concurrent chemotherapy, analysis was
also undertaken on only the 54% of patients who received trastuzumab sequentially after chemotherapy.
Similar toxicity profiles to those of all patients were observed (see Appendix 2, Figure 24). In order of
frequency, these toxicities were fatigue (12.0% in 12-month patients vs. 8.0% in 6-month patients;
p = 0.003), muscle/joint pains (11.2% vs. 9.5%; p = 0.23), pain (6.1% vs. 2.9%; p = 0.0004), palpitations
(5.3% vs. 3.3%; p = 0.04), cough (4.3% vs. 2.0%; p = 0.004) and chills (4.5% vs. 2.3%; p = 0.007).
To assess the frequency of toxicity throughout treatment, analysis was also conducted that was
restricted to patients randomised upfront before receiving any of their trastuzumab treatment,
for whom full toxicity reporting throughout the entire trastuzumab treatment is expected. There are
1727 patients (12-month patients, n = 865; 6-month patients, n = 862) who were randomised prior to
receiving any trastuzumab treatment for whom we have full treatment details. These patients received
a total of 22,426 trastuzumab cycles (14,458 by 12-month patients and 7968 by 6-month patients).
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TABLE 8 Worst severity suffered for each toxicity over all patients’ cycles
Toxicity
CTCAE grade
12-month patients, n (%) 6-month patients, n (%)
UK 0 1 2 3 4 UK 0 1 2 3 4
Chills – 1380 (71) 353 (18) 133 (7) 59 (3) 10 (1) – 1549 (80) 251 (13) 91 (5) 31 (2) 7 (< 1)
Cough – 1223 (63) 486 (25) 146 (8) 65 (3) 15 (1) – 1436 (74) 361 (19) 90 (5) 37 (2) 5 (< 1)
Diarrhoea – 1185 (61) 497 (26) 194 (10) 47 (2) 12 (1) – 1365 (71) 398 (21) 117 (6) 39 (2) 10 (< 1)
Dizziness – 1397 (72) 386 (20) 121 (6) 27 (2) 4 (< 1) – 1566 (81) 281 (15) 54 (3) 24 (1) 4 (< 1)
Dyspnoea – 1260 (65) 459 (24) 157 (8) 59 (3) – 1431 (74) 365 (19) 89 (5) 44 (2)
Fatigue 1 (< 1) 557 (29) 643 (33) 511 (26) 184 (10) 39 (2) – 720 (37) 642 (33) 402 (21) 139 (7) 26 (2)
Fever – 1595 (83) 240 (12) 72 (4) 25 (1) 3 (< 1) – 1700 (88) 147 (8) 56 (3) 23 (1) 3 (< 1)
Headache – 1207 (62) 467 (24) 193 (10) 61 (3) 7 (1) – 1357 (70) 403 (21) 122 (6) 42 (2) 5 (1)
Hypertension – 1750 (90) 127 (7) 46 (2) 10 (1) 2 (< 1) – 1807 (94) 88 (5) 28 (1) 5 (< 1) 1 (< 1)
Hypotension – 1881 (97) 49 (3) 4 (< 1) 1 (< 1) – – 1885 (98) 33 (2) 8 (< 1) 3 (< 1) –
Infection – 1463 (76) 190 (10) 238 (12) 41 (2) 3 (< 1) – 1606 (83) 121 (7) 157 (8) 41 (2) 4 (< 1)
Muscle/joint pain 1 (< 1) 720 (37) 545 (28) 450 (24) 175 (9) 44 (2) – 948 (49) 480 (25) 331 (17) 137 (7) 33 (2)
Nausea – 1333 (69) 448 (23) 122 (6) 32 (2) – 1503 (78) 322 (17) 84 (4) 20 (1)
Pain – 1123 (58) 427 (22) 285 (15) 86 (4) 14 (1) – 1394 (72) 296 (15) 180 (9) 48 (3) 11 (1)
Palpitations – 1540 (79) 303 (16) 92 (5) – 1661 (86) 214 (11) 54 (3)
Rash – 1512 (78) 299 (16) 102 (5) 21 (1) 1 (< 1) – 1609 (84) 235 (12) 63 (3) 17 (1) 5 (< 1)
Vomiting – 1672 (86) 163 (8) 86 (5) 10 (1) 4 (< 1) – 1765 (92) 117 (6) 36 (2) 9 (< 1) 2 (< 1)
Shaded cells indicate that dyspnoea and nausea have a maximum CTCAE toxicity grade of 3 (no grade 4), and palpitations has a maximum CTCAE grade of 2 (no grade 3 or 4).
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Frequencies of reported CTCAE toxicity grades were analysed across two 6-month windows. There are
toxicity details on:
l 15,179 cycles in the first 6-month treatment period, by 1727 patients –
¢ 7603 cycles by 865 12-month patients
¢ 7576 cycles by 862 6-month patients
l 7247 cycles in the second 6-month treatment period, by 848 patients –
¢ 6855 cycles by 800 12-month patients
¢ 392 cycles by 48 6-month patients.
During the first 6 months, when both randomised arms were receiving treatment, as expected, similar
rates of each grade of each toxicity were reported across randomised treatment arms (see Appendix 1,
Table 35). If we look at 12-month patients’ reporting of toxicities in the first 6 months and the second
6 months, the same three toxicities are shown to be reported at a severe grade (CTCAE 3 and 4, and
2 for palpitations) with a frequency of > 1% of cycles; fatigue in 2.8% followed by 2.8% of cycles in
each of the 6-month periods, muscle/joint pain in 2.7% and 2.5% of cycles, and palpitations in 1.2%
and 1.1% of cycles. Therefore, among 12-month patients, the frequencies of toxicities during the
second 6 months of treatment did not alter substantially from the first 6 months, suggesting that no
cumulative toxicity occurred. The frequencies of toxicities during the second 6 months of treatment for
6-month patients were not investigated owing to the small number of patients (n = 48).
Safety
First 100 patients receiving concomitant trastuzumab and chemotherapy
The first 100 patients in PERSEPHONE who received concomitant chemotherapy and trastuzumab
provided data ‘in real time’ on SAEs and treatment delays. These data were collected and analysed by
the PERSEPHONE trials office and were reported to and discussed by the Independent Data and Safety
Monitoring Committee on 15 December 2010. These were confirmed to be within the acceptable safety
limits expected for concomitant trastuzumab and chemotherapy.
Serious adverse events
During the trial, 475 SAEs were reported by 384 patients:
l 291 by 227 12-month patients
l 184 by 157 6-month patients.
The most common reason for reporting a SAE was inpatient hospitalisation or prolongation of hospital
stay (83%) (see Appendix 1, Table 36). There were nine patients for whom death was either the reason
for reporting or the outcome of the SAE, and none of these was judged related to trastuzumab. One
sudden death occurred 6 months after completion of trastuzumab, and autopsy revealed a pulmonary
embolus with no evidence of metastatic disease. Eight deaths occurred during trastuzumab treatment
and causes were as follows: one pulmonary embolus on chemotherapy; one pneumonia with metastatic
liver and mediastinal disease; one subarachnoid haemorrhage; two pneumonitis and pulmonary infection
related to taxane; one suicide by drug overdose; one death on chemotherapy (autopsy report stated that
no cause found); and one patient second primary diagnosis glioblastoma multiforme.
In the 12-month arm the five most common SAEs reported were infection (118, 41% of SAEs reported),
cardiac (38, 13%), pain (19, 7%), gastrointestinal (10, 3%) and neurology (14, 5%). In the 6-month arm,
the five most common SAEs reported were infection (80, 43%), cardiac (15, 8%), gastrointestinal (12, 7%),
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pain (11, 6%) and neurology or pulmonary/upper respiratory (both 8, 4%) (see Appendix 1, Table 36).
Only 103 (22%) of the SAEs were SARs (see Serious adverse reactions), as the cause of many SAEs was
chemotherapy. The severity of the reported SAEs illustrate that only the minority were mild (19% of
12- and 6-month patients), and 5% of SAEs in the 12-month arm and 6% in the 6-month arm were
fatal or life-threatening.
Serious adverse reactions
A total of 103 serious adverse reactions (SAEs that were deemed by the PERSEPHONE CI as having
a causality either possibly, probably or definitely related to trastuzumab) were reported during the
trial. Twice as many 12-month as 6-month patients reported a serious adverse reaction:
l 67 by 63 12-month patients
l 36 by 31 6-month patients.
The primary event categories reported for the 103 SARs are shown in Appendix 1, Table 37. There
were no deaths related to trastuzumab. The five most common reasons for reporting a SAR were
cardiac [30 (45%) in the 12-month arm, 15 (42%) in the 6-month arm], infection [12 (18%) and 9 (25%),
respectively], pulmonary/upper respiratory [8 (12%) and 1 (3%), respectively], cardiac arrhythmia
[5 (7%) and 3 (8%), respectively] and allergy/immunology [5 (7%) and 2 (6%), respectively], and these
were all more common in 12-month patients.
Suspected unexpected serious adverse reactions
In total, since the trial opened, five SUSARs were reported among the 4088 patients recruited,
although two were subsequently downgraded to a SAE:
l TNO (trial number) 209 – 39-year-old patient had a miscarriage. The patient became pregnant
approximately during cycle 14–15 of trastuzumab and subsequently had a miscarriage around her
10th week of pregnancy. The miscarriage was reviewed as possibly related to trastuzumab.
l TNO 254 – 61-year-old patient presented with idiopathic pulmonary hypertension. The patient was
still receiving treatment for this condition in 2018. The event was reviewed as possibly related
to trastuzumab.
l TNO 662 – 61-year-old patient died suddenly at home following cycle 2 of trastuzumab/docetaxel
and cyclophosphamide. The postmortem (macroscopic) showed no obvious cause of death.
Pneumonia, pulmonary embolism and myocardial infarction were excluded. The toxicology analyses
showed no drugs detected in the blood. The death was classified as unlikely to be related to
trastuzumab and the event was downgraded to a SAE.
l TNO 1506 – 48-year-old patient was hospitalised with blistering of mouth and fever 10 days
following the fifth cycle of trastuzumab. The event was reviewed as probably related to trastuzumab.
l TNO 3657 – mild visual symptoms not interfering with function. The event was classified as unlikely
to be related to trastuzumab and the event was downgraded to a SAE.
Serious breaches
Six serious breaches were reported to the authorities during the trial. Three were directly linked to
clinical incidents and the three others were related to misconduct by teams involved in participation or
co-ordination. All breaches were escalated to the sponsor and subsequently reported to the MHRA and
the REC. Each breach was investigated and followed up with a corrective and preventative action plan.
1. Patient TNO 858 was administered two cycles of trastuzumab despite having a LVEF measurement
of 35%. The patient was admitted to hospital with chest pains. The error was picked up by the
trial office 10 months later only after receiving a SAE form for the hospital admission. This error
occurred as the principal investigator at the site had not been aware of the LVEF result until two
further trastuzumab cycles had been administered, at which point treatment was held. Corrective
and preventative actions were discussed with the site and a reminder was sent to all sites regarding
LVEF measurements and trastuzumab treatment.
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2. Owing to poor weather conditions, patient TNO 1970’s trastuzumab cycle was delayed by 4 days.
This dose was manufactured by the company Healthcare at Home on the day of intended
administration and had an expiry date of 24 hours later. During administration 4 days later, a
research nurse noticed the expiry date and stopped treatment, by which point around 30–40 mg
had been given to the patient. The PERSEPHONE trial team was alerted to this mistake only
15 days later. The principal investigator at the site reported no ill effects of this administration.
Corrective and preventative actions were discussed with the company, and also with the site,
with regard to communication.
3. Patient TNO 2968 had been confused with another patient taking part in another trial. The
PERSEPHONE patient had potentially been administered pertuzumab/placebo. The site underwent
rigorous monitoring by the PERSEPHONE team and corrective and preventative actions were
discussed with staff at the site.
4. An audit review at a participating site uncovered a number of issues related to patient consent. Six
patients randomised to the trial were consented by a research nurse who had not been authorised
to undertake this responsibility as per protocol. Five additional patient consent forms did not
adhere to GCP guidelines (i.e. the dates had been changed and the consent forms had been posted
to the patient’s address to be signed). Some issues were also found with co-investigators who had
taken consent from patients but were not GCP trained or authorised to take consent as per the site
signature and delegation log. Following the event, the site received a monitoring visit to ensure that
the corrective and preventative actions were implemented.
5. During the development safety update report 2016 development, the sponsor identified that several
updates to the trastuzumab SmPC had been made during the trial. Although important treatment
alert letters were sent to all clinical investigators at the time of the changes, these were not
amended in the PERSEPHONE protocol and patient information sheet. Corrective and preventative
actions were discussed between the sponsor and the trial office.
By this time the trial had completed recruitment (completed July 2015), and after discussion it was
not felt that an amended patient information sheet would be helpful. All sites who had remaining
patients in the trial were contacted with reminders that all patients who were pre-menopausal
and could become pregnant were required to take effective contraceptive precautions during
trastuzumab treatment and up to and including 7 months after completion. In addition, all sites
were asked to identify any other patients who had become pregnant.
6. After her tissue was re-tested during a routine audit of the hospital laboratory, patient TNO 4077
was found to be HER2 negative. The patient was withdrawn from the trial at this point and followed
up as per local practice. A protocol non-compliance was not generated after notification of the
event and the sponsor was not informed as it was felt that the initial laboratory error occurred
outside the trial protocol. The sponsor was made aware of the event when the patient sought legal
action against the hospital. By that time, the hospital had already conducted a root cause analysis,
and corrective and preventative actions had been taken.
During the trial, several updates were made to the trastuzumab SmPC, but these were not implemented
in the PERSEPHONE protocol and patient information sheet. Specifically, the two following major patient
safety updates were made:
l continued use of contraception for 6 months post treatment – SmPC updated August 2010 (up to
7 months in 2016)
l monitoring of long-term cardiac effects of trastuzumab toxicity – SmPC updated May 2015.
Although the PERSEPHONE trial protocol and patient information sheet were not amended to include
these issues, the team was aware of the changes and sent out important treatment alert letters to all
clinical investigators at the time of the changes in both 2010 and 2015.
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Follow-up and events
Deaths
At database lock on 6 March 2019, 389 deaths (10% of the 4088 patients) had been reported [182 (9%)
12-month patients and 207 (10%) 6-month patients]. Median follow-up of the 3699 alive patients was
6.1 years (IQR 4.5–7.6 years), with 97% of alive patients followed up for at least 2 years.
The reported causes of death (multiple for some patients) illustrate that 77% of deaths were from
breast cancer (Table 9). Among the 88 patients who died without breast cancer reported as a cause,
two had reported a local relapse and eight had reported a distant relapse.
TABLE 9 Reported cause(s) of death
Cause(s) of death
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
Breast cancer 143 (79) 158 (76) 301 (77)
Other cancer 13 (7) 23 (11) 36 (9)
Ovarian 2 5 7
Lung 3 3 6
Colorectal 1 3 4
Breast 2 1 3
Stomach 1 1 2
Bladder 1 – 1
Renal 1 – 1
Melanoma 1 – 1
Pancreatic 1 – 1
Angiosarcoma – 1 1
Cholangiocarcinoma – 1 1
Glioblastoma – 1 1
Myeloma – 1 1
Oesophageal – 1 1
Mesothelioma – 1 1
Brain – 1 1
Squamous cell carcinoma/bladder/lung/pleura – 1 1
Uterus – 1 1
Lymphoma – 1 1
Protocol treatment related 0 (0) 0 (0) 0 (0)
Other treatment related 0 (0) 3 (1) 3 (1)
Neutropenic enterocolitis and neutropenia – 1 1
Haemolytic transfusion reaction – 1 1
Docetaxel – drug-related lung injury – 1 1
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Relapses and second primaries
In total, 482 (12%) patients reported a relapse (12-month patients, n = 229; 6-month patients, n = 253)
(Table 10). One hundred and sixty-four (4%) patients reported a local relapse [12-month patients, n = 81
(4%); 6-month patients, n = 83 (4%)]. This was most commonly reported in the ipsilateral breast/chest wall
(n = 92), ipsilateral axillary nodes (n = 28) and ipsilateral supraclavicular nodes (n = 19) (see Appendix 1,
Table 38). Three hundred and ninety-nine (10%) patients reported a distant relapse [12-month patients,
n = 192 (9%); 6-month patients, n = 207 (10%)]. This occurred most commonly in the liver [86/192
patients (45%) in the 12-month arm and 91/207 patients (44%) in the 6-month arm], bone [63 (33%) in
the 12-month arm and 89 (43%) in the 6-month arm], lung/pleura [74 (39%) in the 12-month arm and 78
(38%) in the 6-month arm] and brain [40 (21%) in the 12-month arm and 43 (21%) in the 6-month arm].
One hundred and thirty-four (3%) patients reported a second primary [12-month patients, n = 67 (3%);
6-month patients, n = 67 (3%)]. This was most commonly reported in the contralateral breast [n= 36 (27%):
12-month patients, n= 23 (34%); 6-month patients, n = 13 (19%)], lung [n= 17 (13%): 12-month patients,
n = 9 (13.5%); 6-month patients, n= 8 (12%)] and bowel/colon [n= 15 (11%): 12-month patients, n= 4
(6%); 6-month patients, n = 11 (16.5%)].
TABLE 9 Reported cause(s) of death (continued )
Cause(s) of death
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
Other causes 27 (15) 22 (11) 49 (13)
CVDa 8 10 18
Infection 6 5 11
Liver failure 2 2 4
Renal failure – 1 1
Other 11 4 15
Unknown 3 (2) 7 (3) 10 (3)
CVD, cardiovascular disease.
a CVD includes myocardial infarction, cardiac ischaemia, peripheral vascular disease, pulmonary embolus, venous
thromboembolism, stroke, cerebral haemorrhage and ruptured aortic aneurysm.
Multiple causes are recorded for some patients.
TABLE 10 Number of patients reporting an event
Number of patients with an event reported
12-month patients
(n= 2045)
6-month patients
(n= 2043)
Total
(N= 4088)
Death 182 (9%) 207 (10%) 389 (10%)
Breast cancer listed as a cause 143 (79%) 158 (76%) 301 (77%)
Breast cancer not listed as a cause, but a local or
distant relapse reported
3 (1%) 7 (4%) 10 (3%)
Breast cancer not listed as a cause and no local/
distant relapse reported
36 (20%) 42 (20%) 78 (20%)
Relapse 229 (11%) 253 (12%) 482 (12%)
Local relapse only 37 (2%) 46 (2%) 83 (2%)
Distant relapse only 148 (7%) 170 (8%) 318 (8%)
Local and distant relapse 44 (2%) 37 (2%) 81 (2%)
Relapse or death 270 (13%) 296 (14%) 566 (14%)
Second primary 67 (3%) 67 (3%) 134 (3%)
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Survival outcomes
Disease-free survival
At a median follow-up of 6.1 years, 566 (14%) patients either had experienced a relapse or had died.
The 4-year DFS rate was 90.3% (95% CI 88.9% to 91.5%) in the 12-month group and 89.5% (95% CI
88.1% to 90.8%) in the 6-month group (Figure 6). Thus, with the non-inferiority margin of 3%, the
non-inferiority limit for the HR was set at 1.33. The HR for relapse or death with 6 months’ compared
with 12 months’ trastuzumab was 1.10 (90% CI 0.96 to 1.26). This outcome met the prespecified
definition of non-inferiority (non-inferiority p = 0.01). The two-sided p-value for the difference between
treatments was 0.26. Adjustment for all stratification factors gave the same results, with a HR of 1.10
(90% CI 0.96 to 1.26; non-inferiority p = 0.01).
With a difference of 0.008 in absolute risk of a DFS event at 4 years between patients randomised to
6 months and those randomised to 12 months of trastuzumab, the number needed to treat is 125 for
the overall population. That is, on average, 125 patients would need to receive 12 months’ trastuzumab
for one of them to benefit in terms of a DFS event, compared with the same 125 patients receiving
only 6 months of trastuzumab.
Overall survival
Analysis of the secondary end point of OS also met the prespecified definition of non-inferiority.
The 4-year OS rate was 94.9% (95% CI 93.9% to 95.8%) in the 12-month group and 94.2% (95% CI
93.0% to 95.1%) in the 6-month group (Figure 7). With the same non-inferiority margin of 3%, the
non-inferiority limit for the HR was set at 1.61. The HR for death with 6 months’ trastuzumab
compared with 12 months’ trastuzumab was 1.14 (90% CI 0.96 to 1.34), meeting the prespecified
definition of non-inferiority (non-inferiority p = 0.0003). The two-sided p-value for the difference
between treatments was 0.21, and adjusting for stratification factors gave similar results (HR 1.13,
90% CI 0.95 to 1.33; non-inferiority p = 0.0002).
With the difference of 0.007 in absolute risk of an OS event at 4 years between patients randomised
to 6 months and those randomised to 12 months of trastuzumab, the number needed to treat is
143 for the overall population. That is, on average, 143 patients would need to receive 12 months’
trastuzumab for one of them to benefit in terms of an OS event, compared with the same 143 patients
receiving only 6 months’ trastuzumab.
Landmark analysis of disease-free survival and overall survival
The exploratory landmark analysis, including only patients who were alive and disease free at least
6 months after the start of their trastuzumab treatment, was undertaken on 4008 patients (12-month
patients, n = 2007; 6-month patients, n = 2001). The cohort was balanced across randomised arms in
terms of demographics and baseline disease characteristics (see Appendix 1, Table 39) and, with a median
follow-up of 5.1 years, 365 (9%) deaths and 537 (13%) DFS events have been recorded. DFS and OS were
recalculated from the landmark time point (6 months after each patient’s start of trastuzumab treatment).
The landmark 4-year DFS rate was 88.7% (95% CI 87.2% to 90.1%) in the 12-month group and 88.4%
(95% CI 86.8% to 89.7%) in the 6-month group, and hence the non-inferiority limit for the HR was set
at 1.29 (Figure 8). The calculated HR for relapse or death with 6 months’ trastuzumab compared with
12 months’ trastuzumab was 1.09 (90% CI 0.95 to 1.26), meeting the prespecified definition of non-
inferiority (non-inferiority p = 0.03). The two-sided p-value for difference between treatments was 0.30.
The landmark 4-year OS rate was 93.2% (95% CI 91.9% to 94.3%) in the 12-month group and 92.6%
(95% CI 91.3% to 93.7%) in the 6-month group, and hence the non-inferiority limit for the HR was set
to 1.46 (Figure 9). The calculated HR for death with 6 months’ trastuzumab compared with 12 months’
trastuzumab was 1.12 (90% CI 0.95 to 1.34), meeting the prespecified definition of non-inferiority
(non-inferiority p = 0.006). The two-sided p-value for difference between treatments was 0.27.
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FIGURE 6 Disease-free survival according to randomised group: (a) Kaplan–Meier plot; and (b) HR plot.
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FIGURE 9 Landmark OS according to randomised group: (a) Kaplan–Meier plot; and (b) HR plot.
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Additional analyses
To ensure the robustness of findings from the PERSEPHONE trial, and to facilitate comparisons across
various other studies, additional analyses of invasive DFS [including invasive contralateral breast
cancers and second primary invasive cancers (non-breast) according to the STEEP (standardised
definitions for efficacy end points in adjuvant breast cancer trials) system], distant DFS, and breast
cancer-specific survival were undertaken. Survival curves of these end points were comparable with
those of the protocol-specified primary and secondary end points (see Appendix 2, Figures 25–27).
Forest plots
All patients
Forest plots for DFS including all patients (Figure 10) showed heterogeneity in the treatment effect of
chemotherapy type (p = 0.01), predominantly driven by the small number of events in the taxane-only
group, in which 56% of patients received docetaxel with cyclophosphamide. The timing of trastuzumab
relative to chemotherapy (concurrent or sequential) showed heterogeneity in the treatment effect
(p < 0.001) favouring 12-month patients receiving concurrent trastuzumab. In terms of DFS, no
heterogeneity in the treatment effect was observed for ER status, chemotherapy timing (neoadjuvant
or adjuvant), age, grade, menopausal status or IHC status (IHC3+ or IHC2+ and FISH positive). In
terms of OS, similar results were found with heterogeneity for concurrent/sequential chemotherapy
and trastuzumab, although the heterogeneity in treatment effect was not observed for chemotherapy
type (p = 0.11) (see Appendix 2, Figure 28). Forest plots for landmark DFS show heterogeneity for
chemotherapy type (p = 0.01), chemotherapy timing (adjuvant/neoadjuvant, p = 0.04) and concurrent/
sequential treatment (p = 0.003) (see Appendix 2, Figure 29). Landmark OS showed heterogeneity only
for concurrent/sequential trastuzumab and chemotherapy (p = 0.02) (see Appendix 2, Figure 30).
Adjuvant patients
For the subset of patients receiving adjuvant chemotherapy, exploratory forest plots of the randomised
treatment effect on DFS (Figure 11) showed heterogeneity for chemotherapy type (p = 0.006) and
trastuzumab timing (p = 0.003) and on OS (see Appendix 2, Figure 31) heterogeneity for trastuzumab
timing (p = 0.02). There was no additional heterogeneity in the treatment effect for nodal status at
surgery, tumour size, or combined ER and nodal status.
Neoadjuvant patients
For the subset of patients receiving neoadjuvant chemotherapy, exploratory forest plots of the randomised
treatment effect on DFS (Figure 12) and OS (see Appendix 2, Figure 32) found no heterogeneity in the
treatment effect within the stratification variables. In addition, there was no heterogeneity in the treatment
effect for response to neoadjuvant chemotherapy and trastuzumab (pathological complete response vs.
non-pathological complete response). Thirty per cent (186/614) of patients achieved pathological complete
response (i.e. they had no cancer in breast or axillary lymph nodes) after neoadjuvant chemotherapy and
trastuzumab, and to date DFS events have been seen at follow-up in only 6.4% of these patients (12/186),
compared with 26% (113/428) of patients who failed to achieve pathological complete response. This is
the expected result, as pathological complete response has been shown to predict better outcomes.
The numbers in this group are too small to indicate any interaction with treatment duration.
Trial-level meta-analysis of PERSEPHONE and PHARE
A trial-level meta-analysis of non-inferiority trials comparing 6 months with 12 months of trastuzumab
treatment was undertaken using DerSimonian and Laird random-effects models50 on the latest published
DFS results from the PHARE trial51 (on 3380 patients) and the latest landmark DFS results presented
in this report from the PERSEPHONE trial (on 4008 patients). The weighted 4-year DFS rate from
6 months’ trastuzumab for the combined 7388 patient group was 88.9%. Thus, with a non-inferiority
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Events/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 monthsCharacteristic 12 months (O–E) Variance
ER status
Negative
Positive
Chemotherapy type
Chemotherapy timing
Transtuzumab timing
Anthracycline based
Taxane based
Anthracycline + taxane
Neither anthracycline 
nor taxane
Adjuvant
Neoadjuvant
Concurrent (with CT)
Sequential (after CT)
Age (years)
≤ 50
> 50
Tumour grade
Menopausal status
Pre
Peri
Post
Well differentiated
Moderately differentiated
Poorly differentiated
IHC-score
2+ and FISH positive
3+
Unstratified
95% CI 95% CI
126/631
(20.0%)
170/1412
(12.0%)
107/632
(16.9%)
163/1413
(11.5%)
11.0
2.5
58.2
83.2
Interaction between two groups χ1 = 3.0; p = 0.09
Interaction between two groups χ1 = 11.3; p < 0.001
Interaction between two groups χ1 = 0.3; p = 0.61
Interaction between two groups χ1 = 0.2; p = 0.69
Heterogeneity between three groups χ2 = 2.3; p = 0.31
Heterogeneity between three groups χ2 = 1.6; p = 0.45
Interaction between two groups χ1 = 0.9; p = 0.35
Heterogeneity between four groups χ3 = 11.4; p = 0.01
104/845
(12.3%)
33/202
(16.3%)
159/993
(16.0%)
0/3
(0.0%)
118/851
(13.9%)
14/198
(7.1%)
137/994
(13.8%)
1/2
(50.0%)
–7.2
9.9
11.7
–0.6
55.5
11.7
74.0
0.2
221/1727
(12.8%)
75/316
(23.7%)
141/951
(14.8%)
155/1092
(14.2%)
94/949
(9.9%)
176/1096
(16.1%)
25.3
 
–11.9
1.7
 
11.5
1.4
4.3
5.3
0.7
40.2
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91.5
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218/1735
(12.6%)
52/310
(16.8%)
1.7
11.5
109.7
31.7
103/677
(15.2%)
193/1366
(14.1%)
3/34
(8.8%)
86/645
(13.3%)
196/1297
(15.1%)
87/579
(15.0%)
12/151
(7.9%)
153/1072
(14.3%)
72/510
(14.1%)
215/1489
(14.4%)
296/2043
(14.5%)
270/2045
(13.2%)
76/551
(13.8%)
190/1462
(13.0%)
77/567
(13.6%)
14/110
(12.7%)
154/1145
(13.4%)
4.3
–2.7
3.9
1.1
10.6
13.4 141.5
36.9
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41.0
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FIGURE 10 Forest plot of DFS for all patients. CT, chemotherapy; O–E, observed–expected.
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Events/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 monthsCharacteristic 12 months (O–E) Variance
ER status
Negative
Positive
CT type
Transtuzumab timing
Nodal status at surgery
Anthracycline-based
Taxane-based
Anthracycline + taxane
Neither anthracycline 
nor taxane
Concurrent (with CT)
Sequential (after CT)
NEG
1–3
≥ 4
Tumour size (cm)
ER and node
ER + NODE –
ER – NODE –
ER + NODE +
ER – NODE +
≤ 2
> 2–5
> 5
Unstratified
95% CI 95% CI
87/501
(17.4%)
134/1226
(10.9%)
85/521
(16.3%)
133/1214
(11.0%)
3.1
–1.0
43.0
66.7
Interaction between two groups χ1 = 9.0; p = 0.003
Heterogeneity between three groups χ2 = 2.4; p = 0.31
Heterogeneity between three groups χ2 = 0.3; p = 0.85
Heterogeneity between four groups χ2 = 1.2; p = 0.76
Interaction between two groups χ1 = 0.2; p = 0.66
Heterogeneity between four groups χ3 = 12.3; p = 0.006
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(11.3%)
31/192
(16.1%)
98/715
(13.7%)
0/3
(0.0%)
111/825
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13/194
(6.7%)
93/714
(13.0%)
1/2
(50.0%)
–9.9
9.8
2.8
–0.6
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(12.8%)
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FIGURE 11 Forest plot of DFS for adjuvant patients only. CT, chemotherapy; O–E, observed–expected.
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margin of 2%, using the methodology used in our study, the non-inferiority limit for the HR is 1.19.
There was no detectable difference between the two trials’ results (heterogeneity p = 0.94), and the
pooled HR for DFS from 6 months of trastuzumab treatment of 1.08 (90% CI 0.98 to 1.18) met the
prespecified definition of 2% non-inferiority (non-inferiority p = 0.04) (Figure 13).
Translational research
The collection of blood and archival tissue samples was conducted in parallel with the PERSEPHONE
clinical trial. In total, 3801 (93%) PERSEPHONE patients consented to provide a blood sample to the
project but, owing to capacity and logistics at sites, samples from 3392 (83% of all 4088, 89% of those
consented) patients were collected. The blood samples were used to extract DNA from peripheral blood
mononuclear cells. This DNA has already been profiled with SNP arrays for genome-wide association
studies and pharmacogenetic studies. In addition, germline DNA will be sequenced as ‘normal’ to
facilitate calling of mutations in DNA extracted from paraffin blocks. Similarly, 3814 (93%) PERSEPHONE
patients consented to the accessing of their archival tissue but, owing to capacity and logistics at sites,
samples from 2985 (73% of all 4088, 78% of those consented) patients were collected. The tissue cores
have been used to construct tissue microarrays, which will be used for digital pathology, IHC and imaging
mass cytometry, and for DNA and RNA (ribonucleic acid) extraction (nucleic acids will be used for
genomic profiling with DNA and RNA sequencing).
Events/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 monthsCharacteristic 12 months (O–E) Variance
ER status
Negative
Positive
CT type
Transtuzumab timing
Pathological response
Anthracycline-based
Taxane-based
Anthracycline + taxane
Neither anthracycline 
nor taxane
Concurrent (with CT)
Sequential (after CT)
pCR
No pCR
Unstratified
95% CI 95% CI
39/130
(30.0%)
36/186
(19.4%)
22/111
(19.8%)
30/199
(15.1%)
15.2
16.5
Interaction between two groups χ1 = 1.0; p = 0.32
Interaction between two groups χ1 = 0.3; p = 0.59
Interaction between two groups χ1 = 0.4; p = 0.53
Heterogeneity between four groups χ3 = 0.5; p = 0.93
12/28
(42.9%)
2/10
(20.0%)
61/278
(21.9%)
0/0
(.%)
7/26
(26.9%)
1/4
(25.0%)
44/280
(15.7%)
0/0
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4.7
0.6
26.2
26.2
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(20.7%)
24/70
(34.3%)
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(8.1%)
66/223
(29.6%)
5/100
(5.0%)
47/205
(22.9%)
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19/64
(29.7%)
21.0
10.7
75/316
(23.7%)
52/310
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1.0
11.5 31.7
0.1 0.2 0.3 0.4 0.5 2 3 4 5 10
6 months better 12 months better
1.57 (0.95 to 2.60)
1.25 (0.77 to 2.03)
1.59 (1.03 to 2.44)
1.09 (0.60 to 1.99)
1.82 (0.57 to 5.80)
1.31 (0.90 to 1.89)
1.69 (0.68 to 4.15)
1.41 (0.96 to 2.07)
1.44 (1.01 to 2.03)
2
2
2
2
*
FIGURE 12 Forest plot of DFS for neoadjuvant patients only. CT, chemotherapy; O–E, observed–expected;
pCR, pathological complete response.
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Chapter 4 Cardiac toxicity
Background to cardiac toxicity and trastuzumab
Trastuzumab has transformed the treatment of HER2-positive breast cancer in both the adjuvant and
the metastatic setting. However, cardiac toxicity with a reduction in LVEF has been recognised as a
side effect of trastuzumab therapy from the early days of its use in metastatic disease52 and has been
reported in all adjuvant trials.53–58 The exact pathophysiology of the observed cardiac dysfunction
is not completely understood. HER2 receptors are present on cardiac myocytes, and when normal
HER2 function is inhibited by trastuzumab there may be an accumulation of reactive oxygen species,
resulting in reduced cardiac function.59 Trastuzumab may also cause contractile problems by impairing
mitochondrial function through intracellular downstream events resulting in depletion of adenosine
triphosphate.60 Anthracyclines, which often precede trastuzumab in the adjuvant setting and have
been previously administered when trastuzumab is used in metastatic breast cancer, are also likely
to contribute to cardiac problems because of the sequential cardiac stresses.61,62 The cardiac data
from the PHARE trial (6 vs. 12 months of trastuzumab)63 and HERA (12 vs. 24 months)53–56 trials show
a clear relationship in the adjuvant setting between the duration of trastuzumab exposure and the
incidence of cardiac dysfunction. A recent Cochrane meta-analysis (58 studies in 29,598 patients) of
cardiotoxicity of trastuzumab in both randomised controlled trials (RCTs) and observational data64
showed that severe cardiotoxicity occurred in 2.62% (95% CI 1.97% to 3.35%) of early breast cancer
patients and in 3.14% (95% CI 2.12% to 4.37%) of metastatic patients. Severe cardiotoxicity was
defined as any of the following: symptomatic CHF, myocardial infarction, cardiac dysrhythmia, cardiac
toxicity of grade III/IV according to the National Cancer Institute CTCAE or the New York Heart
Association (NYHA) classification, or LVEF reduction to ≤ 40%. In early breast cancer, cardiotoxicity
occurred in 2.90% of patients treated with taxanes and anthracyclines, compared with 0.92% of
patients treated with taxanes without anthracyclines. Notably, the BCIRG-006 study included an
experimental arm without anthracyclines and added carboplatin to docetaxel.18 This combination
resulted in a 0.4% incidence of severe congestive heart failure, compared with a 2% incidence in
the anthracycline and taxane with trastuzumab group and a 0.7% incidence in the anthracycline and
taxane group.18 Risk factors for cardiotoxicity were older age, smoking, dyslipidaemia, high body mass
index, diabetes, hypertension and a positive history of cardiac disease. RCTs have consistently reported
lower severe cardiac toxicity rates than observational studies (early breast cancer: 1.7% vs. 3.2%).64
The PERSEPHONE trial compared 6 months with 12 months of trastuzumab and also carried out detailed
cardiac ejection fraction assessments on patients during the 12-month treatment period to assess cardiac
toxicity with standard treatment and with reduced treatment. Reducing the risk of cardiac dysfunction
would have clear advantages if adjuvant trastuzumab treatment could be shortened to 6 months without
a reduction in clinical efficacy. We present here the cardiology substudy with the prespecified secondary
end point of cardiac function in all 4088 patients randomised to 6 or 12 months’ trastuzumab. The
PERSEPHONE trial was designed to ‘map on to standard practice’ in the UK and therefore our results
will be applicable to ‘real-world patients’.
Methods
PERSEPHONE exclusion criteria for cardiac problems
The protocol detailed that patients should have no significant cardiac disease or comorbidity that, in
the opinion of the principal investigator, added to the cardiac risks associated with trastuzumab and
chemotherapy. PERSEPHONE was a trial designed to ‘map on to standard practice’ and therefore
did not exclude any patients who, in the opinion of the principal investigators at recruiting sites,
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would otherwise be considered fit enough to receive chemotherapy and the standard of 12 months’
adjuvant trastuzumab.
Definition of clinical cardiac dysfunction
‘Clinical cardiac dysfunction’ was defined as any or all of the following: symptoms of cardiac disease
or signs of CHF or new/altered cardiac medication prescribed during the 12 months after starting
trastuzumab. Following randomisation, side effects specific to trastuzumab were reported in the CRFs
with the aid of patient-recorded diary sheets. Every 3 months, symptoms or signs of CHF and new/
altered cardiac medication were reported on the CRFs to the trials office.
Left ventricular ejection fraction
Left ventricular ejection fraction measurement
Standard methods for assessing LVEF were used in the study; these were either ECHO or MUGA
cardiac scanning. The assessment methods were undertaken as per the standard in each site and, if
possible, the same method was used for each individual throughout. Although we recognise that these
two methods may produce results that differ in some aspects, ECHO and MUGA scan were treated
equivalently in our data analysis.
To start trastuzumab treatment, patients had to have a normal LVEF as defined by the standard at
their site. Following randomisation into PERSEPHONE, patients had LVEF measured every 3 months
up until 12 months after the start of trastuzumab. In standard practice, cardiac monitoring does not
continue after 12 months, and therefore in the study there were no routine measurements of LVEF
after 12 months. However, some LVEF measurements after the 12-month time point were available.
In June 2013, the PERSEPHONE independent DSMC reviewed full data on the first 2500 patients
randomised. The relative changes over time in LVEF, the frequency of abnormal tests reported over
time and the effects of cardiac dysfunction on trastuzumab treatment were scrutinised. For the patients
who had ever had reported LVEF of < 50%, all LVEF results over time were reviewed. The independent
DSMC did not have any concerns and agreed to a proposed amendment to the protocol from the TMG
to reduce the frequency of stipulated cardiology monitoring. The proposal was to change the frequency
of LVEF measurement from 3-monthly to a minimum of 4-monthly, in line with standard practice at
many sites at that time as recommended in National Cancer Research Institute guidelines,36 which were
published after PERSPHONE had been designed. Consequently, more frequent LVEF monitoring was
undertaken in the first cohort of PERSEPHONE patients (n = 2500), whereas the second cohort of
1588 patients typically received 4-monthly LVEF monitoring.
Left ventricular ejection fraction end points
‘Low LVEF’ was a cardiac end point defined as a LVEF measurement of < 50%, or systolic function
below normal but without LVEF values recorded. Substantial reductions in LVEF were also recorded.
‘Substantial’ was defined as an absolute decrease in LVEF of ≥ 10% from baseline to below 50% or a
reduction in LVEF to < 50% after a baseline of ≥ 59%.
Treatment modifications
If LVEF fell below 50%, the protocol advised ‘holding’ trastuzumab and repeating LVEF monitoring at
6-week intervals until LVEF returned to ≥ 50%. After delays for a total of 3 months on account of
cardiotoxicity, the protocol advised to discontinue trastuzumab permanently. In the case of NYHA
class III/IV heart failure symptoms (breathlessness at rest or on minimal exertion), trastuzumab
was permanently discontinued even after resolution of symptoms or normalisation of LVEF with
treatment.65,66 In the later part of the study, standard practice for patients on trastuzumab changed
in many sites following the publication of new guidelines.36 Patients on trastuzumab who had an
asymptomatic reduction in LVEF to below the lower limit of normal and ≥ 40% could be treated with
CARDIAC TOXICITY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
cardiac medication while continuing trastuzumab and having their LVEF monitored. Changes to the
protocol were not made and therefore these instances were reported as protocol non-compliances.
Statistical analysis
Incidences of clinical cardiac dysfunction, low LVEF, substantial falls in LVEF and treatment modifications
as a result of these cardiac events were assessed using chi-squared tests. Changes from patients’ baseline
LVEF score (i.e. before they started trastuzumab treatment) were assessed using Wilcoxon signed-rank
tests. Random-effects modelling was applied to patients’ LVEF scores over time, and the results are
presented graphically as the average patient values over time for each treatment arm as predicted by
the model. Further random-effects modelling investigated the influence of chemotherapy type, number
of anthracycline cycles and trastuzumab timing (concurrent/sequential). Potential predictive factors
of experiencing a low LVEF during the 12-month reporting period were investigated using univariate
logistic regressions and are presented with odds ratios (ORs) and 95% CIs.
Results
Chemotherapy, timing of randomisation and prior cardiac medication
Factors relevant to cardiac risk appeared balanced across randomised treatment arms; 90% of patients
(12-month patients, 90%; 6-month patients, 90%) received an anthracycline as part of either anthracycline-
based (12-month patients, 41%; 6-month patients, 41%) or anthracycline plus taxane-based (12-month
patients, 49%; 6-month patients, 49%) chemotherapy (see Table 5). Fifty-four per cent of patients received
trastuzumab sequentially after chemotherapy (12-month patients, 54%; 6-month patients, 53%), and 46%
received trastuzumab concurrently with the non-anthracycline component of chemotherapy (12-month
patients, 46%; 6-month patients, 47%). Only 2% of patients reported being on cardiac medication prior
to starting trastuzumab (12-month patients, 2%; 6-month patients, 3%). Randomisation was before the
start of trastuzumab or at any time up to and including the ninth cycle. Forty-four per cent (1782/4088) of
patients were randomised upfront and 81% (3320/4088) were randomised prior to cycle 5, and the timing
of randomisation was balanced between the 6- and 12-month arms (see Table 6).
Cardiac events
Full clinical cardiac data were available for 3995 patients (98% of 4088 randomised): 1987 (97% of
2045 randomised) 12-month patients and 2008 (98% of 2043 randomised) 6-month patients. Clinical
cardiac dysfunction was reported in 384 (10% of 3995) patients (Table 11), with 188 (5% of 3995)
reporting symptoms of cardiac disease, 65 (2% of 3995) having signs of CHF, and 274 (7%) reporting
new or altered cardiac medication (see Appendix 1, Table 40). Clinical cardiac dysfunction was more
common in 12-month than in 6-month patients [228/1987 (11%) vs. 156/2008 (8%), respectively;
p < 0.0001]. Some differences in rates were apparent in the first 6 months of trastuzumab [168/1987
(8%) 12-month patients vs. 127/2008 (6%) 6-month patients; p = 0.01], which we would assume
a chance finding as we would expect these to be similar at this point. A more significant difference
between the two arms emerged during the 7- to 12-month period [158/1953 (8%) vs. 97/1914 (5%),
respectively; p = 0.0002], as expected.
In total, 19,458 LVEF measurements (ECHO, 73%; MUGA, 17%; unknown, 10%) were reported in
4080 patients: 10,193 in 2042 12-month patients and 9265 in 2038 6-month patients. The use of each
modality was balanced across the randomised treatment arms (12-month patients: ECHO, 73%, MUGA,
18%, unknown, 9%; 6-month patients: ECHO, 73%, MUGA, 17%, unknown, 10%). MUGA scans appear
to have a higher rate of low LVEF readings (< 50%, or percentage unknown but classified on report
as abnormal): 10% of MUGA scans compared with 3% of ECHO (see Appendix 1, Table 41). During
the first 6 months of treatment, the proportion of patients with low LVEF was 7% in both groups,
149 out of 2042 (7%) in the 12-month arm and 145 out of 2038 (7%) in the 6-month arm (p = 0.87).
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However, during months 7–12, this proportion increased for 12-month patients (150/1942; 8%) but fell
for 6-month patients (84/1758; 5%) (p = 0.0003 for difference between groups). Patients with substantial
decreases in LVEF, defined as absolute decrease in LVEF of ≥ 10% from baseline to < 50%, were seen
in months 1–6 of treatment in similar numbers: 99 out of 1955 (5%) patients in the 12-month arm and
101 out of 1957 (5%) in the 6-month arm. However, during months 7–12, there were more patients
with substantial decreases in the 12-month arm than in the 6-month arm [102/1880 (5%) and 61/1701
(4%), respectively; p = 0.01]. Substantial falls in LVEF, defined as decreasing to < 50% after a baseline of
≥ 59%, occurred in the first 6 months in similar numbers of patients: in 64 out of 1955 (3%) 12-month
patients and in 70 out of 1957 (4%) 6-month patients. However, in months 7–12 these figures were
71 out of 1880 (4%) and 33 out of 1701 (2%), respectively (p = 0.0015).
A landmark analysis was carried out on 3415 patients who had not reported any cardiac dysfunction
(defined as clinical cardiac dysfunction or low LVEF) within their first 6 months of treatment and for
whom data were available in months 7–12. Significantly more 12-month patients (97/1714; 6%) than
6-month patients (39/1701; 2%) reported cardiac dysfunction in the second 6-month period (p < 0.0001).
Eleven deaths were reported to have had a ‘cardiac’ cause, either first cause or contributory cause (see
Appendix 1, Table 42). None occurred during the first 12 months after starting trastuzumab treatment.
Nine patients died with no metastatic disease and two had metastatic disease. In all cases, the TMG
and the cardiologist who reviewed the cases judged trastuzumab as unrelated or unlikely to have been
related to cardiac problems. Four deaths were caused by ischaemic heart disease, which has no known
association with trastuzumab. One patient developed a decrease in LVEF with CHF; this was very
unlikely to have been related to trastuzumab, as the patient received only four cycles, treatment was
TABLE 11 Cardiac monitoring over the two 6-month periods
Number of patients
reporting at least one
incidence of
12-month patients, n/N (%) 6-month patients, n/N (%)
Overall
In months
1–6
In months
7–12 Overall
In months
1–6
In months
7–12
Clinical cardiac dysfunctiona 228/1987 (11) 168/1987 (8) 158/1953 (8) 156/2008 (8) 127/2008 (6) 97/1914 (5)
Low LVEFb 228/2042 (11) 149/2042 (7) 150/1942 (8) 175/2038 (9) 145/2038 (7) 84/1758 (5)
Substantial falls in LVEF
Absolute decrease of
≥ 10% from baseline
to < 50%
164/1964 (8) 99/1955 (5) 102/1880 (5) 131/1961 (7) 101/1957 (5) 61/1701 (4)
LVEF < 50% after a
baseline of ≥ 59%
109/1964 (6) 64/1955 (3) 71/1880 (4) 86/1961 (4) 70/1957 (4) 33/1701 (2)
Stopped trastuzumab
permanently owing to
cardiac toxicity
146/1941 (8) 63/1941 (3) 83/1809 (5) 61/1977 (3) 60/1977 (3) 1/102 (1)
Cardiac deathc 7/2045 0/2045 0/2018d 4/2043 0/2043 0/2017d
Cardiac death related to
trastuzumabc
0/2044e 0/2044e 0/2018d 0/2041e 0/2041e 0/2017d
a Clinical cardiac dysfunction = symptoms of cardiac disease and/or signs of congestive heart failure and/or new or
altered medication for cardiac disease.
b Low LVEF= number of patients with at least one LVEF measurement < 50%, or LVEF % unknown but classified on
report as abnormal.
c Eleven deaths were reported to have a ‘cardiac’ cause, either first or contributory. None occurred during the first
12 months after starting trastuzumab treatment. Nine patients died with no metastatic disease, and two had metastatic
disease. In all cases, trastuzumab was judged to have been unrelated/unlikely to be related to cardiac problems.
d Denominators reduced owing to either deaths or withdrawal of consent for follow-up within the first 6 months.
e Denominators reduced owing to the removal of the three patients known not to have started trastuzumab treatment.
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stopped because of reduced LVEF, and left ventricular function then recovered > 3 months after
treatment had stopped. The patient was then diagnosed with chronic obstructive pulmonary disease,
which accounted for her breathlessness, and died of chronic obstructive pulmonary disease 78 months
after breast cancer diagnosis. There was one case of cardiac amyloid and one of cardiac sarcoid; neither
was judged to be related to trastuzumab. One patient was reported to have right ventricular arrhythmic
cardiomyopathy, which has a known genetic basis (mostly desmosomal genes) with physiological triggers
(e.g. extreme endurance sports), and therefore this was judged unlikely to be related to trastuzumab.
One patient had a low LVEF of 48% recorded after three cycles of trastuzumab; the trastuzumab was
stopped, and the patient was diagnosed with symptomatic CHF and started cardiac medication. Her
LVEF normalised, and she remained on preventative cardiac medication. She had received 300 mg/m2
epirubicin. Her death was due to metastatic breast cancer. One patient had a reduced LVEF during
trastuzumab treatment, which was discontinued after four cycles when LVEF was 30%. The patient
was started on cardiac medication and further investigations revealed that she had coronary artery
disease. After she stopped trastuzumab, her LVEF recovered to normal, at 50%. The cause of her
death 6 years later was recorded as metastatic breast cancer, with a secondary cause of death of
cardiomyopathy. However, no supporting evidence was provided for cardiomyopathy (no autopsy).
Presence of cardiomyopathy was felt unlikely to be related to trastuzumab and most likely to be
related to documented coronary artery disease or otherwise anthracyclines (300 mg/m2 of epirubicin).
Trastuzumab modifications
Complete trastuzumab treatment data are available for 3921 (96%) of the 4088 patients (see Figure 2).
Delays in trastuzumab cycles were caused by cardiotoxicity in 5% of the 12-month patients (fifth most
common reason) and 6% of the 6-month patients (third most common reason) (see Appendix 1, Table 34).
However, cardiotoxicity was the most common reason reported for trastuzumab treatment being
stopped early [206 (46%) out of 449 patients who received fewer cycles than randomised to receive:
(146; 43%) of 336 12-month patients stopping early and 60 (53%) of 113 6-month patients stopping
early] (see Figure 4). Most commonly, patients’ trastuzumab treatment was stopped early because of
cardiotoxicity (i.e. cardiotoxicity was the reason in over half of cases during that cycle) in cycles 4–8 for
both 6- and 12-month patients, and also in cycles 10 and 13 for 12-month patients (Figure 14). Cardiac
monitoring with LVEF commenced after four cycles of trastuzumab, and this corresponded to the time
point at which we observed an increase in the number of patients stopping trastuzumab early because
of cardiac toxicity.
We were interested to see whether cardiac problems occurring within the first 3 months of trastuzumab
(early) correlated with early cessation more than those occurring at 4–12 months (late). Clinical cardiac
dysfunction occurred early in 138 12-month patients, of whom 82 (59.2%) completed 18 cycles, and
late in 217 patients, of whom 105 (48%) completed 18 cycles (see Appendix 1, Table 43). Clinical cardiac
dysfunction occurred early in 149 6-month patients, of whom 106 (71%) completed nine cycles, and late
in 169 patients, of whom 119 (70%) completed nine cycles. Low LVEF occurred early in 74 12-month
patients, of whom 31 (42%) completed 18 cycles, and late in 205 patients, of whom 78 (38%) completed
18 cycles (see Appendix 1, Table 44). Low LVEF occurred early in 81 6-month patients, of whom 53 (65.5%)
completed nine cycles, and late in 145 patients, of whom 96 (66%) completed nine cycles. Therefore,
patients reporting cardiac dysfunction soon after being randomised to their treatment arm were as likely
as those reporting it late to complete their randomised trastuzumab treatment. There was a steady
increase in the cumulative number of patients stopping trastuzumab early as treatment continued.
Relative change of left ventricular ejection fraction at 6 and 12 months
A total of 3925 patients had their LVEF percentage reported both at baseline and at least one other
time point: 1964 12-month and 1961 6-month patients. The two treatment arms were well matched
on baseline LVEF percentages [median (IQR) 63% (59–67%) for 12-month patients and 63% (59–67%)
for 6-month patients; p = 0.43]. There were statistically significant reductions in LVEF at the 6- and
12-month time points in both treatment arms (all p < 0.0001). Despite similar relative changes from
baseline to 6 months across treatment arms [median (IQR) 0.97 (0.90–1.02) for 12-month patients
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and 0.97 (0.90–1.02) for 6-month patients; p = 0.50], 12-month patients showed significantly greater
reductions in LVEF by 12 months [median (IQR) being 0.97 (0.90–1.02) for 12-month patients and
0.98 (0.92–1.03) for 6-month patients; p = 0.0002].
Random-effects modelling
A quadratic curve was found to fit the LVEF data over all patients, demonstrating that cardiac function
recovers post treatment (Figure 15). This was seen for the entire trial population (p < 0.0001) and
for each randomised arm separately (both p < 0.0001). There was a significant difference between
treatments in terms of change over time (p = 0.016); quadratic modelling predicts an earlier recovery
of cardiac function after treatment completion in 6-month patients. No significant differences were
found in trastuzumab timing (concurrent or sequential; p = 0.77) in terms of LVEF changes over time
(see Appendix 2, Figure 33). Quadratic modelling predicted some differences between chemotherapy
types in terms of LVEF changes over time, with anthracycline-based chemotherapy resulting in a lower
nadir and a slower recovery of LVEF than anthracycline/taxane chemotherapy (p = 0.04) (see Appendix 2,
Figure 34). In addition, in terms of LVEF change over time, a significant difference was found depending
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FIGURE 14 Total number of trastuzumab cycles received, indicating the numbers of patients stopping because of
cardiotoxicity: (a) 12-month patients; and (b) 6-month patients. The light blue bar indicates patients who received the
exact number of cycles as randomised.
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on the number of anthracycline cycles patients received, whether three or fewer or more than three
(p = 0.04) (see Appendix 2, Figure 35).
Predictive factors of low left ventricular ejection fraction
Chemotherapy type was found to be predictive of low LVEF (p < 0.0001), with taxane and anthracycline
chemotherapy demonstrating an increased risk of low LVEF compared with taxane only (OR 2.30,
95% CI 1.18 to 4.47) in the 12-month group but not in the 6-month group (OR 1.31, 95% CI 0.68 to
2.51) (Table 12). Anthracycline-based chemotherapy without taxanes also demonstrated an increased
risk of low LVEF compared with the taxane-only group (OR 2.79, 95% CI 1.43 to 5.44 for 12-month
patients, and OR 2.13, 95% CI 1.12 to 4.06 for 6-month patients).
The number of anthracycline cycles received was also found predictive of low LVEF across all patients
(p < 0.0001). Receiving more than three cycles of anthracycline was associated with a significant
increase in the odds of developing low LVEF in both the 12-month arm (OR 1.69, 95% CI 1.27 to
2.25; p = 0.0003) and the 6-month arm (OR 1.76, 95% CI 1.27 to 2.43; p = 0.0007). Baseline LVEF was
also found predictive of low LVEF for all patients (reference ≥ 65%: 55% to < 65%, OR 2.15, 95% CI
1.66 to 2.78; < 55%, OR 15.6, 95% CI 10.8 to 22.5; p < 0.0001). This was the case for both 12-month
(reference ≥ 65%: 55 to < 65%, OR 2.30, 95% CI 1.63 to 3.26; < 55%, OR 18.2, 95% CI 10.8 to 30.6;
p < 0.0001) and 6-month patients (reference ≥ 65%: 55% to < 65%, OR 1.94, 95% CI 1.33 to 2.84;
< 55%, OR 13.7, 95% CI 8.1 to 23.0; p < 0.0001). Left-sided radiotherapy (p = 0.38), body mass index
(p = 0.93) and ethnicity (p = 0.15) were not found to influence the incidence of low LVEF. Among the
small number of patients who were taking cardiac medication before starting trastuzumab (44 in the
12-month arm and 55 in the 6-month arm), those in both arms were at significantly increased risk
(over fourfold) of developing cardiac dysfunction (both p < 0.0001). Age at randomisation predicted
for low LVEF in the 6-month arm (p = 0.0009) but not in the 12-month arm (p = 0.33), with 6-month
patients aged > 60 years having increased risk compared with the reference age of < 50 years
(60 to < 70 years; OR 1.96, 95% CI 1.27 to 3.03, and ≥ 70 years, OR 2.70, 95% CI 1.59 to 4.58).
Discussion
Trastuzumab is a highly effective adjuvant treatment for HER2-positive early breast cancer given in
addition to chemotherapy. Cardiotoxicity has been demonstrated consistently in patients receiving
trastuzumab. In PERSEPHONE, across all the assessments undertaken, less frequent and less severe
cardiotoxicity was demonstrated consistently in patients randomised to 6 months’ treatment than in
those randomised to 12 months’ treatment. Clinical cardiac dysfunction was seen significantly more
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FIGURE 15 Random-effects modelling predicted lines and 95% CIs, by randomised treatment arm.
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TABLE 12 Potential predictive factors of low LVEF, by randomised treatment arm
Factor
12-month patients, n (%) 6-month patients, n (%) Total, n (%)
Cases
(N= 228; 11%)
Controls
(N= 1814; 89%) OR (95% CI)
Cases
(N= 175; 9%)
Controls
(N= 1863; 91%) OR (95% CI)
Cases
(N= 403; 10%)
Controls
(N= 3677; 90%) OR (95% CI)
Chemotherapy p = 0.008 p = 0.003 p < 0.0001
Taxane based 10 (5) 188 (95) 1.00 11 (6) 189 (94) 1.00 21 (5) 377 (95) 1.00
Taxane and
anthracycline
108 (11) 884 (89) 2.30 (1.18 to 4.47) 70 (7) 921 (93) 1.31 (0.68 to 2.51) 178 (9) 1805 (91) 1.77 (1.11 to 2.82)
Anthracycline
based
110 (13) 740 (87) 2.79 (1.43 to 5.44) 93 (11) 751 (89) 2.13 (1.12 to 4.06) 203 (12) 1491 (88) 2.44 (1.54 to 3.88)
Anthracyclines p = 0.0003 p = 0.0007 p < 0.0001
≤ 3 cycles 88 (9) 922 (91) 1.00 63 (6) 915 (94) 1.00 151 (8) 1837 (92) 1.00
> 3 cycles 136 (14) 842 (86) 1.69 (1.27 to 2.25) 109 (11) 902 (89) 1.76 (1.27 to 2.43) 245 (12) 1744 (88) 1.71 (1.38 to 2.12)
Baseline LVEF p < 0.0001 p < 0.0001 p < 0.0001
≥ 65% 46 (6) 760 (94) 1.00 41 (5) 812 (95) 1.00 87 (5) 1572 (95) 1.00
55 to < 65% 134 (12) 961 (88) 2.30 (1.63 to 3.26) 93 (9) 948 (91) 1.94 (1.33 to 2.84) 227 (11) 1909 (89) 2.15 (1.66 to 2.78)
< 55% 44 (52) 40 (48) 18.2 (10.8 to 30.6) 38 (41) 55 (59) 13.7 (8.1 to 23.0) 82 (46) 95 (54) 15.6 (10.8 to 22.5)
Left-sided
radiotherapy
p = 0.15 p = 0.69 p = 0.38
No 145 (12) 1053 (88) 1.00 96 (8) 1052 (92) 1.00 241 (10) 2105 (90) 1.00
Yes 81 (10) 728 (90) 0.81 (0.61 to 1.08) 75 (9) 771 (91) 1.07 (0.78 to 1.46) 156 (9) 1499 (91) 0.91 (0.74 to 1.12)
Body mass index p = 0.90 p = 0.78 p = 0.93
Low/normal 75 (11) 596 (89) 1.00 56 (8) 611 (92) 1.00 131 (10) 1207 (90) 1.00
High 149 (11) 1206 (89) 0.98 (0.73 to 1.32) 119 (9) 1238 (91) 1.05 (0.75 to 1.46) 268 (10) 2444 (90) 1.01 (0.81 to 1.26)
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Factor
12-month patients, n (%) 6-month patients, n (%) Total, n (%)
Cases
(N= 228; 11%)
Controls
(N= 1814; 89%) OR (95% CI)
Cases
(N= 175; 9%)
Controls
(N= 1863; 91%) OR (95% CI)
Cases
(N= 403; 10%)
Controls
(N= 3677; 90%) OR (95% CI)
Age (years) at
randomisation
p = 0.33 p = 0.0009 p = 0.001
< 50 57 (10) 543 (90) 1.00 34 (6) 567 (94) 1.00 91 (8) 1110 (92) 1.00
50 to < 60 66 (11) 541 (89) 1.16 (0.80 to 1.69) 52 (8) 604 (92) 1.44 (0.92 to 2.25) 118 (9) 1145 (91) 1.26 (0.95 to 1.67)
60 to < 70 78 (13) 539 (87) 1.38 (0.96 to 1.98) 61 (11) 519 (89) 1.96 (1.27 to 3.03) 139 (12) 1058 (88) 1.60 (1.21 to 2.12)
≥ 70 27 (12) 191 (88) 1.35 (0.83 to 2.19) 28 (14) 173 (86) 2.70 (1.59 to 4.58) 55 (13) 364 (87) 1.84 (1.29 to 2.63)
Ethnicity p = 0.33 p = 0.27 p = 0.15
White 192 (12) 1464 (88) 1.00 147 (9) 1501 (91) 1.00 339 (10) 2965 (90) 1.00
Other 11 (9) 115 (91) 0.73 (0.39 to 1.38) 7 (6) 111 (94) 0.64 (0.29 to 1.41) 18 (7) 226 (93) 0.70 (0.43 to 1.14)
Cardiac
medication
before
trastuzumab
p < 0.0001 p < 0.0001 p < 0.0001
No 213 (11) 1785 (89) 1.00 160 (8) 1823 (92) 1.00 373 (9) 3608 (91) 1.00
Yes 15 (34) 29 (66) 4.34 (2.29 to 8.22) 15 (27) 40 (73) 4.27 (2.31 to 7.90) 30 (30) 69 (70) 4.21 (2.71 to 6.54)
Cases are patients reporting one or more low LVEF measurement during the 12-month reporting period. Controls are patients reporting no low LVEF measurements during the
12-month reporting period. Results in bold indicate a 95% CI that does not span 1.
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often in 12-month patients than in 6-month patients [228/1987 (11%) vs. 156/2008 (8%) respectively;
p < 0.0001], and more than twice as many 12-month patients stopped trastuzumab early because of
cardiac toxicity (8% vs. 3%; p < 0.0001). Low LVEF measurements were recorded in the PHARE trial,63
and reported reductions in cardiac function (reduced LVEF) occurred in 5.9% (100/1680) of the 12-month
arm and in 3.4% (58/1690) of the 6-month arm (p = 0.001). These rates are somewhat lower than those
seen in PERSEPHONE and this may be partly because all patients in PHARE were randomised after
receiving between 3 and 6 months of trastuzumab and had normal LVEF at that point of randomisation,
whereas in PERSEPHONE 44% of patients were randomised before receiving any trastuzumab, and 82%
were randomised before they had received five cycles. This means that whereas the PHARE trial excluded
all patients who developed low LVEF within the first 3–6 months of treatment, PERSEPHONE did
not. The HERA trial55,56 reported cardiac adverse events, which led to trastuzumab being discontinued
permanently in 9.4% of patients in the 24-month arm and in 5.2% of patients in the 12-month arm. In
PERSEPHONE, 8% of patients in the 12-month arm and 3% of patients in the 6-month arm (p < 0.0001)
stopped trastuzumab permanently because of cardiac dysfunction. In the HERA trial, substantial
reductions in LVEF (to < 50%, with a decrease of ≥ 10% absolute value) were seen in 7.2% of 24-month
patients and 4.1% of 12-month patients. In PERSEPHONE, these substantial reductions were seen in
99 out of 1955 (5%) patients in the 12-month arm and in 101 out of 1957 (5%) in the 6-month arm
in months 1–6 of treatment, but, as expected, during months 7–12 there were more in the 12-month
arm than in the 6-month arm [102/1880 (5%) and 61/1701 (4%) respectively; p = 0.01]. The lower
rates of substantial reductions in LVEF in the HERA trial than in PERSEPHONE are likely to reflect the
stringent entry criteria in the former of LVEF ≥ 55%, whereas PERSEPHONE accepted patients who had
an institutionally normal LVEF, which could be 50–55%. As in the HERA trial 24 months’ trastuzumab
was not shown to be more effective than the standard of 12 months’ trastuzumab,13 but caused more
cardiotoxicity, 12 months’ treatment has remained the standard.
Random-effects modelling of LVEF measurements on the whole population provided some interesting
comparisons between the 6- and the 12-month arms. Both fit best with a quadratic model during
treatment and on recovery up to 15 months after the start of trastuzumab. This suggests recovery from
cardiac effects of trastuzumab similar to that reported in other trastuzumab adjuvant studies.56,58,63
There is a lower LVEF nadir and a slower recovery in 12-month patients than in 6-month patients.
This suggests that the longer the trastuzumab treatment, the greater the cardiac dysfunction and the
longer the recovery time. In terms of trastuzumab timing with chemotherapy, there were no significant
differences between concurrent and sequential treatment delivery. Modelling by type of chemotherapy
(anthracycline based, taxane based or anthracycline/taxane) showed that all treatments fit best into the
quadratic model, but there was a difference in LVEF changes over time, with a lower nadir and slower
recovery with anthracycline-based chemotherapy than with anthracycline/taxane-based treatments.
Higher cumulative anthracycline exposure is likely to be the explanation for this finding.
Analysis of LVEF results by assessment method used highlighted some interesting findings.
ECHO was more frequently used (in 71% of cases) than MUGA scans (17% of cases) (see Appendix 1,
Table 41). However, abnormal values were reported on 10% of MUGA scans compared with only 4%
of echocardiograms. It is possible that MUGA was the ‘preferred’ modality when cardiac problems
were suspected on clinical grounds, perhaps because it was more easily available in clinical practice.
An alternative explanation is that because the abnormal range for LVEF, when measured using MUGA,
varies between institutions, and in many cases is lower (e.g. < 43%) than that for ECHO (< 50%), a
higher proportion of MUGA-derived LVEFs than ECHO-derived LVEFs will be < 50%, including some
patients with normal heart function. In our analysis of monitoring patients on trastuzumab treatment,
we took a cut-off point of 50% as the lower limit of normal regardless of the modality of assessment,
in accordance with national guidelines, and this is likely to have influenced the incidence of ‘abnormal’
results from the MUGA investigations.
Some researchers have reported genetic alterations within the HER2 receptor that may predispose
a patient to cardiac toxicity from trastuzumab.67–69 Most recently, a meta-analysis of available studies
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has identified a HER2 variant, HER2 rs1136201, as a risk variant for reduced LVEF with trastuzumab
(pooled OR 2.43, 95% CI 1.17 to 5.06; p = 0.018).70 In a companion translational pharmacogenetic
research study (PERSEPHONE PGSNPs), a collection of blood samples for germline analysis has been
completed. A total of 3801 (93%) PERSEPHONE patients consented to provide a blood sample to
the project but, owing to capacity and logistical issues at sites, samples from 3392 (83% of all 4088,
89% of those who consented) were collected. These samples will allow us not only to validate these
potential predictive genetic alterations but also, in a genome-wide association study, to discover other
possible genetic factors predisposing to trastuzumab-induced cardiotoxicity.
In terms of predictive factors for cardiac dysfunction, as measured by reduction in LVEF, our study
shows that, regardless of whether treatment lasts 6 or 12 months, baseline LVEF measurements
are important. As a surrogate for effects of radiotherapy on the heart, we compared patients who
had right-sided tumours with those who had left-sided tumours. Despite other reports of increased
cardiotoxicity in patients with left-sided HER2-positive breast cancer,71 we did not find an interaction
with radiotherapy and sidedness. However, the follow-up in our study is relatively short, and cardiac
effects of radiotherapy occur up to 20 years later.72 In the whole group there is an increasing risk with
each decade of age, and those aged > 70 years have an OR of 1.84 for low LVEF, which would suggest
that the predicted benefit of trastuzumab in this older age group would have to be larger to balance
the risk of cardiac dysfunction. However, in the present analysis this effect is seen in 6-month patients
and not in 12-month patients, which is somewhat unexpected. Patients with a lower baseline LVEF,
that is between 50% and 55%, have an OR of 15.6 (95% CI 10.8 to 22.5) of developing reductions
in LVEF measurements, compared with those with a baseline LVEF of ≥ 65%. These data, however,
should be interpreted with caution, as, if baseline values are close to the lower limit of normal LVEF
(i.e. 50%), a small absolute percentage LVEF fall, possibly not clinically meaningful, would reduce the
LVEF below the normal threshold. Anthracyclines have been demonstrated to cause cardiotoxicity in
a dose-dependent way and also to increase trastuzumab cardiotoxicity; this was shown in the BCIRG
trial,18 which excluded anthracyclines in one experimental arm (TCH). In many studies this interactive
effect is greater when more than three cycles of anthracycline are given. In this analysis our study
confirms this in both the 12- and the 6-month arms (OR 1.69, 95% CI 1.27 to 2.25, and OR 1.76, 1.27
to 2.43, respectively). Our previous publication on the first 2500 patients73 suggested that the cardiac
effects of more than three cycles of anthracyclines were not seen when 6 months of trastuzumab was
given. However, this analysis, which includes all patients and limits cardiac effects to the quantifiable
LVEF, does not confirm any differential effect between 6 and 12 months. Although in the BCIRG-006
study Slamon et al.18 showed that anthracyclines can be replaced by carboplatin, there was nevertheless
some reduction in 5-year DFS, 84% in the anthracycline-containing chemotherapy group compared
with 81% in the TCH group, although this difference was not statistically significant for superiority
of AC-TH compared with TCH, and the study was not powered for non-inferiority. Anthracyclines are
highly effective chemotherapeutic agents in the treatment of breast cancer,74,75 and may be particularly
so in HER2-positive breast cancer, with induction of immunogenic cell death one of the mechanisms
of action (see Chapter 7, Anthracycline effectiveness in HER2-positive breast cancer). Anthracyclines are
still received by the majority of breast cancer patients in the adjuvant setting. In addition, CEP17 and
topoisomerase II amplification (more common in the HER2-positive population) have been found to
be predictive biomarkers of anthracycline benefit.76 Controversy remains with regard to discontinuing
the use of anthracyclines altogether in HER2-positive disease, and therefore we should endeavour
to develop guidance to maximise the cardiac safety of the anthracycline–trastuzumab combination.
Clinical trials will often exclude patients who have a number of risk factors for cardiac disease.
However, in practice, patients with some risk factors who would not have been included in clinical
trials are offered new therapies in the clinic as standard. The PERSEPHONE trial, which ‘maps on to
standard practice’, had the advantage that patients in the trial had the same cardiac risk profile as
those receiving standard chemotherapy and 12 months’ trastuzumab. This has important implications
for interpreting and applying the results of this cardiology substudy to routine patients in the clinic in
terms of risk of cardiac toxicity.
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Chapter 5 Health economic analysis and
cost-effectiveness analysis
Introduction
An economic evaluation was conducted to assess the cost-effectiveness of using trastuzumab for
6 months compared with using it for 12 months in the treatment of patients with HER2-positive early
breast cancer. Two types of economic evaluation were performed: (1) a within-trial analysis, in which
cost-effectiveness was assessed 2 years after trastuzumab treatment commenced, using individual
patient data from the trial; and (2) a decision-analytic modelling analysis, in which cost-effectiveness
was estimated over a lifetime horizon using best-practice modelling methods. The primary evaluation
adopted an NHS and Personal Social Services perspective. A secondary within-trial analysis was also
conducted, adopting a societal perspective.
Methods
Within-trial analysis
Individual patient data from the PERSEPHONE trial (database lock 6 March 2019) were analysed to
determine the costs and QALYs associated with the two trastuzumab treatment durations (6 months
and 12 months). To boost recruitment, a protocol change was implemented to allow the individuals to
be randomised into the trial at any point up to 6 months into their trastuzumab treatment. A landmark
analysis from 6 months into trastuzumab treatment was therefore appropriate for the economic
analysis as this represented the point at which the treatment pathways diverged between the arms.
The analysis followed the intention-to-treat principle to calculate the outcomes and costs incurred
by patients in the trial arms during the follow-up period of 18 months. QALYs were estimated using
the patient-completed EuroQol-5 Dimensions, three-level version (EQ-5D-3L), questionnaire77 in
combination with survival data. Information on resource use and treatments received was recorded
in structured CRFs and patient-reported questionnaires, allowing costs to be estimated. In July 2009,
a change to the health economics data collection was made (amended in the protocol). This change
affected the number of data collected at baseline. These data were poorly completed up to that date
and, following the change to the randomisation point, they were no longer needed for the health
economic analysis and so were removed. Full details of the changes can be found in Appendix 1, Table 45.
Cost-effectiveness is summarised as the incremental cost-effectiveness ratio (ICER) and incremental net
health benefit (INB). All analyses were conducted using the statistical package R (The R Foundation for
Statistical Computing, Vienna, Austria).
Quality-adjusted life-years
The primary measure of patient health benefit was the QALY. QALYs are a summary measure
combining estimates of patient survival (life-years) and the associated quality of life (utility).
Patient health-related quality of life was derived from the EQ-5D-3L questionnaire77 that was filled in
by patients at 0, 3 6, 9, 12, 18 and 24 months following the start of trastuzumab. Only the EQ-5D-3L
data collected from 6 months onwards are included in this landmark analysis, although the data
collected at 0 and 3 months are used in the multiple imputation (see Missing data). The EQ-5D-3L
is recommended by NICE as a generic measure of health-related quality of life for cost-effectiveness
analyses.78 It comprises five domains: mobility, self-care, usual activities, pain/discomfort and anxiety/
depression. Each domain consists of three levels: no problems, some problems and severe problems.
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This is a preference-based instrument whereby the values for each health state are elicited from the
UK population using the time trade-off method.79
Quality-adjusted life-years are then derived from the number of life-years weighted by the utility value
during that time.80 In this analysis, we implemented the area under the curve approach, which assumes
a linear transition between each follow-up time point.
If a participant died during the trial, it was assumed that his or her utility score was 0 from the date of
death until the end date of the trial and the transition to zero from the last non-zero score was linear.81,82
Where EQ-5D-3L data were missing and it was known that the individual had either a local recurrence
or a distant recurrence during that time period, data were imputed with average utility values identified
in the literature for each of these health states. For a distant recurrence, an average utility of 0.69 was
imputed.83 For a local recurrence, an average utility of 0.78 was imputed.83
The mean QALYs were derived by adjusting the baseline (6 months) utility using a linear regression
model. This can account for any potential imbalance between the two arms, as randomisation may have
not adequately addressed this issue.84,85
Resource use and costs data
Resource use data were sourced from the trial CRFs and from patient-completed questionnaires returned
at 6, 9, 12, 18 and 24 months. Partially completed patient questionnaires were supplemented by data
available in the CRFs. When data were available in both, the reported use was compared between the
two sources to account for any potential duplication.
The resource use data and costs can be classified into the following categories: community-based
health and social care, including visits or contacts with GPs, district nurses, physiotherapists,
occupational therapists, etc.; and hospital services, including outpatients, accident and emergency
attendances due to SAEs and hospitalisation costs (inpatients). These data were collected from the
patient questionnaires. Data on trastuzumab treatment including acquisition (endocrine therapies and
trastuzumab), administration and monitoring (including cardiology assessment) were all collected via
CRFs. In addition, details of surgical interventions undertaken during follow-up and the related costs
were collected using the CRFs.
The analysis adopted a NHS and Personal Social Services perspective for the cost evaluation, in line
with NICE recommendations.78 All of the unit costs used in the analysis can be found in Table 13 and
in Appendix 1, Tables 46–50. Costs were obtained from relevant sources, including the Unit Costs of
Health and Social Care,86 NHS Reference Costs 2017–1887 and the British National Formulary (BNF).88
TABLE 13 Unit costs associated with trastuzumab (including administration)
Cost (£) Source
150mg i.v. vial (Herceptin) 407.40 BNF 2018: NHS indicative price88
First dose, i.v. administration 252.36 NHS Reference Costs 2017–18:87 deliver complex chemotherapy, including
prolonged infusional treatment, at first attendance (OP, SB14Z)
Subsequent dose, i.v.
administration
95.24 NHS Reference Costs 2017–18:87 deliver simple parenteral chemotherapy at
first attendance (other, SB12Z)
Subcutaneous dose
(Herceptin) of 600 mg/5 g
1222.20 BNF 2018: NHS indicative price88
Subcutaneous dose
administration
18.45 Administration cost of €21.07 taken from O’Brien et al.89 and converted
from euros to Great British pounds
i.v., intravenous.
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Given the short time frame of the analysis, a discount rate was not applied to the costs and benefits.
The costs used in the analysis were obtained for or inflated to the price year of 2017/18 and reported
in Great British pounds.
Trastuzumab acquisition and administration costs
During the trial, a subcutaneous formulation of trastuzumab became available, allowing trastuzumab
to be delivered via a handheld syringe or single-use injection instead of as an intravenous infusion. The
difference in cost between the delivery routes was taken into account, in addition to the difference in
cost of administration (see Table 13).
For those receiving trastuzumab intravenously, the total dose administered was obtained from the
dose used (8 mg for the first and 6 mg for the subsequent doses) multiplied by the patient weight. The
difference in time to administer the first dose (which typically takes longer) versus subsequent doses
was accounted for. The acquisition cost assigned to trastuzumab is £407.40 for a 150-mg intravenous
vial. Assuming vials being shared, the cost of 1 mg was £407.40/150 mg. The cost of administration
assigned was £252.36 for the first dose and £95.24 for subsequent doses.
For those receiving trastuzumab subcutaneously, the NHS cost of a fixed dose of 600 mg/5 g was
£1222.20.
Cardiology assessment costs
The main tests used for monitoring for cardiac complications as a result of trastuzumab were the
MUGA scan and ECHO. However, a number of patients also had other types of cardiology tests
reported on the CRF as free text, for example electrocardiography, magnetic resonance imaging (MRI),
X-ray and cardiologist opinion. The costs associated with each of these tests were obtained and added
to the cost of an outpatient visit (see Appendix 1, Table 46).
Cardiac treatment costs
Cardiac medication prescribed during the trial was also recorded on CRFs as free text, in addition to
the start date of treatment and (if relevant) the stop date. The duration of treatment was calculated for
each patient. If no stop date was reported, it was assumed that the treatment was taken permanently.
The cost of the cardiac medication was obtained by multiplying the cost of the daily dose of the
medication (see Appendix 1,Table 47) by the number of days.
Endocrine therapies
Costs associated with hormone therapies typically prescribed to breast cancer patients, including
anastrazole, exemestane, letrozole, goserelin and tamoxifen, were included in the analysis. The duration
of treatment was obtained from the trial CRFs using the start and stop dates; if the latter was not
reported, the treatment was assumed to be taken permanently. The cost of endocrine therapy was
obtained by multiplying the cost of the daily dose of the medication (see Appendix 1, Table 48) by the
number of days for which the medication was taken.
It was assumed that the bisphosphonate given in the trial as osteoporosis treatment was alendronate;
its cost was derived following the same approach.
Surgery costs
Details on surgical interventions related to tumour excision, biopsy and ovarian suppression (oophorectomy)
were captured during the follow-up. Surgery data coded in the trial CRF included delayed reconstruction,
mastectomy of treated breast, mastectomy of treated breast with reconstruction, mastectomy of contralateral
breast, mastectomy of contralateral breast with reconstruction and oophorectomy. The CRF allowed for
other surgical interventions relating to the patient’s primary breast cancer to be recorded as free text. These
were coded in line with the cost codes reported in NHS Reference Costs 2017–18.87 Where cost codes were
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unavailable, surgical interventions were categorised and costed as either minor or intermediate breast surgical
procedures, following discussion with clinicians in the team (see Appendix 1, Table 49).
Hospital services and community-based health and social care
Resource use information related to community-based health and social care, including visits or
contacts with GPs, district nurses, physiotherapists, occupational therapists and so on, and hospital
services, including outpatients, accident and emergency attendances due to SAEs, was collected from
patient questionnaires.
Inpatient data were also obtained primarily from the patient questionnaires; if these data were missing,
they were supplemented by the hospitalisation data reported in the treatment forms. The data reported
in the SAEs report did not include accurate admission and discharge dates and were therefore not used
in this analysis.
The unit costs assigned to this resource use can be found in Appendix 1, Table 50.
Missing data
Trastuzumab treatment
The total trastuzumab dose administered intravenously was based on the number of doses and patient’s
weight as recorded in the CRFs. Where the weight of the patient was missing but the dose number
was available, the weight was imputed with the previous measurement, or, if it was the first dose, the
subsequent measurement. Where the dose number and weight were missing, the average cost for that
dose across all individuals was imputed.
Cardiac treatment
When the start date of the cardiac treatment was missing, the date of the first abnormal result from
cardiology assessment was imputed. When dose information was missing for particular treatments, the
most commonly given dose of that medication was imputed. When the stop date of the medication was
missing, the medication was assumed to be taken until the end of follow-up and costed accordingly.
Missing data in the patient questionnaires
It was expected that some of the patient questionnaires would not be returned and that some of the
questionnaires would not be complete. Multiple imputation was carried out using the ‘mice’ package in R
version 3.6.2 (The R Foundation for Statistical Computing, Vienna, Austria), which implements a chained
equations approach. Imputation was carried out for each arm of the trial separately, as recommended.90
Costs were imputed for each patient at a total level for each subcategory (e.g. community health costs
or hospital services) at each time point. Utility scores were imputed at each time point.
Cost categories that did not have any missing data (e.g. trastuzumab treatment, surgical costs) were
used as predictors in the imputation model, in addition to other patient questionnaire data, DFS and
OS, and data collected in the baseline questionnaire (ER status, chemotherapy type, chemotherapy
timing, trastuzumab timing). Patient questionnaire data, including utility scores collected prior to
the landmark point (i.e. at 0 and 3 months), were also used as predictors. Whether an individual
experienced a local recurrence, a distant recurrence or a new primary during the follow-up period
was also added as an additional predictor.
A hierarchical multiple imputation approach was attempted to account for correlations between cost
categories within individuals at different time points; however, many of the missing data applied to all
time points for an individual and, therefore, data were insufficient to support this type of analysis.
Secondary analyses
A secondary analysis was carried out for the within-trial analysis, adopting a societal perspective.
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Patients were asked in the patient questionnaires whether or not they had lost earnings because of
their diagnosis and, if so, how much. They were also asked whether or not they had had to meet any
major one-off expenses of ≥ £50. As a secondary analysis, these data were used to compare out-of-
pocket patient expenses across the two arms. Where individuals reported major one-off expenses,
these were costed at £50 each (the minimum amount that could have been spent). This was combined
with the amount reported in terms of lost earnings. Where lost earnings were reported but the actual
amount was not specified, the average for each arm was imputed.
Uncertainty analyses
To calculate the potential impact of sampling uncertainty in the within-trial analysis, bootstrapping
with replacement from the full trial data set (including imputed values) using 10,000 simulations was
carried out. For each permutation of the data set, the total cost, QALY, ICER and incremental net
benefit were calculated. For each of these summary statistics, the median and 95% CIs (based on
percentiles) were calculated based on the 10,000 estimates. The incremental QALYs and costs for each
simulation were also plotted on a cost-effectiveness plane to provide a visual representation of the
impact that uncertainty has on the overall ICER result. These simulations were also used to calculate
the probability that 6 months’ trastuzumab treatment is more cost-effective than 12 months’ treatment.
Sensitivity analyses
It was anticipated that the majority of any cost difference between the two arms would result from
the difference in trastuzumab treatment costs. At the start of the trial, standard practice was to
deliver trastuzumab intravenously. Part-way through the trial, a subcutaneous version of trastuzumab
became available and, although the cost of this is higher, the savings in administrative time makes
it a cost-effective alternative. Since the end of the trial, the patent for intravenous trastuzumab has
expired and a significantly cheaper biosimilar intravenous drug has been released,88 and therefore
many hospitals have shifted back to delivering trastuzumab intravenously. In a sensitivity analysis,
we will explore the impact on cost and ICERs of the two drug formats: (1) Herceptin, delivered
subcutaneously; and (2) biosimilar trastuzumab, delivered intravenously [e.g. Herzuma® (Napp
Pharmaceuticals Ltd, Cambridge, UK), Kanjinti (Amgen Ltd, Thousand Oaks, CA, USA), Ontruzant
(Merck Sharp & Dohme Ltd, Hoddesdon, UK), Trazimera™ (Pfizer Inc., New York, NY, USA)].
In addition, in the main analysis we assumed that vials were shared for trastuzumab delivered
intravenously, as is standard practice at many sites. However, practice varies by site and therefore
we explored the impact of this assumption by calculating the cost if vials were not shared.
Lifetime decision model analysis
Some of the long-term health benefits and costs associated with the two trastuzumab treatment
durations occur beyond the PERSEPHONE trial follow-up period, such as the costs associated with
the treatment of recurrence and secondary primary cancers. A de novo decision-analytic model was
therefore developed to extrapolate the costs and health benefits of the two treatment durations over
a lifetime horizon. In line with the within-trial analysis, the base case adopts an NHS and social care
perspective. Costs and QALYs beyond the first year were discounted at an annual rate of 3.5%. The
statistical software R, version 3.6 (The R Foundation for Statistical Computing, Vienna, Austria), was
used to build the model.
Modelling approach and structure
A Markov model was built to estimate the total QALYs and costs per patient in each treatment arm.
Patients with HER2-positive breast cancer are at long-term risk of relapsing or dying and therefore the
model captures the time to these events and the associated quality of life and costs.
The structure of the model was developed in discussion with clinical experts and health economists,
and it was adapted from the structure of a previously published model.91 A 3-month model cycle was
selected in line with this model. Patients enter the model 6 months into their trastuzumab treatment.
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Cost and QALY data were elicited directly from patients and from CRFs for the subsequent 18 months,
and these data were used to inform the first six cycles of the model (summarised in the within-trial
analysis). During this period, the costs associated with symptomatic or asymptomatic reversible cardiac
toxicity were captured. As each state in a Markov model has no memory of ’time in state’, there is also
the assumption that each cycle in a recurrence state incurs identical transition probabilities. Where
necessary, this was overcome by building in tunnel states that allow transition probabilities, costs and
utility parameters to change depending on the number of cycles in that state.
After the treatment period, individuals could move to either a disease-free (follow-up) state or a
recurrence state. As data from the PERSEPHONE trial are the primary source of data for the model
parameters, the recurrence states and their definitions align with those used in the trial:
l locoregional (ipsilateral breast/chest wall, axillary and ipsilateral supraclavicular nodes)
l distant (excluding ipsilateral supraclavicular nodes)
l second primary (including contralateral malignant breast disease).
There is evidence that the cost of locoregional recurrence is high in the first year after relapse and then
falls to minimal levels.92 For this reason, we incorporated a 1-year tunnel state for non-distant relapses,
after which patients move into a ‘disease free after locoregional recurrence state’, provided that no
distant relapse has occurred. This also allowed us to build in an ongoing higher risk of developing a
distant recurrence for those who had experienced a locoregional recurrence. Those who had a second
primary cancer stayed in that state but could move to the locoregional, distant or death state. If
individuals developed a distant recurrence, they could stay in the same state or die, but they could
not transition to any of the other states. Individuals in the death state could not transition to any of
the other states, as death is an absorbing state. In addition, individuals in all states were at risk of dying
as a result of breast cancer, chronic heart failure or unrelated causes. The model structure is depicted
in Figure 16.
Disease free
Distant
recurrence
New primary or
contralateral BC
Locoregional
recurrence
Trastuzumab
treatment
Symptomatic or
asymptomatic
reversible
cardiac toxicity 
Death states
(1) Death from BC
(2) Death from CHF
All states Death
FIGURE 16 Model structure. BC, breast cancer.
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The model was run for the lifetime of the cohort (assuming that no one survived beyond 100 years old),
with a start age of 56 years (the median age at the landmark date in the trial). A half-cycle correction
was implemented in the model.
Cardiac toxicity
A key side effect of trastuzumab is cardiotoxicity.93 Throughout trastuzumab treatment, individuals in
the PERSEPHONE trial were monitored for signs of cardiotoxicity based on their LVEF. Data on cause
of death, including death as a result of chronic heart failure, were collected on a specific CRF that was
filled in when required.
Beyond the trial follow-up period, we looked to the literature for evidence of a long-term impact of
trastuzumab treatment on cardiovascular outcomes. The HERA trial collected long-term data (up to
11 years) on cardiotoxicity.13 A primary cardiac end point was defined as NYHA class III or IV toxicity
(confirmed by a cardiologist), and a clinically significant LVEF drop of at least 10 percentage points
from baseline to an absolute LVEF below 50%, or cardiac death. A secondary cardiac end point
was defined as asymptomatic (NYHA class I) or mildly symptomatic (NYHA class II), with a clinically
significant LVEF drop of at least 10 percentage points from baseline and to an absolute LVEF below
50%, confirmed by repeat assessment.
After 2 years post randomisation, there was no evidence that trastuzumab had a significant impact
on the number of primary cardiac end-point events. After between 4 and 5 years, there was also no
evidence that trastuzumab had a significant impact on either primary or secondary cardiac end points.
Therefore, in the model, the rates of symptomatic and asymptomatic reversible cardiotoxicity during
the trial follow-up period are incorporated, but it is assumed that beyond this point the rate of death
as a result of chronic heart failure follows UK population national statistics.94
Transition probabilities
The probability of being in each health state outlined in Figure 16 was calculated based on three
key sources of information: (1) data from the PERSEPHONE trial, (2) data from the HERA trial13 and
(3) published UK statistics on mortality rates95 and breast cancer rates96 (see Appendix 1, Table 51).
Up to 5.1 years (the median length of follow-up in the PERSEPHONE landmark analysis, i.e. from
6 months into trastuzumab treatment), the probability of being in each health state was based entirely
on data from the PERSEPHONE trial. Three-monthly transition probabilities (along with 95% CIs) for
each trial arm were estimated using the ‘msm’ package in R, which allows multistate modelling,
accounting for the competing risk of being in each health state.97
Parametric survival analysis was used to extrapolate DFS (which is a composite of locoregional
and distant recurrence) observed in the PERSEPHONE trial using the R package ‘flexsurv’. Survival
analysis was conducted by arm to relax the proportional hazards assumption. A range of distributions
(exponential, Weibull, Gompertz, log-normal and log-logistic) were fitted and compared visually
and based on the Akaike information criterion and the Bayesian information criterion. Plots of the
extrapolated curves and a table reporting the Bayesian information criterion and Akaike information
criterion values can be found in Appendix 2, Figure 36, and Appendix 1, Table 52. The log-normal
distribution was the better fit, which makes clinical sense as the peak rate of disease relapse is
between 2 and 5 years in the majority of landmark trials in early breast cancer, including the HERA
trial.13 The derived transition probabilities were compared with the numbers of DFS patients at risk
for years 5–11 in the HER2-positive subgroup analysis reported for the HERA trial.13 The proportions
of locoregional recurrences and distant recurrences were back-calculated from the DFS transition
probabilities by carrying forward the relative proportions from the PERSEPHONE trial period. The
probability of a second primary was based on UK national statistics, inflated by a relative risk identified
in the literature to account for the increased risk among treated individuals with breast cancer. Once
in a recurrence or a secondary primary cancer state, the same transition probabilities observed in the
trial were applied to capture movements from one recurrent state to another or transition to death.
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After the trial follow-up period, the risk of death from chronic heart failure was based on UK national
statistics. The risk of death from other causes was calculated by selecting the remaining individuals
(i.e. those who were transitioning to another state or dying from breast cancer or CHF) and multiplying
it by UK statistics on background mortality.
Utilities
Health state utility values were identified through a targeted literature review (see Appendix 1, Table 53).
The study by Seferina et al.98 reported utility values for the disease-free state, local recurrence and distant
recurrence. In this study, health-related quality of life was based on a cross-sectional survey among breast
cancer patients in four Dutch medical sites, using the EQ-5D-3L questionnaire. Utility values were
calculated using the UK tariff.79 The utility value for patients experiencing a new primary or contralateral
cancer was based on an alternative study.83 The utility associated with death was assumed to be zero.
Costs
The assessment of resource use and costs was performed adopting the NHS and social services
perspective. Unit costs were reported for 2018 values, where available. Cost estimations based on
values from other years were inflated to 2018 values using the Bank of England inflation calculator,
which is based on the Office for National Statistics’ composite price index.99 An annual 3.5% discount
rate (calculated monthly) was applied.
Resources used in the disease-free state corresponded to follow-up imaging (i.e. mammography, and clinical
follow-up), as indicated by NICE guidelines NG101.100 The unit costs were retrieved from the literature101
and based on NHS Reference Costs 2017–18.87 First-year costs as well as annual costs associated with
having a local recurrence were taken from a preliminary study of an Optimal Personalised Treatment of
early breast cancer (OPTIMA).102,103 Annual costs associated with having a distant recurrence were taken
from the same study. First-year costs and annual costs associated with developing a new primary or
contralateral breast cancer were taken from a previous economic evaluation.91 The cost of a new primary
or contralateral breast cancer was estimated by calculating the expected cost for a 5-year period (based on
a higher first-year cost and lower subsequent year costs) and converting this to a 3-monthly cost.
Costs of terminal care were applied as a one-off cost to all patients who died from breast cancer.
These costs corresponded to costs of care given to patients, in a hospital, in a hospice or at home,
in the last 2 weeks before dying. These costs were reported in the single technology appraisal TA563
submitted to NICE.104 The proportion of patients receiving hospital, hospice or home care was taken
from NICE clinical guideline CG81.105 The cost of a heart failure event was applied to all those who
died from chronic heart failure, incurred at the point of death.
Costs falling outside the health-care perspective were not included in the analysis.
Uncertainty analyses
Distributions around all parameters feeding into the lifetime model were modelled (see Appendix 1,
Tables 51, 53 and 54). The impact of uncertainty in the model parameters on cost-effectiveness
summary statistics was calculated in a probabilistic sensitivity analysis based on 10,000 simulations.
Cost-effectiveness analysis
The relative cost-effectiveness of using trastuzumab for 6 compared with 12 months was assessed using
standard decision rules, estimating the pairwise ICER.106 The ICER examines the additional cost that the
use of trastuzumab for 6 months incurs over its use for 12 months and compares this with the additional
benefits. The ICER estimate represents the additional cost required to generate one additional unit of
health outcome (QALY), which provides the basis for establishing whether or not the new approach
appears to provide good value for money to the NHS. Guidance from NICE suggests that an incremental
cost per additional QALY of around £20,000–30,000 is considered to represent an appropriate threshold
to establish value for money in the NICE Guide to the Methods of Technology Appraisal 2013.78
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To provide monetary value for the effectiveness, net monetary benefits were estimated by assigning a
monetary value for the threshold λ, where λ = £20,000 was used:
NMB = (λ × ΔQALY)−ΔCOST. (1)
The analysis followed the intention-to-treat principle, so that patient data were analysed based on the
treatment group to which patients were randomised. As the two trial arms were expected to differ
after 6 months of trastuzumab treatment onwards, the economic analysis was performed on data
reported from that point, consistent with the landmark analysis. The baseline EQ-5D-3L values were
obtained from the patient questionnaires returned at 6 months of trastuzumab treatment.
The point estimate of the ICER was obtained from the ratio of the difference between the adjusted
mean QALYs in the two trial arms to the difference in the mean costs.
Validation
Internal validation was conducted for both the within-trial analysis and the decision-analytic modelling.
Two health economists worked on different parts of the R code necessary to conduct the analyses and
verified the equations and parameters used in the analyses relative to their sources. Furthermore, each
one explained their part of the code to the other to look for possible computational errors. In the end,
all sections of the code were verified by both health economists.
In the discussion, we also compare the results of the present analysis with those of other relevant
published studies.
Subgroup analyses
Across both the within-trial analysis and the lifetime decision model, subgroup analyses were conducted
for the following groups, in line with the statistical analysis of the main trial:
l ER status – negative versus positive
l chemotherapy type – (1) anthracycline-based (no taxanes), (2) taxanes and anthracyclines or
(3) taxane-based (no anthracyclines)
l chemotherapy timing – adjuvant versus neoadjuvant
l trastuzumab timing – concurrent versus sequential (with respect to chemotherapy).
For the within-trial subgroup analyses, each imputed iteration of the trial data was filtered to those
in each subgroup, and a probabilistic sensitivity analysis via bootstrap simulation with replacement
(10,000 simulations) was conducted.
For the lifetime model subgroup analyses, the ‘msm’ package in R97 was used to calculate transition
probability matrices for each subgroup. Subgroup-specific DFS curves were then estimated and the
proportion of local and distant recurrences was calculated using the same method described for the
main model analysis (see Transition probabilities).
Results
Within-trial results
Costs
Individual resource use was gathered from CRFs and patient questionnaires. Around one-third of
the patient questionnaires were missing at each time point throughout the trial, with the proportion
increasing slightly towards the end of the follow-up period (Table 14). For the base-case cost analysis,
these missing data were imputed using the methods described previously.
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The within-trial costs from the landmark point to the end of follow-up included in the base-case analysis
(NHS and Personal Social Services perspective) are reported in Table 15. The total individual costs over
the 18-month period were significantly higher in the 12-month trastuzumab arm than in the 6-month
trastuzumab arm (mean: £15,298 vs. £5762; p < 0.01 based on Wilcoxon signed-rank test). This cost
difference is driven primarily by the reduction in trastuzumab treatment cost (mean: £10,060 vs. £1008).
There were some other cost-saving implications of shortening the duration of trastuzumab: lower costs
associated with hospital services (mean: £1418 vs. £1021) and lower costs associated with cardiology
assessment and medication (mean: £591 vs. £475).
Utilities
Table 16 reports the proportion of missing EQ-5D-3L data at each time point in the trial follow-up.
There was no notable difference in the proportion missing between trial arms. The EQ-5D-3L data are
presented for the time points included in this analysis (6, 12, 18 and 24 months). We also report the
data collected at 0 and 3 months, as these variables were used in the multiple imputation model to
predict individual-specific utility scores from 6 months onwards.
TABLE 14 Proportion of patient questionnaires returned
Follow-up time
point (months)
Treatment duration
12 months 6 months
Received (n) Expected (n) Missing (%) Received (n) Expected (n) Missing (%)
6 1439 2007 568 (28) 1403 2001 598 (30)
9 1399 2007 608 (30) 1347 2000 653 (33)
12 1418 2004 586 (29) 1397 1997 600 (30)
18 1303 1997 694 (35) 1303 1986 683 (34)
24 1242 1977 735 (37) 1189 1962 773 (39)
TABLE 15 Within-trial base-case costs: summary of the average per-patient NHS and social care costs by
trastuzumab duration
Cost category
Trastuzumab duration
Mean
difference (£)
p-value
(Wilcoxon
signed-rank
test)
12 months (£) 6 months (£)
Mean Median SD Mean Median SD
Community-based
health care
291.65 185.00 384.07 266.68 176.40 358.55 –24.98 0.06
Community-based
social care
135.54 0.00 630.75 173.44 0.00 946.48 37.90 0.91
Hospital services including
inpatient stays
1418.38 804.00 1970.13 1021.24 445.36 1582.87 –397.14 < 0.001
Trastuzumab treatment 10,059.73 11,087.79 4686.66 1008.15 0 2693.31 –9051.58 < 0.001
Surgical interventions 448.12 0.00 1760.46 515.34 0.00 1812.73 67.22 0.16
Cardiology assessment and
medication
590.98 507.40 234.43 475.34 507.40 234.14 –115.65 < 0.001
Endocrine therapies 571.59 44.56 729.48 551.78 44.48 718.63 –19.81 0.57
Total cost 15,297.61 15,060.00 6332.38 5761.88 4139.25 4927.89 –9535.74 < 0.001
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Table 17 provides a summary of the average utilities at each time-point in each arm after multiple
imputation for missing data. The SDs are relatively large, representing the uncertainty in these
estimates due to the multiple imputation. Individual-reported utilities were similar at baseline. There
was evidence of a slight increase in utility for the 6-month arm at 9, 12 and 18 months’ follow-up.
TABLE 16 Summary of missing utility data
Time point
12-month patients
(N= 2007), n (%)
6-month patients
(N= 2001), n (%) Total (N= 4008), n (%)
0 months 985 (49.1) 989 (49.4) 1974 (49.3)
3 months 764 (38.1) 710 (35.5) 1474 (36.8)
6 months (baseline) 625 (31.1) 645 (32.2) 1270 (31.7)
9 months 655 (32.6) 702 (35.1) 1357 (33.9)
12 months 641 (31.9) 666 (33.3) 1307 (32.6)
18 months 764 (38.1) 755 (37.7) 1519 (37.9)
24 months 811 (40.4) 864 (43.2) 1675 (41.8)
TABLE 17 Patient-reported utilities over time for imputed utilities (used in the within-trial base-case analysis)
Time point (months) Statistic
Treatment duration
p-value (base case;
Wilcoxon signed-rank test)12 months 6 months
6 (baseline) Mean 0.75 0.75 0.56
Median 0.76 0.76
SD 0.22 0.23
9 Mean 0.76 0.76 0.73
Median 0.80 0.80
SD 0.22 0.21
12 Mean 0.76 0.77 0.03
Median 0.80 0.80
SD 0.23 0.23
18 Mean 0.76 0.77 0.123
Median 0.80 0.80
SD 0.24 0.24
24 Mean 0.77 0.76 0.71
Median 0.80 0.80
SD 0.24 0.25
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Cost-effectiveness
The within-trial cost-effectiveness results are presented in Table 18 (deterministic results) and Table 19
(probabilistic results). During the 18-month follow-up period from the landmark point (6 months),
6 months of trastuzumab was associated with an estimated incremental cost saving of £9537 (95% CI
£9183 to £9890) and an incremental effect of +0.003 QALYs (95% CI −0.015 to 0.021 QALYs)
compared with 12 months of trastuzumab. Six months of trastuzumab is, therefore, cost-effective
and dominates the longer duration of trastuzumab treatment (INB 0.48, 95% CI 0.45 to 0.51).
Figure 17 shows the within-trial probabilistic cost-effectiveness analysis on the cost-effectiveness plane.
Each point (light blue) is one of the 10,000 simulated results and the triangle is the average of these points.
The spread around this point illustrates the estimated uncertainty around the average cost-effectiveness
TABLE 18 Within-trial analysis base-case deterministic cost-effectiveness results (NHS perspective and imputed QALYs)
Treatment
duration
(months)
Total
cost (£) Total QALY Life-years
Incremental
cost (£)
Incremental
QALY ICER (£)
Net benefit
(QALYs)
Incremental
net benefit
(QALYs)
12 15,298 1.14 1.472 – – – 0.38 –
6 5762 1.15 1.475 –9536 0.003 Dominant 0.86 0.48
TABLE 19 Within-trial probabilistic sensitivity analysis cost-effectiveness results (NHS perspective and imputed QALYs)
Treatment
duration
(months)
Total cost,
£ (95% CI)
Total QALY
(95% CI)
Life-years
(95% CI)
Incremental
cost, £
(95% CI)
Incremental
QALY
(95% CI) ICER (£)
Net benefit
(95% CI)
Incremental
net benefit
(95% CI)
12 15,298
(15,023 to
15,579)
1.14
(1.13 to
1.16)
1.471
(1.464 to
1.478)
– – – 0.38
(0.36 to 0.40)
–
6 5762
(5548 to
5981)
1.15
(1.13 to
1.16)
1.475
(1.468 to
1.481)
–9537
(–9890 to
–9183)
0.003
(–0.015 to
0.021)
Dominant 0.86
(0.84 to 0.88)
0.48
(0.45 to 0.51)
–0.2
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FIGURE 17 Within-trial probabilistic analysis on the cost-effectiveness plane.
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result. The diagonal line represents a willingness-to-pay threshold of £20,000 per QALY. All of the points
fall below this line, indicating 100% probability that 6 months of trastuzumab is more cost-effective
than 12 months. There is 100% probability that 6 months of trastuzumab is cost saving compared with
12 months; however, the probability that 6 months is more effective in terms of QALYs is 63%.
Subgroup analyses
The results of the within-trial subgroup analyses are reported in Appendix 1, Table 55. Across all of the
subgroups, there are no notable differences in the main results; the incremental QALY is consistently
close to 0 across all groups and 6 months of trastuzumab is consistently cost saving compared with
12 months of trastuzumab.
Sensitivity analyses
Sensitivity analysis 1: societal cost analysis
Costs to the patient were estimated based on the patient-reported loss in earnings and major expenses
incurred (Table 20). There was no evidence of a significant difference in costs to the patient between
the trial arms, although the mean total cost to the patient was slightly higher in the 12-month arm
(£3026 vs. £2048). The total patient costs were combined with the NHS and Personal Social Services
costs to provide an overall estimate of the societal cost in each arm.
Sensitivity analysis 2: comparing trastuzumab drug costs
Given the recent changes to the cost of trastuzumab, we carried out a sensitivity analysis to explore
the implications of these changes on the cost of trastuzumab for 6 months compared with 12 months.
During the trial, a total of 52,765 doses of trastuzumab were given; 42,044 (80%) doses were
administered intravenously and the remaining doses were administered subcutaneously (n = 10,721,
20%). For the within-trial analysis, the cost of intravenous trastuzumab was based on the price of
Herceptin, as this was the only intravenous option at the time. The patent for intravenous trastuzumab
has since expired, and a number of cheaper biosimilar alternatives are now on the market.
The following analysis compares the cost of trastuzumab if everyone is treated with (1) subcutaneous
Herceptin, (2) intravenous Herceptin or (3) biosimilar intravenous trastuzumab.
The results indicate that there remains a significant difference in trastuzumab treatment cost between
the arms across all of the different pricing options (Table 21). The average overall cost for the intravenous
biosimilar options is lowest, followed by subcutaneous Herceptin.
Sensitivity analysis 3: exploring the impact of the vial-sharing assumption
In the base-case analysis, we assumed that vials were shared when trastuzumab was delivered
intravenously, which is standard practice in many sites with a large number of treatments as it
TABLE 20 Within-trial societal perspective analysis
Cost category
Trastuzumab duration
Mean
difference (£)
p-value
(Wilcoxon
signed-rank
test)
12 months (£) 6 months (£)
Mean Median SD Mean Median SD
Lost earnings 3008.03 0.000 8722.83 2030.94 0.000 6900.06 –977.09 0.65
Major expenses 17.07 0.00 40.74 17.54 0.00 41.27 –0.47 0.68
Total cost to patient 3025.57 0.00 8730.62 2048.00 0.00 6907.32 –977.56 0.44
Total cost to NHS and
patient
18,323.18 15,897.79 11,416.77 7809.88 4902.65 8984.75 –10,513.30 < 0.001
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minimises wastage and saves costs. However, this may not be standard practice across all sites, and
therefore we explored the impact on cost if vials were not shared (see Table 21). The overall cost of
trastuzumab treatment increases, in addition to the cost saving between the two arms.
Lifetime model results
Cost-effectiveness results
The results of the lifetime model base-case analysis are presented in Table 22. Compared with 12 months
of trastuzumab, reducing treatment duration to 6 months is estimated to produce a lifetime cost saving
of £9316 and a slight reduction of 0.01 QALYs per individual. Reducing the length of treatment of
trastuzumab therefore has a negligible negative impact on QALYs and is significantly cost saving, with
an expected INB of 0.46 QALYs. There is notable uncertainty around this result, however, with a wide
95% CI around this mean value (95% CI –2.21 to 1.98 QALYs).
The lifetime model base-case analysis results are presented in Figure 18 on the cost-effectiveness
plane. The triangle point is the mean incremental cost and QALYs across all of the simulations. Each
of the points on the graph represent one of the 10,000 simulated model results. The spread of these
points therefore illustrates the uncertainty around the average result. The diagonal line represents the
NICE willingness-to-pay threshold of £20,000 per QALY. Points that fall beneath this line are deemed
cost-effective; the spread of points above and below the line shows the uncertainty around the lifetime
cost-effectiveness of reducing the duration of trastuzumab to 6 months. This uncertainty is driven
TABLE 22 Lifetime decision model probabilistic sensitivity analysis of cost-effectiveness results (NHS perspective and
imputed QALYs)
Treatment
duration
(months)
Total cost
(95% CI)
Total QALY
(95% CI)
Life-years
(95% CI)
Incremental
cost (95% CI)
Incremental
QALY (95% CI) ICER
Net benefit
(95% CI)
Incremental
net benefit
(95% CI)
12 25,340
(21,660 to
30,702)
11.13
(10.35 to
11.85)
14.018
(13.23 to
14.66)
– – – 9.86
(8.91 to 10.70)
–
6 16,024
(10,371 to
28,569)
11.12
(9.09 to
12.27)
14.017
(11.57 to
15.14)
–9316
(–16,485 to
2907)
–0.008
(–2.09 to 1.19)
9016 10.32
(7.69 to 11.69)
0.46
(–2.21 to 1.98)
TABLE 21 Within-trial sensitivity analyses comparing trastuzumab costs
Sensitivity analysis
Trastuzumab duration
Mean
difference (£)
p-value
(Wilcoxon
signed-rank
test)
12 months (£) 6 months (£)
Mean Median SD Mean Median SD
Within-trial analysis 10,059.73 11,087.79 4686.66 1008.15 0.00 2693.31 –9051.58 < 0.001
Sensitivity analysis 2: comparing drug costs
Subcutaneous
Herceptin
9628.48 11,165.85 4116.19 956.06 0.00 2506.87 –8672.42 < 0.01
i.v. Herceptin 10,188.48 11,051.94 4756.50 1025.23 0.00 2748.28 –9163.25 < 0.01
i.v. biosimilar 9229.41 10,015.94 4303.39 928.850 0.00 2488.87 –8300.56 < 0.001
Sensitivity analysis 3: impact of vial-sharing assumption
No vial sharing 11,263.60 11,856.96 5334.86 1119.80 0.00 2972.26 –10,143.80 < 0.001
i.v., intravenous.
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primarily by uncertainty in the estimated effectiveness of 6 months’ trastuzumab: the probability that
reduced treatment duration is cost saving is 95%, whereas the probability that 6 months’ trastuzumab
is as effective as or more effective than 12 months’ is 58%.
The cost-effectiveness acceptability curve (Figure 19) shows the probability that each treatment
duration is the most cost-effective alternative (i.e. has the highest expected net benefit) across varying
willingness to pay per QALY thresholds. At a threshold of £20,000, 6 months of trastuzumab has a 73%
probability of being cost-effective compared with 12 months of trastuzumab, dropping to 66% at a
£50,000 willingness-to-pay threshold and remaining above 61% at a £150,000 threshold.
Subgroup analyses
The results of the lifetime decision model subgroup analyses are reported in Table 23 and shown
in Figure 20. For some subgroups (concurrent trastuzumab timing, taxane-based chemotherapy and
neoadjuvant chemotherapy timing), the incremental net benefits are negative. For these subgroups,
the total QALYs for 12 months of trastuzumab treatment compared with 6 months are notably higher.
For example, individuals who received taxane-based chemotherapy and 6 months of trastuzumab had
an estimated incremental QALY loss of –0.73 (95% CI –1.52 to 0.33) compared with 12 months of
trastuzumab. Six months of trastuzumab remained cost-saving, although the cost savings were slightly
lower than those observed in the main trial analysis (–£8318 vs. –£9316). The cost-effectiveness
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FIGURE 19 Lifetime decision model cost-effectiveness acceptability curve.
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TABLE 23 Lifetime decision model probabilistic sensitivity analysis cost-effectiveness results: subgroup analyses
Subgroup
Treatment
duration Total cost, £ (95% CI) Total QALY (95% CI)
Incremental cost,
£ (95% CI)
Incremental
QALY (95% CI) ICER (£)
Net benefit
(95% CI)
Incremental net
benefit (95% CI)
ER status negative 12 months 27,596 (23,612 to 33,069) 10.67 (10.06 to 11.25) – – – 9.29 (8.57 to 9.97) –
6 months 19,712 (15,284 to 25,747) 10.38 (9.74 to 10.98) –7884 (–11,351 to –4108) –0.29 (–0.88 to 0.28) 26,851 9.39 (8.61 to 10.11) 0.10 (–0.65 to 0.84)
ER status positive 12 months 25,177 (22,385 to 28,980) 11.24 (10.68 to 11.78) – – – 9.98 (9.36 to 10.57) –
6 months 15,726 (12,837 to 19,699) 11.24 (10.69 to 11.78) –9450 (–11,749 to –7109) –0.002 (–0.39 to 0.38) 3,924,828 10.45 (9.82 to 11.04) 0.47 (–0.03 to 0.96)
Anthracycline-based
chemotherapy
12 months 24,299 (21,522 to 27,935) 11.16 (10.60 to 11.69) – – – 9.94 (9.33 to 10.52) –
6 months 14,767 (12,164 to 18,330) 11.33 (10.79 to 11.85) –9532 (–11,701 to –7392) 0.17 (–0.18 to 0.52) Dominant 10.59 (9.99 to 11.16) 0.65 (0.19 to 1.09)
Concurrent trastuzumab 12 months 26,421 (23,685 to 30,084) 11.30 (10.76 to 11.82) – – – 9.98 (9.38 to 10.55) –
6 months 19,569 (15,766 to 24,875) 10.75 (10.15 to 11.32) –6852 (–9521 to –3472) –0.55 (–1.01 to –0.10) 12,564 9.78 (9.05 to 10.44) –0.20 (–0.81 to 0.38)
Sequential trastuzumab 12 months 26,705 (23,120 to 31,566) 10.79 (10.23 to 11.34) – – – 9.45 (8.79 to10.09) –
6 months 15,835 (12,789 to 19,975) 11.11 (10.55 to 11.64) –10,871 (–13,770 to –8412) 0.32 (–0.10 to 0.75) Dominant 10.32 (9.68 to 10.91) 0.86 (0.33 to 1.42)
Adjuvant chemotherapy 12 months 25,210 (22,189 to 29,350) 11.12 (10.57 to 11.66) – – – 9.86 (9.24 to 10.46) –
6 months 15,235 (12,344 to 19,235) 11.18 (10.62 to 11.72) –9975 (–12,440 to –7560) 0.05 (–0.34 to 0.45) Dominant 10.41 (9.78 to 11.01) 0.55 (0.05 to 1.06)
Neoadjuvant
chemotherapy
12 months 29,321 (25,377 to 34,656) 10.73 (10.12 to 11.33) – – – 9.26 (8.51 to 9.97) –
6 months 25,948 (19,699 to 34,464) 9.83 (9.09 to 10.52) –3373 (–7726 to 2340) –0.91 (–1.64 to –0.22) 3727 8.53 (7.56 to 9.41) –0.74 (–1.71 to 0.17)
Taxane-based
chemotherapy
12 months 27,323 (23,167 to 35,160) 11.01 (9.95 to 11.73) – – – 9.64 (8.28 to 10.48) –
6 months 19,005 (14,524 to 25,428) 10.27 (9.56 to 10.92) –8318 (–14,911 to –3011) –0.73 (–1.52 to –0.33) 11,344 9.32 (8.43 – 10.09) –0.32 (–1.35 to 1.07)
Anthracycline- and taxane-
based chemotherapy
12 months 28,146 (24,319 to 33,300) 10.90 (10.30 to 11.48) – – – 9.49 (8.79 to 10.16) –
6 months 18,995 (15,008 to 24,503) 10.75 (10.12 to 11.36) –9151 (–12,479 to –5617) –0.15 (–0.69 to 0.39) 63,049 9.80 (9.05 to 10.51) 0.31 (–0.41 to 1.01)
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results for the remaining subgroups were roughly in line with the main trial analysis results, except for
those receiving trastuzumab sequentially to chemotherapy. The incremental QALY gain for the sequential
subgroup was 0.32 (95% CI –0.10 to 0.75), with estimated cost savings of £10,871 (95% CI –£13,770 to
–£8412). However, the CIs indicate that there is some uncertainty associated around this result.
Twelve months of trastuzumab is therefore the preferred option in the three contextual subgroups:
neoadjuvant, concurrent and taxane-only chemotherapy.
Sensitivity analyses
One-way sensitivity analyses were conducted by modifying the base-case value for each parameter
by 20% higher and lower and assessing the impact on incremental net health benefit. The results
can be found in the tornado plot in Figure 37 (see Appendix 2). Varying the cost of trastuzumab had
the biggest impact, as expected. Varying the utility associated with the disease-free health state and
the new primary cancer health state had the next largest impact on the results, followed by varying the
rate of distant recurrence.
Discussion
This chapter has presented an economic evaluation of the cost-effectiveness of 6 months of trastuzumab
compared with 12 months for individuals with HER2-positive early breast cancer. The evaluation
consists of a within-trial analysis and a lifetime decision model. The within-trial analysis assessed
cost-effectiveness using individual patient data collected in the PERSEPHONE trial from the landmark
point (6 months post initiation of trastuzumab treatment) for a duration of 18 months. The lifetime
decision model evaluated cost-effectiveness over a lifetime horizon by extrapolating data from the main
trial. Both analyses were conducted from an NHS and Personal Social Services perspective. Subgroup
analyses for both were also conducted in line with the statistical analysis plan for the main trial. For the
within-trial analysis, data collected on patient out-of-pocket expenses and lost earnings were used to
inform a secondary analysis adopting a societal perspective.
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The within-trial cost-effectiveness results estimated that 6 months of trastuzumab was associated with
an incremental cost saving of £9537 (95% CI £9183 to £9890) and an incremental effect of +0.003
QALYs (95% CI −0.015 to 0.021 QALYs) compared with 12 months of trastuzumab. Six months of
trastuzumab is therefore cost-effective and dominates the longer duration of trastuzumab treatment
(INB 0.48, 95% CI 0.45 to 0.51). The probability that 6 months compared with 12 months of trastuzumab
was cost-effective was 100%. This result held across all of the subgroup analyses; there were no notable
differences in DFS 18 months post the landmark date (2 years after initiation of trastuzumab). However,
uncertainty was evident in whether 6 months’ trastuzumab is the more effective strategy (probability
of 63%) in terms of incremental QALYs gained. The sensitivity analysis that compared different delivery
and drug cost options for trastuzumab indicated that the biosimilar intravenous options recently made
available are likely to result in the largest cost savings. A further sensitivity analysis was conducted
exploring the impact of the assumption that vials of intravenous trastuzumab would be shared. As
expected, the overall costs are higher if vials are not shared, leading to a larger cost saving for the
shorter duration of treatment. The results of the within-trial analysis should be interpreted with caution
by decision-makers as they do not take account of the long-term consequences of trastuzumab duration
for cancer recurrence and survival.
The lifetime decision model, which is the preferred analysis for NHS decision-making, estimated
cost savings of £9316 and a slight reduction of 0.01 QALYs per individual, indicating that a reduced
length of trastuzumab treatment of 6 months has a negligible impact on QALYs and is significantly
cost saving (INB of 0.46 QALYs). The slight negative difference in QALYs compared with the within-trial
analysis is likely to be due to the non-significant difference in DFS between the two trial arms. In this
analysis, however, there is notable uncertainty around the effectiveness results: the probability that
6 months’ trastuzumab is as effective as or more effective than 12 months’ trastuzumab is 58%. There
is, inevitably, large uncertainty around any model extrapolation. If DFS in the 12-month and 6-month
trastuzumab arms was to start to diverge as follow-up continues beyond the trial, then the results
of the lifetime modelling would be likely to be compromised. The HERA trial compared 1 years’ with
2 years’ trastuzumab treatment and found no additional benefit of the longer treatment duration over
a 10-year follow-up,13 suggesting that the main treatment benefits are realised in the first few years of
follow-up. Further to this, although the overall trial results demonstrate that 6 months of trastuzumab is
non-inferior to 12 months, the subgroup analyses for the lifetime model suggest that some individuals
may benefit from a longer duration of trastuzumab treatment. For example, those who received
taxane-based chemotherapy had an estimated incremental QALY loss of 0.73 (95% CI –1.52 to –0.33).
These results align with the DFS estimates reported for the main trial, but it is important to note the
considerable uncertainty around these results, given the much smaller sample sizes, and the significant
limitations of subgroup analyses.
A key strength of this analysis is the consideration of both the short- and long-term consequences of
different trastuzumab treatment durations. Interestingly, the within-trial subgroup analyses highlighted
no notable differences between groups because the differences in DFS emerge only after 2 years of
follow-up. This highlights the importance of using caution when interpreting and drawing conclusions
from early trial data. We were keen to use the data from the PERSEPHONE trial as far as possible
within the model, and the ‘msm’ (which stands for multistate model) package in R97 was incredibly useful
for fitting a multistate model to the longitudinal data available and estimating transition probability
matrices from the model. The main limitation of the model was that we could not find a study that
reported long-term (i.e. beyond 5 years) rates for local and distant recurrence in this patient group
with respect to trastuzumab duration. We therefore had to assume the same event rates observed in
the trial beyond 5 years, which may not reflect reality.
Clarke et al.107 recently conducted a three-arm cost-effectiveness analysis comparing different durations
(0 weeks, 9 weeks and 12 months) of adjuvant trastuzumab for those with early breast cancer. The
evaluation was based on a network meta-analysis of the various clinical trials evaluating the effectiveness
of different trastuzumab durations. The conclusions of the authors’ analysis suggested that 9 weeks of
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trastuzumab was cost saving and led to more QALYs than 12 months of trastuzumab (although the 95% CIs
overlapped across all arms).107 Unfortunately, data from the PHARE trial,47 which evaluated 6 months of
trastuzumab, could not be included owing to the late randomisation of individuals recruited. It would
be interesting to add the PERSEPHONE trial data to this existing network meta-analysis to include a
6-month arm comparison, although, given the later randomisation of individuals in the trial, the same
problems may be incurred as in the PHARE trial.
The next key step in this research is to explore whether or not we can predict who would benefit
from 12 months of trastuzumab and who needs a shorter treatment duration. Baseline data collected
in the trial could be used to develop a prediction model to start to answer this question, enabling
an economic evaluation comparing a stratified-risk approach to determining trastuzumab treatment
duration. On a more ambitious scale, an individual patient data meta-analysis of all of the trials
evaluating different trastuzumab treatment durations would allow a more powerful exploration
of potential predictors and the inclusion of shorter trastuzumab durations (e.g. 9 weeks).
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Chapter 6 Quality of life, patient-reported
experiences and reporting of results to patients
Introduction
In addition to standard quality-of-life tools and bespoke health economic booklets, patient-reported
experiences collected in a clinical trial provide valuable insight into the impact of treatment on patients’
daily lives. In the PERSEPHONE trial, patient-reported experiences were collected at the end of the
patient quality-of-life booklet on a free-text page leading with ‘Please use this page to make any
comments you would like about the study or your treatment that you think we or future patients
should know about’. All patients were encouraged to complete the full patient booklets but this was
not a mandatory part of the trial and patients were not excluded if they did not want to complete the
patient booklets. Hence there was no bias in the reporting of these data.
Methods
The aim was to assess the quality of life of all patients before they started trastuzumab treatment and
then after 3, 6, 9, 12, 18 and 24 months. However, for those entering the trial after their trastuzumab
treatment had begun, the same time points throughout their treatment were used but with the initial
form(s) missed. The quality-of-life questions comprised a question regarding the patient’s general health
and the EQ-5D-3L. Patients were invited to record comments about the study or their treatment on
a free-text page at the back of the patient booklet of all questionnaires collected from patients after
treatment or at follow-up.
Statistical methods
To assess the quantification of patients’ health, the frequencies of the different responses to the
general health question were assessed, and patients’ EuroQol-5 Dimensions (EQ-5D) visual analogue
scale scores over time were assessed graphically using box-and-whisker plots.
The free-text data were entered into the NVivo database and coded by treatment arm and time point
of the questionnaire. Two researchers and a patient representative looked at the data and began
by performing a simple content analysis. Many themes emerged from these data. This broad initial
analysis included all free text across all time points, regardless of treatment arm, to explore the whole
experience for patients undergoing trastuzumab.
Quality-of-life results
Patients were asked how they would describe their health in general. In total, 3910 patients (12-month
patients, n = 1960; 6-month patients, n = 1950) answered this question for at least one time point.
In both treatment arms, feelings of general health are seen to decline during the first 3 months of
trastuzumab treatment, with the proportion of patients reporting feeling ‘very good’ halving from
the baseline time point to the 3-month time point (from 32% to 16% and from 35% to 17% for 12- and
6-month patients, respectively) and the proportion of patients feeling ‘fair’ almost doubling over the
same time period (17% to 29% and 14% to 28% for 12- and 6-month patients, respectively) (Figure 21).
This period of time is when 46% of patients would have been receiving concurrent chemotherapy. In
both arms, feelings of general health are then seen to steadily improve after trastuzumab treatment
is completed.
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Patients were also asked to rate their own health state using the EQ-5D visual analogue scale. In total,
3902 patients (12-month patients, n = 1958; 6-month patients, n = 1944) completed the visual analogue
scale for at least one of the time points. In both randomised treatment arms, health states are seen to
remain steady from baseline to 3 months into treatment, with a trend towards a slow increase after this,
occurring slightly earlier for 6-month patients (Figure 22).
Patient-reported experiences
Across all time points, a total of 5610 free-text fields were completed. Some patients had completed
the free text at all or most time points; others had completed it just once, twice or not at all. Patients
offered information on all aspects of the study, including their views on the treatment, their care, the
questionnaire they were asked to complete and research itself. However, the most often mentioned
aspect of the study reported was the impact of the drug on patients personally: physically, psychologically
or socially.
0
0 3 6 9 12 18 24
1035
 
Patients (n) 1263 1394 1373 1288 1237 1218
General health
Months since starting trastuzumab
25
%
 o
f p
at
ie
n
ts
50
75
100
Very good
Good
Fair
Poor
(a)
4 3 3 2 2 3 3
17
29
47
51 57 57
55 53
52
24 25 23 20 17
32
16 17 16 20
24 28
0
0 3 6 9 12 18 24
1038 Patients (n) 1325 1338 1254 1195 1239 1165
General health
Months since starting trastuzumab
25
%
 o
f p
at
ie
n
ts
50
75
100
Very good
Good
Fair
Poor
(b)
2 4 2 2 2 2 3
14
28
25 20 19 20
17
49
51
55
57 53 52
53
35
17 19 21
26 26 28
FIGURE 21 General health: (a) 12-month patients; and (b) 6-month patients.
QUALITY OF LIFE, PATIENT-REPORTED EXPERIENCES AND REPORTING OF RESULTS TO PATIENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
Which side effects are due to trastuzumab?
The side effects patients reported were sometimes difficult to attribute to one specific treatment,
as many of the treatments were given concurrently or in close succession. This could potentially
cause problems with treatment management and should be kept in mind when reviewing the data:
Aches and pains especially below the waist slowing me down considerably; not sure if it’s my age,
the Herceptin treatment or the drug Arimidex to be taken for next 5 years. Also not sure if itching
on my back and top of arms is caused by Herceptin or Arimidex. I know the Arimidex can cause hot
flushes etc. so it could be a combination of each.
878
It is difficult to decide whether tiredness and hot flushes are due to Herceptin or the taking of
Anastrozole/Arimidex tablets.
1084
0
0
25
E
Q
-5
D
 v
is
u
al
 a
n
al
o
gu
e 
sc
al
e
50
75
100
(a)
3 6 9 12 15 18 21 24
Months since starting trastuzumab
0
0
25
E
Q
-5
D
 v
is
u
al
 a
n
al
o
gu
e 
sc
al
e
50
75
100
(b)
3 6 9 12 15 18 21 24
Months since starting trastuzumab
FIGURE 22 The EQ-5D visual analogue scale: (a) 12-month patients; and (b) 6-month patients.
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It is really difficult to tell which side effects are due to Herceptin and which ones are due to the
chemotherapy – especially when they are taken together.
1052
Results from the simple content analysis
From the first, simple content, analysis, 19 themes emerged (Figure 23).
The five most commonly reported aspects were:
1. aches and pains
2. fatigue
3. shortness of breath
4. emotional fragility
5. financial impact.
Aches and pains
Although aches and pains are effects known and reported by health-care organisations (Table 24), they
do not appear at the top of lists of side effects and are, arguably, not highlighted, but they appear to
have had a huge impact on patients and their daily activities. It is not known whether patients wished
to highlight them because of the perceived lack of emphasis elsewhere or because their impact was
particularly great but, for many patients, these side effects did appear to be particularly distressing
and intractable.
Aches and pains were mentioned in 524 responses. Common descriptions of this included an ‘aching of
leg muscles’ (4027), ‘a general feeling of aching in the joints which impedes exercise’ (4001) and ‘joints
and muscles hurt most of the time’ (325).
However, this could be extremely severe and debilitating and often seemed to increase over time:
Muscle and bone pain so bad it reduces me to tears.
2489
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My body aches more. I feel like a woman of 80 some days.
17
Joint pain has increased as months have passed.
619
TABLE 24 Side effects of trastuzumab as reported by high-traffic websites
Genetech 2017
(makers of
trastuzumab) Breast Cancer Care 2016 NHS Choices 2016
1 Fever Flu-like symptoms e.g. chills and
mild pain in some parts of the
body can occur during or shortly
after treatment
Reaction to medication e.g. chills,
high temperature, swelling of face
and lips, headache, hot flushes,
feeling sick, wheezing and
breathlessness
2 Feeling sick to your
stomach (nausea)
Nausea (feeling sick) – normally
mild and doesn’t last long
Tiredness and difficulty sleeping
3 Throwing up (vomiting) Diarrhoea (mild) Diarrhoea or constipation
4 Infusion reactions Soreness at the injection site Low number of infection-fighting
white blood cells which increases
risk of infections
5 Diarrhoea Less common side effects e.g.
headaches, dizziness, joint &
muscle pain, rash, vomiting or
breathlessness (often mild and
don’t usually happen after other
treatments)
Loss of appetite and weight loss
6 Increased cough Allergic reaction (rare) e.g.
flushing, skin rash, itching,
back pain, shortness of breath,
faintness, fever or chills
Pain in your muscles, joints, chest
or tummy
7 Headache Heart problems such as abnormal
heart rhythm (rare) can cause
symptoms such as breathlessness
and palpitations
Runny nose
8 Tiredness – Sore red eyes or watery eyes
9 Shortness of breath – Shaking
10 Rash – Dizziness
11 Low red and white
blood cell counts
– Cough
12 Muscle pain – Increased or decreased blood
pressure
13 – – Heart problems
Sources (accessed
July 2020)
www.gene.com/
patients/medicines/
herceptin
https://breastcancernow.org/
information-support/facing-breast-
cancer/going-through-breast-
cancer-treatment/targeted-
biological-therapy/trastuzumab-
herceptin#What%20are%20the%
20side%20effects%20of%
20trastuzumab
www.nhs.uk/conditions/herceptin/
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Bone pain in the hands and wrists – very painful. Plus occasional bone pain in elbows and ankles.
Pain still occurring since finishing Herceptin approximately six weeks ago.
3719
I still suffer with joint pain which I’ve had since I started Herceptin.
481
Achy joints. Shooting pains in arm . . .
860
Fatigue
Fatigue or tiredness was reported in 461 responses. Fatigue is the most common side effect of cancer
treatment and is increased with a combination of therapy.108 Its cause and effects are highly complex
and disruptive and have often been, arguably until recently, downplayed or overlooked.109 Here this was
described as ‘always tired’ (379), ‘extreme tiredness’ (489), ‘totally depleted of energy’ (4018) and ‘my
energy levels are down’ (14). However, this was again was often experienced as extreme and debilitating:
I do think that people receiving Herceptin should be told that it can cause increasing fatigue because
I thought I was going mad until someone told me.
188
Be prepared to be very tired during your treatment, I have found the fatigue hard to deal with. I am
usually a very active person and the tiredness has been difficult to deal with. The tiredness is horrid.
3650
Fatigue gets worse as treatment goes on.
3606
The fatigue and anxiety is unreal; I’ve become quite depressed. It’s not easy to explain to people this
might happen . . . but more information would be so helpful.
223
Fed up with tiredness & weariness. Sometimes only able to iron or garden for 20 mins then need to
sit down.
200
You should put in a question about extreme tiredness which cannot be regarded as an illness but really
affects your life.
1977
Shortness of breath
It is not clear whether shortness of breath correlates with the cardiac damage that trastuzumab is
known to cause,64 anaemia or infection. However, it is known that shortness of breath is a particularly
distressing, uncomfortable and frightening experience that limits both physical and social activity,
which may have led to its dominance among the responses:
Following my Herceptin treatment I became breathless very soon after walking (more than 500 yards)
or hoovering.
419
I have mitral valve weakening thus I am breathless. I am to visit [a specialist hospital] for this.
For these reasons I have to catch a taxi for dentist, doctor, optician etc.
3889
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I am still suffering with shortness of breath, extreme tiredness and severe aches in my joints. I had hoped
that by now I would have made a far better recovery from my treatment but sadly I feel rather
despondent that I am still so low and exhausted.
3626
Shortness of breath may also be significant as it is a reminder of potential cardiac damage, which
seemed particularly distressing to some patients:
I was extremely shocked at the damage to my heart as a direct result of Herceptin at such an early stage
in treatment. I feel that future patients should be made aware of the risk of heart failure in relation
to Herceptin.
1294
Herceptin treatment affected my heart. Although the MRI scan shows heart function is now OK,
I get anxiety and fear that the future prognosis is not good due to this . . . and worry constantly that
I will have problems in the future. I remain positive on a day to day basis, but have some bleak and
despairing moments.
123
I was told about the risks to my heart but I don’t think this was emphasised to the extent it should have
been. Because of the affect it has had on my heart I now have to undergo an MRI scan and angiogram.
Therefore I have decided to quit the Herceptin programme.
1051
Emotional fragility or depression
‘Emotional fragility’ was a term coined by one participant (1698), who felt that it was a more
appropriate descriptor than ‘depression’. Another participant (553) wanted to emphasise that anxiety
and depression should never be ‘lumped together’ as she felt that they were significantly different.
Many patients described a ‘black cloud’ (1510) and felt that they had lost all of their self-confidence as
a result of the impact of the treatment and side effects. They wanted to warn others that they should
be ‘prepared to feel down’ (1) and would ‘cry a lot’ (2627). Although patients seemed to equate this
with being in the trial or receiving treatment, arguably it may have been due to the loss and fear that
is known to occur after cancer treatment:
As far as the herceptin treatment the side effects are manageable and not as bad as chemo or
radiotherapy . . . I find my anxiety and depression increasing now though. I feel a bit lost and my safety
nets are being removed one at a time; I find myself dwelling increasingly on the possibility of recurrence
of the cancer my moods are often erratic and often unreasonable. I’m snappy and sullen instead of the
normal happy and philosophical/positive.
1377
The network & support has been really important e.g. friends/well-being group/family/hospital services/
activities etc. Initially for more physical & practical support but towards the end of treatment for mental/
emotional support & support in managing long-term recovery which has taken longer than I expected &
I don’t feel I’m there yet. Anything you can do to support & help people through this stage I feel is just as
important as the medical help & support given at early diagnosis & during treatment.
4061
Not sure whether it is the side effects from the Herceptin but have been feeling really low which is out of
character for me. Feeling really tired, depressed and anxious a lot.
381
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At times I have been quite depressed for a couple of days after having Herceptin . . . for 2/3 days
following treatment I felt quite depressed- on occasions this could be fairly bad: I’d be very tearful,
could not face socialising and was pessimistic about the future.
665
I have felt a little stressed and quite tearful over the past weeks.
735
I feel that a little more emphasis should be placed on the psychological effects felt by Cancer patients.
1038
I felt somewhat abandoned as I seemed to fall through the cracks of the support services on offer.
I didn’t know or have the emotional strength to call on the breast care nurse service and was unsure
whether I was still eligible for such support.
1100
. . . you feel well looked after physically, but the emotional side of the treatment journey is not really talked
about. I need and I feel I want to be looked after even now, I need more hugs, cuddles, reassurances.
1344
Financial impact
A total of 125 responses mentioned the importance of subsequent patients being made aware of the
financial aspects of treatment and involvement. This impact was from increased costs such as travel and
car parking or because of an inability to function and, therefore, to work in the same capacity as before.
Although patients seemed to be aware that this was unavoidable, they wanted to raise awareness:
Financially it’s crippling. If you’re low paid there is no help, nearly cost me my home as I wasn’t always
well enough to work overtime or do my 2nd job. Still in debt now. But I’m alive!!
2840
I have had increased regular outgoings arising solely from the effects of my illness since diagnosis.
I live alone and am not eligible for a social services care plan because I am in my 50s. Consequently I
have had to buy in the following services from time to time: home help/meal deliveries, laundry services,
taxis to appointments, putting the cat in the cattery during periods of incapacity/hospitalisation. Since
diagnosis, I would estimate that these additional regular cost amount to several thousands of pounds.
This together with the reduction in my income (end of paid sick pay, return to work on reduced hours,
ill health retirement) has had a considerable effect on my standard of living.
1581
Although I have not incurred big one off costs I have had to spend between £4–6 every three weeks
whilst having Herceptin. This soon adds up over the year I will be having this treatment. Free parking
would be of great benefit.
2262
The financial cost of my diagnosis has been huge to my family. We have had no help with this burden as
my husband is working.
3843
The main input on my diagnosis has been on my work/employment. I have had to reduce my work hours
from 37 per week to 18 1/2 hours. Although I now spend more time keeping fit i.e. swimming, walking,
etc. I no longer feel that I have a career – just a job. I can’t see me going back to full time employment
which makes me sad. On the other hand I now have a better work/life balance but this would not be the
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case if I had children or my husband did not have such a good job. I don’t think I would have had the
choice about taking a reduction in hours and would have struggles with the ongoing fatigue.
582
People should be aware of the cost involved in coming to hospital every 3 weeks – car parking, petrol,
time off work; it all mounts up.
39
My treatment and care has been excellent, but no-one prepares you for life after. I have been 24 years as
a Senior Court Usher and loving my work. Since I returned on a phase return, I can’t do my work because
of my pain and disability in my legs after the Herceptin, sleepless nights and this has made me very low
although I’m grateful to be here after my treatment. You do need ongoing support to help you through,
especially if your work is affected. I’m now doing a job I dislike but as a widow at 47 I have to earn a wage.
2106
The Herceptin injections cause the most trouble. They make you ache to the extreme you can’t walk
or stand if at all not for long. Due to my work (HGV driver) I can’t afford to not be able to stand.
Now I’ve had 6 months I’m stopping further injections.
3683
Other participant experiences
Between 50 and 100 responses cited another raft of aspects that were arguably more ‘visible’ to
others and matched more closely with the side effects described by organisations (see Table 24):
l Anxiety (95 responses): ‘I have lost a lot of confidence and get very anxious’ (336).
l Nail changes and soreness (95 responses): ‘Every fingernail was broken/torn (3429)’; ‘I can’t peel an
orange or use Sellotape’ (2728); ’very soft nails, sore hands, skin irritation’ (816).
l Hot flushes (88 responses): ‘I never feel very comfortable! I have to wear cotton/light clothing – not
nice in cold weather’ [14].
l Sore/’dripping’ nose (68 responses): ‘Constantly dripping nose’ [1424]; Very, very, very dry, scabby
nose (internal) when having the Herceptin [1412].
l Weight gain (67 responses): ‘Gradually worsening problem with water retention/swollen feet/legs/
body with each of the first 4 Herceptin injections – sometimes gaining over a stone in weight in
3 or 4 days and starting earlier with each cycle. For cycle 5 have swapped to intravenous Herceptin
to see if it makes any improvement – watch this space!’ [4081].
l Neuropathy (64 responses): ‘Continuous pins and needles in hands and feet, with finger tips
becoming increasingly sore. Painful balls of feet (like walking on marbles!) making walking
uncomfortable – have to wear shoes with very squashy, soft soles’ [4081].
l Skin rashes/dryness (52 responses): ‘Dry and cracked skin’ [1016]; ‘Skin looks like porridge oats’ [1185].
Other side effects
Although it is impossible to explore issues further with patients, certain aspects stood out during analysis.
These were the cumulative impact of the side effects of Herceptin, the perceived ‘downplaying’ of the
effects of Herceptin by health-care staff and the impact of Herceptin treatment on other chronic illnesses:
General health has been good. However, the cumulative effect of treatment – chemotherapy, radio-therapy
and Herceptin – has been one of fatigue, exhaustion and general debilitation.
1628
Although Herceptin is said to have few side effects (by comparison with chemotherapy), I think it would
be helpful to patients if they were made aware of the full range possible. In my own case, I remain very
tired after each treatment for several days so that it would not be possible to resume my employment at
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present. I also continue to have diarrhoea a day or two after each treatment and also disturbed sleeping
patterns. Each effect taken singly is not significant but in combination is most significant and does impact
on my ’normal life’. My GP – generally sympathetic – reads the current literature provided by Macmillan
and does not necessarily appreciate the debilitating effect of this treatment in my case and so is pressing
me to return to work. This isn’t helpful – indeed it is very stressful. So, fuller communication to GPs and
patients needed I think.
1581
I have found Herceptin equally as challenging as chemo because it has caused significant fluid retention
and joint pain in hands, fingers, knees and ankles that makes normal day to day tasks and walking
difficult. Unfortunately I have been discriminated against at work and lost my job – I believe as a result of
being absent – but couldn’t afford to take my ex-employer to court. I think people should be very wary of
taking time off as the law does not protect cancer patients as well as you expect.
2476
I think Herceptin is very ’chemo’ like. My treatment is 3 weekly and the first 2 weeks are miserable.
I am bolstered by the fact that after that I begin to feel myself again. I am looking forward to when
the Herceptin is out of my system and I’ll begin to feel my old self again – hopefully!
3943
I was given a great deal of information and support to assist with the effects of chemotherapy and
radiotherapy but far less on the possible effects of the Herceptin injections. I had assumed that my
health would start to improve after the chemotherapy and radiotherapy and was not expecting that
the Herceptin alone would have such an impact.
3941
My condition with other problems have become worse. I had problems doing things because of mobility
problems before breast cancer but the pain has got worse.
470
As I have chronic fatigue syndrome and fibromyalgia I have found all the treatment for cancer extra hard
and very tiring! I can’t live my life because my body doesn’t work properly.
3517
I suffer with osteoarthritis in hands and knees and have noticed a very considerable increase in the pain
and stiffness since the start of Herceptin, particularly in my hands, sometimes making it impossible to
unlock my hand joints to do simple tasks.
242
The Diabetes that I had under control [has] become uncontrollable. My blood sugar has been between
10 and 20 since last September; now I am type 1 taking insulin.
1606
Additional themes
Having received such a large number of rich, qualitative data from patients, the researchers felt that
it would be interesting to share some emerging themes not necessarily related to side effects of the
diagnosis or treatment:
l Taking part in the trial: how does this impact on patients?
l What do patients on the trial think about receiving less than the standard 12 months’ treatment
with Herceptin?
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l Fear of recurrence.
l Needing more information or support.
l Patients’ relationships with health-care professionals.
l Feeling abandoned after treatment.
l Wanting to move on.
Taking part in the trial: how does this impact on patients?
Reading through the responses from the patients on the trial, it seems that a lot of them felt grateful
that they had been given the opportunity to take part. Sometimes this feeling appeared to be
attributable to the media attention Herceptin received when it first appeared as a treatment for
breast cancer:
I feel very privileged to have this treatment as the press call it the post code lottery.
820
I would like to take the opportunity to say how extremely grateful I am to have been a recipient
of Herceptin.
1141
. . . I am alive & very grateful for the treatment & realise I am lucky to have had the opportunity to
have it.
1483
I am grateful for the Herceptin & believe it has saved my life.
549
The chance to join the trial was a blessing. Any small inconvenience having the treatment paled at chance
to Herceptin . . . and giving hope that my survival could be many more years.
1519
. . . from what I have understood about Herceptin I think it seems a ’wonder drug’. I feel blessed it has
been available for my recovery.
1566
For some, being in the trial gave them a sense of being watched more carefully:
I am happy to be a part of your study/clinical trial of Herceptin. It really helps me psychologically because
with this treatment I felt safe and secure of not recurring from breast cancer.
1453
I do feel slightly more confident due to the extra care the trial affords.
1377
My family are reassured about my health more because of the extra tests that I have had due to being on
the trial.
1016
What do patients on the trial think about having less than the standard 12 months’
treatment with Herceptin?
As the PERSEPHONE trial randomised patients to standard of care (12 months of Herceptin) or a
reduced treatment duration, it is interesting to hear how the patients felt about this, especially those
who received the shorter duration.
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Perhaps surprisingly, not many patients gave negative responses related to risk of receiving fewer
Herceptin treatments. This is perhaps a result of careful explanation of the trial given to prospective
patients. Just a handful of patients referred to being anxious about being ‘undertreated’:
Not having completed half the treatment has left me somewhat anxious as I feel that somehow I have
lowered my chances of the recurrence of cancer. This is having the effect of me feeling vulnerable also.
513
I would sometimes like more re-assurance and information about the 6 months – have I done the right thing??
544
Would have been nice to have a chat at the end of the 9 cycles re the [trial] . . . Reassurance that [trial] was
good and results were showing further cycles didn’t not seem to improve survival [rates] would have been nice.
896
Just one participant reported that she withdrew from the trial in order to continue with a full year
of Herceptin:
I have decided to stop the trial and continue with 1 years treatment of Herceptin – following discussion
with family I feel if the cancer returned within the next five years I would maybe feel that it was partly
my fault – by not having the full treatment.
889
Fear of recurrence
Many of the responses indicated a fear of recurrence:
It never leaves you, and I am always thinking it is going to come back . . . I am always thinking on special
occasions like Christmas birthdays etc., will I be here for the next one?
470
It’s hard to come to terms with the reality that this ’weight’ will never truly be far from my immediate thoughts.
496
I still think I have cancer or it will come back soon.
1482
Although I do not feel ill. I am finding that my fears of cancer returning are a constant ‘niggle’.
963
This is evidently something that causes a lot of angst for patients with this diagnosis and this manifests
in many ways.
Some reported that this fear of recurrence caused them to feel depressed:
Still worry about the cancer coming back which makes me depressed at certain times.
641
Some described it monopolising their life:
I find myself dwelling increasingly on the possibility of recurrence of the cancer. My moods are often
erratic and often unreasonable. I’m snappy and sullen instead of the normal happy and philosophical/
positive. I am more negative than I have even been.
1377
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Many sought more reassurance that their cancer had really gone and was not coming back:
It is frustrating that there is no test to confirm whether the cancer has gone – you are left to see
what happens.
1140
I would also like to know when any tests could be performed to see if I’m completely cured or not (always
at the back of my mind) . . . You must communicate with sample patients more even if it takes a phone
call to put their mind at rest.
608
I finished Herceptin 6 months ago and am coming up to 2 years Post OP. I’m feeling very low and anxious
about reoccurrence as I haven’t got an ultrasound or mammogram for another year.
1414
I feel personally that I need to know my cancer has really gone and is not going to return in the other
breast/or somewhere else in a few years/months. I have not been given this reassurance yet.
730
Many said that they remained anxious about every symptom and felt the need to be able to ask a
health professional about this:
Unfortunately, once having had cancer, one is never free of the worry about it returning, so it is very
important to feel able to report any worrying symptoms that may arise.
1166
Some were worried about becoming overly anxious:
The one element that you have to deal with is that of heightened vigilance of any bump, ill feeling. I think
it makes you ’ultra-aware’ which inevitably leads to scares/panics about the cancer returning. I am not a
hypochondriac – but you begin to feel like one.
1140
Some reported difficulty in remaining objective, with every possible symptom signifying risk of recurrence:
With time, the anxiety over a relapse increases and it becomes difficult to be/remain objective regarding
any sensation.
719
Just a few responses suggested feeling safe from the risk of recurrence:
. . . with this treatment I felt safe and secure of not recurring from breast cancer . . . I feel better and worry
free now that I finish my dose of Herceptin.
1453
Needing more information or support
A common theme running through the responses is wanting more information. Some wanted more
about their own diagnosis and treatment pathway:
It would be good to know how many treatments exactly are involved rather than just a vague 6 or
12 months. I have been asking for 4 months each time I attend for treatment and have been told they
don’t know.
740
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Please keep patients fully informed about their diagnosis as it is not always easy to know the right
questions to ask.
1272
It would have been better if I had known I would not be randomised until after Herceptin (9) – this was
not what I was led to expect earlier.
1368
Some felt that the information they had been given was too complicated or difficult to understand:
The information pack I was given was put in medical terms and not lay man’s terms the information
should be easy to understand it was far too complicated you needed a medical degree to understand it.
1160]
I think that it would be helpful to the patient if they were told (obviously in layman’s terms) how the
Herceptin works in the body. I think that some people are afraid to ask questions.
1243
. . . have treatments explained in layman’s terms.
1524
The time at which information is given is important, as some patients pointed out how difficult
it is to absorb information at the point of diagnosis, when they are in shock and struggling to
process everything:
After being informed of the diagnosis by one consultant my husband and I were taken to another room
and asked if we had any questions. As we were both in a state of shock at the time it was impossible to
think clearly.
505
I would appreciate that things be explained more than once as I tend to forget a lot of information.
1470
Some wanted more clarification about the side effects of Herceptin:
The possible side effects of medication should, most definitely, be explained to patients as, given their
emotional state of mind after being diagnosed with cancer, could cause some anxiety, the patient
believing, as I did, that they could have cancer in their bones!
1038
I wish I had more information about Herceptin and joint pain.
1383
I have peripheral neuropathy in my fingers and toes, and would have liked to be told more about this.
1524
Others wanted more information about Herceptin itself:
I would like to know if they have found out any new information on Herceptin, just interested to find out.
541
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Many wanted more information to help them understand the various tests for their heart function as
well as the symptoms of heart problems:
I think people should be advised about what symptoms may indicate heart problems. I didn’t know my
symptoms of coughing and shortness of breath were due to a lowered E.F. as a result of a reaction to the
Herceptin. If I had I would have drawn the Dr’s attention to it sooner.
1355
I think patients should receive more information regarding the effects Herceptin can have on the heart.
I feel had I received this I would have declined the treatment.
1051
Several asked to be told the results of the trial, perhaps seeking reassurance that they had made the
right decision to take part:
I would like to know the result of trial.
736
If possible, to be kept up to date with findings from trial & outcomes from trial.
928
I would be interested to know what conclusions are reached in the future concerning the Herceptin
6 months vs 1 year trial.
1141
I would be really interested in receiving a copy of the results of the RCT when they are available.
1256
Patients’ relationships with health-care professionals
Many of the responses made reference to the importance of the patient’s relationship with members
of the health-care team. A lot of these responses emphasised that a good relationship led to trust and
less stress about treatment:
Most of the time I am fine. When I go to the hospital if the doctors and nurses explain things and tell
me what is going to happen next I am fine but if I get a letter I am not expecting for the hospital then
I get stressed.
582
I have found it useful that I could consult my research nurse as she put my mind at rest over any
problems I may be suffering.
807
I also feel as if I don’t want to bother staff with trivial questions, but to me these questions are important.
1041
Where to go what to do if you feel you have a problem between appointments with consultants – leaflet
or card . . . Not being treated like an over anxious idiot when asked about ‘new’ lump.
1090
Feeling abandoned after treatment
Some respondents described feeling unsupported or abandoned after completing their treatment.
It would seem that the treatment period can be intense and involves a great deal of contact with the
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health-care team and other patients. Some people have trouble adjusting to the period of follow-up,
when they have little contact with others:
I feel any patient who has gone through this experience and treatment need more contact and support
after treatment finished. The help + support received during treatment was excellent but it just felt like
when treatment was ended I seemed to be abandoned.
1436
After I finished radiotherapy I did tend to feel a bit depressed. Think that was after I had received a great
deal of attention attending 5 days over 5 weeks.
1335
The initial flurry of activity for treatment has died down and now I have to deal with the psychological
implication of my diagnosis. An issue that I was not expecting.
1100
Wanting to move on
A fairly common theme throughout the responses was patients expressing a wish to ‘move on’ with
their lives and to resume some sense of normality or a semblance of ‘pre-diagnosis’ life:
Today is my last treatment and it is with huge relief, as every 3 weeks reminds you, that you are a cancer
patient. It will be somehow nice to close this chapter. Emotionally post treatment is harder than the
chem + radio time, which was most unexpected.
496
I found it too long a constant reminder of being a patient. I wanted to get on with my life.
533
Had hoped to be selected for 6 month trial . . . want to get on with life and put the cancer into
the past.
614
. . . now looking forward to living again.
1502
. . . now it’s time to move on.
644
Some of the respondents felt very positive about this:
I feel the cancer is a thing of the past; I feel positive about my future.
614
Since treatment ceased my feeling of health and wellbeing has improved tremendously and I would
say is nearly back to what it was in April 2009 before I knew anything was wrong and that I had
breast cancer.
616
My health is doing really well. I am just looking forward to the future.
644
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Some suggesting ways of keeping well and staying positive:
I’ve joined a choir which has improved my breathing possibly due to chemo? Being pro-active has
definitely been good for me!
1285
Healthy eating and moderate exercise would help.
1324
Reporting back to patients
On the initial trial consent form, patients were asked if they wanted to receive a copy of the trial
results at the end of the trial. The patient representative on the PERSEPHONE grant, who was a
member of Independent Cancer Patients’ Voice, provided a lay summary of the results. After ethics
approval, the lay summary, together with a PDF copy of the published trial manuscript, was sent to
all recruiting sites, along with a site-specific list of trial numbers for those patients who had indicated
their wish to receive the trial results. As the trial team had not collected the personal identifiable
details of patients, the patients received this information through the NHS clinical teams.
Discussion
The quality-of-life analysis demonstrated that, in both randomised treatment arms, the health states
are seen to remain steady from baseline to 3 months into treatment, with a trend towards a slow
increase after this, occurring slightly earlier for 6-month patients. However, the patient-reported
experience data show the impact of the treatment on patients’ lives.
Collecting ‘quasi-qualitative’ data110 using open-ended questions at the end of a questionnaire or survey
is becoming increasingly common, although analyses of these data remain novel.111 This is championed
as a way to add depth to assessments112 and complement quantitative survey data.113
However, there are certain drawbacks using these data. For example, it is important to be aware that
free-text comments may not represent the survey population, and just because an issue is raised by
one participant does not mean that it is not important to others who did not raise it.114 In addition,
data from general open questions can lack some of the key strengths of qualitative research. It could
be argued that the closed questions indicate the legitimate agenda for the responses to the general
open question and thus may impose constraints on responses. More importantly, there is a lack of
attention to context, and a lack of conceptual richness, because the data in each case often only
consist of a few sentences or less and, typically, only a small space is provided for responses.115
Furthermore, because the data collected are arguably not strictly either qualitative or quantitative,
there is a consequent lack of clarity around how to analyse and report them and about the time and
expertise needed to do so.115
Several issues were noted that may have an impact on the usefulness and reliability of the data
collected here. These were as follows.
Two hundred and seventy-one patients congratulated or thanked staff in the questionnaire, often
mentioning departments and/or staff personally. Another 37 complained about problems that
were relevant only to their local treatment, such as delays in departments, inefficiency and lack of
communication. Therefore, the reason for the data collection may have been unclear and these patients
might not have realised that these data would be going to a central office and not to hospital staff.
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Patients replied to the questions at different times throughout their treatment and in a different
number of instances. This was further complicated when the side effects of chemotherapy were still
having an impact on earlier assessments. Some patients mentioned this themselves:
I have found it difficult to differentiate between the lasting effects of the chemotherapy, steroids and
antibiotics (which I don’t usually use) and the effects of herceptin.
3901
Finally, it was difficult to understand the circumstances or state of mind of patients when they were
completing the questionnaire and whether or not that had an impact on their responses. Within this
framework of patient-reported experience collection, patients could not be asked to expand on,
describe or illustrate certain comments that they made, which is the advantage of more in-depth
qualitative interviews. However, the data collected are informative and provide an insight into the
patient-reported experiences of patients treated within a RCT.
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Chapter 7 Discussion
Interpretation
Adjuvant trastuzumab has improved the outcome of HER2-positive early breast cancer, which, before
the introduction of trastuzumab, was a molecular subtype associated with a poor prognosis.5 The
pivotal registration trials10,15 marked a revolution in treatment116 and improved outcomes so that they
were similar to those of breast cancers with a better prognosis. The registration trials used 12 months
as the duration of trastuzumab; this then became the licensed duration, although shorter durations
were not tested in these trials. At the special symposium at the American Society of Clinical Oncology
in 2005, at which the two licensing trials were presented, views were expressed from the USA that
future trials should usefully assess whether or not shorter durations might produce similar benefits.
Therefore, from the start of trastuzumab’s use as an adjuvant treatment, its optimal duration was
questioned. In addition, in the following year (2006), the publication of the FinHer trial,20 demonstrating
efficacy of a significantly shorter duration of trastuzumab (9 weeks) compared with a no-trastuzumab
control arm, further stimulated interest in trials of shorter duration. Hence, the PERSEPHONE trial
was designed to test 6 months of trastuzumab against the standard duration of 12 months. Using an
established non-inferiority design,39,117 PERSEPHONE has demonstrated that 6 months’ trastuzumab
is non-inferior to 12 months’, with a 4-year DFS of 90.3% for 12 months compared with 89.5% for
6 months (HR 1.10, 90% CI 0.96 to 1.26). This result is statistically significant for non-inferiority, with
a p-value of 0.01, and, in addition, the p-value for superiority (two-sided) of 12 months compared
with 6 months is not significant (p = 0.26). Our definition of non-inferiority was an absolute difference
of no worse than 3% below the standard group’s 4-year DFS rate, and the non-inferiority limit was
calculated as a HR of < 1.33. The upper confidence limit of the HR was 1.26, which does not cross this
non-inferiority limit or critical value. This reflects that, although the non-inferiority boundary was set
at 3%, the actual point estimate reduction observed was much smaller, at 0.8% for 4-year DFS and
0.3% for the landmark 4-year DFS (from 6 months after the start of trastuzumab). Other outcome
analyses, including OS, landmark OS (6 months after the start of trastuzumab), and sensitivity analyses
for invasive DFS,118 distant DFS and breast cancer specific survival, are all congruent (see Appendix 2,
Figures 25–27). All measures of cardiac and other toxicity showed significantly decreased rates with
6 months’ treatment and, therefore, the balance of risk and benefit favours shorter treatment.
The within-trial cost-effectiveness analysis showed that 6 months of trastuzumab was associated with
an estimated incremental cost saving of £9537 (95% CI £9183 to £9890) and an incremental effect of
+0.003 QALYs (95% CI −0.015 to 0.021 QALYs) compared with 12 months of trastuzumab. Six months
of trastuzumab is therefore cost-effective and dominates the longer duration of trastuzumab (INB 0.48,
95% CI 0.45 to 0.51). The probability that 6 months compared with 12 months of trastuzumab was
cost-effective was 100%. The sensitivity analysis that compared different delivery and drug cost
options for trastuzumab indicated that the biosimilar intravenous options recently made available are
likely to result in the largest cost savings. The lifetime decision model, which is the preferred analysis
for NHS decision-making, estimated cost savings of £9316 and a slight reduction of 0.01 QALYs per
individual, indicating that a reduced length of trastuzumab treatment of 6 months has a negligible
impact on QALYs and is significantly cost saving (INB of 0.46 QALYs).
Overall evidence from trials of reduced duration trastuzumab
PHARE: 6 versus 12 months
The PHARE trial was a French national study, funded by the Institut National du Cancer, that was carried
out between May 2006 and July 2010; 3380 patients were randomised to either 6 or 12 months’
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trastuzumab (Table 25). Prior to the start of the PERSEPHONE trial and during the trial’s recruitment
phase, the trials teams met and agreed on common data collection items so that a joint analysis of
individual patient data could occur once both trials had been completed and published. The two trials
had significant similarities, including mapping on to standard national practice for the treatment of
HER2-positive early breast cancer. Differences included the randomisation time point; in PHARE, this
was between 3 and 6 months of trastuzumab, which would have excluded all patients who developed
cardiac toxicity in the first 3–6 months, whereas at the start of the PERSEPHONE trial randomisation
was carried out prior to any trastuzumab treatment. Subsequently, the PHARE TMG advised that
entering patients into a 6 versus 12 months trial was in their opinion more acceptable to patients after
they had already received some trastuzumab. As recruitment into PERSEPHONE was slow at this point,
the TSC and TMG decided to make the randomisation point more flexible, allowing recruitment up to
and including the ninth cycle of trastuzumab. The original PHARE statistical plan was to recruit 7000
patients so that non-inferiority could be detected at the 2% level. With a 2-year DFS estimated at 85%,
the HR limit or critical value was predetermined to be 1.15. Shortly after the start of the trial, there was
a change in the statistical plan that allowed for longer recruitment time and follow-up, which altered the
recruitment target to 3400 patients. The PHARE trial published the results of 2-year DFS in 2013,23
which failed to demonstrate non-inferiority, with 12-month patients having a 2-year DFS of 93.8%
(95% CI 92.6% to 94.9%) and 6-month patients having a 2-year DFS of 91.1% (95% CI 89.7% to 92.4%)
(HR 1.28, 95% CI 1.05 to 1.56; non-inferiority p = 0.29). More recently, the PHARE trial published
long-term follow-up data and demonstrated a HR after 7.5 years’ median follow-up very similar to
that in PERSEPHONE (PHARE HR 1.08, 95% CI 0.93 to 1.25; p = 0.39). The statistical analysis plan with
a critical value of HR 1.15 does not allow a conclusion of non-inferiority, although the similarity of the
results from the two trials is striking.
TABLE 25 Trastuzumab duration trials and results
Trial
characteristic
Trial name/design
PERSEPHONE PHARE HORG SOLD Short-HER
Duration of
trastuzumab
6 months vs.
12 months
6 months vs.
12 months
6 months vs.
12 months
9 weeks vs.
12 months
9 weeks vs.
12 months
Recruited (n)/
target (N)
4088/4000 3384/3400
(revised from
7000)
481/480 2174/2168 (revised
from 3000)
1253/2500 (funding
finished early)
Median follow-up
(months)
73 42.5a 49 62.4 72
90b
Number of DFS
events; patients
with an event (%)
566 events; 14% 175 events; 5.2%a 45 events; 9.3% 245 events; 11.2% 200 events; 15.9%
704 events; 21%b
Primary outcome
reported
4-year DFS 2-year DFSa 3-year DFS 5-year DFS 5-year DFS
Design Non-inferiority Non-inferiority Non-inferiority Non-inferiority Non-inferiority
Absolute non-
inferiority margin
< 3% < 2% < 8% < 4% < 3%
HR non-
inferiority limit
< 1.33 < 1.15 < 1.53 < 1.385 < 1.29
Alpha power 5% one-sided
significance, 85%
power
5% one-sided
significance,
80% power
5% one-sided
significance,
80% power
5% one-sided
significance
5% one-sided
significance, 56%
power for revised
sample size of 1250
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HORG: 6 versus 12 months
This trial from the Hellenic Oncology Research Group reported 3-year DFS in 481 randomised patients
(see Table 25); 67% of patients had ER-positive tumours and 79% had malignant involvement of axillary
lymph nodes, with 14% having more than four nodes positive, demonstrating a higher risk of relapse
profile than patients in the other duration trials. The non-inferiority HR limit of 1.53 was derived from
an estimated absolute difference in 3-year DFS of 8%, based on an expected DFS in the 12-month group
of 85%. This was calculated before the start of the trial. The 3-year DFS was 95.7% for 12 months’
trastuzumab and 93.3% for 6 months’ trastuzumab, with a HR of 1.57 (95% CI 0.86 to 2.10; non-
inferiority p = 0.137), thus failing to demonstrate non-inferiority. Had non-inferiority been demonstrated
in this trial, it is debatable whether or not, with a non-inferiority margin of 8%, the result would have
been practice-changing.
SOLD: 9 weeks versus 12 months
The SOLD trial has been described in Chapter 1. In a time-driven analysis 2 years after the last patient
was randomised, the 5-year DFS of 2174 patients was analysed, with a median follow-up of 5.2 years25
(see Table 25). The non-inferiority limit was derived from the true (observed) standard-arm 5-year DFS
of 88.7%, and the HR limit or critical value was 1.385, which was calculated when the statistical design
of the trial was changed from superiority to non-inferiority in February 2014. The results showed a
5-year invasive DFS of 90.5% for the 12-month arm and 88.0% for the 9-week arm, with a HR of
1.39 with two-sided 90% CI of 1.12 to 1.72, and therefore the upper CI crossed the non-inferiority
boundary, failing to demonstrate non-inferiority. However, distant DFS (94.2% for 12 months and
93.2% for 9 weeks) and OS (95.9% and 94.4%, respectively) did not differ substantially between the
groups. The design of the trial was based on the original FinHer experimental arm in which 9 weeks’
trastuzumab was given concurrently with docetaxel and was the first adjuvant treatment, followed
by FEC chemotherapy and then completion of 12 months’ trastuzumab in the standard arm. The total
dose of trastuzumab in the 9-week arm was 20 mg/kg, in comparison with 56 mg/kg in the 6-month
arms of PERSEPHONE, PHARE and HORG, and perhaps this lower dose is insufficient to demonstrate
non-inferiority, despite being given upfront and concurrently with docetaxel. An exploratory subgroup
analysis with relatively small numbers suggests that docetaxel at a dose of 100 mg/m2 rather than
80 mg/m2 may be associated with non-inferiority of 9 weeks’ trastuzumab, but this would have to be
confirmed in a further randomised trial.
TABLE 25 Trastuzumab duration trials and results (continued )
Trial
characteristic
Trial name/design
PERSEPHONE PHARE HORG SOLD Short-HER
Time point DFS
rates reported at
2-year DFS:
96.2% vs. 95.8%
4-year DFS:
90.3% vs. 89.5%
2-year DFS:
93.8% vs. 91.1%a
3-year DFS:
95.7% vs. 93.3%
5-year DFS: 90.5%
vs. 88%
5-year DFS: 87.5%
vs. 85.4%
5-year DFS:
86.2% vs. 84.2%b
HR 1.10 (90% CI
0.96 to 1.26;
non-inferiority
p = 0.01)
1.28 (95% CI
1.05 to 1.56;
p = 0.29)a
1.57 (95% CI
0.86 to 2.10;
p = 0.137)
1.39 (90% CI 1.12
to 1.72)
1.15 (95% CI 0.91
to 1.46)
1.08 (95% CI
0.93 to 1.25;
p = 0.39)b
Conclusion Non-inferior Not non-inferiorb Not non-inferior Not non-inferior Not non-inferior
a PHARE publication 2013.23
b PHARE publication 2019.51
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Short-HER: 9 weeks versus 12 months
The Short-HER trial has been described in Chapter 1. There were some differences in the chemotherapy
given in the experimental arm and the standard arm, which was required by the government funders.
The standard arm used chemotherapy that was in the national guidelines and the experimental arm
was the same as in the FinHer and SOLD trials. Chemotherapy in the standard arm consisted of
AC or EC with a dose of epirubucin of 90 mg/m2 administered every 3 weeks for four cycles followed
by 175 mg/m2 paclitaxel or 100 mg/m2 docetaxel every 3 weeks for four cycles. Trastuzumab was
administered every 3 weeks for 18 cycles, starting with the first taxane dose (8 mg/kg loading dose at
first cycle, and 6 mg/kg thereafter). Chemotherapy in the experimental arm consisted of 100 mg/m2
docetaxel every 3 weeks for three cycles with concurrent trastuzumab weekly for 9 weeks followed
by FEC (60 mg/m2 of epirubicin) for three cycles. Therefore, the standard arm had higher doses of
epirubucin, and four cycles rather than three of each chemotherapy type. Accrual was planned for
2332 patients, but the trial was required to meet timelines from the funders and therefore had to
complete recruitment after 1254 patients, which meant that the trial was underpowered, with a power
of 56% for the non-inferiority end point (see Table 25). Five-year DFS was 88% in the standard and
85% in the experimental arm, with a HR of 1.13 (90% CI 0.89 to 1.42) and with the upper limit of
the CI crossing the non-inferiority limit, which was set at 1.29. Therefore, the trial could not claim
non-inferiority. A Bayesian analysis showed that the probability that the 9-week arm was non-inferior
to the 12-month arm was 80%. The 5-year OS did not differ substantially between the groups, at 95.2%
in the standard arm and 95.0% in the short arm (HR 1.07, 90% CI 0.74 to 1.56).
Trial-level meta-analysis
In a meta-analysis of the latest published data from the PHARE trial51 and the PERSEPHONE trial
(this analysis), we compared 6 months and 12 months of trastuzumab treatment.119 As the PHARE trial
randomised patients to 3 or 6 months of trastuzumab treatment and timed DFS from randomisation,
we used the landmark analysis timed from 6 months after the start of trastuzumab as the most
appropriate end point comparable with that used in the PHARE trial. The weighted 4-year DFS rate
was 88.9%. Thus, with the methodology used in our study, and with a non-inferiority limit of 2%, the
non-inferiority limit for the HR was calculated as 1.19. There was no detectable difference between
the two trials’ results (heterogeneity p = 0.94), and the pooled HR for DFS of 1.08 (90% CI 0.98
to 1.18) met the prespecified definition of 2% non-inferiority (non-inferiority p = 0.04). The data
from both PERSEPHONE and this meta-analysis of trial-level evidence demonstrate that 6 months’
trastuzumab is non-inferior to 12 months’ trastuzumab in the population as a whole. In this population
there will, therefore, be a significant number of patients in whom reducing trastuzumab to 6 months
should be possible.
Generalisability
Strengths of the study
The PERSEPHONE trial was pragmatic and mapped on to standard practice in the UK. Study sites
could approach all patients in whom treatment with adjuvant or neoadjuvant chemotherapy and
trastuzumab was planned. It therefore examined the effect of reducing trastuzumab to 6 months in
a ‘real world’, post-licensing population treated with chemotherapy and trastuzumab. All types of
chemotherapy were included in the trial and therefore as standard chemotherapy practice gradually
changed over the course of the trial, continued recruitment was facilitated and the recruitment target
was successfully reached. This also means that results will be applicable to this population treated in
routine clinics. Detailed cardiology and health economic substudies are further strengths and include
within-trial cost-effectiveness analysis and modelling the long-term cost-effectiveness of trastuzumab.
Collection of germline blood samples and formalin-fixed paraffin-embedded tissue from around 80% of
patients provides an invaluable translational resource to explore pharmacogenetics and trastuzumab
cardiotoxicity, inherited germline predisposition to HER2-positive breast cancer and molecular markers
predicting outcomes for different durations of trastuzumab.
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Limitations of the study
There are some limitations because of the wide range of chemotherapy treatments accepted in the trial,
and subgroup analysis based on specific regimens is not possible. However, the recruitment of required
numbers for sufficient levels of significance and statistical power outweighs this limitation in our view.
The selection of chemotherapy and trastuzumab timing according to perceived risk by the investigators
(i.e. concurrent preferred in higher-risk patients) is a further limitation. The changes in standard practice
during the trial and, therefore, the different lengths of follow-up also bring some limitations. The variable
timing of randomisation potentially introduces ascertainment bias. The analyses were performed in
accordance with the intention-to-treat principle. We believe that this is the most appropriate approach
to use as it ensures unbiased estimates. There are some concerns that it can potentially underestimate
differences between treatment arms and thus drive the results towards non-inferiority. However, this
concern is valid only when adherence to treatment is low and/or differential loss to follow-up occurs.
In the PERSEPHONE trial, adherence to protocol-mandated treatment is high and loss to follow-up is
low and balanced across randomised treatment arms, which we believe mitigates this concern.
Anthracycline effectiveness in HER2-positive breast cancer
Recently, chemotherapy regimens that avoid anthracyclines completely have been introduced in
low-risk HER2-positive breast cancer.120–122 The BCIRG-006 study18 is the randomised Phase III trial
that addressed the question of anthracycline-free chemotherapy with trastuzumab. This trial was
undertaken in a similar risk population to that in the HERA trial and reported that substituting
standard adjuvant chemotherapy of AC-TH for carboplatin and docetaxel with trastuzumab (TCH)
resulted in similar 5-year DFS of 84% and 81%, respectively, although the trial was not powered to
assess non-inferiority between the two arms. Later follow-up results showed 10-year DFS of 74.6%
for AC-TH and 73.0% for TCH. Two other trials are Phase II non-randomised studies in HER2-positive
patients,120–122 with a low risk of recurrence (in the trial reported by Tolaney120,121 axillary lymph
node negative and tumour size < 3 cm), and, although the reported results are excellent, there is no
comparator standard arm. In the UK, at present, for patients at sufficient risk of recurrence to be
recommended chemotherapy and trastuzumab, standard practice is to use anthracyclines (usually in
combination with taxanes) unless the patient has specific contraindications, for example pre-existing
cardiac problems.
There is a very long history of anthracyclines being used in the treatment of breast cancer, including
HER2-positive breast cancer.75 There is evidence of the additive effects of doxorubicin and antibodies
to HER2 receptors in cell culture, and significant synergy has been observed in xenografts in mice.123
Doxorubicin and epirubicin cause cytotoxic activity by DNA intercalation, inhibition of the Type II
topoisomerase enzyme, free-radical production, and promotion of histone eviction from transcriptionally
active chromatin.124–127 Additional mechanisms of action for anthracyclines include ‘immunogenic cell
death’ and the induction of anticancer immune responses.128,129 There is evidence that anthracyclines can
produce therapy-induced immunosurveillance,130 thereby inducing an immune response to cancer cells.
There is also evidence that anthracyclines can stimulate cancer cell-autonomous production of type I
interferon in mouse models,131 and recently they have also been found to activate STING (stimulator of
interferon genes)-dependent innate immune signalling pathways.132 There is also some evidence that
anthracyclines have an enhanced effect in ER-negative tumours that have CD8+ tumour-infiltrating
lymphocytes.133 The presence of greater numbers of tumour-infiltrating lymphocytes is a good prognostic
finding in early HER2-positive breast cancer133,134 and also in metastatic disease, as found in CLEOPATRA
(Clinical Evaluation of Pertuzumab and Trastuzumab Trial).135 Not only are tumour-infiltrating lymphocytes
prognostic, but there is evidence that greater numbers of tumour-infiltrating lymphocytes improve the
responsiveness to anti-HER2 directed therapy in the metastatic setting.135 Recently, there has been a
report that > 20% tumour-infiltrating lymphocytes in HER2-positive breast cancer provides a prognostic
biomarker in the Short-HER trial as well as an indication that 9 weeks of trastuzumab is sufficient,
compared with 12 months.136 The mechanisms of action of trastuzumab include antibody-dependent
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cell-mediated cytotoxicity and the activation of antigen-specific antitumour immune response.129
This evidence would point to significant immune mechanisms for activity of both anthracyclines and
trastuzumab, as well as that anthracyclines, by producing an induced immune response, could enhance
the effect of trastuzumab given after anthracyclines. There is some evidence supporting this in the clinical
literature. The BCIRG-006 trial reported initial 5-year DFS results that demonstrated a 3% difference
between AC-paclitaxel/trastuzumab (84%) and the non-anthracycline regimen TCH (81%).18 In the HERA
trial, most trastuzumab was given sequentially after chemotherapy, and the subgroup analysis comparing
anthracycline only and anthracycline with taxane chemotherapy hinted that the effect of trastuzumab
was greater with anthracycline chemotherapy than with the combination.10 Our own data also point to
the activity of anthracyclines given for six cycles with sequential trastuzumab, which was a more common
regimen early in the trial, and therefore these patients have the longest median follow-up and yet similar
outcomes to the patients receiving anthracycline with taxane chemotherapy and concurrent trastuzumab.
Our view remains that, for patients with tumours of enough risk to warrant chemotherapy and trastuzumab,
careful consideration needs to be given in discussion with the patients with regard to anthracycline-free
chemotherapy regimens.
Concurrent versus sequential trastuzumab and chemotherapy
When the PERSEPHONE trial started, the existing evidence was from two large registration trials that
had demonstrated a significant effect of adjuvant trastuzumab compared with a no-treatment control.
HERA used trastuzumab sequentially after chemotherapy, and NSABP B-31 and NCCTG N9831 (joint
analysis) used only trastuzumab concurrent with the taxane component of chemotherapy. Therefore,
when the PERSEPHONE trial started, there was evidence to support both sequential and concurrent
trastuzumab with chemotherapy, and in this pragmatic trial, mapping on to standard practice, patients
receiving sequential or concurrent trastuzumab and chemotherapy were able to be included. With the
publication of PACS-0419 and N983116 evidence was emerging that suggested that delivering trastuzumab
concurrently might be the better approach, and so it became more standard in routine clinics. Therefore,
as more evidence was published, we saw a gradual decrease in the use of sequential, anthracycline-based
chemotherapy and an increase in concurrent treatments with anthracycline and taxane combinations in
our trial population.
Subgroup analysis in the trial
Experts including Altman137 and Peto138 have written extensively about the limitations of subgroup
analyses, which can lead to subgroup findings being applied incorrectly to change patient treatments,
either to introduce ineffective treatments in, or to withhold effective treatments from, certain subgroups.
Ten criteria have been put forward for assessing the credibility of the subgroup effects reported in
clinical trials139,140 to judge whether or not it would be appropriate to take these forward into clinical
practice. The PERSEPHONE trial has an adequate sample size to answer the question of non-inferiority
of 6 months’ trastuzumab compared with 12 months’ in the trial as a whole, but not to answer the
question in specific subgroups.
An interaction was seen between the concurrent and sequential administration of trastuzumab and
chemotherapy and 6 and 12 months’ trastuzumab. Factors supporting the credibility of this observed
effect was that concurrent versus sequential treatment was a stratification factor at randomisation,
that the test for interaction was significant (p < 0.001), and that the subgroup effect was consistent
across related outcomes. However, factors that did not support credibility of this subgroup finding
were that the subgroup variable was not a baseline patient characteristic but was chosen by treating
clinicians depending on patient characteristics, centre-based protocols, and the national standards at
the time of treatment. In addition, this particular subgroup hypothesis was not specified a priori, and
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there was no indirect evidence to support the apparent subgroup effect; in fact, the opposite was the
case. Concurrent trastuzumab and chemotherapy had been found to be more effective than sequential
treatments,16 and a hypothesis emerged that, with the greater effect of concurrent treatment, if there
was an interaction between sequential and concurrent trastuzumab and chemotherapy it was likely
to be in favour of 6 months’ treatment with concurrent trastuzumab and chemotherapy. Therefore,
the subgroup interaction observed in the PERSEPHONE trial was in the opposite direction to that
hypothesised and also to that initially seen in the PHARE trial. There is no obvious, plausible biological
explanation for our finding. Therefore, although the test of interaction was significant (p < 0.001), this
was not seen in other studies (PHARE), and so, on balance, this subgroup analysis is more likely to be
misleading and to have been affected by the play of chance.
Evidence for additional anti-HER2 treatments
There have been changes to treatments for HER2-positive early breast cancer since the study started,
particularly in the 3 years after the last patient in the trial completed treatment. This has included
11 years’ follow-up of the HERA trial, which included extending adjuvant therapy to 24 months,13
trials testing newly developed HER2-directed therapies both antibodies with pertuzumab,141 (Perjeta®;
Roche, Switzerland) and small-molecule treatments with neratinib.142,143 In addition, there have been
successful neoadjuvant trials including studies of pertuzumab (NeoSphere),144,145 and, most recently,
studies in the post-neoadjuvant context with the use of trastuzumab emtansine in patients who have
not achieved a pathological complete response from neoadjuvant treatment.
Trastuzumab and pertuzumab
The APHINITY (Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer) trial
was published in 2017.141 This compared adjuvant chemotherapy and 12 months’ trastuzumab with or
without 12 months’ pertuzumab for the treatment of HER2-positive breast cancer; 63% of patients
were node positive and 36% were ER negative. Invasive DFS was timed from randomisation and
included local and distant recurrence, contralateral new breast cancer and death from any cause,
but did not include second primaries. The estimates of 3-year invasive DFS rate were 94.1% in the
pertuzumab group and 93.2% in the placebo group (HR 0.81, 95% CI 0.66 to 1.00; p = 0.045). Among
the cohort of patients with node-positive disease, the 3-year rate of invasive DFS was 92.0% in the
pertuzumab group, compared with 90.2% in the placebo group (HR for an invasive-disease event 0.77,
95% CI 0.62 to 0.96; p = 0.02). Among patients with node-negative disease there was no improvement
in invasive DFS with added pertuzumab at this early time point. In December 2017146 the US Food and
Drug Administration (FDA) licensed adjuvant pertuzumab for the treatment of patients who had a high
risk of recurrence. In March 2019, NICE approved pertuzumab for use in the NHS with trastuzumab
biosimilars147 in patients with node-positive disease. The landscape of the treatment of HER2-positive
early breast cancer is therefore very different from that when the trial started.
Neratinib for 12 months after trastuzumab
Neratinib is a potent, irreversible tyrosine kinase inhibitor of HER1, HER2, HER3 and epidermal
growth factor receptor. It inhibits the phosphorylation of these receptors by irreversibly binding to the
intracellular signalling domain, thereby inhibiting HER-mediated downstream signalling. The ExteNET
trial142,143 examined the use of an additional 12 months of neratinib in patients after they had completed
1 year of adjuvant treatment with chemotherapy and 12 months of trastuzumab. A total of 2840
women were randomly assigned up to 2 years after completing primary treatment (amended to 1 year
after, during the study) to 12 months’ neratinib or placebo. The 2-year invasive DFS rate was 93.9%
(95% CI 92.4% to 95.2%) in the neratinib group and 91.6% (95% CI 90.0% to 93.0%) in the placebo
group, with a stratified HR of 0.67 (95% CI 0.50 to 0.91; p = 0.0091). The most common severe adverse
event (grade 3 or above) was diarrhoea, with a 40% incidence. In a prespecified subgroup analysis,
patients with ER-positive disease seemed to gain more benefit than those with ER-negative disease
[ER positive, HR 0.51, 95% CI 0.33 to 0.77, p = 0.0013; ER negative, HR 0.93, 95% CI 0.60 to 1.43,
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p = 0.74; p (for interaction) = 0.054]. Neratinib’s activity in ER-positive disease has raised questions
about the predominant mechanism of action in these tumours and whether or not it also inhibits
ER-related signalling pathways. Although 1 year’s neratinib has received marketing authorisation
approval from both the FDA and the European Medicines Agency, uptake has been low in the USA
and Europe, thought to be because of neratinib’s modest effect and the high incidence of severe
diarrhoea. NICE has now appraised neratinib and has approved it for 1-year extended use in patients
with ER-positive, HER2-positive breast cancer but only if they had received 1 year of single agent
adjuvant trastuzumab and no pertuzumab.148 However, the NICE appraisal states that it is unclear which
patients would receive neratinib in clinical practice.
HERA and 24 months’ trastuzumab
The HERA trial also tested 24 months’ trastuzumab compared with 12 months’ trastuzumab and a
no-treatment control arm.10 The 11-year follow-up, published in 2017,13 showed that 24 months was
no better than 12 months in terms of DFS (HR 1.02, 95% CI 0.89 to 1.17), with 10-year DFS of 69%
for 1 year and 69% for 2 years of trastuzumab. Extending trastuzumab treatment beyond 12 months
did not improve DFS further.
Neoadjuvant trials in HER2-positive disease
Neoadjuvant trials are an excellent route for accelerated drug approval and have been particularly
effectively used in HER2-positive breast cancer to speed the process of new drug approval in the
adjuvant setting.149 The NeoSphere trial looked at neoadjuvant trastuzumab and pertuzumab144,145
in a 417-patient randomised Phase II study with four arms. Group A received standard trastuzumab
with docetaxel; group B received pertuzumab and trastuzumab with docetaxel; group C received
pertuzumab and trastuzumab; and group D received pertuzumab and docetaxel. The primary end
point was pathological complete response. This was highest in group B, at 45.8%, followed by group A
(29%) and then group D (24%), with the lowest rate in group C (16.8%). The 5-year follow-up analysis
confirmed that progression-free survival mirrored the pathological complete response rates and
demonstrated differences in 5-year progression-free survival that, because of the small numbers in
the trial, did not reach statistical significance. These were 86% (95% CI 77% to 91%) for group B, 81%
(95% CI 71% to 87%) for group A, 73% (95% CI 64% to 81%) for group C, and 73% (95% CI 63% to
81%) for group D (group B vs. group A: HR 0.69, 95% CI 0.34 to 1.40; group C vs. group A: HR 1.25,
95% CI 0.68 to 2.30; group D vs. group B: HR 2.05, 95% CI 1.07 to 3.93). NeoSphere prompted
the accelerated approval of neoadjuvant pertuzumab with trastuzumab and chemotherapy from the
FDA,149 the EMA150 and NICE.151 The promising early results of neoadjuvant pertuzumab had already
led to the APHINITY trial, which tested the addition of pertuzumab to standard chemotherapy and
trastuzumab treatment in the adjuvant setting.141 This trial had already completed recruitment when
the FDA stipulated that if the adjuvant APHINITY trial did not demonstrate benefit from the addition
of pertuzumab, then approval for its use in the neoadjuvant setting would be withdrawn.
In the recently published Katherine Trial,152 trastuzumab emtansine (Kadcyla®; Roche, Switzerland) was
tested against trastuzumab after the failure of neoadjuvant chemotherapy and anti-HER2 therapy to
produce a complete pathological response. The estimated proportion of patients who were free of invasive
disease at 3 years was 88.3% in the trastuzumab emtansine group and 77.0% in the trastuzumab group.
Invasive DFS was significantly higher in the trastuzumab emtansine group than in the trastuzumab group
(HR for invasive disease or death 0.50, 95% CI 0.39 to 0.64; p < 0.001). This significant improvement in
outcome is likely to lead to an appropriate escalation of standard treatment in the post-neoadjuvant setting,
at least for patients who do not achieve a pathological complete response with neoadjuvant treatment.
Trials are now being developed of the de-escalation of adjuvant anti-HER2 therapy after a pathological
complete response to neoadjuvant treatment has been achieved. This is an important development in
the portfolio of trials for HER2-positive early breast cancer.
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Challenges of implementing de-escalation of established treatments
The common pathways for improvements in cancer outcomes are the introduction of additional
treatments and the escalation of existing treatments. These often result in more toxicities for patients
and a slower return to normal life, and this is accepted when there are proven, clear and significant
improvements in outcomes. The introduction of adjuvant trastuzumab led to routine HER2 testing
of all breast cancers, and patients with tumours testing positive then received chemotherapy and
trastuzumab according to the licence. Many of these patients have small (pT1a–b), node-negative
tumours and would not have been considered for chemotherapy prior to 2005 but are now receiving
it routinely. Our goals for treatment are to produce best outcomes for patients, while minimising the
cost in terms of toxicity, not only treatment side effects but also ‘financial toxicity’ for both patients
and health-care systems. However, the challenges of introducing de-escalated treatments remain
considerable and are particularly relevant in the case of trastuzumab, as over the past 13 years we
have seen this treatment transform the lives of patients with breast cancer. Inevitably, in de-escalation
trials there is likely to be some loss of efficacy, however small, and the challenge is to balance this
against the gains in terms of reduced toxicity. Even so, there may be an understandable nervousness on
the part of specialist teams and some patients to consider a change to practice, despite the potential
benefits to the individual patient of reduced toxicity, shorter treatment and a more rapid return to
normal life. After reflecting on all of these aspects of the trial, we would argue that registration trials
are optimal for evaluating shorter treatment durations, and we would strongly encourage such testing
for new, targeted adjuvant cancer therapies. Questions of treatment duration in registration trials
could occur only with significant international collaboration between the pharmaceutical industry,
international academic groups, and governments/medicines approval bodies such as the European
Medicines Agency and FDA, with input from the wider cancer specialist teams and cancer patients,
as has been discussed.153 In registration trials, discussion would be required about whether shorter
treatments would have to prove non-inferiority compared with longer treatments, or whether longer
treatments would have to prove superiority compared with shorter treatments. In general, the escalating
cost of effective novel anticancer treatments is rapidly becoming unsustainable, even for wealthy nations,
and we believe that clinical trials designed to test shorter treatments as part of pivotal registration trials
should become one of the priorities for cancer research.
Global burden of HER2-positive breast cancer and delivery of trastuzumab
as a World Health Organization essential medicine
In 2018, GLOBOCAN (Global Cancer Incidence, Mortality and Prevalence from the International
Agency for Research on Cancer) estimated that the incidence of new cases of breast cancer was
2.08 million per year.154 Assuming 12% of breast cancers are HER2 positive, this means that nearly
250,000 new cases of HER2-positive breast cancer are estimated to occur worldwide every year.
In November 2015, trastuzumab was included on the World Health Organization’s essential medicines
list for both early and metastatic HER2-positive breast cancer for the first time.155 Marie-Paule Kieny,
World Health Organization Assistant Director General for Health and Innovation, has emphasised that
essential medicines should be available everywhere at all times, and are chosen according to evidence
of safety, efficacy and public health relevance.156 It is difficult to access accurate figures for the global
delivery of trastuzumab, but in low- and middle-income countries it is likely that many women with
HER2-positive breast cancer cannot access trastuzumab in either the early or the metastatic setting.
On a recent working visit to India to give talks about the PERSEPHONE trial, the chief investigator,
Helena Earl, learnt that 5 years ago only 20% of women with HER2-positive breast cancer had been
able to access trastuzumab. There has been some improvement in access recently through the licensing
of an increasing number of biosimilars, but even in the largest cancer centre in India (Tata Memorial)
the estimated availability is still only 53%. Those women who do receive adjuvant trastuzumab will
often receive the FinHer regimen of 9 weeks. Evidence from the PERSEPHONE trial will help to
improve delivery of trastuzumab globally to achieve the stated aim of the World Health Organization
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Essential Medicines listing to deliver the medicine to all women with HER2-positive breast cancer.
Global implementation of 6 months’ trastuzumab treatment will save a significant number of lives and
there is significant interest globally in the PERSEPHONE results for this reason. Implementing 6 months’
adjuvant trastuzumab in low- and middle-income countries would halve the cost of treatment and
produce similar outcomes to 12 months’ treatment.
Trastuzumab biosimilars
As of May 2019, five trastuzumab biosimilars had been approved by the European Medicines Agency
(see Appendix 1, Table 56) and four had been approved by the FDA (see Appendix 1, Table 57). There
have been Phase III trials of these biosimilars demonstrating non-inferiority of outcomes and safety
when compared with the originator trastuzumab in both neoadjuvant and metastatic settings.157 These
biosimilars are marketed at lower cost and are already in widespread use in the UK. NICE’s recent
approval of adjuvant pertuzumab and trastuzumab in the treatment of node-positive, HER2-positive
breast cancer advises the use of biosimilar trastuzumab with pertuzumab.147 Therefore, a combination
of the introduction of biosimilars and the reduction of trastuzumab duration to 6 months in some
patients will significantly reduce the costs of trastuzumab delivery in the NHS.
Conclusions
The PERSEPHONE trial has demonstrated non-inferiority of 6 months’ trastuzumab compared with
12 months’ trastuzumab. DFS at 4 years is 89.5% for 6 months compared with 90.3% for 12 months,
a difference of only 0.8%. Cardiotoxicity was reduced in the 6-month arm, with only 3% of patients
stopping trastuzumab early on account of cardiotoxicity, compared with 8% of 12-month patients.
The incidence of severe adverse events was also lower among the 6-month patients (19%) than among
the 12-month patients (24%). Patient-reported experiences showed that the side effects of trastuzumab,
particularly fatigue and aches/pains, had a significant impact on daily life. Health economic analysis
showed that, with significantly lower lifetime costs and similar lifetime QALYs, there is a high probability
that 6 months’ trastuzumab is cost-effective compared with 12 months’ trastuzumab.
Future research
Future research will include a risk-based analysis of non-inferiority using recognised clinical prognostic
categories and predictive tools. Multivariable analysis will be carried out to explore whether or not,
among the trial population who have superior outcomes with 12 months’ trastuzumab compared with
6 months’ trastuzumab, there are high-risk groups. A joint analysis with the PHARE trial group has
been planned from the start of the PERSEPHONE trial. An individual patient data meta-analysis is
planned with other trastuzumab duration trials. Translational research exploring tumour biomarkers of
response to shorter durations of trastuzumab will be carried out. The collection of blood for germline
analysis will allow studies of inherited germline predisposition for HER2-positive breast cancer and
pharmacogenetic studies of trastuzumab outcomes and cardiotoxicity.
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Dr Conrad Lewanski, Dr Constantine Alifrangis, Dr Hanine Medani,
Dr Laura Kenny, Dr Matthew Flook, Dr Sean O’Cathail, Dr Susan Cleator,
Professor Charles Coombes, Professor Justin Stebbing and
Professor Robert Leonard
Cheltenham General Hospital Dr Jo Bowen, Dr Kim Benstead, Dr Peter Jenkins, Dr Radhika Counsell,
Dr Roger Owen and Dr Sean Elyan
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Dr Helen Mitchell, Dr Juliette Loncaster and Dr Sasha Howell
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Clatterbridge Centre for Oncology Dr Allison Hall, Dr Douglas Errington, Dr Farida Alam, Dr Khizar Hayat,
Dr Susan O’Reilly and Dr Zafar Malik
Conquest Hospital Dr Craig Knighton and Dr Gillian Sadler
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Dewsbury and District Hospital Dr Jay Naik
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George Eliot Hospital Dr Lydia Fresco, Dr Medy Tsalic and Dr Susan Lupton
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Good Hope Hospital Dr Andrea Stevens and Dr Medy Tsalic
Great Western Hospital Dr Anne Kendall, Dr David Cole, Dr Kinnari Patel and
Dr Shiroma De Silva-Minor
Guy’s Hospital Dr Eleni Karapanagiotou, Dr Janine Mansi, Dr Mark Harries, Dr Paul Ellis
and Dr Sarah Harris
Halton General Hospital Professor Peter Clark
Hexham General Hospital Dr Anthony N Branson
Hinchingbrooke Hospital Dr Cheryl Palmer, Dr Clary Evans and Dr Simon Russell
Ipswich Hospital Dr Karen E Sherwin and Dr Ramachandran Venkitaraman
James Paget Hospital Dr Adrian Harnett and Dr May Thu Han
Kent and Canterbury Hospital Dr Carys Thomas, Dr Julia Hall and Dr Natasha Mithal
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Kidderminster Hospital Dr Mark Churn
King Edward VII Hospital Dr Narottam Thanvi and Dr Ruth Davis
King’s College Hospital Dr Anne Rigg, Dr Fiona Castell and Dr Vasiliki Michalarea
King’s Mill Hospital Dr Sarah Khan and Dr Victoria Brown
Leighton Hospital Dr Laura Horsley
Lincoln County Hospital Dr Abhro Chaudhuri, Dr Elisabeth Murray and Dr Thiagarajan Sreenivasan
Lister Hospital Dr Nihal Shah
Luton and Dunstable Hospital Dr Mei-Lin Ah-See
Macclesfield District General Hospital Dr Lisa Barraclough and Dr Mark Lawrence
Maidstone Hospital Dr Catherine Harper-Wynne, Dr Charlotte Abson, Dr Rema Jyothirmayi
and Dr Russell Burcombe
Manor Hospital Dr Indrajit Fernando and Dr Suhail Anwar
Medway Maritime Hospital Dr Charlotte Abson and Dr Maher Hadaki
Milton Keynes Hospital Dr Hany Eldeeb, Dr Maria Karina and Dr S Azhar Rizvi
Mount Vernon Hospital Dr Amy Guppy, Dr Andreas Makris, Dr Arshi Denton, Dr David Miles,
Dr Peter Ostler and Professor Jane Maher
Musgrove Park Hospital Dr Emma Cattell, Dr Hilary Barlow, Dr John Graham, Dr Mohini Varughese
and Dr Saiqa Spensley
Nevill Hall Hospital Dr Nayyer Iqbal, Dr Simon Waters and Dr Theresa Howe
New Cross Hospital Dr Caroline Brammer, Dr Georgi Georgiev, Dr Laura Pettit, Dr Mark Churn,
Dr Prakash Ramachandra and Dr Rakesh Mehra
Newham General Hospital Dr Chris Gallagher, Dr Karen Tipples and Dr Virginia Wolstenholme
Norfolk & Norwich University Hospital Dr Adrian Harnett, Dr Andrew Bulman, Dr Daniel Epurescu,
Dr Dinos Geropantas and Dr Susanna Alexander
North Devon District Hospital Dr Kate Scatchard
North Middlesex Hospital Dr Fharat Raja, Dr Jacqueline Newby and Dr Stephen Karp
North Tyneside General Hospital Dr Anthony N Branson
Northampton General Hospital Dr Craig Knighton, Dr Craig Macmillan and Dr Hany Eldeeb
Northwick Park Hospital Dr Andreas Makris and Dr Arshi Denton
Nottingham City Hospital Dr Sarah Khan and Dr Stephen Chan
Peterborough City Hospital Dr Catherine Jephcott, Dr Karen McAdam and Dr Sarah Ayers
Pilgrim Hospital Dr Chiara Intrivici and Dr Elisabeth Murray
Pinderfields Hospital Dr Jay Naik
Poole Hospital Dr Amitabha Chakrabarti, Dr Darcy Goode, Dr Joanne Brady and
Dr Susan Dean
Prince Charles Hospital Dr Helen Passant
Princess of Wales Hospital Dr James Powell and Dr Rosie Stevens
Princess Royal University Hospital Dr Elinor Sawyer and Dr Mark Harries
Queen Alexandra Hospital Dr Caroline Archer, Dr Helen Cooper, Dr Joanna Gale and
Dr Timothy Gulliford
Queen Elizabeth Hospital (Birmingham) Dr Andrea Stevens, Dr Daniel Rea and Dr Suhail Anwar
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Queen Elizabeth Hospital (Gateshead) Dr Daniela Lee, Dr Goudarz Mazdai, Dr Helen Lucraft, Dr Helen Turnbull,
Dr Nicola Cresti, Dr Prithvi Jampana, Dr Rebecca Goranova and
Dr Wendy Taylor
Queen Elizabeth Hospital (King’s Lynn) Dr Athar Ahmad, Dr Ellen Gokkel, Dr Margaret Daly, Dr Nicola
Ainsworth and Dr Shahzeena Aslam
Queen Elizabeth Hospital (London) Dr Bruce Bryant, Dr Hartmut Kristeleit and Dr Mark Harries
Queen Elizabeth The Queen Mother
Hospital
Dr Carys Thomas, Dr Jane Brown, Dr Julia Hall, Dr Natasha Mithal and
Dr Rohit Malde
Queen’s Hospital (Burton) Dr Ad Chetiyawardana and Dr Mojca Persic
Queen’s Hospital (Romford) Dr Anwar Al-Saffar, Dr Caroline Bridgewater, Dr Eliot Sims, Dr Elizabeth
Croydon, Dr Emma Staples, Dr Mark Prentice and Dr Mary Quigley
Raigmore Hospital Dr Alison Nicholls, Dr Carol MacGregor, Dr David Whillis, Dr Kay Kelly,
Dr Marion Paterson, Dr Neil McPhail, Dr Pinelopi Gkogkou and
Dr Prantik Das
Rotherham General Hospital Dr Alex Bradshaw, Dr Bernadette Birtwhistle and Dr Matthew Hatton
Royal Albert Edward Infirmary Dr Elena Takeuchi and Dr Gregory Wilson
Royal Berkshire Hospital Dr Jocelyn Adams, Dr Madhumita Bhattacharyya and Dr Richard Brown
Royal Bournemouth Hospital Dr Tamas Hickish
Royal Derby Hospital Dr Mojca Persic, Dr Pamela Woodings and Dr Prabir Chakraborti
Royal Free Hospital Dr Alison Jones and Dr Jacqueline Newby
Royal Glamorgan Hospital Dr Jacinta Abraham
Royal Gwent Hospital Dr Carys Morgan, Dr Chris Gaffney, Dr Mohammed Harb, Dr Robert Jones
and Dr Simon Waters
Royal Hampshire County Hospital Dr Nicholas Murray, Dr Sanjay Raj and Dr Virginia Hall
Royal Lancaster Infirmary Dr David Eaton and Dr Sarah Moon
Royal Liverpool University Hospital Dr Nicola Thorp and Dr Susan O’Reilly
Royal Shrewsbury Hospital Dr Huzeifa Gadir, Dr Laura Pettit, Dr Rajiv Agrawal and
Dr Sheena Khanduri
Royal Surrey County Hospital Dr Anthony Neal, Dr Robert Laing and Dr Stephen Houston
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Whiston Hospital Dr Helen Innes and Dr Rajamram Sripadam
William Harvey Hospital Dr Julia Hall and Dr Natasha Mithal
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Wrexham Maelor Hospital Dr Audrey Champion, Dr Niladri Ghosal and Dr Win Soe
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Data-sharing statement
The trial is registered on the EU Clinical Trials Register (www.clinicaltrialsregister.eu) (EudraCT number
2006-007018-39) and on ClinicalTrials.Gov (https://clinicaltrials.gov/) (number NCT00712140).
All relevant results-related information regarding the trial will be kept in the EU Clinical Trials Database
(EudraCT) and be publicly available through the EU Clinical Trials Register. The information will be
posted within 1 year after the end of the trial.
Participant data are stored on a secure server at Warwick Clinical Trials Unit (the Data Processor) on
behalf of the sponsor (Cambridge University Hospital and the University of Cambridge). Each participant
has been assigned a de-identified trial number. No identifiable data such as name, address, hospital
number, NHS number, date of birth or any other identifying data will be shared and should not be
requested. A data dictionary will be available and will include descriptions of patient demographics,
treatment allocation and primary outcome data. A SAS® Programme will be applied to produce clinical
study output together with the statistical analysis plan (plan to analyse data). Any requests for access to
the trial data should be sent to the chief investigator, who will inform the data custodians, and agreement
will be made through the data access committee, which will comprise the principal investigators from
the trial management group. For each data-sharing request it is essential that a pro forma is completed
that will describe the purpose, scope, data items requested, analysis plan and acknowledgement of the
trial management team. Requestors who are granted access to the data will be required to complete
a data-sharing agreement that will be signed by the requester, sponsor and principal investigator(s).
The study protocol and statistical analysis plan will be made available on request. Please note that
exclusive use will be retained until the publication of major outputs.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to make
better use of information from people’s patient records, to understand more about disease, develop
new treatment, monitor safety, and plan NHS services. Patient data should be kept safe and secure to
protect everyone’s privacy, and it’s important there are safeguards to make sure that it is stored and
used responsibly. Everyone should be able to find out how patient data are used. #datasaveslives. You
can find out more about the background to this citation here: https://understandingpatientdata.org.uk/
data-citation.
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Appendix 1 Additional tables
TABLE 26 Reasons given on screening logs for non-randomisation into PERSEPHONE
n (%)
Total approached 7975
Total recruited 1848 (23)
Total not recruited 6127 (77)
Reason given for non-recruitment
Patient would prefer to have standard treatment 1576 (26)
Not eligible 1502 (24.5)
Patient declined, no reason 1015 (16.5)
Awaiting patient’s decision 783 (13)
Patient has no interest in the trial 204 (3)
Clinician’s decision 92 (1.5)
Outside timescale for starting Herceptin 34 (0.5)
Other 279 (4.5)
Unknown 642 (10.5)
TABLE 27 Recruitment by randomising site (cancer centres in bold)
Site
12-month patients
(N= 2045)
6-month patients
(N= 2044)
Total
(N= 4089)
n % n % n %
Aberdeen Royal Infirmary 10 0.5 12 0.6 22 0.5
Addenbrooke’s Hospital 54 2.6 41 2.0 95 2.3
Airedale General Hospital 9 0.4 4 0.2 13 0.3
Alexandra Hospital 5 0.2 5 0.2 10 0.2
Ashford Hospital 2 0.1 3 0.1 5 0.1
Barnet Hospital 19 0.9 25 1.2 44 1.1
Barnsley District Hospital 8 0.4 9 0.4 17 0.4
Basildon and Thurrock University Hospitals 8 0.4 6 0.3 14 0.3
Basingstoke and North Hampshire Hospital 5 0.2 6 0.3 11 0.3
Bedford General Hospital 14 0.7 12 0.6 26 0.6
Birmingham Heartlands Hospital 3 0.1 5 0.2 8 0.2
Bishop Auckland General Hospital 1 0.05 4 0.2 5 0.1
Blackpool Victoria Hospital 8 0.4 9 0.4 17 0.4
Borders General Hospital 12 0.6 10 0.5 22 0.5
continued
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TABLE 27 Recruitment by randomising site (cancer centres in bold) (continued )
Site
12-month patients
(N= 2045)
6-month patients
(N= 2044)
Total
(N= 4089)
n % n % n %
Bradford Royal Infirmary 7 0.3 17 0.8 24 0.6
Broomfield Hospital 8 0.4 7 0.3 15 0.4
Castle Hill Hospital 9 0.4 11 0.5 20 0.5
Charing Cross Hospital 29 1.4 28 1.4 57 1.4
Cheltenham General Hospital 23 1.1 18 0.9 41 1.0
Chesterfield Royal Hospital 12 0.6 17 0.8 29 0.7
Christie Hospital 22 1.1 27 1.3 49 1.2
City Hospital 20 1.0 21 1.0 41 1.0
Clatterbridge Cancer Centre 16 0.8 18 0.9 34 0.8
Conquest Hospital 21 1.0 20 1.0 41 1.0
County Hospital 9 0.4 13 0.6 22 0.5
Cumberland Infirmary 24 1.2 26 1.3 50 1.2
Darent Valley Hospital 15 0.7 16 0.8 31 0.8
Darlington Memorial Hospital 6 0.3 7 0.3 13 0.3
Dewsbury and District Hospital 1 0.05 0 0.0 1 0.02
Diana, Princess of Wales Hospital 28 1.4 13 0.6 41 1.0
Doncaster Royal Infirmary 2 0.1 8 0.4 10 0.2
Dorset County Hospital 10 0.5 11 0.5 21 0.5
Dumfries and Galloway Royal Infirmary 8 0.4 9 0.4 17 0.4
Ealing Hospital 5 0.2 2 0.1 7 0.2
East Surrey Hospital 9 0.4 12 0.6 21 0.5
Eastbourne District General Hospital 24 1.2 26 1.3 50 1.2
Essex County Hospital 17 0.8 10 0.5 27 0.7
Freeman Hospital 2 0.1 1 0.05 3 0.1
Friarage Hospital 1 0.05 2 0.1 3 0.1
Furness General Hospital 6 0.3 4 0.2 10 0.2
George Eliot Hospital 11 0.5 11 0.5 22 0.5
Glan Clwyd Hospital 9 0.4 6 0.3 15 0.4
Good Hope Hospital 5 0.2 5 0.2 10 0.2
Great Western Hospital 13 0.6 33 1.6 46 1.1
Guy’s Hospital 16 0.8 21 1.0 37 0.9
Halton General Hospital 10 0.5 10 0.5 20 0.5
Hexham General Hospital 1 0.05 3 0.1 4 0.1
Hinchingbrooke Hospital 5 0.2 6 0.3 11 0.3
Ipswich Hospital 6 0.3 8 0.4 14 0.3
James Paget University Hospital 22 1.1 21 1.0 43 1.1
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TABLE 27 Recruitment by randomising site (cancer centres in bold) (continued )
Site
12-month patients
(N= 2045)
6-month patients
(N= 2044)
Total
(N= 4089)
n % n % n %
Kent and Canterbury Hospital 15 0.7 12 0.6 27 0.7
Kidderminster Hospital 13 0.6 12 0.6 25 0.6
King Edward VII’s Hospital 3 0.1 0 0.0 3 0.1
King’s College Hospital 16 0.8 24 1.2 40 1.0
King’s Mill Hospital 5 0.2 3 0.1 8 0.2
Leighton Hospital 1 0.05 0 0.0 1 0.02
Lincoln County Hospital 8 0.4 7 0.3 15 0.4
Lister Hospital 10 0.5 11 0.5 21 0.5
Luton and Dunstable University Hospital 27 1.3 28 1.4 55 1.3
Macclesfield District General Hospital 21 1.0 18 0.9 39 1.0
Maidstone Hospital 35 1.7 22 1.1 57 1.4
Medway Maritime Hospital 16 0.8 27 1.3 43 1.1
Milton Keynes Hospital 4 0.2 7 0.3 11 0.3
Mount Vernon Hospital 24 1.2 17 0.8 41 1.0
Musgrove Park Hospital 16 0.8 12 0.6 28 0.7
Nevill Hall Hospital 1 0.05 5 0.2 6 0.1
New Cross Hospital 30 1.5 26 1.3 56 1.4
Newham General Hospital 9 0.4 10 0.5 19 0.5
Norfolk and Norwich University Hospital 36 1.8 42 2.1 78 1.9
North Devon District Hospital 10 0.5 4 0.2 14 0.3
North Middlesex University Hospital 17 0.8 14 0.7 31 0.8
North Tyneside General Hospital 6 0.3 11 0.5 17 0.4
Northampton General Hospital 8 0.4 15 0.7 23 0.6
Northwick Park Hospital 5 0.2 2 0.1 7 0.2
Nottingham City Hospital 4 0.2 6 0.3 10 0.2
Peterborough City Hospital 36 1.8 47 2.3 83 2.0
Pilgrim Hospital 1 0.05 7 0.3 8 0.2
Pinderfields Hospital 6 0.3 6 0.3 12 0.3
Poole Hospital 3 0.1 9 0.4 12 0.3
Prince Charles Hospital 3 0.1 2 0.1 5 0.1
Princess of Wales Hospital 4 0.2 6 0.3 10 0.2
Princess Royal University Hospital 20 1.0 22 1.1 42 1.0
Queen Alexandra Hospital 14 0.7 14 0.7 28 0.7
Queen Elizabeth Hospital Birmingham 21 1.0 18 0.9 39 1.0
Queen Elizabeth Hospital Gateshead 13 0.6 12 0.6 25 0.6
continued
DOI: 10.3310/hta24400 Health Technology Assessment 2020 Vol. 24 No. 40
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Earl et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
143
TABLE 27 Recruitment by randomising site (cancer centres in bold) (continued )
Site
12-month patients
(N= 2045)
6-month patients
(N= 2044)
Total
(N= 4089)
n % n % n %
Queen Elizabeth Hospital King’s Lynn 17 0.8 17 0.8 34 0.8
Queen Elizabeth Hospital London 16 0.8 18 0.9 34 0.8
Queen Elizabeth The Queen Mother Hospital 7 0.3 7 0.3 14 0.3
Queen’s Hospital Burton 30 1.5 18 0.9 48 1.2
Queen’s Hospital Romford 29 1.4 29 1.4 58 1.4
Raigmore Hospital 18 0.9 23 1.1 41 1.0
Rotherham General Hospital 1 0.05 5 0.2 6 0.1
Royal Albert Edward Infirmary 5 0.2 2 0.1 7 0.2
Royal Berkshire Hospital 9 0.4 6 0.3 15 0.4
Royal Bournemouth Hospital 4 0.2 3 0.1 7 0.2
Royal Derby Hospital 34 1.7 26 1.3 60 1.5
Royal Free Hospital 16 0.8 17 0.8 33 0.8
Royal Glamorgan Hospital 5 0.2 7 0.3 12 0.3
Royal Gwent Hospital 13 0.6 13 0.6 26 0.6
Royal Hampshire County Hospital 24 1.2 23 1.1 47 1.1
Royal Lancaster Infirmary 22 1.1 23 1.1 45 1.1
Royal Liverpool University Hospital 26 1.3 28 1.4 54 1.3
Royal Shrewsbury Hospital 28 1.4 27 1.3 55 1.3
Royal Surrey County Hospital 14 0.7 8 0.4 22 0.5
Royal Sussex County Hospital 39 1.9 35 1.7 74 1.8
Royal United Hospital 10 0.5 21 1.0 31 0.8
Russells Hall Hospital 27 1.3 24 1.2 51 1.2
Salisbury District Hospital 15 0.7 13 0.6 28 0.7
Sandwell General Hospital 2 0.1 2 0.1 4 0.1
Scarborough General Hospital 12 0.6 8 0.4 20 0.5
Scunthorpe General Hospital 3 0.1 3 0.1 6 0.1
Solihull Hospital 4 0.2 1 0.05 5 0.1
South Tyneside District Hospital 8 0.4 12 0.6 20 0.5
Southampton General Hospital 27 1.3 34 1.7 61 1.5
Southend Hospital 34 1.7 26 1.3 60 1.5
Southport and Formby District General Hospital 10 0.5 24 1.2 34 0.8
St Bartholomew’s Hospital 30 1.5 35 1.7 65 1.6
St George’s Hospital 16 0.8 20 1.0 36 0.9
St Mary’s Hospital Isle of Wight 10 0.5 14 0.7 24 0.6
St Mary’s Hospital London 14 0.7 8 0.4 22 0.5
Stepping Hill Hospital 0 0.0 1 0.05 1 0.02
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TABLE 27 Recruitment by randomising site (cancer centres in bold) (continued )
Site
12-month patients
(N= 2045)
6-month patients
(N= 2044)
Total
(N= 4089)
n % n % n %
Stoke Mandeville Hospital 16 0.8 18 0.9 34 0.8
Sunderland Royal Hospital 16 0.8 15 0.7 31 0.8
The County Hospital 22 1.1 15 0.7 37 0.9
The James Cook University Hospital 17 0.8 11 0.5 28 0.7
The Tunbridge Wells Hospital 9 0.4 4 0.2 13 0.3
The Whittington Hospital 10 0.5 11 0.5 21 0.5
Torbay Hospital 23 1.1 16 0.8 39 1.0
University Hospital 12 0.6 14 0.7 26 0.6
University Hospital Aintree 7 0.3 12 0.6 19 0.5
University Hospital of Hartlepool 13 0.6 4 0.2 17 0.4
University Hospital of North Durham 15 0.7 24 1.2 39 1.0
University Hospital of North Tees 16 0.8 11 0.5 27 0.7
Velindre Hospital 8 0.4 4 0.2 12 0.3
Walsall Manor Hospital 28 1.4 13 0.6 41 1.0
Wansbeck General Hospital 4 0.2 7 0.3 11 0.3
Warrington Hospital 13 0.6 7 0.3 20 0.5
Warwick Hospital 17 0.8 21 1.0 38 0.9
West Cumberland Hospital 0 0.0 1 0.05 1 0.02
West Middlesex University Hospital 7 0.3 9 0.4 16 0.4
West Suffolk Hospital 15 0.7 12 0.6 27 0.7
Western General Hospital 11 0.5 9 0.4 20 0.5
Weston Park Hospital 6 0.3 5 0.2 11 0.3
Wexham Park Hospital 31 1.5 27 1.3 58 1.4
Whiston Hospital 10 0.5 14 0.7 24 0.6
William Harvey Hospital 17 0.8 15 0.7 32 0.8
Worcester Royal Infirmary 5 0.2 6 0.3 11 0.3
Worthing Hospital 15 0.7 9 0.4 24 0.6
Wrexham Maelor Hospital 8 0.4 9 0.4 17 0.4
Wycombe General Hospital 13 0.6 12 0.6 25 0.6
Yeovil District Hospital 18 0.9 17 0.8 35 0.9
Ysbyty Gwynedd 13 0.6 14 0.7 27 0.7
Total 2045 100 2044 100 4089 100
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TABLE 28 Return rates of trial CRFs
CRF Received Expected %
Eligibility form 4072 4088 99.6
Randomisation form 4080 4088 99.8
On-study form 4076 4087 99.7
Neoadjuvant diagnostic biopsy form 618 625 98.9
Surgery form 4064 4083 99.5
Trastuzumab treatment form (cycles 1–4) 4067 4083 99.6
Trastuzumab treatment form (cycles 5–8) 4031 4048 99.6
Trastuzumab treatment form (cycles 9–12) 4004 4027 99.4
Trastuzumab treatment form (cycles 13–16/9-month LVEF) 3849 3927 98.0
Trastuzumab treatment form (cycles 17–18/12-month LVEF) 3837 3927 97.7
Treatment summary form 4029 4080 98.8
Radiotherapy form 4026 4065 99.0
Annual follow-up forms (years 1–10) 21,699 23,924 90.7
TABLE 29 ER status, nodal status and tumour size in adjuvant trastuzumab trials
Trial ER positive (%) Node negative (%) ≤ 2 cm (%) Patient numbers (total)
SOLD 66 60 56 2176
Short-HER 68 54 41 1253
HORG 67 20 – 481
PHARE 58 55 53 3383
PERSEPHONE 69 58 47 4088
HERA 46 33 40 5081
NSABP-B31/NCCTG N9381 46 7 38 4046
BCIRG-006 54 29 40 3222
FINHER 47 16 35 232
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TABLE 30 Baseline characteristics of all patients, split by adjuvant and neoadjuvant chemotherapy
Characteristic
Adjuvant
CT, n (%)
Neoadjuvant
CT, n (%) Total, N (%) p-value
Randomised treatment
12 months 1735 (50) 310 (50) 2045 (50) 0.82
6 months 1727 (50) 316 (50) 2043 (50)
ER statusa
Negative 1022 (30) 241 (39) 1263 (31) < 0.0001
Positive 2440 (70) 385 (61) 2825 (69)
Chemotherapy typea
Anthracycline based 1642 (48) 54 (9) 1696 (41) < 0.0001
Taxane based (no anthracycline) 386 (11) 14 (2) 400 (10)
Anthracycline and taxane based 1429 (41) 558 (89) 1987 (49)
No taxane and no anthracycline 5 (< 1) 0 (0) 5 (< 1)
Trastuzumab timinga
Concurrent 1408 (41) 492 (79) 1900 (46) < 0.0001
Sequential 2054 (59) 134 (21) 2188 (54)
Sex
Female 3456 (99) 626 (100) 4082 (99) 0.63
Male 6 (1) 0 (0) 6 (1)
Age (years) at randomisation
Median (range) 57 (23–83) 52 (23–82) 56 (23–83) < 0.0001
< 35 72 (2) 23 (4) 95 (2) < 0.0001
35–49 867 (25) 242 (38) 1109 (27)
50–59 1058 (31) 206 (33) 1264 (31)
60–69 1069 (31) 130 (21) 1199 (30)
≥ 70 396 (11) 25 (4) 421 (10)
Nodal status at surgery (of the 3462 adjuvant patients)
Negative 2017 (58) – 2017 (58) –
1–3 nodes positive 964 (28) – 964 (28)
≥ 4 nodes positive 455 (13) – 455 (13)
Unknown 26 (1) – 26 (1)
Tumour sizeb (of the 3462 adjuvant patients)
≤ 2 cm 1626 (47) – 1626 (47) –
> 2 and ≤ 5 cm 1565 (45) – 1565 (45)
> 5 cm 169 (5) – 169 (5)
Unknown 102 (3) – 102 (3)
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TABLE 30 Baseline characteristics of all patients, split by adjuvant and neoadjuvant chemotherapy (continued )
Characteristic
Adjuvant
CT, n (%)
Neoadjuvant
CT, n (%) Total, N (%) p-value
Tumour gradeb
I (well differentiated) 61 (2) 1 (< 1) 62 (2) 0.001
II (moderately differentiated) 1035 (30) 241 (39) 1276 (31)
III (poorly differentiated) 2282 (66) 340 (54) 2622 (64)
Unknown 84 (2) 44 (7) 128 (3)
Ethnicity
White 2851 (83) 456 (73) 3307 (81) < 0.0001
Asian 83 (2) 26 (4) 109 (3)
Black 74 (2) 23 (4) 97 (2)
Other 25 (1) 13 (2) 38 (1)
Unknown 429 (12) 108 (17) 537 (13)
Menopausal status before chemotherapy
Pre 904 (26) 242 (39) 1146 (28) < 0.0001
Peri 213 (6) 48 (8) 261 (6)
Post 1947 (56) 270 (43) 2217 (54)
Not assessable/not available 398 (12) 66 (10) 464 (12)
Reported prior use of cardiac medication
Yes 92 (3) 7 (1) 99 (2) 0.03
No 3370 (97) 619 (99) 3989 (98)
IHC-score and FISH positivity (HER2 test result)
3+ 2484 (72) 467 (75) 2951 (72) 0.002
2+ and FISH positive 935 (27) 126 (20) 1061 (26)
HER2 positive – IHC and FISH score not
available
43 (1) 33 (5) 76 (2)
Median (IQR) follow-up (years) 6.2 (4.6–7.7) 5.4 (4.1–7.2) 6.1 (4.5–7.6)
Number of deaths reported (%) 305 (9) 84 (13) 389 (10)
Number of DFS events reported 439 (13) 127 (20) 566 (14)
CT, chemotherapy.
a Stratification variable.
b Of largest invasive tumour at diagnosis.
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TABLE 31 Baseline characteristics of all patients, split by concurrent or sequential chemotherapy
Characteristic
Concurrent
patients, n (%)
Sequential
patients, n (%) Total, N (%) p-value
Randomised treatment
12 months 949 (50) 1096 (50) 2045 (50) 0.95
6 months 951 (50) 1092 (50) 5043 (50)
ER statusa
Negative 597 (31) 666 (30) 1263 (31) 0.52
Positive 1303 (69) 1522 (70) 2825 (69)
Chemotherapy typea
Anthracycline based 55 (3) 1641 (75) 1696 (41) < 0.0001
Taxane based (no anthracycline) 342 (18) 58 (3) 400 (10)
Anthracycline and taxane based 1503 (79) 484 (22) 1987 (49)
No taxane and no anthracycline 0 (0) 5 (< 1) 5 (< 1)
Chemotherapy timinga
Adjuvant 1408 (74) 2054 (94) 3462 (85) < 0.0001
Neoadjuvant 492 (26) 134 (6) 626 (15)
Sex
Female 1898 (99) 2184 (99) 4082 (99) 0.69
Male 2 (1) 4 (1) 6 (1)
Age (years) at randomisation
Median (range) 54 (23–82) 57 (23–83) 56 (23–83) < 0.0001
< 35 65 (3) 30 (1) 95 (2) < 0.0001
35–49 565 (30) 544 (25) 1109 (27)
50–59 593 (31) 671 (31) 1264 (31)
60–69 525 (28) 674 (31) 1199 (30)
≥ 70 152 (8) 269 (12) 421 (10)
Nodal status at surgery (of the 3462 adjuvant patients)
Negative 642 (46) 1375 (67) 2017 (58) < 0.0001
1–3 nodes positive 506 (36) 458 (22) 964 (28)
≥ 4 nodes positive 241 (17) 214 (10) 455 (13)
Unknown 19 (1) 7 (< 1) 26 (1)
Tumour sizeb (of the 3462 adjuvant patients)
≤ 2 cm 577 (41) 1049 (51) 1626 (47) < 0.0001
> 2 and ≤ 5 cm 690 (49) 875 (43) 1565 (45)
> 5 cm 89 (6) 80 (4) 169 (5)
Unknown 52 (4) 50 (2) 102 (3)
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TABLE 31 Baseline characteristics of all patients, split by concurrent or sequential chemotherapy (continued )
Characteristic
Concurrent
patients, n (%)
Sequential
patients, n (%) Total, N (%) p-value
Tumour gradeb
I (well differentiated) 28 (1) 34 (2) 62 (2) 0.08
II (moderately differentiated) 560 (30) 716 (33) 1276 (31)
III (poorly differentiated) 1233 (65) 1389 (63) 2622 (64)
Unknown 79 (4) 49 (2) 128 (3)
Ethnicity
White 1465 (77) 1842 (84) 3307 (81) < 0.0001
Asian 69 (4) 40 (2) 109 (3)
Black 55 (3) 42 (2) 97 (2)
Other 24 (1) 14 (1) 38 (1)
Unknown 287 (15) 250 (11) 537 (13)
Menopausal status before chemotherapy
Pre 606 (32) 540 (25) 1146 (28) < 0.0001
Peri 134 (7) 127 (6) 261 (6)
Post 971 (51) 1246 (57) 2217 (54)
Not assessable/not available 189 (10) 275 (12) 464 (12)
Reported prior use of cardiac medication
Yes 48 (3) 51 (2) 99 (2) 0.76
No 1852 (97) 2137 (98) 3989 (98)
IHC-score and FISH positivity (HER2 test result)
3+ 1400 (74) 1551 (71) 2951 (72) 0.01
2+ and FISH positive 454 (24) 607 (28) 1061 (26)
HER2 positive – IHC and FISH score
not available
46 (2) 30 (1) 76 (2)
Median (IQR) follow-up (years) 5.3 (4.2–6.6) 6.7 (5.2–8.2) 6.1 (4.5–7.6)
Number of deaths reported 148 (8) 241 (11) 389 (10)
Number of DFS events reported 235 (12) 331 (15) 566 (14)
a Stratification variable.
b Of largest invasive tumour at diagnosis.
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TABLE 32 Chemotherapy regimens received by PERSEPHONE patients
Stratification/chemotherapy regimen 12-month patients, n (%) 6-month patients, n (%) Total, N (%)
Anthracycline based (no taxane) 851 (41) 845 (41) 1696 (41)
FEC 544 567 1111
EC 124 106 230
E-CMF 98 84 182
AC 61 55 116
EX 7 11 18
FAC 4 4 8
Other 13 19 32
Taxane-based (no anthracycline) 198 (10) 202 (10) 400 (10)
TC 112 112 224
TCH 38 41 79
Pac 29 32 61
T 6 6 12
Other 13 11 24
Anthracycline and taxane based 994 (49) 993 (49) 1987 (49)
FEC-T 818 795 1613
EC-T 65 79 144
AC-Paclitaxel 19 16 35
AC-T 14 18 32
FEC-Pac 11 13 24
TAC 6 12 18
FEC-TPaca 9 6 15
EC-TPaca 9 4 13
EC-Pac 4 7 11
FEC-TAbraxa 4 6 10
ACTPaca 1 1 2
EC-GT 1 1 2
FEC-Abrax 1 1 2
Other 32 34 66
Neither anthracycline nor taxanes 2 (< 1) 3 (< 1) 5 (< 1)
CMF 2 3 5
A, doxorubicin; F, 5-fluorouracil; M, methotrexate; T, docetaxel; X, capecitabine.
a Following allergic reaction to docetaxel (T) switched to either paclitaxel or abraxane (Abrax).
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TABLE 33 Details of protocol non-compliances
Type of protocol non-compliance
12-month
patients (n)
6-month
patients (n) N/A (n) Total (N)
Trastuzumab dose issue (including too few/too many cycles) 46 29 0 75
Reloading dose of 8 mg/kg not given 35 20 0 55
Healthcare at Home issue (including dispensing non-Investigational
Medicinal Product)
24 16 2 42
Pharmacy error (including labelling) 24 15 1 40
Missed or late LVEF 15 22 0 37
Low LVEF and treatment not held 13 6 1 20
Ineligible patient 7 12 0 19
Site administration error (including staff not GCP trained) 5 3 1 9
Patient identifiers not redacted 1 2 0 3
Late-reported SAE 1 0 0 1
> 3 month gap between chemotherapy and trastuzumab 0 1 0 1
Trial Management Group error 0 0 1 1
Total 171 126 6 303
N/A, not applicable.
TABLE 34 Reason for trastuzumab cycles being delayed/held
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
Holiday 588 (23) 296 (22) 884 (23)
Administration/clinic dates/i.v. access problems 376 (15) 197 (15) 573 (15)
Patient request for family/personal reasons 178 (7) 63 (5) 241 (6)
Surgery, radiotherapy or procedure (e.g. line insertion) 136 (5) 70 (5) 206 (5)
Cardiotoxicity due to trastuzumab 120 (5) 74 (6) 194 (5)
Sepsis/infection/fevera 113 (4) 80 (6) 193 (5)
Unrelated medical problems 112 (4) 39 (3) 151 (4)
Awaiting cardiac function tests 52 (2) 27 (2) 79 (2)
Viral infection 44 (2) 18 (1) 62 (2)
Myelosuppression/neutropeniaa 32 (1) 26 (2) 58 (1)
Dyspnoea/cough 27 (1) 19 (1) 46 (1)
Did not attend 30 (1) 12 (1) 42 (1)
Oral/gastrointestinal tract toxicitya 15 (1) 12 (1) 27 (1)
Fatigue 12 (< 1) 13 (1) 25 (1)
Toxicity due to Herceptin 6 (< 1) 12 (1) 18 (< 1)
Adverse weather conditions 12 (< 1) 5 (< 1) 17 (< 1)
Toxicity due to chemotherapya 3 (< 1) 12 (1) 15 (< 1)
Allergy 7 (< 1) 3 (< 1) 10 (< 1)
Other 38 (1) 30 (2) 68 (2)
Unknown 695 (27) 364 (27) 1059 (27)
i.v., intravenous.
a Toxicities likely to be due to concurrent chemotherapy.
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TABLE 35 Frequency of toxicities during trastuzumab cycles in 1727 patients randomised before trastuzumab, split by cycles received in the first and second 6 months of treatment
Toxicity
CTCAE grade
Cycles by 12-month patients, n (%) Cycles by 6-month patients, n (%)
UK 0 1 2 3 4 UK 0 1 2 3 4
During the first 6 months of trastuzumab treatment
Chills 8 (< 1) 6755 (89) 590 (8) 186 (2) 58 (1) 6 (< 1) 1 (< 1) 6960 (92) 468 (6) 105 (1) 33 (< 1) 9 (< 1)
Cough 2 (< 1) 6739 (89) 708 (9) 112 (1) 24 (< 1) 18 (< 1) – 6748 (89) 695 (9) 95 (1) 35 (< 1) 3 (< 1)
Diarrhoea 5 (< 1) 6639 (87) 753 (10) 169 (2) 27 (< 1) 10 (< 1) – 6674 (88) 702 (9) 160 (2) 34 (< 1) 6 (< 1)
Dizziness 5 (< 1) 7021 (92) 473 (6) 85 (1) 17 (< 1) 2 (< 1) – 7030 (93) 458 (6) 54 (1) 27 (< 1) 7 (< 1)
Dyspnoea 18 (< 1) 6675 (88) 660 (8) 210 (3) 40 (1) 4 (< 1) 6655 (87) 753 (10) 118 (2) 46 (1)
Fatigue 15 (< 1) 4319 (57) 2201 (29) 857 (11) 177 (2) 34 (< 1) 5 (< 1) 4365 (58) 2217 (29) 726 (10) 234 (3) 29 (< 1)
Fever 3 (< 1) 7385 (97) 163 (2) 41 (1) 11 (< 1) – 1 (< 1) 7329 (97) 164 (2) 58 (1) 22 (< 1) 2 (< 1)
Headache 7 (< 1) 6482 (85) 876 (12) 177 (2) 58 (1) 3 (< 1) 1 (< 1) 6469 (85) 894 (12) 167 (2) 37 (< 1) 8 (< 1)
Hypertension 1 (< 1) 7500 (99) 72 (1) 24 (< 1) 5 (< 1) 1 (< 1) 1 (< 1) 7456 (98) 87 (1) 21 (< 1) 11 (< 1) –
Hypotension 3 (< 1) 7569 (99) 29 (< 1) 1 (< 1) 1 (< 1) – – 7543 (99) 26 (< 1) 4 (< 1) 3 (< 1) –
Infection 1 (< 1) 7298 (96) 153 (2) 132 (2) 17 (< 1) 2 (< 1) 5 (< 1) 7251 (96) 160 (2) 127 (2) 30 (< 1) 3 (< 1)
Muscle/joint pain 13 (< 1) 5096 (67) 1558 (20) 727 (10) 164 (2) 45 (1) 2 (< 1) 5132 (68) 1487 (20) 700 (9) 223 (3) 32 (< 1)
Nausea 13 (< 1) 6956 (91) 534 (7) 80 (1) 20 (< 1) 5 (< 1) 7022 (93) 444 (6) 91 (1) 14 (< 1)
Pain 18 (< 1) 6696 (88) 594 (8) 231 (3) 57 (1) 7 (< 1) 4 (< 1) 6774 (89) 492 (6) 232 (3) 58 (1) 16 (< 1)
Palpitations 2 (< 1) 7111 (94) 398 (5) 92 (1) 3 (< 1) 7161 (94) 343 (5) 69 (1)
Rash 7 (< 1) 7222 (95) 301 (4) 57 (1) 16 (< 1) – 4 (< 1) 7181 (95) 291 (4) 81 (1) 18 (< 1) 1 (< 1)
Vomiting 1 (< 1) 7429 (97) 127 (2) 40 (1) 3 (< 1) 3 (< 1) 1 (< 1) 7433 (98) 110 (1) 25 (< 1) 6 (< 1) 1 (< 1)
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TABLE 35 Frequency of toxicities during trastuzumab cycles in 1727 patients randomised before trastuzumab, split by cycles received in the first and second 6 months of
treatment (continued )
Toxicity
CTCAE grade
Cycles by 12-month patients, n (%) Cycles by 6-month patients, n (%)
UK 0 1 2 3 4 UK 0 1 2 3 4
During the second 6 months of trastuzumab treatment
Chills – 6401 (93) 348 (5) 77 (1) 26 (< 1) 3 (< 1)
Cough – 6174 (90) 540 (8) 98 (1) 35 (1) 8 (< 1)
Diarrhoea 1 (< 1) 6284 (92) 461 (7) 88 (1) 19 (< 1) 2 (< 1)
Dizziness 4 (< 1) 6359 (93) 396 (6) 81 (1) 11 (< 1) 4 (< 1)
Dyspnoea 6 (< 1) 6164 (90) 522 (8) 130 (2) 33 (< 1)
Fatigue 12 (< 1) 4165 (61) 1879 (27) 610 (9) 161 (2) 28 (< 1)
Fever 1 (< 1) 6691 (98) 141 (2) 16 (< 1) 5 (< 1) 1 (< 1)
Headache – 5945 (87) 726 (10) 140 (2) 40 (1) 4 (< 1)
Hypertension – 6724 (98) 100 (1) 20 (< 1) 11 (< 1) –
Hypotension – 6826 (99) 28 (< 1) 1 (< 1) – –
Infection 2 (< 1) 6635 (97) 137 (2) 77 (1) 4 (< 1) –
Muscle/joint pain 12 (< 1) 4663 (68) 1402 (20) 605 (9) 139 (2) 34 (1)
Nausea – 6497 (95) 305 (4) 48 (1) 5 (< 1)
Pain 6 (< 1) 6063 (88) 510 (7) 226 (3) 42 (1) 8 (< 1)
Palpitations 1 (< 1) 6470 (94) 311 (5) 73 (1)
Rash 1 (< 1) 6618 (97) 198 (3) 33 (< 1) 5 (< 1) –
Vomiting – 6737 (98) 79 (1) 34 (1) 4 (< 1) 1 (< 1)
Dyspnoea and nausea have a maximum CTCAE grade of 3. Palpitations has a maximum CTCAE grade of 2.
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TABLE 36 Serious adverse event information for all 475 SAEs by randomised treatment arm (291 for 12-month patients
and 184 for 6-month patients)
12-month patients, n (%) 6-month patients, n (%) Total, N (%)
Reason for reportinga
Inpatient hospitalisation/prolongation of stay 242 (83) 153 (83) 395 (83)
Life-threatening event 23 (9) 18 (10) 41 (9)
Persistent or significant disability/incapacity 11 (4) 5 (3) 16 (3)
Death 3 (1) 3 (2) 6 (1)
New primary 1 (< 1) 2 (1) 3 (< 1)
Other 36 (12) 19 (10) 55 (11)
Reported severity
Mild 55 (19) 35 (19) 90 (19)
Moderate 155 (53) 87 (47) 242 (51)
Severe 63 (22) 50 (27) 113 (24)
Fatal/life-threatening 14 (5) 11 (6) 25 (5)
Missing 4 (1) 1 (1) 5 (1)
Reported causality related to trastuzumab
Definitely 27 (9) 16 (9) 43 (9)
Probably 19 (7) 12 (5) 31 (6)
Possibly 21 (7) 8 (4) 29 (6)
Unlikely 48 (17) 36 (20) 84 (18)
Unrelated 176 (60) 112 (61) 288 (61)
Outcome
Resolved – no sequelae 208 (71) 140 (76) 348 (73)
Resolved – with sequelae 47 (16) 28 (15) 75 (16)
Unresolved 32 (11) 10 (6) 42 (9)
Death 3 (1) 6 (3) 9 (2)
Missing 1 (< 1) 0 (0) 1 (< 1)
Reported primary CTCAE category
Infection 118 (41) 80 (43) 198 (42)
Cardiac general 38 (13) 15 (8) 53 (11)
Pain 19 (7) 11 (6) 30 (6)
Gastrointestinal 10 (3) 12 (7) 22 (5)
Neurology 14 (5) 8 (4) 22 (5)
Pulmonary/upper respiratory 13 (4) 8 (4) 21 (4)
Blood/bone marrow 14 (5) 6 (3) 20 (4)
Musculoskeletal/soft tissue 12 (4) 5 (3) 17 (4)
Constitutional symptoms 5 (2) 9 (5) 14 (3)
Vascular 8 (3) 5 (3) 13 (3)
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TABLE 36 Serious adverse event information for all 475 SAEs by randomised treatment arm (291 for 12-month patients
and 184 for 6-month patients) (continued )
12-month patients, n (%) 6-month patients, n (%) Total, N (%)
Cardiac arrhythmia 7 (2) 5 (3) 12 (3)
Allergy/immunology 6 (2) 3 (2) 9 (2)
Dermatology/skin 6 (2) 3 (2) 9 (2)
Haemorrhage/bleeding 3 (1) 2 (1) 5 (1)
Hepatobiliary/pancreas 4 (1) 1 (< 1) 5 (1)
Sexual/reproductive 4 (1) 1 (< 1) 5 (1)
Secondary malignancy 3 (1) 1 (< 1) 4 (< 1)
Death 1 (< 1) 2 (1) 3 (< 1)
Endocrine 1 (< 1) 2 (1) 3 (< 1)
Metabolic/laboratory 1 (< 1) 2 (1) 3 (< 1)
Renal/genitourinary 2 (1) 0 (0) 2 (< 1)
Lymphatics 1 (< 1) 1 (< 1) 2 (< 1)
Ocular/visual 1 (< 1) 0 (0) 1 (< 1)
Auditory/ear 0 (0) 1 (< 1) 1 (< 1)
Surgery/intraoperative injury 0 (0) 1 (< 1) 1 (< 1)
a Multiple reasons for reporting are given for some SAEs.
TABLE 37 Reported primary CTCAE category for all 103 SARs by randomised treatment arm
12-month patients, n (%) 6-month patients, n (%) Total, N (%)
Cardiac general 30 (45) 15 (42) 45 (43)
Infection 12 (18) 9 (25) 21 (20)
Pulmonary/upper respiratory 8 (12) 1 (3) 9 (9)
Cardiac arrhythmia 5 (7) 3 (8) 8 (8)
Allergy/immunology 5 (7) 2 (6) 7 (7)
Pain 3 (5) 2 (6) 5 (5)
Sexual/reproductive 1 (1.5) 1 (2.5) 2 (2)
Dermatology/skin 1 (1.5) 1 (2.5) 2 (2)
Constitutional symptoms 0 (0) 1 (2.5) 1 (1)
Gastrointestinal 0 (0) 1 (2.5) 1 (1)
Lymphatics 1 (1.5) 0 (0) 1 (1)
Vascular 1 (1.5) 0 (0) 1 (1)
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TABLE 38 Sites of relapses and second primaries
12-month patients, n (%) 6-month patients, n (%) Total, N (%)
Local relapse 81 (4%) 83 (4%) 164 (4%)
Site
Ipsilateral breast/chest wall 40 (49) 52 (63) 92 (56)
Ipsilateral axilla nodes 18 (22) 10 (12) 28 (17)
Ipsilateral supraclavicular nodes 7 (9) 12 (14) 19 (12)
Contralateral breast disease 5 (6) 6 (7) 11 (7)
Other 11 (14) 3 (4) 14 (9)
Distant relapse 192 (9%) 207 (10%) 399 (10%)
Site
Liver 86 (45) 91 (44) 177 (44)
Bone 63 (33) 89 (43) 152 (38)
Lung/pleura 74 (39) 78 (38) 152 (38)
Brain 40 (21) 43 (21) 83 (21)
Contralateral supraclavicular nodes 4 (2) 3 (1) 7 (2)
Other 27 (14) 23 (11) 50 (13)
Second primaries 67 (3%) 67 (3%) 134 (3%)
Site
Contralateral breast 23 (34) 13 (19) 36 (27)
Lung 9 (13.5) 8 (12) 17 (13)
Bowel/colon 4 (6) 11 (16.5) 15 (11)
Ovary 5 (7.5) 5 (7.5) 10 (7.5)
Bladder/urothelial cells 2 (3) 4 (6) 6 (4)
Endometrium 3 (4.5) 3 (4.5) 6 (4)
Lymphatic system 1 (1.5) 3 (4.5) 4 (3)
Kidney 4 (6) – 4 (3)
Skin 2 (3) 2 (3) 4 (3)
Skin (melanoma) 3 (4.5) – 3 (2)
AML 2 (3) 1 (1.5) 3 (2)
Stomach 1 (1.5) 2 (3) 3 (2)
Brain – 3 (4.5) 3 (2)
Oesophagus – 3 (4.5) 3 (2)
Bile duct 1 (1.5) 1 (1.5) 2 (1.5)
Head and neck 2 (3) – 2 (1.5)
Ipsilateral breast 2 (3) – 2 (1.5)
Pancreas 1 (1.5) – 1 (< 1)
Soft tissue sarcoma 1 (1.5) – 1 (< 1)
Thyroid 1 (1.5) – 1 (< 1)
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TABLE 38 Sites of relapses and second primaries (continued )
12-month patients, n (%) 6-month patients, n (%) Total, N (%)
Basal cell carcinoma (skin cancer) – 1 (1.5) 1 (< 1)
Bone and liver – 1 (1.5) 1 (< 1)
Cervix – 1 (1.5) 1 (< 1)
LAMN – 1 (1.5) 1 (< 1)
Liver – 1 (1.5) 1 (< 1)
Mesothelioma – 1 (1.5) 1 (< 1)
Myeloma – 1 (1.5) 1 (< 1)
Vulva – 1 (1.5) 1 (< 1)
AML, acute myeloid leukaemia; LAMN, low-grade appendiceal mucinous neoplasm.
TABLE 39 Baseline characteristics of the 4008 patients (2007 12-month patients and 2001 6-month patients) included in
the landmark analysis
Characteristic
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
ER statusa
Negative 615 (31) 618 (31) 1233 (31)
Positive 1392 (69) 1383 (69) 2775 (69)
Chemotherapy typea
Anthracycline based 837 (42) 829 (41) 1666 (41)
Taxane based 193 (10) 196 (10) 389 (10)
Anthracycline and taxane
based
975 (48) 973 (49) 1948 (49)
No taxane and no
anthracycline
2 (< 1) 3 (< 1) 5 (< 1)
Chemotherapy timinga
Adjuvant 1708 (85) 1693 (85) 3401 (85)
Neoadjuvant 299 (15) 308 (15) 607 (15)
Trastuzumab timinga
Concurrent 933 (46) 928 (46) 1861 (46)
Sequential 1074 (54) 1073 (54) 2147 (54)
Sex
Female 2003 (99) 1999 (99) 4002 (99)
Male 4 (1) 2 (1) 6 (1)
Age (years) at randomisation
Median (range) 56 (23–82) 56 (23–83) 56 (23–83)
< 35 48 (2) 43 (2) 91 (2)
35–49 537 (27) 545 (27) 1082 (27)
50–59 600 (30) 641 (32) 1241 (31)
60–69 608 (30) 574 (29) 1182 (30)
≥ 70 214 (11) 198 (10) 412 (10)
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TABLE 39 Baseline characteristics of the 4008 patients (2007 12-month patients and 2001 6-month patients) included in
the landmark analysis (continued )
Characteristic
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
Nodal status at surgery (of the 3401 adjuvant patients)
Negative 987 (58) 997 (59) 1984 (58)
1–3 nodes positive 470 (27) 479 (28) 949 (28)
≥ 4 nodes positive 241 (14) 207 (12) 448 (13)
Unknown 10 (1) 10 (1) 20 (1)
Tumour sizeb (of the 3401 adjuvant patients)
≤ 2 cm 812 (47) 791 (47) 1603 (47)
> 2 and ≤ 5 cm 766 (45) 772 (45) 1538 (45)
> 5 cm 86 (5) 80 (5) 166 (5)
Unknown 44 (3) 50 (3) 194 (3)
Tumour gradeb
I (well differentiated) 28 (1) 34 (2) 62 (2)
II (moderately
differentiated)
624 (31) 637 (32) 1261 (31)
III (poorly differentiated) 1296 (65) 1271 (63) 2567 (64)
Unknown 59 (3) 59 (3) 118 (3)
Ethnicity
White 1636 (82) 1619 (81) 3255 (81)
Asian 56 (3) 51 (3) 107 (3)
Black 51 (3) 44 (2) 95 (2)
Other 16 (< 1) 21 (1) 37 (1)
Unknown 248 (12) 266 (13) 514 (13)
Menopausal status before chemotherapy
Pre 554 (28) 567 (28) 1121 (28)
Peri 108 (5) 150 (8) 258 (6)
Post 1127 (56) 1054 (53) 2181 (54)
Not assessable/not available 218 (11) 230 (11) 448 (11)
Reported prior use of cardiac medication
Yes 43 (2) 54 (3) 97 (2)
No 1964 (98) 1947 (97) 3911 (98)
IHC-score and FISH positivity (HER2 test result)
3+ 1437 (72) 1464 (73) 2901 (72)
2+ and FISH positive 541 (27) 499 (25) 1040 (26)
HER2 positive – IHC and
FISH score not available
29 (1) 38 (2) 67 (2)
a Stratification variable.
b Of largest invasive tumour at diagnosis.
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TABLE 40 Breakdown of reporting of clinical cardiac dysfunction (n = 3995 patients)
Symptoms of
cardiac disease Signs of CHF
New/altered
medication for
cardiac disease
12-month
patients, n (%)
6-month
patients, n (%) Total, N (%)
✓ ✓ ✓ 20 (1) 9 (< 1) 29 (< 1)
✓ ✓ 10 (< 1) 4 (< 1) 14 (< 1)
✓ ✓ 39 (2) 23 (1) 62 (1.5)
✓ ✓ 7 (< 1) 2 (< 1) 9 (< 1)
✓ 52 (3) 31 (2) 83 (2)
✓ 7 (< 1) 6 (< 1) 13 (< 1)
✓ 93 (5) 81 (4) 174 (4)
✗ ✗ ✗ 1759 (89) 1852 (92) 3611 (90)
TABLE 41 Results from the 3401 MUGA scans and 14,207 echocardiograms
LVEF scan type 12-month patients, n (%) 6-month patients, n (%) Total, N (%)
MUGA
Normal result 1672 (90) 1405 (91) 3077 (90)
Low LVEFa 183 (10) 141 (9) 324 (10)
ECHO
Normal result 7102 (96) 6610 (97) 13,712 (97)
Low LVEFa 282 (4) 213 (3) 495 (3)
a LVEF < 50%, or percentage unknown but classified on report as abnormal.
TABLE 42 Cardiac deaths recorded in CRFs
TNO
Metastatic
(Y/N)
Treatment
group
Trastuzumab
cycles
Time from
diagnosis to
death (months) Cardiac causes Comment
144 N 12 months 18 44 Ischaemic heart
disease
Unrelated/unlikely. Death due
to acute MI 44 months after
diagnosis. No association
between trastuzumab and
coronary artery disease
938 N 12 months 8 21 Ischaemic heart
disease
Unrelated/unlikely. Death due
to acute MI 21 months after
diagnosis. No association
between trastuzumab and
coronary artery disease
1754 N 12 months 18 51 Cardiac amyloid Unrelated – no association
between trastuzumab and
amyloidosis
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TABLE 42 Cardiac deaths recorded in CRFs (continued )
TNO
Metastatic
(Y/N)
Treatment
group
Trastuzumab
cycles
Time from
diagnosis to
death (months) Cardiac causes Comment
2003 N 12 months 14 29 Cardiac sarcoid Unrelated – no association
between trastuzumab and
sarcoidosis
3021 N 12 months 18 46 Right ventricular
arrhythmic
cardiomyopathy
Unlikely – arrhythmic
cardiomyopathy (ARVC
in old terminology) has a
known genetic basis (mostly
desmosomal genes) with
physiological triggers (e.g.
extreme endurance sports).
It is plausible that cardiac
dysfunction caused by
trastuzumab could have been
a trigger but unlikely in this
case as heart function had
recovered long before ARVC
developed
3463 N 6 months 9 53 Acute heart failure/
left ventricular
hypertrophy/mitral
valve disease
Unrelated/unlikely – there is
no known association with left
ventricular hypertrophy or
mitral valve disease, and it is
difficult to think of a mechanism
for any effect months after the
discontinuation of trastuzumab
35 N 6 months 9 111 Ischaemic heart
disease
Unrelated/unlikely. Death due
to acute MI 111 months after
diagnosis. No association
between trastuzumab and
coronary artery disease
1051 N 6 months 4 78 CHF and type II
respiratory failure
Unrelated/unlikely – very
unlikely to be related to
trastuzumab – received only
four cycles; recovery of LV
function > 3 months after
cessation; diagnosis of COPD;
died 78 months after diagnosis
1086 N 6 months 9 43 Not cardiac N/A
2654 N 6 months 9 41 Myocardial infarction –
pulmonary embolism –
atrial myxoma
Unrelated – no effect of
trastuzumab during treatment;
no association between
trastuzumab and atrial
myxoma or myocardial
infarction
104 Y 12 months 18 39 No cardiac problems –
brain metastases –
died during a seizure
N/A
625 Y 12 months 3 35 Controlled NYHA
class II CHF
Cause of death was metastatic
disease with bone and liver
metastases. LVEF pre treatment
was 56%; after three cycles
of trastuzumab was 51%
(abnormal at site). Trastuzumab
stopped after three cycles and
not restarted. LVEF dropped to
48%, and patient was referred
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TABLE 42 Cardiac deaths recorded in CRFs (continued )
TNO
Metastatic
(Y/N)
Treatment
group
Trastuzumab
cycles
Time from
diagnosis to
death (months) Cardiac causes Comment
to cardiology and diagnosed
with NYHA class II CHF and
started on ACE inhibitors and
bisoprolol and continued
follow-up in heart failure clinic.
LVEF was then 51% and then
46%; patient continued on
cardiac meds and never
restarted trastuzumab.
Returned to normal at LVEF
55%, 1 year after stopping
trastuzumab; was on cardiac
medication at the time and
remained on this. Then
developed metastatic disease
3 years after diagnosis and
deteriorated rapidly with
liver impairment and was not
fit enough for metastatic
treatment that was being
considered (capecitabine/
lapatinib)
Had previously received
FEC × 4 cycles and T × 3 cycles
(no cycle 8 as allergic reaction)
with sequential trastuzumab.
Total dose of epirubicin:
75 mg/m2 × 4= 300 mg/m2
At time of death from metastatic
breast cancer had recovery of
function and remained on
preventative cardiac medication
1279 Y 12 months 4 75 Cardiomyopathy Died with metastatic disease
in lung/pleura, which was
recorded as a cause of death.
Cardiomyopathy recorded as
contributing cause of death;
however, no autopsy was
carried out
FE(100 mg/m2)C × 3 cycles/
T (80 mg/m2) × 3 cycles.
Total dose of epirubicin=
300mg/m2. Trastuzumab given
concurrently with docetaxel.
Clear effect of trastuzumab
causing reduced LVEF during
treatment. LVEF baseline
normal at 55%; after four cycles
fell to 30%, and trastuzumab
stopped, and not restarted.
Commenced cardiac medication
perindopril and bisoprolol.
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Cardiac deaths recorded without metastatic disease (n = 10):
l ischaemic heart disease – unrelated/unlikely to be related (n = 4)
l LVEF decreased and CHF – unrelated/unlikely to be related (n = 1)
l acute heart failure/left ventricular hypertrophy and mitral valve disease – unrelated/unlikely to be
related (n = 1)
l cardiac amyloid – unrelated/unlikely to be related (n = 1)
l cardiac sarcoid – unrelated/unlikely to be related (n = 1)
l right ventricular cardiomyopathy – unrelated/unlikely to be related (n = 1)
l death after routine computerised tomography scan – clinical anaphylaxis – no sign of this post mortem
– no cardiac pathology found. Not cardiac (n = 1).
Deaths with metastatic disease recorded as contributed to by cardiac problems (n = 3):
l controlled NYHA class II CHF – unrelated/unlikely to be related (n = 1)
l cardiomyopathy – unrelated/unlikely to be related (n = 1)
l brain metastases and died during a seizure – unrelated/unlikely to be related. Not cardiac (n = 1).
TABLE 42 Cardiac deaths recorded in CRFs (continued )
TNO
Metastatic
(Y/N)
Treatment
group
Trastuzumab
cycles
Time from
diagnosis to
death (months) Cardiac causes Comment
Coronary angiograms at the
time showed coronary artery
disease. Recovery of LVEF by
1 year later to LVEF 50%; on
perindopril and bisoprolol.
Death 6 years later judged not
related to trastuzumab. No
supporting information for
cardiomyopathy – no histology,
and LVEF had previously
recovered. If present, most
likely explanation is coronary
artery disease or otherwise
anthracyclines
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; N, no; N/A, not applicable; Y, yes.
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TABLE 43 Number of trastuzumab cycles received by patients who reported clinical cardiac dysfunctiona
Number of trastuzumab
cycles received
12-month patients, n (%) 6-month patients, n (%)
Reported clinical
cardiac dysfunction
in months 0–3
Reported clinical
cardiac dysfunction
in months 4–12
Reported clinical
cardiac dysfunction
in months 0–3
Reported clinical
cardiac dysfunction
in months 4–12
1 2 (1.5) 1 (< 1) – –
2 3 (2) 1 (< 1) 2 (1) 2 (1)
3 1 (1) 1 (< 1) – –
4 8 (6) 10 (5) 10 (7) 11 (7)
5 6 (4) 8 (4) 5 (3) 4 (2)
6 6 (4) 4 (2) 4 (3) 5 (3)
7 5 (4) 6 (3) 7 (5) 7 (4)
8 6 (4) 13 (6) 9 (6) 9 (5)
9 2 (1.5) 7 (3) 106 (71) 119 (70)
10 2 (1.5) 7 (3) – 1 (< 1)
11 3 (2) 5 (2) – –
12 – 3 (1) – –
13 2 (1.5) 15 (7) – –
14 2 (1.5) 10 (5) – –
15 2 (1.5) 9 (4) – –
16 2 (1.5) 5 (2) – –
17 3 (2) 6 (3) – 2 (1)
18 82 (59.5) 105 (48) 4 (3) 6 (4)
19 1 (1) 1 (< 1) – –
Unknown – – 2 (1) 3 (2)
Total 138 (100) 217 (100) 149 (100) 169 (100)
a Clinical cardiac dysfunction = symptoms of cardiac disease OR signs of congestive heart failure OR new/altered
medication for cardiac disease.
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TABLE 44 Number of trastuzumab cycles received by patients who reported a low LVEFa
Number of trastuzumab
cycles received
12-month patients, n (%) 6-month patients, n (%)
Reported low LVEF
in months 0–3
Reported low LVEF
in months 4–12
Reported low LVEF
in months 0–3
Reported low LVEF
in months 4–12
0 1 (1.3) – – –
1 – – – –
2 2 (3) 1 (1) 1 (1) 2 (1)
3 1 (1.3) 1 (1) 1 (1) 1 (< 1)
4 15 (20) 11 (5) 10 (12.5) 10 (7)
5 6 (8) 8 (4) 6 (7.5) 3 (2)
6 8 (11) 8 (4) 3 (4) 3 (2)
7 – 5 (2) 4 (5) 7 (5)
8 1 (1.3) 15 (7) 2 (2.5) 17 (12)
9 1 (1.3) 6 (3) 53 (65.5) 96 (66)
10 – 10 (5) 1 (1) 1 (< 1)
11 1 (1.3) 9 (4.5) – –
12 1 (1.3) 3 (1) – –
13 – 17 (8) – –
14 1 (1.3) 7 (3) – –
15 1 (1.3) 8 (4) – –
16 1 (1.3) 9 (4.5) – –
17 2 (3) 8 (4) – 1 (< 1)
18 31 (42) 78 (38) – 4 (3)
Unknown 1 (1.3) 1 (1) – –
Total 74 (100) 205 (100) 81 (100) 145 (100)
a Low LVEF = score of < 50% at any point, or an echocardiogram/MUGA scan reported as ‘abnormal’.
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TABLE 45 Details of data collection changes (July 2009)
Old CRFs (baseline at start of trastuzumab) New CRFs (baseline at 6 months of trastuzumab)
Adjuvant/neoadjuvant eligibility form
LVEF measurement
Eligibility form
LVEF measurement prior to trastuzumab dose 1
Adjuvant/neoadjuvant randomisation form
Chemotherapy type, timing
Adjuvant/neoadjuvant randomisation form
Chemotherapy type, timing
Trastuzumab start date, number of doses
Neoadjuvant diagnostic biopsy form
Planned surgery (could use to check surgery recorded on
surgery form)
Neoadjuvant diagnostic biopsy form
Planned surgery (could use to check surgery recorded on
surgery form)
Surgery form (for both neoadjuvant and adjuvant)
Type of surgery
Surgery form (for both neoadjuvant and adjuvant)
Type of surgery
Chemotherapy form
Cycle number
Drug dose
Dose reduction: plus reason (e.g. cardiotoxicity)
Dose delay: plus reason (e.g. cardiotoxicity)
Hospital admission: plus reason (e.g. cardiotoxicity)
Number of admissions; total days in hospital
If patient receiving concurrent trastuzumab with
chemotherapy
Supportive treatments
Toxicity
Trastuzumab treatment form
Dose
Dose reduction: plus reason (e.g. cardiotoxicity)
Dose delayed: plus reason (e.g. cardiotoxicity)
Dose held: plus reason (e.g. cardiotoxicity)
Hospital admission: plus reason (e.g. cardiotoxicity)
Number of admissions; total days in hospital
Toxicity
Cardiology assessment:
Symptoms of cardiac disease
Signs of congestive heart failure
Physical findings of cardiac disease
Trastuzumab treatment form: over last 3 months
whether before or after randomisation
Dose
Dose reduction: plus reason (e.g. cardiotoxicity)
Dose delayed: plus reason (e.g. cardiotoxicity)
Dose held: plus reason (e.g. cardiotoxicity)
Hospital admission: plus reason (e.g. cardiotoxicity)
Number of admissions; total days in hospital
Toxicity
Cardiology assessment:
Symptoms of cardiac disease
Signs of congestive heart failure
Physical findings of cardiac disease
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TABLE 45 Details of data collection changes (July 2009) (continued )
Old CRFs (baseline at start of trastuzumab) New CRFs (baseline at 6 months of trastuzumab)
Medication for cardiac disease – all symptomatic signs of
cardiotoxicity/cardiac problems
LVEF measurement
Medication for cardiac disease – all symptomatic signs of
cardiotoxicity/cardiac problems
LVEF measurement
Treatment summary form
Chemotherapy summary
Number of cycles
Drug
If less than intended, reason
Trastuzumab summary
Number of doses
If fewer than randomised to, reason
Catheter use
Treatment summary form
Chemotherapy summary
Number of cycles
Drug
If less than intended, reason
Trastuzumab summary
Number of doses
If fewer than randomised to, reason
Radiotherapy form
Summary of radiotherapy
Modifications to radiotherapy
Radiotherapy form
Summary of radiotherapy
Modifications to radiotherapy
Annual follow-up form
Medication
Toxicities
Further chemotherapy
Further surgery
Ovation suppression/ablation
Disease free
Dead
Relapse/death form
Trastuzumab treatment
Relapse: locoregional, distant, first/second primary
Death, cause of: breast cancer, other cancer, protocol
treatment related, other treatment related, other cause
Hospital transfer form
Reason for transfer
Details of transfer
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TABLE 46 Unit costs associated with cardiology assessment
Cardiology assessment Unit cost (£) Source
MUGA scan 252.64 NHS Reference Costs 2017/18: MUGA scan (RN22Z)87
ECHO 253.70 NHS Reference Costs 2017/18: complex echocardiogram for
congenital heart disease (EC21Z)87
MRI 227.60 NHS Reference Costs 2017/18: cardiac magnetic resonance
imaging scan without contrast (RD08Z)87
Electrocardiogram 120.32 NHS Reference Costs 2017/18: electrocardiogram monitoring or
stress testing, for congenital heart disease (EC22Z)87
X-ray 31.49 NHS Reference Costs 2017/18: direct access plain film (DAPF)87
Myocardial perfusion 290.46 NHS Reference Costs 2017/18: myocardial perfusion scan,
stress only (RN21Z)87
Computerised tomography
angiography
106.22 NHS Reference Costs 2017/18: computerised tomography scan
of one area, with post-contrast only, 19 years and over
(RD21A)87
Exercise stress test 159.53 NHS Reference Costs 2017/18: cardiopulmonary exercise
testing (DZ31Z)87
Blood tests 1.11 + 2.83 NHS Reference Costs 2017/18: clinical biochemistry
(DAPS04) + phlebotomy (DAPS08)87
Assessment by cardiologist 128.05 NHS Reference Costs 2017/18: non-admitted face-to-face
attendance, follow-up (WF01A)87
Cardiac catheterisation 1131.89 NHS Reference Costs 2017/18: standard cardiac catheterisation
with CC score 0–1 (EY43F)87
CC, complications and comorbidities.
TABLE 47 Unit costs associated with cardiac medication
Cardiac medication Unit cost (£) Source
Warfarin (5 mg) 0.02 (0.59/28 tablets) BNF 2018: NHS indicative price88
Carvedilol (3.125 mg) 0.03 (0.73/28 tablets)
Carvedilol (12.5 mg) 0.03 (0.75/28 tablets)
Sotalol (40 mg) 0.04 (1.11/28 tablets)
Clopidogrel (75 mg) 0.04 (1.16/28 tablets)
Furosemide (40 mg) 0.01 (3.50/250 tablets)
Amlodipine (5 mg) 0.02 (0.67/28 tablets)
Amlodipine (10 mg) 0.02 (0.68/28 tablets)
Aspirin (75 mg) 0.04 (1.10/28 tablets)
Ramipril (1.25 mg) 0.05 (1.35/28 tablets)
Ramipril (2.5 mg) 0.18 (5/28 tablets)
Ramipril (5 mg) 0.03 (0.81/28 tablets)
Ramipril (10 mg) 0.03 (0.93/28 tablets)
Celecoxib (200mg) 0.05 (1.62/30 capsules)
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TABLE 48 Unit costs of endocrine medications and bisphosphonates
Endocrine medications and
bisphosphonates; daily dose Unit cost (£) Source
Anastrozole 1 mg (Arimidex; AstraZeneca
UK Limited, Macclesfield, UK)
2.45 (68.56/28 tablets) BNF 2018: NHS indicative price88
Exemestane 25mg (Aromasin; Pfizer
Limited, Sandwich, UK)
2.96 (88.80/30 tablets)
Letrozole 2.5 mg (Femara®; Novartis
Pharmaceuticals UK Ltd, London, UK)
3.03 (90.92/30 tablets)
Goserelin 3.6 mg (Zoladex®; AstraZeneca
UK Limited)
2.50 (70/28 days)
Tamoxifen 20mg (Nolvadex®; AstraZeneca
UK Limited)
0.08 (2.35/30 tablets)
Bisphosphonates (alendronate 10mg) 0.05 (1.29/28 tablets)
TABLE 49 Unit costs associated with surgical interventions
Surgical intervention Unit cost (£) Source
Delayed reconstruction 5462.48 NHS Reference Costs 2017/18: unilateral
delayed pedicled myocutaneous breast
reconstruction (JA30Z)87
Mastectomy of treated breast 3490.00 NHS Reference Costs 2017/18: unilateral
major breast procedures with CC score 6+
(JA20D)87
Mastectomy of treated breast with
reconstruction
5462.48 NHS Reference Costs 2017/18: unilateral
delayed pedicled myocutaneous breast
reconstruction (JA30Z)87
Mastectomy of contralateral breast 3490.00 NHS Reference Costs 2017/18: unilateral
major breast procedures with CC score 6+
(JA20D)87
Mastectomy of contralateral breast with
reconstruction
5462.48 NHS Reference Costs 2017/18: unilateral
delayed pedicled myocutaneous breast
reconstruction (JA30Z)87
Oophorectomy 4834.47 NHS Reference Costs 2017/18: major open
upper genital tract procedures with CC
score 3–4 (oophorectomy) (MA07F)87
Biopsy 351 NHS Reference Costs 2017/18: biopsy of
lesion of breast and associated lymph
nodes (YJ03Z)87
Mammoplasty 4331 NHS Reference Costs 2017/18: unilateral
therapeutic mammoplasty (JA40Z)87
Minor breast procedure 1616 NHS Reference Costs 2017/18: unilateral
minor breast procedures (JA45Z)87
Intermediate breast procedures 2362 NHS Reference Costs 2017/18: unilateral
intermediate breast procedures with CC
score 0–2 (JA43B)87
Lymph node clearance 3863 NHS Reference Costs 2017/18: unilateral
major breast procedures with lymph node
clearance, with CC score 0–1 (JA38C)87
CC, complications and comorbidities.
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TABLE 50 Unit costs of hospital services and community-based health and social care
Service Unit cost (£) Source
Hospital services
Hospital inpatient stay/day 337.36 NHS Reference Costs 2017/18: non-elective inpatients – excess
bed-days87
Hospital day centre/day 201.00 PSSRU Unit Costs of Health and Social Care 2018, p. 89: inpatient,
hospital specialist palliative care support (adults only)86
Outpatient clinic visit 108.00 PSSRU Unit Costs of Health and Social Care 2018, p. 89:
outpatient, medical specialist palliative care attendance (adults
and children)86
A&E visit 153.32 NHS Reference Costs 2017/18: emergency medicine, category 1
investigation with category 1–2 treatment (T01, VB09Z)87
Community-based health care
GP surgery face to face 37.00 PSSRU Unit Costs of Health and Social Care 2018, p. 127: general
practitioner, per surgery consultation lasting 9.22 minutes86
GP surgery telephone-contact 28.40 PSSRU Unit Costs of Health and Social Care 2018, p. 127: general
practitioner, per patient contact assuming a 7.1-minute call
including direct staff costs86
GP home face to face 120.00 PSSRU Unit Costs of Health and Social Care 2018, p. 127: general
practitioner, per patient contact assuming a 30-minute
appointment86
GP home telephone contact 28.40 PSSRU Unit Costs of Health and Social Care 2018, p. 127: general
practitioner, per patient contact assuming a 7.1-minute call
including direct staff costs86
District nurse face to face 36.48 PSSRU Unit Costs of Health and Social Care 2015, p. 169: per hour
of patient-related work, including qualifications, assuming
30-minute appointment (inflated)86
District nurse telephone contact 8.51 PSSRU Unit Costs of Health and Social Care 2015, p. 169: per hour
of patient-related work, including qualifications, assuming
7-minute telephone call (inflated)86
Health visitor face to face 41.39 PSSRU Unit Costs of Health and Social Care 2015, p. 171: per hour
of patient related work, including qualifications, assuming
30-minute appointment (inflated)86
Health visitor telephone contact 9.66 PSSRU Unit Costs of Health and Social Care 2015, p. 171: per hour
of patient-related work, assuming a 7-minute call (inflated)86
Occupational therapist visit 23.50 PSSRU Unit Costs of Health and Social Care 2018, p. 142: NHS
community occupational therapist, assuming a 30-minute
appointment86
Occupational therapist
telephone contact
5.48 PSSRU Unit Costs of Health and Social Care 2018, p. 142: NHS
community occupational therapist, assuming a 7-minute call86
Physiotherapist visit 20.67 PSSRU Unit Costs of Health and Social Care 2017, p. 186:
community physiotherapist mean cost of one-to-one contact,
assuming a 30-minute appointment (taken out of 2018 edition)
(inflated)86
Physiotherapist telephone
contact
5.17 PSSRU Unit Costs of Health and Social Care 2017, p. 186: assuming
a 7-minute call (inflated)86
Community-based social care
Social worker Macmillan visit 42.00 PSSRU Unit Costs of Health and Social Care 2018, p. 139: assuming
30-minute appointment86
Social worker Macmillan
telephone contact
9.80 PSSRU Unit Costs of Health and Social Care 2018, p. 139: assuming
a 7-minute call86
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TABLE 50 Unit costs of hospital services and community-based health and social care (continued )
Service Unit cost (£) Source
Palliative social worker visit 42.00 PSSRU Unit Costs of Health and Social Care 2018: assuming social
worker for palliative care same as the Macmillan visit86
Palliative social worker
telephone contact
9.80 PSSRU Unit Costs of Health and Social Care 2018: assuming social
worker for palliative care same as the Macmillan contact86
Counsellor visit 25.50 PSSRU Unit Costs of Health and Social Care 2018, p. 50: assuming
30-minute appointment86
Counsellor telephone contact 5.95 PSSRU Unit Costs of Health and Social Care 2018, p. 50: assuming
7-minute call86
Citizen adviser visit 23.50 PSSRU Unit Costs of Health and Social Care 2018: assuming same
as for occupational therapist86
Citizen adviser telephone
contact
5.48 PSSRU Unit Costs of Health and Social Care 2018: assuming same
as for occupational therapist86
Psychiatrist visit 57.87 PSSRU Unit Costs of Health and Social Care 2017, p. 62: specialist
prescribing, unit costs per patient per week (taken from 2018
edition) (inflated)158
Psychiatrist telephone contact 28.40 PSSRU Unit Costs of Health and Social Care 2018, p. 127: per
minute of patient contact (7.1 minutes) including direct care
staff costs86
Convalescent day 261.05 NHS Reference Costs 2017/18: paediatric, convalescent or other
relief care (Day Case, PX54Z)87
Convalescent visit 37.40 PSSRU Unit Costs of Health and Social Care 2018, p. 127: =GP
contact lasting 9.22 minutes86
Nursing home day 126.86 PSSRU Unit Costs of Health and Social Care 2018, p. 174: not-for-
profit care home fees in England, mid-point of minimum fees for
2017/18 for shared rooms per day (£888/7)86
Nursing home visit 37.40 PSSRU Unit Costs of Health and Social Care 2018, p. 127: =GP
contact lasting 9.22 minutes86
A&E, accident and emergency; PSSRU, Personal Social Services Research Unit.
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TABLE 51 Transition probabilities
Parameter Mean Standard error Distribution Source
5.1 years of follow-up data
6-month arm
DF to NP 0.001693 0.002088 Beta PERSEPHONE trial
DF to LR 0.001873 0.002324 Beta PERSEPHONE trial
DF to DR 0.004234 0.004889 Beta PERSEPHONE trial
DF to BC death 0 0 Fixed PERSEPHONE trial
DF to cardiac death 0.000048 0.000163 Beta PERSEPHONE trial
DF to background death 0.000674 0.000669 Beta PERSEPHONE trial
NP to DF 0 0 Fixed PERSEPHONE trial
NP to LR 0.003092 0.010954 Beta PERSEPHONE trial
NP to DR 0.004465 0.013006 Beta PERSEPHONE trial
NP to BC death 0.000275 0.000806 Beta PERSEPHONE trial
NP to cardiac death 0.000004 0.000034 Beta PERSEPHONE trial
NP to background death 0.026313 0.026328 Beta PERSEPHONE trial
LR to DF 0 0 Fixed PERSEPHONE trial
LR to NP 0.004199 0.015795 Beta PERSEPHONE trial
LR to DR 0.054839 0.048247 Beta PERSEPHONE trial
LR to BC death 0.009398 0.029416 Beta PERSEPHONE trial
LR to cardiac death 0.002193 0.014763 Beta PERSEPHONE trial
LR to background death 0.000209 0.000428 Beta PERSEPHONE trial
DR to DF 0 0 Fixed PERSEPHONE trial
DR to NP 0 0 Fixed PERSEPHONE trial
DR to LR 0 0 Fixed PERSEPHONE trial
DR to BC death 0.109534 0.039779 Beta PERSEPHONE trial
DR to cardiac death 0 0 Fixed PERSEPHONE trial
DR to background death 0.005066 0.009336 Beta PERSEPHONE trial
12-month arm
DF to NP 0.001666 0.000845 Beta PERSEPHONE trial
DF to LR 0.001439 0.000796 Beta PERSEPHONE trial
DF to DR 0.003993 0.001348 Beta PERSEPHONE trial
DF to BC death 0 0 Fixed PERSEPHONE trial
DF to cardiac death 0.000142 0.000292 Beta PERSEPHONE trial
DF to background death 0.000692 0.000508 Beta PERSEPHONE trial
NP to DF 0 0 Fixed PERSEPHONE trial
NP to LR 0.001584 0.011769 Beta PERSEPHONE trial
NP to DR 0.003447 0.013256 Beta PERSEPHONE trial
NP to BC death 0.008326 0.015342 Beta PERSEPHONE trial
NP to cardiac death 0.000004 0.000029 Beta PERSEPHONE trial
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TABLE 51 Transition probabilities (continued )
Parameter Mean Standard error Distribution Source
NP to background death 0.012970 0.019627 Beta PERSEPHONE trial
LR to DF 0 0 Fixed PERSEPHONE trial
LR to NP 0 0 Fixed PERSEPHONE trial
LR to DR 0.045659 0.041194 Beta PERSEPHONE trial
LR to BC death 0.013969 0.023254 Beta PERSEPHONE trial
LR to cardiac death 0.000056 0.000222 Beta PERSEPHONE trial
LR to background death 0.000088 0.000269 Beta PERSEPHONE trial
DR to DF 0 0 Fixed PERSEPHONE trial
DR to NP 0 0 Fixed PERSEPHONE trial
DR to LR 0 0 Fixed PERSEPHONE trial
DR to BC death 0.099780 0.035325 Beta PERSEPHONE trial
DR to cardiac death 0 0 Fixed PERSEPHONE trial
DR to background death 0.003547 0.009777 Beta PERSEPHONE trial
Mortality
Cardiac mortality (6-month arm) 0.0015 0.0014 Beta PERSEPHONE trial
Cardiac mortality (12-month arm) 0.0040 0.0009 Beta PERSEPHONE trial
Beyond 5.1 years of follow-up data
New/second primary cancer
Increased risk of NP after BC treatment 1.57 1.07408 Log-normal Marcheselli et al.159
Probability of NP Age-specific Fixed UK population rates
for females160
Cardiac toxicity
Background levels of CHF Age-specific Fixed Registry data
Mortality
Background all-cause mortality in UK females Age-specific Fixed Registry data
Breast cancer-specific mortality in UK females Age-specific Fixed Registry data
BC, breast cancer; DR, distant recurrence; DF, disease free; LR, local recurrence; NP, new/secondary primary cancer.
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TABLE 52 The AIC and BIC values for DFS model fits
DFS AIC BIC
12 months
Exponential 2226.070 2231.675
Weibull 2228.057 2239.266
Gompertz 2226.749 2237.958
Log-normal 2219.691 2230.899
Log-logistic 2226.469 2237.678
6 months
Exponential 2260.195 2265.796
Weibull 2261.519 2272.722
Gompertz 2256.466 2267.668
Log-normal 2250.34 2261.543
Log-logistic 2259.327 2270.53
AIC, Akaike information criterion; BIC, Bayesian information criterion.
TABLE 53 Utility weights
Parameter Mean Standard error Distribution Source
Disease free 0.805 0.021 Beta Seferina et al.98
Local recurrence 0.708 0.088 Beta Seferina et al.98
New/second primary cancer 0.696 0.032 Beta Lidgren et al.83
Distant recurrence 0.604 0.046 Beta Seferina et al.98
TABLE 54 Costs (£)
Parameter
Mean
cost (£)
Standard
error Distribution Source
Disease-free annual cost
Mammogram 60.29 12.06 Log-normal Robertson et al.101 (inflated)
Breast cancer follow-up clinic 165.85 33.17 Log-normal NHS Reference Costs87
Heart failure costs
Cost per heart failure event 1979.71 395.94 Log-normal NHS Reference Costs87
Cancer recurrence costs
Local recurrence first year 6896.48 1379.30 Log-normal OPTIMA Prelim HTA model (2013)
Local recurrence annual cost 575.27 115.05 Log-normal OPTIMA Prelim HTA model (2013)
Second primary cancer first year 26,744.39 5348.88 Log-normal Hall et al.91
Second primary cancer annual
cost
2659.37 531.87 Log-normal Hall et al.91
Distant recurrence annual cost 1893.55 378.71 Log-normal OPTIMA Prelim HTA model (2013)
Terminal care cost 4687.58 937.52 Log-normal NICE TA563,104 NICE TA496,161 NICE CG81
Package 3105 (2015/16) (inflated)
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TABLE 55 Within-trial probabilistic sensitivity analysis cost-effectiveness results: subgroup analyses
Subgroup
Treatment
duration Total cost, £ (95% CI)
Total QALY
(95% CI)
Incremental cost, £
(95% CI)
Incremental QALY
(95% CI) ICER (£) NB (95% CI)
Incremental NB
(95% CI)
ER status negative 12 months
(n= 615)
14,806 (14,291 to 15,312) 1.14 (1.11 to 1.16) – – – 0.40 (0.36 to 0.43) –
6 months
(n= 618)
5632 (5224 to 6052) 1.13 (1.11 to 1.16) –9178 (–9826 to –8517) –0.003 (–0.038 – 0.032) 2,928,179 0.85 (0.81 to 0.89) 0.46 (0.40 to 0.51)
ER status positive 12 months
(n= 1392)
15,515 (15,184 to 15,851) 1.15 (1.13 to 1.16) – – – 0.37 (0.35 to 0.40)
6 months
(n= 1383)
5820 (5575 to 6080) 1.15 (1.14 to 1.17) –9693 (–10,115 to –9270) 0.005 (–0.016 – 0.027) Dominant 0.86 (0.84 to 0.88) 0.49 (0.46 to 0.52)
Anthracycline-based
chemotherapy
12 months
(n= 837)
14,285 (13,876 to 14,703) 1.16 (1.14 to 1.18) – – – 0.45 (0.42 to 0.47) –
6 months
(n= 829)
5106 (4801 to 5419) 1.17 (1.14 to 1.19) –9182 (–9699 to –8651) 0.006 (–0.023 – 0.035) Dominant 0.91 (0.88 to 0.94) 0.47 (0.42 to 0.51)
Concurrent
trastuzumab
12 months
(n= 933)
16,119 (15,718 to 16,531) 1.15 (1.13 to 1.17) – – – 0.34 (0.31 to 0.37) –
6 months
(n= 928)
6298 (5969 to 6631) 1.14 (1.12 to 1.16) –9823 (–10,339 to –9295) –0.007 (–0.034 – 0.019) 1,401,899 0.83 (0.80 to 0.85) 0.48 (0.44 to 0.52)
Sequential
trastuzumab
12 months
(n= 1074)
14,584 (14,209 to 14,952) 1.14 (1.12 to 1.16) – – – 0.41 (0.39 to 0.44) –
6 months
(n= 1073)
5301 (5029 to 5585) 1.15 (1.14 to 1.17) –9278 (–9749 to –8805) 0.011 (–0.014 – 0.037) Dominant 0.89 (0.86 to 0.91) 0.48 (0.44 to 0.51)
Adjuvant
chemotherapy
12 months
(n= 1708)
15,050 (14,759 to 15,342) 1.15 (1.14 to 1.17) – – – 0.40 (0.38 to 0.42) –
6 months
(n= 1693)
5494 (5276 to 5724) 1.15 (1.14 to 1.17) –9555 (–9924 – –9184) 0.000 (–0.020 – 0.020) Dominant 0.88 (0.86 to 0.90) 0.48 (0.45 to 0.51)
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TABLE 55 Within-trial probabilistic sensitivity analysis cost-effectiveness results: subgroup analyses (continued )
Subgroup
Treatment
duration Total cost, £ (95% CI)
Total QALY
(95% CI)
Incremental cost, £
(95% CI)
Incremental QALY
(95% CI) ICER (£) NB (95% CI)
Incremental NB
(95% CI)
Neoadjuvant
chemotherapy
12 months
(n= 299)
16,701 (15,941 to 17,491) 1.10 (1.07 to 1.14) – – – 0.27 (0.21 to 0.32) –
6 months
(n= 308)
7220 (6589 to 7880) 1.12 (1.09 to 1.16) –9482 (–10,503 to –8480) 0.018 (–0.032 – 0.068) Dominant 0.76 (0.71 to 0.81) 0.49 (0.41 to 0.57)
Taxane-based
chemotherapy
12 months
(n= 193)
16,141 (15,287 to 17,055) 1.13 (1.09 to 1.18) – – – 0.33 (0.25 to 0.39) –
6 months
(n= 196)
5446 (4883 to 6070) 1.14 (1.10 to 1.18) –10,689 (–11,77 to –9647) 0.006 (–0.053 – 0.066) Dominant 0.87 (0.81 to 0.92) 0.54 (0.45 to 0.63)
Anthracycline and
taxane-based
chemotherapy
12 months
(n= 975)
16,015 (15,625 to 16,406) 1.13 (1.10 to 1.16)) – – – 0.33 (0.29 to 0.37) –
6 months
(n= 973)
6361 (6035 to 6702) 1.13 (1.10 to 1.17) –9651 (–10,167 to –9141) 0.000 (–0.042 – 0.041) Dominant 0.82 (0.76 to 0.85) 0.48 (0.43 to 0.53)
A
P
P
E
N
D
IX
1
N
IH
R
Jo
u
rn
als
Lib
rary
w
w
w
.jo
u
rn
alslib
rary.n
ih
r.ac.u
k
1
7
6
TABLE 56 Trastuzumab biosimilars May 2019 European Medicines Agency
Date of authorisation Product name Marketing authorisation holder
15 November 2017 Ontruzant Samsung Bioepis NL B.V.
8 February 2018 Herzuma Celltrion Healthcare Hungary Kft. (Budapest, Hungary)
16 May 2018 Kanjinti Amgen Europe B.V. (Breda, the Netherlands)
26 July 2018 Trazimera Pfizer Europe MA EEIG (Brussels, Belgium)
12 December 2018 Ogivri Mylan S.A.S. (Saint-Priest, France)
TABLE 57 Trastuzumab biosimilars authorised May 2019 FDA
Date of authorisation Product name Marketing authorisation holder
February 2018 Ogiviri Mylan S.A.S.
14 December 2018 Herzuma Celltrion Inc.
January 2019 Ontruzant Samsung Bioepis NL B.V.
March 2019 Trazimera Pfizer Europe MA EEIG
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Dyspnoea
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0.003
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FIGURE 24 Patients (%) reporting at least one adverse event of severe grade (CTCAE ≥ 3, or 2 for palpitations) (patients receiving trastuzumab sequentially after chemotherapy).
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FIGURE 25 Invasive DFS [including invasive contralateral breast cancers and second primary invasive cancers (non-breast)].
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FIGURE 26 Distant DFS.
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FIGURE 27 Breast cancer-specific survival.
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Deaths/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 monthsCharacteristic 12 months (O–E) Variance
ER status
Negative
Positive
98/631
(15.5%)
109/1412
(7.7%)
73/632
(11.6%)
109/1413
(7.7%)
Interaction between two groups χ1 = 2.7; p = 0.10
2
Anthracycline-based
Taxane-based
Anthracycline + taxane
Neither anthracycline 
nor taxane
Heterogeneity between four groups χ3 = 6.0; p = 0.11
78/845
(9.2%)
26/202
(12.9%)
103/993
(10.4%)
0/3
(0.0%)
80/851
(9.4%)
13/198
(6.6%)
88/994
(8.9%)
1/2
(50.0%)
2
Chemotherapy type
Chemotherapy timing
Adjuvant
Neoadjuvant
Interaction between two groups χ1 = 1.5; p = 0.22
157/1727
(9.1%)
50/316
(15.8%)
148/1735
(8.5%)
34/310
(11.0%)
2
Transtuzumab timing
Concurrent (with CT)
Sequential (after CT)
Interaction between two groups χ1 = 7.6; p = 0.006
91/951
(9.6%)
116/1092
(10.6%)
57/949
(6.0%)
125/1096
(11.4%)
2
Age (years)
≤ 50
> 50
Interaction between two groups χ1 = 1.4; p = 0.24
54/677
(8.0%)
153/1366
(11.2%)
56/657
(8.5%)
126/1388
(9.1%)
2
Tumour grade
Well differentiated
Moderately differentiated
Poorly differentiated
Heterogeneity between three groups χ2 = 0.6; p = 0.74
1/34
(2.9%)
56/645
(8.7%)
141/1297
(10.9%)
0/28
(0.0%)
50/631
(7.9%)
129/1325
(9.7%)
2
Menopausal status
Pre
Peri
Post
Heterogeneity between three groups χ2 = 0.2; p = 0.92
46/579
(7.9%)
8/151
(5.3%)
118/1072
(11.0%)
46/567
(8.1%)
6/110
(5.5%)
113/1145
(9.9%)
2
IHC-score
2 + and FISH positive
3 +
Unstratified
Interaction between two groups χ1 = 0.3; p = 0.57
54/510
(10.6%)
147/1489
(9.9%)
207/2043
(10.1%)
182/2045
(8.9%)
48/551
(8.7%)
132/1462
(9.0%)
13.5
–1.0
–1.0
6.9
7.5
–0.6
4.6
7.6
18.0
 
–5.5
–1.7
 
14.3
0.4
2.2
7.7
–0.1
0.1
5.3
5.4
5.7
12.5
42.7
54.5
39.5
9.7
47.7
0.2
76.2
21.0
37.0
 
60.2
27.5
 
69.7
0.2
26.5
67.5
23.0
3.4
57.7
97.2
25.4
69.7
2
1.37 (1.02 to 1.85)
0.98 (0.75 to 1.28)
1.06 (0.85 to 1.33)
1.43 (0.93 to 2.20)
1.63 (1.18 to 2.24)
0.91 (0.71 to 1.18)
0.94 (0.65 to 1.37)
1.23 (0.97 to 1.55)
0.97 (0.71 to 1.33)
2.05 (1.09 to 3.85)
1.17 (0.88 to 1.56)
1.09 (0.74 to 1.59)
1.12 (0.88 to 1.42)
0.99 (0.66 to 1.50)
1.02 (0.35 to 2.94)
1.10 (0.85 to 1.42)
1.24 (0.84 to 1.83)
1.09 (0.86 to 1.37)
1.14 (0.93 to 1.39)
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6 months better 12 months better
95% CI 95% CI*
FIGURE 28 Forest plot of OS for all patients. CT, chemotherapy; O–E, observed–expected.
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Events/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 months 12 months (O–E) Variance
ER status
Characteristic
Negative
Positive
Chemotherapy type
Chemotherapy timing
Transtuzumab timing
Anthracycline based
Taxane based
Anthracycline + taxane
Neither anthracycline 
nor taxane
Adjuvant
Neoadjuvant
Concurrent (with CT)
Sequential (after CT)
Age (years)
≤ 50
> 50
Tumour grade
Menopausal status
Pre
Peri
Post
Well differentiated
Moderately differentiated
Poorly differentiated
IHC-score
2 + and FISH positive
3 +
Unstratified
95% CI 95% CI
121/618
(19.6%)
159/1383
(11.5%)
103/615
(16.7%)
154/1392
(11.1%)
Interaction between two groups χ1 = 4.0; p = 0.04
Interaction between two groups χ1 = 8.7; p = 0.003
Interaction between two groups χ1 = 0.1; p = 0.82
Interaction between two groups χ1 = 0.2; p = 0.65
Heterogeneity between three groups χ2 = 2.3; p = 0.32
Heterogeneity between three groups χ2 = 1.1; p = 0.59
Interaction between two groups χ1 = 0.9; p = 0.35
Heterogeneity between four groups χ3 = 10.6; p = 0.01
97/829
(11.7%)
30/196
(15.3%)
153/973
(15.7%)
0/3
(0.0%)
111/837
(13.3%)
13/193
(6.7%)
132/975
(13.5%)
1/2
(50.0%)
209/1693
(12.3%)
71/308
(23.1%)
133/928
(14.3%)
147/1073
(13.7%)
93/933
(10.0%)
164/1074
(15.3%)
210/1708
(12.3%)
47/299
(15.7%)
96/660
(14.5%)
184/1341
(13.7%)
3/34
(8.8%)
83/637
(13.0%)
183/1271
(14.4%)
83/567
(14.6%)
12/150
(8.0%)
144/1054
(13.7%)
67/499
(13.4%)
204/1464
(13.9%)
280/2001
(14.0%)
257/2007
(12.8%)
72/541
(13.3%)
181/1437
(12.6%)
71/554
(12.8%)
12/108
(11.1%)
151/1127
(13.4%)
10.4
1.6
–7.2
9.0
11.2
–0.6
21.9
 
–10.0
2.8
 
9.0
1.4
3.4
4.7
–0.4
12.2
5.5
–1.6
0.7
0.4
9.8
11.9
56.0
78.2
52.0
10.7
71.2
0.2
0.7
39.2
90.2
46.0
 
88.2
56.5
 
77.7
104.7
29.4
134.2
34.7
96.2
38.5
5.9
73.7
0/28
(0.0%)
74/624
(11.9%)
178/1296
(13.7%)
88/640
(13.8%)
169/1367
(12.4%)
0.1 0.2 0.3 0.4 0.5 2 3 4 5 10
6 months better 12 months better
1.20 (0.93 to 1.56)
1.02 (0.82 to 1.27)
1.00 (0.82 to 1.21)
1.52 (1.06 to 2.18)
1.47 (1.14 to 1.91)
0.88 (0.70 to 1.10)
1.06 (0.80 to 1.42)
1.11 (0.90 to 1.36)
0.87 (0.66 to 1.14)
2.31 (1.27 to 4.20)
1.17 (0.93 to 1.48)
1.09 (0.80 to 1.49)
1.05 (0.86 to 1.29)
1.15 (0.84 to 1.58)
0.76 (0.34 to 1.70)
1.01 (0.80 to 1.27)
1.01 (0.72 to 1.41)
1.11 (0.91 to 1.35)
1.09 (0.92 to 1.29)
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FIGURE 29 Forest plot of landmark DFS for all patients. CT, chemotherapy; O–E, observed–expected.
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Deaths/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 months 12 months (O–E) Variance
ER status
Characteristic
Negative
Positive
Chemotherapy type
Chemotherapy timing
Transtuzumab timing
Anthracycline based
Taxane based
Anthracycline + taxane
Neither anthracycline 
nor taxane
Adjuvant
Neoadjuvant
Concurrent (with CT)
Sequential (after CT)
Age (years)
≤ 50
> 50
Tumour grade
Menopausal status
Pre
Peri
Post
Well differentiated
Moderately differentiated
Poorly differentiated
IHC-score
2 + and FISH positive
3 +
Unstratified
95% CI 95% CI
94/618
(15.2%)
99/1383
(7.2%)
70/615
(11.4%)
102/1392
(7.3%)
Interaction between two groups χ1 = 2.5; p = 0.12
Interaction between two groups χ1 = 5.7; p = 0.02
Interaction between two groups χ1 = 0.7; p = 0.40
Interaction between two groups χ1 = 0.1; p = 0.76
Heterogeneity between three groups χ2 = 0.7; p = 0.69
Heterogeneity between three groups χ2 = 0.1; p = 0.97
Interaction between two groups χ1 = 3.0; p = 0.08
Heterogeneity between four groups χ3 = 5.7; p = 0.13
71/829
(8.6%)
23/196
(11.7%)
99/973
(10.2%)
0/3
(0.0%)
75/837
(9.0%)
12/193
(6.2%)
84/975
(8.6%)
1/2
(50.0%)
146/1693
(8.6%)
47/308
(15.3%)
84/928
(9.1%)
109/1073
(10.2%)
56/933
(6.0%)
116/1074
(10.8%)
142/1708
(8.3%)
30/299
(10.0%)
49/660
(7.4%)
144/1341
(10.7%)
1/34
(2.9%)
54/637
(8.5%)
129/1271
(10.1%)
44/567
(7.8%)
8/150
(5.3%)
109/1054
(10.3%)
49/499
(9.8%)
138/1464
(9.4%)
193/2001
(9.6%)
172/2007
(8.6%)
46/541
(8.5%)
124/1437
(8.6%)
41/554
(7.4%)
5/108
(4.6%)
111/1127
(9.8%)
13.1
–2.3
–2.1
6.0
7.8
–0.6
15.2
 
–4.5
–0.7
 
11.5
0.4
1.7
6.2
2.1
8.3
1.5
0.5
1.8
3.7
5.6
10.7
41.0
50.2
36.5
8.7
45.7
0.2
0.2
25.7
62.2
24.5
 
66.7
35.0
 
56.2
72.0
19.2
91.2
23.7
65.5
21.2
3.2
55.0
0/28
(0.0%)
49/624
(7.9%)
120/1296
(9.3%)
49/640
(7.7%)
123/1367
(9.0%)
0.1 0.2 0.3 0.4 0.5 2 3 4 5 10
6 months better 12 months better
1.38 (1.01 to 1.87)
0.96 (0.72 to 1.26)
1.03 (0.82 to 1.30)
1.54 (0.99 to 2.41)
1.54 (1.11 to 2.15)
0.92 (0.71 to 1.20)
0.97 (0.66 to 1.45)
1.19 (0.93 to 1.51)
0.94 (0.68 to 1.31)
1.99 (1.02 to 3.86)
1.19 (0.89 to 1.58)
1.07 (0.73 to 1.57)
1.11 (0.86 to 1.42)
1.07 (0.70 to 1.64)
1.19 (0.39 to 3.56)
1.03 (0.79 to 1.35)
1.17 (0.78 to 1.75)
1.09 (0.85 to 1.39)
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FIGURE 30 Forest plot of landmark OS for all patients. CT, chemotherapy; O–E, observed–expected.
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Deaths/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 months 12 months (O–E) Variance
ER status
Characteristic
Negative
Positive
CT type
Transtuzumab timing
Nodal status at surgery
Anthracycline-based
Taxane-based
Anthracycline + taxane
Neither anthracycline 
nor taxane
Concurrent (with CT)
Sequential (after CT)
NEG
1–3
≥ 4
Tumour size (cm)
ER and node
ER + NODE –
ER – NODE –
ER + NODE +
ER – NODE +
≤ 2
> 2–5
> 5
Unstratified
95% CI 95% CI
69/501
(13.8%)
88/1226
(7.2%)
57/521
(10.9%)
91/1214
(7.5%)
Interaction between two groups χ1 = 5.5 ; p = 0.02  
Heterogeneity between three groups χ2 = 1.6; p = 0.45
Heterogeneity between three groups χ2 = 0.8; p = 0.69
Heterogeneity between four groups χ3 = 3.3; p = 0.34
Interaction between two groups χ1 = 1.6; p = 0.20
Heterogeneity between four groups χ3 = 7.5; p = 0.06
68/817
(8.3%)
25/192
(13.0%)
64/715
(9.0%)
0/3
(0.0%)
76/825
(9.2%)
12/194
(6.2%)
59/714
(8.3%)
1/2
(50.0%)
58/705
(8.2%)
99/1022
(9.7%)
65/1016
(6.4%)
45/486
(9.3%)
46/210
(21.9%)
51/1001
(5.1%)
39/478
(8.2%)
58/245
(23.7%)
37/703
(5.3%)
111/1032
(10.8%)
42/803
(5.2%)
88/786
(11.2%)
20/82
(24.4%)
36/719
(5.0%)
29/297
(9.8%)
52/496
(10.5%)
39/200
(19.5%)
157/1727
(9.1%)
148/1735
(8.5%)
31/710
(4.4%)
20/291
(6.9%)
60/497
(12.1%)
37/226
(16.4%)
7.5
–2.6
–4.2
7.2
2.6
–0.6
6.8
 
2.1
–2.7
–2.7
4.1
1.0
10.9
–6.3
2.3
4.5
–5.4
3.4
4.6
31.5
44.7
36.0
9.2
30.7
0.2
22.5
42.0
9.4
29.0
 
21.0
25.9
23.7
52.5
76.2
16.7
12.2
28.0
18.9
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80/779
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18/87
(20.7%)
0.1 0.2 0.3 0.4 0.5 2 3 4 5 10
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1.27 (0.90 to 1.80)
0.94 (0.70 to 1.26)
1.58 (1.06 to 2.37)
0.89 (0.68 to 1.16)
1.26 (0.88 to 1.82)
1.11 (0.72 to 1.70)
0.90 (0.61 to 1.32)
0.89 (0.64 to 1.24)
2.19 (1.15 to 4.18)
1.09 (0.76 to 1.55)
0.89 (0.59 to 1.34)
1.10 (0.81 to 1.49)
1.11 (0.59 to 2.10)
1.15 (0.71 to 1.85)
1.45 (0.83 to 2.53)
0.82 (0.57 to 1.19)
1.20 (0.76 to 1.88)
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FIGURE 31 Forest plot of OS for adjuvant patients only. CT, chemotherapy; O–E, observed–expected.
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No significant difference was found between trastuzumab timing in terms of LVEF change over time
(p = 0.77).
CT type
Anthracycline-based
Taxane-based
Anthracycline + taxane
Neither anthracycline 
nor taxane
10/28
(35.7%)
1/10
(10.0%)
39/278
(14.0%)
0/0
(.%)
4/26
(15.4%)
1/4
(25.0%)
29/280
(10.4%)
0/0
(.%)
0.1 0.2 0.3 0.4 0.5 2 3 4 5 10
6 months better 12 months better
1.59 (0.88 to 2.85)
1.20 (0.64 to 2.25)
1.70 (0.99 to 2.91)
0.99 (0.49 to 2.00)
1.35 (0.86 to 2.10)
1.43 (0.93 to 2.20)
2.26 (0.79 to 6.48)
1.34 (0.83 to 2.15)
Deaths/patients 6-month events *HR and CI
(6 months : 12 months)
*HR and CI
(6 months : 12 months)6 monthsCharacteristic 12 months (O–E) Variance
Unstratified
95% CI 95% CI
50/316
(15.8%)
34/310
(11.0%)
ER status
Negative
Positive
29/130
(22.3%)
21/186
(11.3%)
16/111
(14.4%)
18/199
(9.0%)
Interaction between two groups χ1 = 0.4; p = 0.53
2
Heterogeneity between four groups χ3 = 2.1; p = 0.54
2
Transtuzumab timing
Concurrent (with CT)
Sequential (after CT)
Interaction between two groups χ1 = 1.4; p = 0.23
33/246
(13.4%)
17/70
(24.3%)
20/246
(8.1%)
14/64
(21.9%)
2
Pathological response
pCR
No pCR
Interaction between two groups χ1 = 0.2; p = 0.65
2.8
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5.0
5.0
7.6
5.2
1.8
7.0
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17.0
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11.2
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2/86
(2.3%)
46/223
(20.6%)
3/100
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31/205
(15.1%)
2
*
FIGURE 32 Forest plot of OS for neoadjuvant patients only. CT, chemotherapy; O–E, observed–expected;
pCR, pathological complete response.
55
0 3 6 9
Months from start of trastuzumab
LV
E
F
 (%
)
12 15
60
65
70
Concurrent
Sequential
Trastuzumab timing
FIGURE 33 Random-effects modelling predicted lines and 95% CIs, split by trastuzumab timing.
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A significant difference was found between chemotherapy types in terms of LVEF change over time
(p = 0.04).
A significant difference was found between number of anthracycline cycles in terms of LVEF change
over time (p = 0.04).
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FIGURE 34 Random-effects modelling predicted lines and 95% CIs, split by chemotherapy type.
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FIGURE 35 Random-effects modelling predicted lines and 95% CIs, split by number of anthracycline cycles.
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FIGURE 36 Disease-free survival model fits: (a) 6 months exponential; (b) 6 months Gompertz; (c) 6 months log-normal;
(d) 6 months log-logistic; (e) 6 months Weibull; (f) 12 months exponential; (g) 12 months Gompertz; (h) 12 months
log-normal; (i) 12 months log-logistic; (j) 12 months Weibull. (continued )
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
188
Years
0
0.0
0.2
0.4
0.6
0.8
1.0
(g)
1 2 3 4 5
Years
0
0.0
0.2
0.4
0.6
0.8
1.0
(h)
1 2 3 4 5
Years
0
0.0
0.2
0.4
0.6
0.8
1.0
(i)
1 2 3 4 5
Years
0
0.0
0.2
0.4
0.6
0.8
1.0
(j)
1 2 3 4 5
FIGURE 36 Disease-free survival model fits: (a) 6 months exponential; (b) 6 months Gompertz; (c) 6 months log-normal;
(d) 6 months log-logistic; (e) 6 months Weibull; (f) 12 months exponential; (g) 12 months Gompertz; (h) 12 months
log-normal; (i) 12 months log-logistic; (j) 12 months Weibull.
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FIGURE 37 Tornado plot: one-way sensitivity analyses. DF, disease free; DR, distant recurrence; LR, local recurrence; NP, new primary.
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